Libertad y Orden

REPÚBLICA DE COLOMBIA

DIVISIÓN DE PROPIEDAD INDUSTRIAL

PCT

PATENTE DE INVENCIÓN

Industria y Comercio
SUPERINTENDENCIA

06-28475

TITULO: AMINOACIDOS CON AFINIDAD PÒR LA PROTEINA c2δ.

CIP: C07C229/08, 229/23, 229/34, A61K31/197, A61P25/00

SOLICITANTE: WARNER LAMBERT COMPANY LLC.

DIRECCIÓN: 201 Tabor Road, Morris Plains, New Jersey 07950, E.U.A

APODERADO: CARLOS R. OLARTE

BOGOTÁ, Marzo 22 de 2006

P2006/000031

OLARTE RAISBECK

06131.

Industria y Comercio
SUPERINTENDENCIA

SUPERINDUSTRIA Y COMERCIO
Radicacion : 06028475 00000000 Folios: 435
Fecha (AMD): 2006-03-22 17:29:04
Tramite : 011 PCT-PATENT 378 FASE NACI 411 PRESENTAC
Dependencia: 2020 DIVISION DE NUEVAS CREACIONES

PETITORIO - FORMULARIO ÚNICO DE SOLICITUD
PATENTE PCT
ENTRADA EN FASE NACIONAL : 25-04-2006

SOLICITUD DE:

(1) [X] Patente de Invención. [ ] Patente de Modelo de Utilidad.

[ ] Capítulo I. [X] Capítulo II.

(2) **SOLICITANTE (71)**	**Nombre:** WARNER LAMBERT COMPANY LLC **Dirección:** 201 Tabor Road, Morris Plains, New Jersey 07950, E.U.A. **Nacionalidad o Domicilio:** ESTADOUNIDENSE **Lugar de Constitución:** Estados Unidos de América. **Teléfono:** _____ **Fax:** _____ **E-mail:** _____	**IDENTIFICACIÓN** **C.C.** [ ] **NIT** [ ] **C.E.** [ ] **Otro** [ ] **Cual** _____ **Número** _____
REPRESENTANTE O APODERADO	**Nombre:** CARLOS R. OLARTE **Dirección:** World Trade Center Torre A, Calle 100 No. 8A-37 Piso 10 **Teléfono:** 601-7700 **Fax:** 601-7799 **E-mail:** office@olarteraisbeck.com	**IDENTIFICACIÓN** **C.C.** [X] **NIT** [ ] **C.E.** [ ] **Otro** [ ] **Cual** _____ **Número** 79782747Bta **TP** 74.295
INVENTOR (ES) (72)	**Nombre:** VER PAGINA ADJUNTA **Dirección:** VER PAGINA ADJUNTA **Nacionalidad o Domicilio:** VER PAGINA ADJUNTA	

(5) **PCT (86)**

Solicitud Internacional No. PCT/IB2004/002985 Fecha Septiembre 13, 2004

Publicación Internacional No. WO 2005/030700 Fecha Abril 7, 2005

(6) **Título (54)** **AMINOACIDOS CON AFINIDAD POR LA PROTEINA c2δ.**

Clasificación Internacional (51) **C07C 229/08, 229/28, 229/34, A61K 31/197, A61P 25/00**

Prioridad **SI** [X] **NO** [ ]

(33) País de Origen	(32) Fecha	(31) Número de Solicitud
US	Septiembre 25, 2003	60/505.953
US	Septiembre 30, 2003	60/507,443

(9) **Comprobante de pago No.** 06-21,060 **Fecha** Marzo 16, 2006

(10) **ANEXOS**

- [x] Comprobante de pago de la tasa de presentación de la solicitud.
- [ ] Documento que acredita la existencia y representación legal cuando el solicitante sea persona jurídica.
- [x] Poderes, si fuere el caso.
- [x] Documento de cesión del inventor al solicitante o a su causante
- [ ] Declaraciones
- [x] Copia de la solicitud internacional. (Resumen, descripción, reivindicaciones, dibujos).
- [x] Traducción de la solicitud internacional al castellano. (Resumen, descripción, reivindicaciones, dibujos).
- [x] Copia del examen preliminar internacional efectuado por la Autoridad Internacional de Examen Preliminar (IPEA)
- [x] Traducción del examen preliminar internacional efectuado por la IPEA.
- [ ] De ser el caso, copia del contrato de acceso.
- [ ] De ser el caso, documento que acredite la licencia o autorización de uso de conocimientos tradicionales de las comunidades indígenas
- [ ] De ser el caso, certificado de depósito del material biológico.
- [ ] Arte final 12 x 12.
- [ ] De ser el caso, información sobre otras solicitudes de patente o títulos obtenidos en el extranjero por el mismo titular o su causante, relacionadas parcial o totalmente con la invención de esta solicitud.
- [ ] De ser el caso, modificaciones efectuadas a la solicitud internacional.
- [x] Otros. Búsqueda Internacional

(11) **FIGURA CARACTERÍSTICA:**

(12) Solicito la concesión de la patente,

NOMBRE: CARLOS R. OLARTE FIRMA:

C.C. 79.782.747 Bta T.P. 74.295

LISTA DE INVENTORES PCT/IB2004/002985

CHRISTOPHER JAMES DEUR
2800 Plymouth Road, Ann Arbor,
Michigan 48105,
Estados Unidos de América
Nacionalidad: Estadounidense

CHRISTINE NYLUND KOLZ
2800 Plymouth Road, Ann Arbor,
Michigan 48105,
Estados Unidos de América
Nacionalidad: Estadounidense

AUGUSTINE TOBI OSUMA
2800 Plymouth Road, Ann Arbor,
Michigan 48105,
Estados Unidos de América
Nacionalidad: Estadounidense

MARK STEPHEN PLUMMER
2800 Plymouth Road, Ann Arbor,
Michigan 48105,
Estados Unidos de América
Nacionalidad: Estadounidense

JACOB BRADLEY SCHWARZ
2800 Plymouth Road, Ann Arbor,
Michigan 48105,
Estados Unidos de América
Nacionalidad: Estadounidense

ANDREW JOHN THORPE
2800 Plymouth Road, Ann Arbor,
Michigan 48105,
Estados Unidos de América
Nacionalidad: Británico

DAVID JUERGEN WUSTROW
2800 Plymouth Road, Ann Arbor,
Michigan 48105,
Estados Unidos de América
Nacionalidad: Estadounidense

SUPERINDUSTRIA Y COMERCIO
Radicacion : 06028475 00000000 Folios: 435
Fecha (AMD): 2006-03-22 17:29:04
Tramite : 011 PCT-PATENT 378 FASE NACI 411 PRESENTAC
Dependencia: 2020 DIVISION DE NUEVAS CREACIONES

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

NIT : 800176089-2

RECIBO OFICIAL DE CAJA : 06 - 21,060
FECHA : MARZO 16 DE 2006

C O N S I G N A C I O N

DEPOSITANTE	TIPO PAGO	BANCO	CUENTA	No. PAGO	FECHA PGO	Vr. PAGO
OLARTE RAISBEGR	CONSIGNACION	BANCO POPULAR	050-00110-6	51156203	16/03/2006	3.953,000.00

C O N C E P T O

CANT.	RENTISTICO	CONCEPTO	TOTAL CONCEPTO
1	50005-01-01 SOLICITUDES	1 TRAMITES DE SOL. DE PATENTE DE IN	463,000.00
		TOTAL : $	463,000.00

SON: CUATROCIENTOS SESENTA Y TRES MIL PESOS

RESPONSABLE : _____

RECIBO DE CAJA APLICADO AL EXPEDIENTE No._____

Traducción oficial del Inglés por Marlén Neira Castro, resolución 2117 del Ministerio de Justicia de Colombia

APOSTILLA EN PODER DE REPRESENTACIÓN DE

WARNER- LAMBERT COMPANY LLC.

Bilingüe inglés- español otorgado en Nueva York, Estados Unidos el 14 de julio de 2003 y firmado por J. Trevor Lumb, Vicepresidente de Pfizer Products Inc.

Sello: recibido el 21 julio de 2003 Departamento de Patentes NYD- Pfizer Inc.

CERTIFICACION NOTARIAL

Bilingüe inglés- español, el 14 de julio de 2003 el suscrito notario Kenneth Greenwood certifica que J. Trevor Lumb, domiciliado en Nueva York ejercía funciones de Secretario Asistente de Warner-Lambert Company LLC, con sede en Morris Plains, Nueva Jersey, Estados Unidos.

Firma del notario: Kenneth Greenwood

Sello notarial: certificado, verificado y autenticado en la Localidad de Egham en Surrey, 14 julio, 2003 por el Notario Kenneth Greenwood-Horne Engall & Freeman

Sello Notario Público en alto relieve rojo.

APOSTILLA

(Convención de la Haya del 5 de octubre de 1961)
REINO UNIDO DE GRAN BRETAÑA E IRLANDA DEL NORTE

1. País :Reino Unido de Gran Bretaña e Irlanda del Norte
   Este documento Público 2.ha sido firmado por K. Greenwood
3. ejerce funciones de Notario Público
4. Lleva el sello de dicho Notario Público

CERTIFICADO 5. En Londres 6. El 17 de julio de 2003

7. Por el Secretario de Estado Principal de su Majestad para Asuntos exteriores y de la mancomunidad.
8. No. G210433
9. Sello del Secretario de Estado Principal de su Majestad para Asuntos exteriores y de la mancomunidad
10. Firma de R. Bawden - Por Secretario de Estado

Si el documento se usa en un país que no es parte de la convención de la Haya del 5 de octubre 1961, debe presentarse en sección consular de la misión que representa el país.
Es traducción fiel del inglés, con copia archivo para confrontación. Bogotá 25 de julio-2003. Marlen Neira C

MARLEN NEIRA CASTRO
Traductor e Intérprete Oficial
Inglés - Español - Inglés
Resolución No 2117 del 7 OCT 1998

OLARTERAISBECK

OLARTE RAISBECK & FRIERI, LTDA.
LEGAL & PROFESSIONAL SERVICES

WORLD TRADE CENTER – TORRE C
CALLE 100 NO 8A-55 PISO 10
BOGOTA, COLOMBIA
TELEPHONE: +57-1 638-6200
FAX: +57-1 638-6201

www.olarteraisbeck.com

6

RECEIVED
JUL 21 2003
PFIZER INC
PATENT DEPT. NYO

Power of Attorney

The undersigned,

Warner-Lambert Company LLC

domiciled in

201 Tabor Road, Morris Plains, New Jersey 07950 USA

by means of these presents hereby grants to **Carlos R. Olarte, J. Ian Raisbeck and Ana María Frieri** full and sufficient Power of Attorney to file, prosecute, obtain, defend and enforce any and all of the company's **Patents, Utility Models and Industrial Designs** in the Republic of Colombia, to which end it empowers them to take all steps necessary before any administrative or judicial authority of any class for the objects stated, to file petitions, appeals, replies and oppositions, pay taxes and annuities, request testimonies, receive documents and securities, abandon applications and collect refunds. Sufficient power is hereby granted to receive notifications on behalf of the Company, to confer powers on those who are to represent the company judicially and extrajudicially, to answer in court in the matter of all claims and demands that may be presented in connection with the objects stated, giving them likewise power to substitute these presents and revoke such substitutions.

Poder

El suscrito,

Warner-Lambert Company LLC

domiciliado en

201 Tabor Road, Morris Plains, New Jersey 07950 USA

por medio del presente otorga a **Carlos R. Olarte, J. Ian Raisbeck y Ana María Frieri** poder especial, amplio y suficiente para presentar, tramitar, obtener, defender y hacer respetar todas y cualquiera de **Patentes, Modelos de Utilidad y Diseños Industriales** de la compañía en la República de Colombia, a cuyo efecto los faculta para dar todos los pasos necesarios ante cualquier autoridad administrativa o judicial de cualquier jerarquía para cumplir con lo encomendado, elevar solicitudes, apelaciones, respuestas y oposiciones, pagar impuestos y anualidades, solicitar testimonios, recibir documentos y valores, desistir y percibir Se concede poder bastante para recibir notificaciones a nombre de la compañía, otorgar poderes a quienes vayan a representar a la compañía judicial y extrajudicialmente, responder en juicio a todas las reclamaciones o demandas que por motivo de lo encomendado se presentaren, dándoles asimismo facultad para sustituir el presente y revocar dichas sustituciones.

Signature/Firma: _____

Date/Fecha: July 14, 2003

City,Country/Ciudad,País: New York, USA



1937

OLARTERAISBECK

OLARTE RAISBECK & FRIERI, LTDA.
LEGAL & PROFESSIONAL SERVICES

WORLD TRADE CENTER – TORRE C
CALLE 100 NO 8A-55 PISO 10
BOGOTA, COLOMBIA
TELEPHONE +57-1 638-6200
FAX +57-1 638-6201

www.olarteraisbeck.com

Notarial Certification

On this date,
July 14, 2003
The undersigned Notary Public certifies:

1. That J. Trevor Lumb
of legal age and domiciled in New York, USA
signed the foregoing document

2 That the grantor has executed the foregoing document as Assistant Secretary of Warner-Lambert Company LLC

3. That Warner-Lambert Company LLC, having its principal place of business located in Morris Plains, New Jersey, U.S.A. is duly incorporated, is currently in existence, and that the purposes for which the Power of Attorney is granted are within the scope of its corporate purposes.

4. That the grantor has the authority to execute the Power of Attorney and that his/her representation is legal.

5. The foundation for my certifications contained in points 2, 3 and 4 was the exhibition of the following authentic document(s).

NOTARY PUBLIC (Signature):

EXECUTION
Certified Verified and Authenticated
In The Town Of Egham In Surrey
This 14th Day Of July 2003
KENNETH GREENWOOD
NOTARY PUBLIC
HORNE ENGALL AND FREEMAN

Certificación Notarial

En esta fecha,

el Notario Público suscrito certifica:

1. Que
J. Trevor Lumb
mayor de edad y domiciliado
New York
suscribió el documento que antecede.

2 Que el otorgante ha suscrito el referido documento en su carácter de
de

4. Que
con sede principal ubicada en

está legalmente constituida, que tiene existencia legal vigente y que los propósitos para los cuales se otorga el poder se encuentra dentro de los que comprenden su objeto social.

4. Que el otorgante tiene la representación para suscribir el poder, y que ésta es legítima

5. El fundamento de mis certificaciones contenidas en los puntos 2, 3 y 4 fue la exhibición de los (del) siguiente(s) documento(s) auténtico(s):

Notaría Treintaisiete del Círculo de Santafé de Bogotá, Cédula Ciudadanía Ventidós Mega cuatro cero cero. Cédula colocada con documento que acaba de ser presentado para su autenticación. Original auténtico. Santafé de Bogotá, D.C. República de Colombia
28 OCT 2003
María Eugenia Rojas de Urueta
NOTARIA TREINTAISIETE

8

APOSTILLE
(Hague Convention of 5 October 1961 / Convention de La Haye du 5 octobre 1961)

UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND

1 Country. United Kingdom of Great Britain and Northern Ireland
Pays. Royaume-Uni de Grande-Bretagne et d'Irlande du Nord

This public document / Le présent acte public

2 Has been signed by **K Greenwood**
a été signé par

3. Acting in the capacity of **Notary Public**
agissant en qualité de

4 Bears the seal/stamp of **The Said Notary Public**
est revêtu du sceau/timbre de

Certified/Attesté
5. at London/à Londres 6 the/le **17 July 2003**

7 by Her Majesty's Principal Secretary of State for Foreign and Commonwealth Affairs /
par le Secrétaire d'Etat Principal de Sa Majesté aux Affaires Etrangères et du Commonwealth.

8 Number/sous No **G210433**

9 Stamp.
timbre:

10 Signature **R. Bawden**

FOREIGN AND COMMONWEALTH OFFICE LONDON

For the Secretary of State / Pour le Secrétaire d'Etat

If this document is to be used in a country which is not party to the Hague Convention of 5 October 1961, it should be presented to the consular section of the mission representing that country

Notaria Veintisiete del Círculo de Bogotá. Como Notaria Veintisiete hago constar que esta copia coincide con documento original presentado para su autenticación. Sello de Ley. D. C. República de Colombia

29 OCT 2003

María Eugenia Rojas de Urueta
NOTARIA VEINTISIETE

APOSTILLA

(Convención de la Haya del 5 de Octubre de 1961)

1. País: Distrito de Columbia

   Estados Unidos de América

2. El presente documento público fue firmado por: Albert L. Themes

3. Que actuó en su calidad de Notario Público del Distrito de Columbia

4. Lleva el sello de Albert L. Themes Notario Público del Distrito de Columbia

   Se certificó

5. En Washington D.C.

6. El 25 de enero de 2006

7. Por parte del Secretario del Distrito de Columbia.

8. Bajo el Número 151387

9. Aparece el sello del Distrito de Columbia

10. Firmado por Patricia Elwood.

o

PC26111A
CO-1

10

CESION

Por contraprestación valiosa pagada a nosotros por **WARNER-LAMBERT COMPANY LLC.,** sociedad constituida en virtud de las leyes del **Estado de Delaware, Estados Unidos de América,** cuya dirección postal completa es **201 Tabor Road, Morris Plains, New Jersey 07950, Estados Unidos de América,** por el presente vendemos y traspasamos a la citada **WARNER-LAMBERT COMPANY LLC.,** todo nuestro derecho, titulo e interés en y sobre nuestro invento de una nueva y útil mejora en **AMINOACIDOS CON AFINIDAD POR LA PROTEINA α2δ**, en cuanto respecta a la República de Colombia, tal como se indica y describe plenamente en la especificación y por el presente autorizamos y solicitamos al Comisionado de Patentes de Colombia expedir dicha patente a nombre de la citada **WARNER-LAMBERT COMPANY LLC** de conformidad con esta cesión.

En fe de lo cual, firmamos de nuestro puño y letra,

Ann Arbor, MI, 29-julio-2004 (Fdo) Christopher James DEUR
Lugar, fecha y firma - Christopher James DEUR

Ann Arbor, MI, 29-julio-2004 (Fdo) Christine Nylund KOLZ
Lugar, fecha y firma - Christine Nylund KOLZ

Ann Arbor, MI, 29-julio-2004 (Fdo) Agustine Tobi OSUMA
Lugar, fecha y firma - Agustine Tobi OSUMA

Ann Arbor, MI, 29-julio-2004 (Fdo) Mark Stephen PLUMMER
Lugar, fecha y firma - Mark Stephen PLUMMER

Ann Arbor, MI, 29-julio-2004 (Fdo) Jacob Bradley SCHWARZ
Lugar, fecha y firma - Jacob Bradley SCHWARZ

Ann Arbor, MI, 29-julio-2004 (Fdo) Andrew John THORPE
Lugar, fecha y firma - Andrew John THORPE

Ann Arbor, MI, 30-julio-2004 (Fdo) David Juergen WUSTROW
Lugar, fecha y firma - David Juergen WUSTROW

Por el presente certifico que este es el documento original.
(Fdo) Sami Swadek 24/Ene/06
Suscrito y jurado ante mí, el 24 de enero de 2006.
(Fdo.) ALBERT L. THEMES, Notario Público de Washington Distrito Capital, cuyo cargo vence el 14 de junio de 2009, según consta en su correspondiente sello notarial.
(Sello Oficial)

31

12


Apostille

(Convention de La Haye du 5 octobre 1961)

1. *District of Columbia*
   United States of America
2. This public document has been signed by ALBERT L. THEMES
3. acting in the capacity of NOTARY PUBLIC IN AND FOR THE DISTRICT OF COLUMBIA
   ~~ALBERT L. THEMES, PUBLIC IN AND FOR THE~~
4. bears the seal/stamp of ~~DISTRICT OF COLUMBIA~~

CERTIFIED

5. at Washington, D.C.
6. the 25 day of JANUARY 2006
7. by *Secretary of the District of Columbia*
8. No. 151387
9. Seal/Stamp



10. Signature PATRICIA ELWOOD

Patricia Elwood

PC26111A

CO-1

13

ASSIGNMENT

For valuable consideration paid to me (us) by **WARNER-LAMBERT COMPANY LLC** a limited liability company organized and existing under the laws of **the State of Delaware, United States of America** whose full post office address is **201 Tabor Road, Morris Plains, New Jersey 07950, United States of America,** I (we) do hereby sell and assign to the said **WARNER-LAMBERT COMPANY LLC,** all my (our) right, title and interest in and to my (our) invention for a new and useful Improvement in **AMINO ACIDS WITH AFFINITY FOR THE α2δ-PROTEIN** so far as the Republic of Colombia is concerned, as fully set forth and described in the specification, and I (we) do hereby authorize and request the Commissioner of Patents of Colombia to issue said patent to the said **WARNER-LAMBERT COMPANY LLC** in accordance with this assignment.

In witness whereof I (we) have hereunto set my (our) hand(s) this

Ann Arbor, MI 7/29/04 _____
Place, date and signature - Christopher James DEUR

Ann Arbor, MI 7/29/04 _____
Place, date and signature - Christine Nylund KOLZ

Ann Arbor MI 7/29/04 _____
Place, date and signature - Augustine Tobi OSUMA

Ann Arbor, MI 7/29/04 _____
Place, date and signature - Mark Stephen PLUMMER

Ann Arbor MI 7-29-04 _____
Place, date and signature - Jacob Bradley SCHWARZ

Ann Arbor MI 7/29/04 _____
Place, date and signature - Andrew John THORPE

Ann Arbor MI 7/30/04 _____
Place, date and signature - David Juergen WUSTROW

I HEREBY CERTIFY THAT THIS
IS THE ORIGINAL DOCUMENT
SAMI SWANEK 1.24.06

Subscribed and sworn to before me, in my presence, this
24 day of JAN, 2006 a Notary Public
in and for the Washington D.C.

Albert L. Themes
Notary Public

My commission expires 6/14, 2009.

ALBERT L. THEMES
NOTARY PUBLIC DISTRICT OF COLUMBIA
My Commission Expires June 14, 2009

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
7 April 2005 (07.04.2005)

PCT

(10) International Publication Number
WO 2005/030700 A3

(51) International Patent Classification[7]: C07C 229/08, 229/28, 229/34, A61K 31/197, A61P 25/00

(21) International Application Number: PCT/IB2004/002985

(22) International Filing Date: 13 September 2004 (13.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/505,953 25 September 2003 (25.09.2003) US
60/507,443 30 September 2003 (30.09.2003) US

(71) Applicant (*for all designated States except US*): WARNER-LAMBERT COMPANY LLC [US/US], 201 Tabor Road, Morris Plains, NJ 07950 (US)

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): DEUR, Christopher, James [US/US], Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, MI 48105 (US). KOLZ, Christine, Nylund [US/US], Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, MI 48105 (US). OSUMA, Augustine, Tobi [US/US], Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, MI 48105 (US). PLUMMER, Mark, Stephen [US/US], Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, MI 48105 (US). SCHWARZ, Jacob, Bradley [US/US], Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, MI 48105 (US). THORPE, Andrew, John [GB/US], Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, MI 48105 (US). WUSTROW, David, Juergen [US/US], Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, MI 48105 (US)

(74) Agent: FULLER, Grover, E., Jr., Pfizer Inc., 201 Tabor Road, Morris Plains, NJ 07950 (US)

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report: 4 August 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette

(54) Title: AMINO ACIDS WITH AFFINITY FOR THE ALPHA2DELTA-PROTEIN

(57) Abstract: Certain β-amino acids that bind to the alpha-2-delta (α2δ) subunit of a calcium channel are disclosed. These compounds and their pharmaceutically acceptable salts are useful in the treatment of a variety of psychiatric, pain and other disorders.

WO 2005/030700 A3

15


AMINO ACIDS WITH AFFINITY FOR THE α2δ-PROTEIN

BACKGROUND OF THE INVENTION

This invention relates to certain β-amino acids that bind to the alpha-2-delta (α2δ) subunit of a calcium channel. These compounds and their pharmaceutically acceptable salts are useful in the treatment of a variety of psychiatric, pain, and other disorders.

SUMMARY OF THE INVENTION

This invention provides compounds of formula I,



I

and their pharmaceutically acceptable salts, wherein

R_1 is a hydrogen atom or $(C_1\text{-}C_6)$alkyl optionally substituted with from one to five fluorine atoms;

R_2 is a hydrogen atom or $(C_1\text{-}C_6)$alkyl optionally substituted with from one to five fluorine atoms; or

R_1 and R_2, together with the carbon to which they are attached, form a three- to six-membered cycloalkyl ring;

R_3 is a hydrogen atom, $(C_1\text{-}C_6)$alkyl, $(C_3\text{-}C_6)$cycloalkyl, $(C_3\text{-}C_6)$cycloalkyl-$(C_1\text{-}C_3)$alkyl, phenyl, phenyl-$(C_1\text{-}C_3)$alkyl, pyridyl, or pyridyl-$(C_1\text{-}C_3)$alkyl, wherein the alkyl and cycloalkyl moieties or substituents are optionally substituted with from one to five fluorine atoms, preferably with from zero to three fluorine atoms, and the phenyl and pyridyl substituents and the phenyl and pyridyl moieties of the phenyl-$(C_1\text{-}C_3)$alkyl and the pyridyl-$(C_1\text{-}C_3)$alkyl substituents are optionally substituted with from one to five substituents, preferably with from zero to two substituents, independently

selected from chloro, fluoro, amino, nitro, cyano, hydroxy, (C_1-C_3)alkylamino, (C_1-C_3)alkyl optionally substituted with from one to three fluorine atoms, and (C_1-C_3)alkoxy optionally substituted with from one to three fluorine atoms;

R_4 is a hydrogen atom or (C_1-C_6)alkyl optionally substituted with from one to five fluorine atoms;

R_5 is a hydrogen atom or (C_1-C_6)alkyl optionally substituted with from one to five fluorine atoms;

R_4 and R_5, together with the carbon to which they are attached, form a three- to six-membered cycloalkyl ring; and

R_6 is a hydrogen atom or (C_1-C_6)alkyl;

with the proviso that R_1, R_2, R_3, R_4, R_5, and R_6 are not simultaneously hydrogen atoms.

Specific compounds of formula I include the following compounds and their pharmaceutically acceptable salts:

3-Amino-4,5-dimethyl-hexanoic acid;
3-Amino-4,5-dimethyl-heptanoic acid;
3-Amino-4,5-dimethyl-octanoic acid;
3-Amino-4,5-dimethyl-nonanoic acid;
3-Amino-4,5-dimethyl-decanoic acid;
3-Amino-4-ethyl-5-methyl-heptanoic acid;
3-Amino-4-ethyl-5-methyl-octanoic acid;
3-Amino-4-ethyl-5-methyl-nonanoic acid;
3-Amino-4-ethyl-5,6-dimethyl-heptanoic acid;
3-Amino-4-ethyl-5,7-dimethyl-octanoic acid;
3-Amino-4-ethyl-5,8-dimethyl-nonanoic acid;
3-Amino-5-ethyl-4-methyl-octanoic acid;
3-Amino-5-ethyl-4-methyl-nonanoic acid;
3-Amino-4,5-diethyl-heptanoic acid;
3-Amino-4,5-diethyl-octanoic acid;
3-Amino-4,5-diethyl-nonanoic acid;
3-Amino-5-ethyl-4,7-dimethyl-octanoic acid;
3-Amino-5-ethyl-4,8-dimethyl-nonanoic acid;

3-Amino-4,5-diethyl-6-methyl-heptanoic acid;
3-Amino-4,5-diethyl-7-methyl-octanoic acid;
3-Amino-4,5-diethyl-8-methyl-nonanoic acid;
3-Amino-4,5,6-trimethyl-heptanoic acid;
3-Amino-4,5,7-trimethyl-octanoic acid;
3-Amino-4,5,8-trimethyl-nonanoic acid;
3-Amino-4-ethyl-5-methyl-hexanoic acid;
3-Amino-5-ethyl-4-methyl-octanoic acid;
3-Amino-5-ethyl-4-methyl-heptanoic acid;
3-Amino-4-methyl-5-propyl-octanoic acid;
3-Amino-4-methyl-6-ethyl-octanoic acid;
3-Amino-4-methyl-6-ethyl-nonanoic acid;
3-Amino-4,6-diethyl-octanoic acid;
3-Amino-4,6-diethyl-nonanoic acid;
3-Amino-6-cyclopentyl-4,5-dimethyl-hexanoic acid;
3-Amino-7-cyclopentyl-4,5-dimethyl-heptanoic acid;
3-Amino-5-ethyl-4,6-dimethyl-heptanoic acid;
3-Amino-5-ethyl-4,7-dimethyl-octanoic acid;
3-Amino-5-ethyl-4,8-dimethyl-nonanoic acid;
(3R,4R)-3-Amino-4,5-dimethyl-hexanoic acid;
(3R,4R,5R)-3-Amino-4,5-dimethyl-heptanoic acid;
(3R,4R,5R)-3-Amino-4,5-dimethyl-octanoic acid;
(3R,4R,5R)-3-Amino-4,5-dimethyl-nonanoic acid;
(3R,4R,5R)-3-Amino-4,5-dimethyl-decanoic acid;
3-Amino-5-cyclopropyl-4-ethyl-hexanoic acid;
3-Amino-6-cyclopropyl-4-ethyl-5-methyl-hexanoic acid;
3-Amino-5-cyclobutyl-4-ethyl-hexanoic acid;
3-Amino-6-cyclobutyl-4-ethyl-5-methyl-hexanoic acid;
3-Amino-5-cyclopentyl-4-methyl-hexanoic acid;
3-Amino-6-cyclopentyl-4-ethyl-5-methyl-hexanoic acid;
3-Amino-5-cyclohexyl-4-ethyl-hexanoic acid;
3-Amino-6-cyclohexyl-4-ethyl-5-methyl-hexanoic acid;

3-Amino-5-cyclopropyl-4-methyl-hexanoic acid;
3-Amino-6-cyclopropyl-4,5-dimethyl-hexanoic acid;
3-Amino-5-cyclobutyl-4-methyl-hexanoic acid;
3-Amino-6-cyclobutyl-4,5-dimethyl-hexanoic acid;
3-Amino-5-cyclopentyl-4-methyl-hexanoic acid;
3-Amino-6-cyclopentyl-4,5-dimethyl-hexanoic acid;
3-Amino-5-cyclohexyl-4-methyl-hexanoic acid;
3-Amino-6-cyclohexyl-4,5-dimethyl-hexanoic acid;
3-Amino-8-cyclohexyl-4,5-dimethyl-octanoic acid;
3-Amino-8-cyclohexyl-4,5-dimethyl-octanoic acid;
3-Amino-4,6-dimethyl-heptanoic acid;
3-Amino-4,6-dimethyl-octanoic acid;
3-Amino-4,6-dimethyl-nonanoic acid;
3-Amino-4,6-dimethyl-decanoic acid;
3-Amino-4,6,7-trimethyl-octanoic acid;
3-Amino-4,6,8-trimethyl-nonanoic acid;
3-Amino-4,6,9-trimethyl-decanoic acid;
3-Amino-6-cyclopropyl-4-methyl-heptanoic acid;
3-Amino-6-cyclobutyl-4-methyl-heptanoic acid;
3-Amino-6-cyclopentyl-4-methyl-heptanoic acid;
3-Amino-6-cyclohexyl-4-methyl-heptanoic acid;
3-Amino-7-cyclopropyl-4,6-dimethyl-heptanoic acid;
3-Amino-7-cyclobutyl-4,6-dimethyl-heptanoic acid;
3-Amino-7-cyclopentyl-4,6-dimethyl-heptanoic acid;
3-Amino-7-cyclohexyl-4,6-dimethyl-heptanoic acid;
3-Amino-8-cyclopropyl-4,6-dimethyl-octanoic acid;
3-Amino-8-cyclobutyl-4,6-dimethyl-octanoic acid;
3-Amino-8-cyclopentyl-4,6-dimethyl-octanoic acid;
3-Amino-8-cyclohexyl-4,6-dimethyl-octanoic acid;
3-Amino-6-(3-chloro-phenyl)-4-methyl-heptanoic acid;
3-Amino-6-(3,4-dichloro-phenyl)-4-methyl-heptanoic acid;
3-Amino-4-methyl-6-(3-trifluoromethyl-phenyl)-heptanoic acid;

3-Amino-4-methyl-6-(4-trifluoromethyl-phenyl)-heptanoic acid;
3-Amino-7-(3-chloro-phenyl)-4,6-dimethyl-heptanoic acid;
3-Amino-7-(3,4-dichloro-phenyl)-4,6-dimethyl-heptanoic acid;
3-Amino-4,6-dimethyl-7-(3-trifluoromethyl-phenyl)-heptanoic acid;
3-Amino-4,6-dimethyl-7-(4-trifluoromethyl-phenyl)-heptanoic acid;
3-Amino-8-(3-chloro-phenyl)-4,6-dimethyl-octanoic acid;
3-Amino-8-(3,4-dichloro-phenyl)-4,6-dimethyl-octanoic acid;
3-Amino-4,6-dimethyl-8-(3-trifluoromethyl-phenyl)-octanoic acid;
3-Amino-4,6-dimethyl-8-(4-trifluoromethyl-phenyl)-octanoic acid;
3-Amino-4-ethyl-6-methyl-octanoic acid;
3-Amino-4-ethyl-6-methyl-nonanoic acid;
3-Amino-4-ethyl-6-methyl-decanoic acid;
3-Amino-4-ethyl-6,7-dimethyl-octanoic acid;
3-Amino-4-ethyl-6,8-dimethyl-nonanoic acid;
3-Amino-4-ethyl-6,9-dimethyl-decanoic acid;
3-Amino-6-cyclopropyl-4-ethyl-heptanoic acid;
3-Amino-6-cyclobutyl-4-ethyl-heptanoic acid;
3-Amino-6-cyclopentyl-4-ethyl-heptanoic acid;
3-Amino-6-cyclohexyl-4-ethyl-heptanoic acid;
3-Amino-7-cyclopropyl-4-ethyl-6-methyl-heptanoic acid;
3-Amino-7-cyclobutyl-4-ethyl-6-methyl-heptanoic acid;
3-Amino-7-cyclopentyl-4-ethyl-6-methyl-heptanoic acid;
3-Amino-7-cyclohexyl-4-ethyl-6-methyl-heptanoic acid;
3-Amino-8-cyclopropyl-4-ethyl-6-methyl-octanoic acid;
3-Amino-8-cyclobutyl-4-ethyl-6-methyl-octanoic acid;
3-Amino-8-cyclopentyl-4-ethyl-6-methyl-octanoic acid;
3-Amino-8-cyclohexyl-4-ethyl-6-methyl-octanoic acid;
3-Amino-6-(3-chloro-phenyl)-4-ethyl-heptanoic acid;
3-Amino-6-(3,4-dichloro-phenyl)-4-ethyl-heptanoic acid;
3-Amino-4-ethyl-6-(3-trifluoromethyl-phenyl)-heptanoic acid;
3-Amino-4-ethyl-6-(4-trifluoromethyl-phenyl)-heptanoic acid;
3-Amino-7-(3-chloro-phenyl)-4-ethyl-6-methyl-heptanoic acid;

3-Amino-7-(3,4-dichloro-phenyl)-4-ethyl-6-methyl-heptanoic acid;
3-Amino-4-ethyl-6-methyl-7-(3-trifluoromethyl-phenyl)-heptanoic acid;
3-Amino-4-ethyl-6-methyl-7-(4-trifluoromethyl-phenyl)-heptanoic acid;
3-Amino-8-(3-chloro-phenyl)-4-ethyl-6-methyl-octanoic acid;
3-Amino-8-(3,4-dichloro-phenyl)-4-ethyl-6-methyl-octanoic acid;
3-Amino-4-ethyl-6-methyl-8-(3-trifluoromethyl-phenyl)-octanoic acid;
3-Amino-4-ethyl-6-methyl-8-(4-trifluoromethyl-phenyl)-octanoic acid;
3-Amino-4-methyl-heptanoic acid;
3-Amino-4,6-dimethyl-heptanoic acid;
3-Amino-4,7-dimethyl-octanoic acid;
3-Amino-4,8-dimethyl-nonanoic acid;
3-Amino-4-methyl-hexanoic acid;
3-Amino-4-methyl-heptanoic acid;
3-Amino-4-methyl-octanoic acid;
3-Amino-4-methyl-nonanoic acid;
3-Amino-5-cyclopropyl-4-methyl-pentanoic acid;
3-Amino-6-cyclopropyl-4-methyl-hexanoic acid;
3-Amino-7-cyclopropyl-4-methyl-heptanoic acid;
3-Amino-5-cyclobutyl-4-methyl-pentanoic acid;
3-Amino-6-cyclobutyl-4-methyl-hexanoic acid;
3-Amino-7-cyclobutyl-4-methyl-heptanoic acid;
3-Amino-5-cyclopentyl-4-methyl-pentanoic acid;
3-Amino-6-cyclopentyl-4-methyl-hexanoic acid;
3-Amino-7-cyclopentyl-4-methyl-heptanoic acid;
3-Amino-5-cyclohexyl-4-methyl-pentanoic acid;
3-Amino-6-cyclohexyl-4-methyl-hexanoic acid;
3-Amino-7-cyclohexyl-4-methyl-heptanoic acid;
3-Amino-5-cyclopropyl-4-ethyl-pentanoic acid;
3-Amino-6-cyclopropyl-4-ethyl-hexanoic acid;
3-Amino-7-cyclopropyl-4-ethyl-heptanoic acid;
3-Amino-5-cyclobutyl-4-ethyl-pentanoic acid;
3-Amino-6-cyclobutyl-4-ethyl-hexanoic acid;


3-Amino-7-cyclobutyl-4-ethyl-heptanoic acid;
3-Amino-5-cyclopentyl-4-ethyl-pentanoic acid;
3-Amino-6-cyclopentyl-4-ethyl-hexanoic acid;
3-Amino-7-cyclopentyl-4-ethyl-heptanoic acid;
3-Amino-5-cyclohexyl-4-ethyl-pentanoic acid;
3-Amino-6-cyclohexyl-4-ethyl-hexanoic acid;
3-Amino-7-cyclohexyl-4-ethyl-heptanoic acid;
3-Amino-4,4,5-trimethyl-heptanoic acid;
3-Amino-4,4,5-trimethyl-octanoic acid;
3-Amino-4,4,5-trimethyl-hexanoic acid;
3-Amino-4,5,5-trimethyl-heptanoic acid;
3-Amino-4,5,5-trimethyl-octanoic acid; and
3-Amino-4,5,5-trimethyl-hexanoic acid.

Other compounds of formula I include the following compounds, and their pharmaceutically acceptable salts:

3-Amino-4-methyl-5-phenyl-pentanoic acid;
3-Amino-4-methyl-6-phenyl-hexanoic acid;
3-Amino-4-methyl-7-phenyl-heptanoic acid;
3-Amino-5-(2-chloro-phenyl)-4-methyl-pentanoic acid;
3-Amino-5-(3-chloro-phenyl)-4-methyl-pentanoic acid;
3-Amino-5-(4-chloro-phenyl)-4-methyl-pentanoic acid;
3-Amino-5-(2,4-dichloro-phenyl)-4-methyl-pentanoic acid;
3-Amino-5-(3,4-dichloro-phenyl)-4-methyl-pentanoic acid;
3-Amino-4-(2-chloro-benzyl)-hexanoic acid;
3-Amino-4-(3-chloro-benzyl)-hexanoic acid;
3-Amino-4-(4-chloro-benzyl)-hexanoic acid;
3-Amino-4-(2,4-dichloro-benzyl)-hexanoic acid;
3-Amino-4-(3,4-dichloro-benzyl)-hexanoic acid;
3-Amino-6-(2-chloro-phenyl)-4-methyl-hexanoic acid;
3-Amino-6-(3-chloro-phenyl)-4-methyl-hexanoic acid;
3-Amino-6-(4-chloro-phenyl)-4-methyl-hexanoic acid;
3-Amino-6-(2,4-dichloro-phenyl)-4-methyl-hexanoic acid;

3-Amino-6-(3,4-dichloro-phenyl)-4-methyl-hexanoic acid;
3-Amino-6-(2-chloro-phenyl)-4-ethyl-hexanoic acid;
3-Amino-6-(3-chloro-phenyl)-4-ethyl-hexanoic acid;
3-Amino-6-(4-chloro-phenyl)-4-ethyl-hexanoic acid;
3-Amino-6-(2,4-dichloro-phenyl)-4-ethyl-hexanoic acid;
3-Amino-6-(3,4-dichloro-phenyl)-4-ethyl-hexanoic acid;
3-Amino-7-(2-chloro-phenyl)-4-methyl-heptanoic acid;
3-Amino-7-(3-chloro-phenyl)-4-methyl-heptanoic acid;
3-Amino-7-(4-chloro-phenyl)-4-methyl-heptanoic acid;
3-Amino-7-(2,4-dichloro-phenyl)-4-methyl-heptanoic acid;
3-Amino-7-(3,4-dichloro-phenyl)-4-methyl-heptanoic acid;
3-Amino-7-(2-chloro-phenyl)-4-ethyl-heptanoic acid;
3-Amino-7-(3-chloro-phenyl)-4-ethyl-heptanoic acid;
3-Amino-7-(4-chloro-phenyl)-4-ethyl-heptanoic acid;
3-Amino-7-(2,4-dichloro-phenyl)-4-ethyl-heptanoic acid; and
3-Amino-7-(3,4-dichloro-phenyl)-4-ethyl-heptanoic acid.

This invention also provides compounds of formula II



II

and their pharmaceutically acceptable salts, wherein R_1, R_3, and R_4 are as defined above in formula I, with the proviso that R_1 is not a hydrogen atom.


Specific compounds of formula II include the following compounds and their pharmaceutically acceptable salts:

3-Amino-4,5-dimethyl-hexanoic acid;
3-Amino-4,5-dimethyl-heptanoic acid;
3-Amino-4,5-dimethyl-octanoic acid;
3-Amino-4,5-dimethyl-nonanoic acid;
3-Amino-4-ethyl-5-methyl-heptanoic acid;

3-Amino-4-ethyl-5-methyl-octanoic acid;
3-Amino-4-ethyl-5-methyl-nonanoic acid;
3-Amino-4-ethyl-5,6-dimethyl-heptanoic acid;
3-Amino-4-ethyl-5,7-dimethyl-octanoic acid;
3-Amino-4-ethyl-5,8-dimethyl-nonanoic acid;
3-Amino-5-ethyl-4-methyl-octanoic acid;
3-Amino-5-ethyl-4-methyl-nonanoic acid;
3-Amino-4,5-diethyl-heptanoic acid;
3-Amino-4,5-diethyl-octanoic acid;
3-Amino-4,5-diethyl-nonanoic acid;
3-Amino-5-ethyl-4,7-dimethyl-octanoic acid;
3-Amino-5-ethyl-4,8-dimethyl-nonanoic acid;
3-Amino-4,5-diethyl-6-methyl-heptanoic acid;
3-Amino-4,5-diethyl-7-methyl-octanoic acid;
3-Amino-4,5-diethyl-8-methyl-nonanoic acid;
3-Amino-4,5,6-trimethyl-heptanoic acid;
3-Amino-4,5,7-trimethyl-octanoic acid;
3-Amino-4,5,8-trimethyl-nonanoic acid;
3-Amino-4-ethyl-5-methyl-hexanoic acid;
3-Amino-5-ethyl-4-methyl-octanoic acid;
3-Amino-5-ethyl-4-methyl-heptanoic acid;
3-Amino-4-methyl-5-propyl-octanoic acid;
3-Amino-6-cyclopentyl-4,5-dimethyl-hexanoic acid;
3-Amino-7-cyclopentyl-4,5-dimethyl-heptanoic acid;
3-Amino-5-ethyl-4,6-dimethyl-heptanoic acid;
3-Amino-5-ethyl-4,7-dimethyl-octanoic acid;
3-Amino-5-ethyl-4,8-dimethyl-nonanoic acid;
(3R,4R)-3-Amino-4,5-dimethyl-hexanoic acid;
(3R,4R,5R)-3-Amino-4,5-dimethyl-heptanoic acid;
(3R,4R,5R)-3-Amino-4,5-dimethyl-octanoic acid;
(3R,4R,5R)-3-Amino-4,5-dimethyl-nonanoic acid;
(3R,4R,5R)-3-Amino-4,5-decanoic acid;

3-Amino-5-cyclopropyl-4-ethyl-hexanoic acid;
3-Amino-6-cyclopropyl-4-ethyl-5-methyl-hexanoic acid;
3-Amino-5-cyclobutyl-4-ethyl-hexanoic acid;
3-Amino-6-cyclobutyl-4-ethyl-5-methyl-hexanoic acid;
3-Amino-5-cyclopentyl-4-methyl-hexanoic acid;
3-Amino-6-cyclopentyl-4-ethyl-5-methyl-hexanoic acid;
3-Amino-5-cyclohexyl-4-ethyl-hexanoic acid;
3-Amino-6-cyclohexyl-4-ethyl-5-methyl-hexanoic acid;
3-Amino-5-cyclopropyl-4-methyl-hexanoic acid;
3-Amino-6-cyclopropyl-4,5-dimethyl-hexanoic acid;
3-Amino-5-cyclobutyl-4-methyl-hexanoic acid;
3-Amino-6-cyclobutyl-4,5-dimethyl-hexanoic acid;
3-Amino-5-cyclopentyl-4-methyl-hexanoic acid;
3-Amino-6-cyclopentyl-4,5-dimethyl-hexanoic acid;
3-Amino-5-cyclohexyl-4-methyl-hexanoic acid;
3-Amino-6-cyclohexyl-4,5-dimethyl-hexanoic acid;
3-Amino-8-cyclohexyl-4,5-dimethyl-octanoic acid and
3-Amino-8-cyclohexyl-4,5-dimethyl-octanoic acid.

This invention also provides compounds of formula III



III


and their pharmaceutically acceptable salts, wherein R_1 and R_3 are as defined above in formula I, with the proviso that R_1 and R_3 are not hydrogen atoms.

Specific compounds of formula III include the following compounds and their pharmaceutically acceptable salts:

3-Amino-4,5-dimethyl-hexanoic acid;
3-Amino-4,5-dimethyl-heptanoic acid;
3-Amino-4,5-dimethyl-octanoic acid;

3-Amino-4,5-dimethyl-nonanoic acid;
3-Amino-4,5,6-trimethyl-heptanoic acid;
3-Amino-4,5,7-trimethyl-octanoic acid;
3-Amino-4,5,8-trimethyl-nonanoic acid;
3-Amino-4-methyl-5-propyl-octanoic acid;
3-Amino-6-cyclopentyl-4,5-dimethyl-hexanoic acid;
3-Amino-7-cyclopentyl-4,5-dimethyl-heptanoic acid;
3-Amino-5-ethyl-4,6-dimethyl-heptanoic acid;
3-Amino-5-ethyl-4,7-dimethyl-octanoic acid;
3-Amino-5-ethyl-4,8-dimethyl-nonanoic acid;
(3R,4R)-3-Amino-4,5-dimethyl-hexanoic acid;
(3R,4R,5R)-3-Amino-4,5-dimethyl-heptanoic acid;
(3R,4R,5R)-3-Amino-4,5-dimethyl-octanoic acid;
(3R,4R,5R)-3-Amino-4,5-dimethyl-nonanoic acid;
(3R,4R,5R)-3-Amino-4,5-dimethyl-decanoic acid;
3-Amino-5-cyclopentyl-4-methyl-hexanoic acid;
3-Amino-5-cyclopropyl-4-methyl-hexanoic acid;
3-Amino-6-cyclopropyl-4,5-dimethyl-hexanoic acid;
3-Amino-5-cyclobutyl-4-methyl-hexanoic acid;
3-Amino-6-cyclobutyl-4,5-dimethyl-hexanoic acid;
3-Amino-5-cyclopentyl-4-methyl-hexanoic acid;
3-Amino-6-cyclopentyl-4,5-dimethyl-hexanoic acid;
3-Amino-5-cyclohexyl-4-methyl-hexanoic acid;
3-Amino-6-cyclohexyl-4,5-dimethyl-hexanoic acid;
3-Amino-8-cyclohexyl-4,5-dimethyl-octanoic acid and
3-Amino-8-cyclohexyl-4,5-dimethyl-octanoic acid.

This invention also provides compounds of formula IV



IV

and their pharmaceutically acceptable salts, wherein R_3 is as defined above in formula I, with the proviso that R_3 is not a hydrogen atom.

Specific compounds of formula IV include the following compounds and their pharmaceutically acceptable salts:

(3R,4R)-3-Amino-4,5-dimethyl-hexanoic acid;


(3R,4R,5R)-3-Amino-4,5-dimethyl-heptanoic acid;

(3R,4R,5R)-3-Amino-4,5-dimethyl-octanoic acid;

(3R,4R,5R)-3-Amino-4,5-dimethyl-nonanoic acid and

(3R,4R;5R)-3-Amino-4,5-dimethyl- decanoic acid.

This invention also relates to compounds of formula V



V

and their pharmaceutically acceptable salts, wherein R_1, R_2, R_3, R_4, and R_5 are as defined above in formula I, with the proviso that R_1, R_2, R_3, R_4, and R_5 are not simultaneously hydrogen atoms.

Specific compounds of formula V include the following compounds and their pharmaceutically acceptable salts:

2-Aminomethyl-4-(2-fluoro-phenyl)-pentanoic acid;

2-Aminomethyl-4-(3-fluoro-phenyl)-pentanoic acid;

2-Aminomethyl-4-(4-fluoro-phenyl)-pentanoic acid;

2-Aminomethyl-4-(2,3-difluoro-phenyl)-pentanoic acid;

2-Aminomethyl-4-(2,4-difluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,5-difluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,6-difluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3,4-difluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3,5-difluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,4-trifluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,5-trifluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,6-trifluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,4,6-trifluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,4,5-tetrafluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,4,6-tetrafluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,5,6-tetrafluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-pentafluorophenyl-pentanoic acid;
2-Aminomethyl-4-(2-fluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3-fluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(4-fluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3-difluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,4-difluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,5-difluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,6-difluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3,4-difluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3,5-difluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,4-trifluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,5-trifluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,6-trifluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,4,6-trifluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,4,5-tetrafluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,4,6-tetrafluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,5,6-tetrafluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-pentafluorophenyl-hexanoic acid;
2-Aminomethyl-5-(2-fluoro-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3-fluoro-phenyl)-4-methyl-pentanoic acid;

2-Aminomethyl-5-(4-fluoro-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,3-difluoro-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,4-difluoro-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,5-difluoro-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,6-difluoro-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3,4-difluoro-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3,5-difluoro-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4-trifluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5-trifluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,6-trifluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,4,6-trifluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4,5-tetrafluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4,6-tetrafluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5,6-tetrafluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-pentafluorophenyl-pentanoic acid;
2-Aminomethyl-5-(2-fluoro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3-fluoro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(4-fluoro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,3-difluoro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,4-difluoro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,5-difluoro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,6-difluoro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3,4-difluoro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3,5-difluoro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4-trifluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5-trifluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,6-trifluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,4,6-trifluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4,5-tetrafluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4,6-tetrafluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5,6-tetrafluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-pentafluorophenyl-hexanoic acid;

2-Aminomethyl-6-(2-fluoro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3-fluoro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(4-fluoro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,3-difluoro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,4-difluoro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,5-difluoro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,6-difluoro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3,4-difluoro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3,5-difluoro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,4-trifluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,5-trifluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,6-trifluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,4,6-trifluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,4,5-tetrafluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,4,6-tetrafluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,5,6-tetrafluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-pentafluorophenyl-hexanoic acid;
2-Aminomethyl-5-(2-fluoro-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3-fluoro-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(4-fluoro-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,3-difluoro-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,4-difluoro-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,5-difluoro-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,6-difluoro-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3,4-difluoro-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3,5-difluoro-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4-trifluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,5-trifluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,6-trifluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,4,6-trifluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4,5-tetrafluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4,6-tetrafluoro-phenyl)-pentanoic acid;

30

2-Aminomethyl-4-ethyl-5-(2,3,5,6-tetrafluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-pentafluorophenyl-pentanoic acid;
2-Aminomethyl-6-(2-fluoro-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3-fluoro-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(4-fluoro-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,3-difluoro-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,4-difluoro-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,5-difluoro-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,6-difluoro-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3,4-difluoro-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3,5-difluoro-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,4-trifluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,5-trifluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,6-trifluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,4,6-trifluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,4,5-tetrafluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,4,6-tetrafluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,5,6-tetrafluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-pentafluorophenyl-hexanoic acid;
2-Aminomethyl-7-(2-fluoro-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3-fluoro-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(4-fluoro-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,3-difluoro-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,4-difluoro-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,5-difluoro-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,6-difluoro-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3,4-difluoro-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3,5-difluoro-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,4-trifluoro-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,5-trifluoro-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,6-trifluoro-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,4,6-trifluoro-phenyl)-heptanoic acid;

2-Aminomethyl-4-methyl-7-(2,3,4,5-tetrafluoro-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,4,6-tetrafluoro-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,5,6-tetrafluoro-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-pentafluorophenyl-heptanoic acid;
2-Aminomethyl-7-(2-fluoro-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3-fluoro-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(4-fluoro-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,3-difluoro-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,4-difluoro-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,5-difluoro-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,6-difluoro-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3,4-difluoro-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3,5-difluoro-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,4-trifluoro-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,5-trifluoro-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,6-trifluoro-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,4,6-trifluoro-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,4,5-tetrafluoro-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,4,6-tetrafluoro-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,5,6-tetrafluoro-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-pentafluorophenyl-heptanoic acid;
2-Aminomethyl-4-(2-chloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3-chloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(4-chloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3-dichloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,4-dichloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,5-dichloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,6-dichloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3,4-dichloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3,5-dichloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,4-trichloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,5-trichloro-phenyl)-pentanoic acid;

32

2-Aminomethyl-4-(2,3,6-trichloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,4,6-trichloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,4,5-tetrachloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,4,6-tetrachloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,5,6-tetrachloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-pentachlorophenyl-pentanoic acid;
2-Aminomethyl-4-(2-chloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3-chloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(4-chloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3-dichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,4-dichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,5-dichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,6-dichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3,4-dichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3,5-dichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,4-trichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,5-trichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,6-trichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,4,6-trichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,4,5-tetrachloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,4,6-tetrachloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,5,6-tetrachloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-pentachlorophenyl-hexanoic acid;
2-Aminomethyl-5-(2-chloro-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3-chloro-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(4-chloro-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,3-dichloro-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,4-dichloro-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,5-dichloro-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,6-dichloro-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3,4-dichloro-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3,5-dichloro-phenyl)-4-methyl-pentanoic acid;

33

2-Aminomethyl-4-methyl-5-(2,3,4-trichloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5-trichloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,6-trichloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,4,6-trichloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4,5-tetrachloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4,6-tetrachloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5,6-tetrachloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-pentachlorophenyl-pentanoic acid;
2-Aminomethyl-5-(2-chloro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3-chloro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(4-chloro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,3-dichloro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,4-dichloro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,5-dichloro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,6-dichloro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3,4-dichloro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3,5-dichloro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4-trichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5-trichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,6-trichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,4,6-trichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4,5-tetrachloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4,6-tetrachloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5,6-tetrachloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-pentachlorophenyl-hexanoic acid;
2-Aminomethyl-5-(2-chloro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3-chloro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(4-chloro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,3-dichloro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,4-dichloro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,5-dichloro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,6-dichloro-phenyl)-4-methyl-hexanoic acid;

2-Aminomethyl-5-(3,4-dichloro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3,5-dichloro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4-trichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5-trichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,6-trichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,4,6-trichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4,5-tetrachloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4,6-tetrachloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5,6-tetrachloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-pentachlorophenyl-hexanoic acid;
2-Aminomethyl-5-(2-chloro-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3-chloro-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(4-chloro-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,3-dichloro-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,4-dichloro-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,5-dichloro-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,6-dichloro-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3,4-dichloro-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3,5-dichloro-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4-trichloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,5-trichloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,6-trichloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,4,6-trichloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4,5-tetrachloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4,6-tetrachloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,5,6-tetrachloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-pentachlorophenyl-pentanoic acid;
2-Aminomethyl-6-(2-chloro-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3-chloro-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(4-chloro-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,3-dichloro-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,4-dichloro-phenyl)-4-ethyl-hexanoic acid;

2-Aminomethyl-6-(2,5-dichloro-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,6-dichloro-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3,4-dichloro-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3,5-dichloro-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,4-trichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,5-trichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,6-trichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,4,6-trichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,4,5-tetrachloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,4,6-tetrachloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,5,6-tetrachloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-pentachlorophenyl-hexanoic acid;
2-Aminomethyl-7-(2-chloro-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3-chloro-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(4-chloro-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,3-dichloro-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,4-dichloro-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,5-dichloro-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,6-dichloro-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3,4-dichloro-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3,5-dichloro-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,4-trichloro-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,5-trichloro-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,6-trichloro-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,4,6-trichloro-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,4,5-tetrachloro-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,4,6-tetrachloro-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,5,6-tetrachloro-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-pentachlorophenyl-heptanoic acid;
2-Aminomethyl-7-(2-chloro-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3-chloro-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(4-chloro-phenyl)-4-ethyl-heptanoic acid;

2-Aminomethyl-7-(2,3-dichloro-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,4-dichloro-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,5-dichloro-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,6-dichloro-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3,4-dichloro-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3,5-dichloro-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,4-trichloro-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,5-trichloro-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,6-trichloro-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,4,6-trichloro-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,4,5-tetrachloro-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,4,6-tetrachloro-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,5,6-tetrachloro-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-pentachlorophenyl-heptanoic acid;
2-Aminomethyl-4-(2-methoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3-methoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(4-methoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3-dimethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,4-dimethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,5-dimethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,6-dimethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3,4-dimethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3,5-dimethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,4-trimethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,5-trimethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,6-trimethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,4,6-trimethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2-methoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3-methoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(4-methoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3-dimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,4-dimethoxy-phenyl)-hexanoic acid;

2-Aminomethyl-4-(2,5-dimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,6-dimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3,4-dimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3,5-dimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,4-trimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,5-trimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,6-trimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,4,6-trimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-5-(2-methoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3-methoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(4-methoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,3-dimethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,4-dimethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,5-dimethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,6-dimethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3,4-dimethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3,5-dimethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4-trimethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5-trimethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,6-trimethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,4,6-trimethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-5-(2-methoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3-methoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(4-methoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,3-dimethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,4-dimethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,5-dimethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,6-dimethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3,4-dimethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3,5-dimethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4-trimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5-trimethoxy-phenyl)-hexanoic acid;

2-Aminomethyl-4-methyl-5-(2,3,6-trimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,4,6-trimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-6-(2-methoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3-methoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(4-methoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,3-dimethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,4-dimethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,5-dimethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,6-dimethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3,4-dimethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3,5-dimethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,4-trimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,5-trimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,6-trimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,4,6-trimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-5-(2-methoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3-methoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(4-methoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,3-dimethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,4-dimethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,5-dimethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,6-dimethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3,4-dimethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3,5-dimethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4-trimethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,5-trimethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,6-trimethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,4,6-trimethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4,5-tetramethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4,6-tetramethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,5,6-tetramethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-pentamethoxyphenyl-pentanoic acid;

39

2-Aminomethyl-6-(2-methoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3-methoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(4-methoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,3-dimethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,4-dimethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,5-dimethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,6-dimethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3,4-dimethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3,5-dimethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,4-trimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,5-trimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,6-trimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,4,6-trimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-7-(2-methoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3-methoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(4-methoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,3-dimethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,4-dimethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,5-dimethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,6-dimethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3,4-dimethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3,5-dimethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,4-trimethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,5-trimethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,6-trimethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,4,6-trimethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-7-(2-methoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3-methoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(4-methoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,3-dimethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,4-dimethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,5-dimethoxy-phenyl)-4-ethyl-heptanoic acid;

2-Aminomethyl-7-(2,6-dimethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3,4-dimethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3,5-dimethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,4-trimethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,5-trimethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,6-trimethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,4,6-trimethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-(2-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(4-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3-di-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,4-di-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,5-di-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,6-di-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3,4-di-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3,5-di-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,4-tri-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,5-tri-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,6-tri-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,4,6-tri-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(4-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3-di-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,4-di-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,5-di-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,6-di-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3,4-di-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3,5-di-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,4-tri-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,5-tri-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,6-tri-trifluoromethyl-phenyl)-hexanoic acid;

2-Aminomethyl-4-(2,4,6-tri-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-5-(2-trifluoromethyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3-trifluoromethyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(4-trifluoromethyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,3-di-trifluoromethyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,4-di-trifluoromethyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,5-di-trifluoromethyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,6-di-trifluoromethyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3,4-di-trifluoromethyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3,5-di-trifluoromethyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4-tri-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5-tri-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,6-tri-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,4,6-tri-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-5-(2-trifluoromethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3-trifluoromethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(4-trifluoromethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,3-di-trifluoromethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,4-di-trifluoromethyl-phenyl)-4-methyl-hexanoic acid;

2-Aminomethyl-5-(2,5-di-trifluoromethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,6-di-trifluoromethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3,4-di-trifluoromethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3,5-di-trifluoromethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4-tri-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5-tri-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,6-tri-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,4,6-tri-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-6-(2-trifluoromethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3-trifluoromethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(4-trifluoromethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,3-di-trifluoromethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,4-di-trifluoromethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,5-di-trifluoromethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,6-di-trifluoromethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3,4-di-trifluoromethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3,5-di-trifluoromethyl-phenyl)-4-methyl-hexanoic acid;

2-Aminomethyl-4-methyl-6-(2,3,4-tri-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,5-tri-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,6-tri-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,4,6-tri-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-5-(2-trifluoromethyl-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3-trifluoromethyl-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(4-trifluoromethyl-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,3-di-trifluoromethyl-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,4-di-trifluoromethyl-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,5-di-trifluoromethyl-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,6-di-trifluoromethyl-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3,4-di-trifluoromethyl-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3,5-di-trifluoromethyl-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4-tri-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,5-tri-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,6-tri-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,4,6-tri-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4,5-tetra-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4,6-tetra-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,5,6-tetra-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-penta-trifluoromethylphenyl-pentanoic acid;

2-Aminomethyl-6-(2-trifluoromethyl-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3-trifluoromethyl-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(4-trifluoromethyl-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,3-di-trifluoromethyl-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,4-di-trifluoromethyl-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,5-di-trifluoromethyl-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,6-di-trifluoromethyl-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3,4-di-trifluoromethyl-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3,5-di-trifluoromethyl-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,4-tri-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,5-tri-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,6-tri-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,4,6-tri-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-7-(2-trifluoromethyl-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3-trifluoromethyl-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(4-trifluoromethyl-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,3-di-trifluoromethyl-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,4-di-trifluoromethyl-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,5-di-trifluoromethyl-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,6-di-trifluoromethyl-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3,4-di-trifluoromethyl-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3,5-di-trifluoromethyl-phenyl)-4-methyl-heptanoic acid;

2-Aminomethyl-4-methyl-7-(2,3,4-tri-trifluoromethyl-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,5-tri-trifluoromethyl-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,6-tri-trifluoromethyl-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,4,6-tri-trifluoromethyl-phenyl)-heptanoic acid;
2-Aminomethyl-7-(2-trifluoromethyl-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3-trifluoromethyl-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(4-trifluoromethyl-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,3-di-trifluoromethyl-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,4-di-trifluoromethyl-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,5-di-trifluoromethyl-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,6-di-trifluoromethyl-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3,4-di-trifluoromethyl-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3,5-di-trifluoromethyl-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,4-tri-trifluoromethyl-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,5-tri-trifluoromethyl-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,6-tri-trifluoromethyl-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,4,6-tri-trifluoromethyl-phenyl)-heptanoic acid;
2-Aminomethyl-4-(2-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(4-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3-di-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,4-di-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,5-di-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,6-di-trifluoromethoxy-phenyl)-pentanoic acid;

2-Aminomethyl-4-(3,4-di-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3,5-di-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,4-tri-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,5-tri-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,6-tri-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,4,6-tri-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(4-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3-di-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,4-di-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,5-di-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,6-di-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3,4-di-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3,5-di-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,4-tri-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,5-tri-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,6-tri-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,4,6-tri-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-5-(2-trifluoromethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3-trifluoromethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(4-trifluoromethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,3-di-trifluoromethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,4-di-trifluoromethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,5-di-trifluoromethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,6-di-trifluoromethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3,4-di-trifluoromethoxy-phenyl)-4-methyl-pentanoic acid;

2-Aminomethyl-5-(3,5-di-trifluoromethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4-tri-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5-tri-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,6-tri-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,4,6-tri-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-5-(2-trifluoromethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3-trifluoromethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(4-trifluoromethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,3-di-trifluoromethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,4-di-trifluoromethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,5-di-trifluoromethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,6-di-trifluoromethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3,4-di-trifluoromethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3,5-di-trifluoromethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4-tri-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,5-tri-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,6-tri-trifluoromethoxy-phenyl)-pentanoic acid;

2-Aminomethyl-4-ethyl-5-(2,4,6-tri-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4,5-tetra-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4,6-tetra-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,5,6-tetra-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-penta-trifluoromethoxyphenyl-pentanoic acid;
2-Aminomethyl-5-(2-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(4-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,3-di-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,4-di-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,5-di-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,6-di-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3,4-di-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3,5-di-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4-tri-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5-tri-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,6-tri-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,4,6-tri-trifluoromethoxy-phenyl)-hexanoic acid;

2-Aminomethyl-6-(2-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(4-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,3-di-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,4-di-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,5-di-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,6-di-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3,4-di-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3,5-di-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,4-tri-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,5-tri-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,6-tri-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,4,6-tri-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-6-(2-trifluoromethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3-trifluoromethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(4-trifluoromethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,3-di-trifluoromethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,4-di-trifluoromethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,5-di-trifluoromethoxy-phenyl)-4-ethyl-hexanoic acid;

SD

2-Aminomethyl-6-(2,6-di-trifluoromethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3,4-di-trifluoromethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3,5-di-trifluoromethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,4-tri-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,5-tri-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,6-tri-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,4,6-tri-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-7-(2-trifluoromethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3-trifluoromethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(4-trifluoromethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,3-di-trifluoromethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,4-di-trifluoromethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,5-di-trifluoromethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,6-di-trifluoromethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3,4-di-trifluoromethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3,5-di-trifluoromethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,4-tri-trifluoromethoxy-phenyl)-heptanoic acid;

51

2-Aminomethyl-4-methyl-7-(2,3,5-tri-trifluoromethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,6-tri-trifluoromethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,4,6-tri-trifluoromethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-7-(2-trifluoromethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3-trifluoromethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(4-trifluoromethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,3-di-trifluoromethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,4-di-trifluoromethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,5-di-trifluoromethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,6-di-trifluoromethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3,4-di-trifluoromethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3,5-di-trifluoromethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,4-tri-trifluoromethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,5-tri-trifluoromethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,6-tri-trifluoromethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,4,6-tri-trifluoromethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-(2-ethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3-ethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(4-ethoxy-phenyl)-pentanoic acid;

2-Aminomethyl-4-(2,3-diethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,4-diethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,5-diethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,6-diethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3,4-diethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3,5-diethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,4-triethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,5-triethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,6-triethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,4,6-triethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2-ethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3-ethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(4-ethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3-diethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,4-diethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,5-diethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,6-diethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3,4-diethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3,5-diethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,4-triethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,5-triethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,6-triethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,4,6-triethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-5-(2-ethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3-ethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(4-ethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,3-diethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,4-diethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,5-diethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,6-diethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3,4-diethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3,5-diethoxy-phenyl)-4-methyl-pentanoic acid;

2-Aminomethyl-4-methyl-5-(2,3,4-triethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5-triethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,6-triethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,4,6-triethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-5-(2-ethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3-ethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(4-ethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,3-diethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,4-diethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,5-diethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,6-diethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3,4-diethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3,5-diethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4-triethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,5-triethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,6-triethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,4,6-triethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4,5-tetraethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4,6-tetraethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,5,6-tetraethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-pentaethoxyphenyl-pentanoic acid;
2-Aminomethyl-5-(2-ethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3-ethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(4-ethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,3-diethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,4-diethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,5-diethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,6-diethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3,4-diethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3,5-diethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4-triethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5-triethoxy-phenyl)-hexanoic acid;

2-Aminomethyl-4-methyl-5-(2,3,6-triethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,4,6-triethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-6-(2-ethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3-ethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(4-ethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,3-diethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,4-diethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,5-diethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,6-diethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3,4-diethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3,5-diethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,4-triethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,5-triethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,6-triethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,4,6-triethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-6-(2-ethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3-ethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(4-ethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,3-diethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,4-diethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,5-diethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,6-diethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3,4-diethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3,5-diethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,4-triethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,5-triethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,6-triethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,4,6-triethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-7-(2-ethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3-ethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(4-ethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,3-diethoxy-phenyl)-4-methyl-heptanoic acid;

55

2-Aminomethyl-7-(2,4-diethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,5-diethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,6-diethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3,4-diethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3,5-diethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,4-triethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,5-triethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,6-triethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,4,6-triethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-7-(2-ethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3-ethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(4-ethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,3-diethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,4-diethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,5-diethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,6-diethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3,4-diethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3,5-diethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,4-triethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,5-triethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,6-triethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,4,6-triethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-(2-methyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3-methyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(4-methyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3-dimethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,4-dimethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,5-dimethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,6-dimethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3,4-dimethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3,5-dimethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,4-trimethyl-phenyl)-pentanoic acid;

56

2-Aminomethyl-4-(2,3,5-trimethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,6-trimethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,4,6-trimethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2-methyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3-methyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(4-methyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3-dimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,4-dimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,5-dimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,6-dimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3,4-dimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3,5-dimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,4-trimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,5-trimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,6-trimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,4,6-trimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-5-(2-methyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3-methyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(4-methyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,3-dimethyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,4-dimethyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,5-dimethyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,6-dimethyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3,4-dimethyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3,5-dimethyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4-trimethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5-trimethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,6-trimethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,4,6-trimethyl-phenyl)-pentanoic acid;
2-Aminomethyl-5-(2-methyl-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3-methyl-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(4-methyl-phenyl)-4-ethyl-pentanoic acid;

97.

2-Aminomethyl-5-(2,3-dimethyl-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,4-dimethyl-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,5-dimethyl-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,6-dimethyl-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3,4-dimethyl-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3,5-dimethyl-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4-trimethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,5-trimethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,6-trimethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,4,6-trimethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4,5-tetramethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4,6-tetramethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,5,6-tetramethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-pentamethylphenyl-pentanoic acid;
2-Aminomethyl-5-(2-methyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3-methyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(4-methyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,3-dimethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,4-dimethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,5-dimethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,6-dimethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3,4-dimethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3,5-dimethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4-trimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5-trimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,6-trimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,4,6-trimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-6-(2-methyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3-methyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(4-methyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,3-dimethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,4-dimethyl-phenyl)-4-methyl-hexanoic acid;

2-Aminomethyl-6-(2,5-dimethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,6-dimethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3,4-dimethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3,5-dimethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,4-trimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,5-trimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,6-trimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,4,6-trimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-6-(2-methyl-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3-methyl-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(4-methyl-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,3-dimethyl-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,4-dimethyl-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,5-dimethyl-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,6-dimethyl-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3,4-dimethyl-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3,5-dimethyl-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,4-trimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,5-trimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,6-trimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,4,6-trimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-7-(2-methyl-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3-methyl-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(4-methyl-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,3-dimethyl-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,4-dimethyl-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,5-dimethyl-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,6-dimethyl-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3,4-dimethyl-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3,5-dimethyl-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,4-trimethyl-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,5-trimethyl-phenyl)-heptanoic acid;

2-Aminomethyl-4-methyl-7-(2,3,6-trimethyl-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,4,6-trimethyl-phenyl)-heptanoic acid;
2-Aminomethyl-7-(2-methyl-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3-methyl-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(4-methyl-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,3-dimethyl-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,4-dimethyl-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,5-dimethyl-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,6-dimethyl-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3,4-dimethyl-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3,5-dimethyl-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,4-trimethyl-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,5-trimethyl-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,6-trimethyl-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,4,6-trimethyl-phenyl)-heptanoic acid;
2-Aminomethyl-4-(2-hydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3-hydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(4-hydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3-dihydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,4-dihydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,5-dihydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,6-dihydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3,4-dihydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3,5-dihydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,4-trihydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,5-trihydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,6-trihydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,4,6-trihydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2-hydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3-hydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(4-hydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3-dihydroxy-phenyl)-hexanoic acid;

60

2-Aminomethyl-4-(2,4-dihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,5-dihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,6-dihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3,4-dihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3,5-dihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,4-trihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,5-trihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,6-trihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,4,6-trihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-5-(2-hydroxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3-hydroxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(4-hydroxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,3-dihydroxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,4-dihydroxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,5-dihydroxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,6-dihydroxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3,4-dihydroxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3,5-dihydroxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4-trihydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5-trihydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,6-trihydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,4,6-trihydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-5-(2-hydroxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3-hydroxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(4-hydroxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,3-dihydroxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,4-dihydroxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,5-dihydroxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,6-dihydroxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3,4-dihydroxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3,5-dihydroxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4-trihydroxy-phenyl)-hexanoic acid;

2-Aminomethyl-4-methyl-5-(2,3,5-trihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,6-trihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,4,6-trihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-6-(2-hydroxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3-hydroxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(4-hydroxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,3-dihydroxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,4-dihydroxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,5-dihydroxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,6-dihydroxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3,4-dihydroxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3,5-dihydroxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,4-trihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,5-trihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,6-trihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,4,6-trihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-5-(2-hydroxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3-hydroxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(4-hydroxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,3-dihydroxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,4-dihydroxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,5-dihydroxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,6-dihydroxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3,4-dihydroxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3,5-dihydroxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4-trihydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,5-trihydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,6-trihydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,4,6-trihydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4,5-tetrahydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4,6-tetrahydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,5,6-tetrahydroxy-phenyl)-pentanoic acid;

62

2-Aminomethyl-4-ethyl-5-pentahydroxyphenyl-pentanoic acid;
2-Aminomethyl-6-(2-hydroxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3-hydroxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(4-hydroxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,3-dihydroxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,4-dihydroxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,5-dihydroxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,6-dihydroxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3,4-dihydroxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3,5-dihydroxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,4-trihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,5-trihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,6-trihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,4,6-trihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-7-(2-hydroxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3-hydroxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(4-hydroxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,3-dihydroxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,4-dihydroxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,5-dihydroxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,6-dihydroxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3,4-dihydroxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3,5-dihydroxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,4-trihydroxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,5-trihydroxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,6-trihydroxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,4,6-trihydroxy-phenyl)-heptanoic acid;
2-Aminomethyl-7-(2-hydroxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3-hydroxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(4-hydroxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,3-dihydroxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,4-dihydroxy-phenyl)-4-ethyl-heptanoic acid;

63

2-Aminomethyl-7-(2,5-dihydroxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,6-dihydroxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3,4-dihydroxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3,5-dihydroxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,4-trihydroxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,5-trihydroxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,6-trihydroxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,4,6-trihydroxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,4,5-tetrahydroxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,4,6-tetrahydroxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,5,6-tetrahydroxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-pentahydroxyphenyl-heptanoic acid;
(2R,4R)-2-Aminomethyl-4-(2,4-difluoro-benzyl)-hexanoic acid;
(2S,4R)-2-Aminomethyl-4-(2,4-difluoro-benzyl)-hexanoic acid;
(2R,4S)-2-Aminomethyl-7-(2,4-difluoro-phenyl)-4-ethyl-heptanoic acid;
(2S,4S)-2-Aminomethyl-7-(2,4-difluoro-phenyl)-4-ethyl-heptanoic acid;
(2R,4S)-2-Aminomethyl-4-(2,4-difluoro-benzyl)-hexanoic acid;
(2S,4S)-2-Aminomethyl-4-(2,4-difluoro-benzyl)-hexanoic acid;
(2S,4S)-2-Aminomethyl-4-(3,5-difluoro-benzyl)-hexanoic acid;
(2S,4S)-2-Aminomethyl-4-(2-fluoro-benzyl)-hexanoic acid;
(2S,4S)-2-Aminomethyl-5-(2,4-difluoro-phenyl)-4-methyl-pentanoic acid;
(2S)-2-Aminomethyl-5-(2,4-difluoro-phenyl)-pentanoic acid;
(2S,4S)-2-Aminomethyl-4-(2,6-difluoro-benzyl)-hexanoic acid;
(2S,4S)-2-Aminomethyl-4-(4-fluoro-benzyl)-hexanoic acid;
(2S,4S)-2-Aminomethyl-4-(2,5-difluoro-benzyl)-hexanoic acid;
(2S,4S)-2-Aminomethyl-4-(3-fluoro-benzyl)-hexanoic acid;
(2S,4S)-2-Aminomethyl-4-pentafluorophenylmethyl-hexanoic acid;
(2S,4R)-2-Aminomethyl-7-(2,4-difluoro-phenyl)-4-ethyl-heptanoic acid;
(2S,4S)-2-Aminomethyl-4-(4-trifluoromethyl-benzyl)-hexanoic acid;
2-Aminomethyl-4-(4-methoxy-2-methyl-benzyl)-hexanoic acid;

2-Aminomethyl-5-(4-methoxy-2-methyl-phenyl)-4-methyl-pentanoic acid;

2-Aminomethyl-4-(4-methoxy-3-methyl-benzyl)-hexanoic acid; and

2-Aminomethyl-5-(4-methoxy-3-methyl-phenyl)-4-methyl-pentanoic acid.

Other compounds of formula V include the following compounds, and their pharmaceutically acceptable salts:

2-Aminomethyl-4-ethyl-5-methyl-hexanoic acid;

2-Aminomethyl-4-ethyl-3-methyl-hexanoic acid;

2-Aminomethyl-3,4-dimethyl-hexanoic acid;

2-Aminomethyl-3-ethyl-4-methyl-hexanoic acid;

2-Aminomethyl-4-ethyl-3-methyl-heptanoic acid;

2-Aminomethyl-3,4-dimethyl-octanoic acid;

2-Aminomethyl-3-methyl-pentanoic acid;

2-Aminomethyl-3-methyl-hexanoic acid;

2-Aminomethyl-3-methyl-heptanoic acid;

2-Aminomethyl-3,4-dimethyl-pentanoic acid;

2-Aminomethyl-3,5-dimethyl-hexanoic acid;

2-Aminomethyl-3,6-dimethyl-heptanoic acid;

2-Aminomethyl-3,5,5-trimethyl-hexanoic acid;

2-Aminomethyl-3-cyclopropyl-butyric acid;

2-Aminomethyl-3-cyclopentyl-butyric acid;

2-Aminomethyl-3-cyclohexyl-butyric acid;

2-Aminomethyl-4-cyclohexyl-3-methyl-butyric acid;

2-Aminomethyl-5-cyclohexyl-3-methyl-pentanoic acid;

2-Aminomethyl-3-methyl-4-(4-methyl-cyclohexyl)-butyric acid;

2-Aminomethyl-3-ethyl-pentanoic acid;

2-Aminomethyl-3-ethyl-hexanoic acid;

2-Aminomethyl-3-ethyl-heptanoic acid;

2-Aminomethyl-3-ethyl-4-methyl-pentanoic acid;


2-Aminomethyl-3-cyclohexylmethyl-pentanoic acid;

2-Aminomethyl-5-(4-methoxy-cyclohexyl)-3-methyl-pentanoic acid;

65

2-Aminomethyl-5-(4-methoxy-phenyl)-3-methyl-pentanoic acid;
2-Aminomethyl-4-(2-methoxy-phenyl)-3-methyl-butyric acid;
2-Aminomethyl-4-(4-methoxy-phenyl)-3-methyl-butyric acid;
2-Aminomethyl-3-phenyl-butyric acid;
2-Aminomethyl-3-methyl-4-phenyl-butyric acid;
2-Aminomethyl-3-methyl-5-phenyl-pentanoic acid;
2-Aminomethyl-3-methyl-4-(3-trifluoromethyl-phenyl)-butyric acid;
2-Aminomethyl-3-(4-ethyl-phenyl)-butyric acid;
2-Aminomethyl-3-(2,5-dimethyl-phenyl)-butyric acid;
2-Aminomethyl-3-methyl-4-p-tolyl-butyric acid;
2-Aminomethyl-3-m-tolyl-butyric acid;
2-Aminomethyl-3-benzyl-pentanoic acid; and
2-Aminomethyl-4-(4-fluoro-phenyl)-3-methyl-butyric acid.

This invention also provides compounds of formula VI



VI

and their pharmaceutically acceptable salts, wherein R_3, R_4, and R_5 are as defined above in formula I, with the proviso that R_3, R_4, and R_5 are not simultaneously hydrogen atoms.

Specific compounds of formula VI include the following compounds and their pharmaceutically acceptable salts:

2-Aminomethyl-5-cyclopropyl-hexanoic acid;
2-Aminomethyl-5-cyclobutyl-hexanoic acid;
2-Aminomethyl-5-cyclopentyl-hexanoic acid;
2-Aminomethyl-5-cyclohexyl-hexanoic acid;
2-Aminomethyl-5-phenyl-hexanoic acid;
2-Aminomethyl-5-(3-chloro-phenyl)-hexanoic acid;
2-Aminomethyl-5-(3-trifluoromethyl-phenyl)-hexanoic acid;

66

2-Aminomethyl-5-(4-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-5-cyclopropyl-heptanoic acid;
2-Aminomethyl-5-cyclobutyl-heptanoic acid;
2-Aminomethyl-5-cyclopentyl-heptanoic acid;
2-Aminomethyl-5-cyclohexyl-heptanoic acid;
2-Aminomethyl-5-phenyl-heptanoic acid;
2-Aminomethyl-5-(3-chloro-phenyl)-heptanoic acid;
2-Aminomethyl-5-(3-trifluoromethyl-phenyl)-heptanoic acid;
2-Aminomethyl-5-(4-trifluoromethyl-phenyl)-heptanoic acid;
2-Aminomethyl-5-methyl-6-phenyl-hexanoic acid;
2-Aminomethyl-6-(3-chloro-phenyl)-5-methyl-hexanoic acid;
2-Aminomethyl-5-methyl-6-(3-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-5-methyl-6-(4-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-5-cyclopropylmethyl-heptanoic acid;
2-Aminomethyl-5-cyclobutylmethyl-heptanoic acid;
2-Aminomethyl-5-cyclopentylmethyl-heptanoic acid;
2-Aminomethyl-5-cyclohexylmethyl-heptanoic acid;
2-Aminomethyl-5-benzyl-heptanoic acid;
2-Aminomethyl-5-(3-chloro-benzyl)-heptanoic acid;
2-Aminomethyl-5-(3-trifluoromethyl-benzyl)-heptanoic acid;
2-Aminomethyl-5-(4-trifluoromethyl-benzyl)-heptanoic acid;
2-Aminomethyl-5-methyl-7-phenyl-heptanoic acid;
2-Aminomethyl-7-(3-chloro-phenyl)-5-methyl-heptanoic acid;
2-Aminomethyl-5-methyl-7-(3-trifluoromethyl-phenyl)-heptanoic acid;
2-Aminomethyl-5-methyl-7-(4-trifluoromethyl-phenyl)-heptanoic acid;
2-Aminomethyl-7-cyclopropyl-5-ethyl-heptanoic acid;
2-Aminomethyl-7-cyclobutyl-5-ethyl-heptanoic acid;
2-Aminomethyl-7-cyclopentyl-5-ethyl-heptanoic acid;
2-Aminomethyl-7-cyclohexyl-5-ethyl-heptanoic acid;
2-Aminomethyl-5-ethyl-7-phenyl-heptanoic acid;
2-Aminomethyl-7-(3-chloro-phenyl)-5-ethyl-heptanoic acid;
2-Aminomethyl-5-ethyl-7-(3-trifluoromethyl-phenyl)-heptanoic acid;

67

2-Aminomethyl-5-ethyl-7-(4-trifluoromethyl-phenyl)-heptanoic acid;

2-Aminomethyl-5,5-dimethyl-heptanoic acid;

2-Aminomethyl-5,5-dimethyl-octanoic acid; and

2-Aminomethyl-5,5-dimethyl-nonanoic acid.

This invention also provides pharmaceutical compositions comprising a therapeutically effective amount of a compound of formula I, II, III, IV, V or VI, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

This invention also provides a method of treating a disorder or condition in a mammal, including a human, the disorder or condition selected from epilepsy, faintness attacks, fibromyalgia, hypokinesia, cranial disorders, hot flashes, essential tremor, chemical dependencies and addictions, (*e.g.*, dependencies on or addictions to alcohol, amphetamines (or amphetamine-like substances), caffeine, cannabis, cocaine, heroin, hallucinogens, tobacco, inhalants and aerosol propellants, nicotine, opioids, phenylglycidine derivatives, sedatives, hypnotics, benzodiazepines and other anxiolytics), and withdrawal symptoms associated with such dependencies or addictions, addictive behaviors such as gambling; migraine, spasticity including muscle spasticity and hypotonia with paralysis, arthritis, irritable bowel syndrome (IBS), chronic pain, acute pain, neuropathic pain, post herpetic neuralgia, lower back pain, surgical pain, vascular headache, chronic headache, sinus headache, inflammatory disorders (e.g., rheumatoid arthritis, osteoarthritis, disease modification of osteoarthritis disease, psoriasis), diuresis, premenstrual syndrome, premenstrual dysphoric disorder, tinnitus, and gastric damage. The method comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound of formula I, II, III, IV, V or VI, or a pharmaceutically acceptable salt thereof.

The present invention also provides a method of treating neurodegenerative disorders termed acute brain injury. These include but are not limited to stroke, head trauma, and asphyxia. Stroke refers to a cerebral vascular disease and may also be referred to as a cerebral vascular incident (CVA) and includes acute thromboembolic stroke. Stroke includes both focal

and global ischemia. Also, included are transient cerebral ischemic attacks and other cerebral vascular problems accompanied by cerebral ischemia, such as those that occur in patients undergoing carotid endarterectomy or other cerebrovascular or vascular surgical procedures, or diagnostic vascular procedures including cerebral angiography and the like.

Compounds of formula I, II, III, IV, V or VI, are also useful in the treatment of head trauma, spinal cord trauma, or injury from general anoxia, hypoxia, hypoglycemia, hypotension as well as similar injuries seen during procedures from embole, hyperfusion, and hypoxia. They are also useful in preventing neuronal damage that occurs during cardiac bypass surgery, in incidents of intracranial hemorrhage, in perinatal asphyxia, in cardiac arrest, and status epilepticus.

This invention also provides a method of treating a disorder or condition in a mammal, including a human, the disorder or condition selected from the group consisting of delirium, dementia, and amnestic and other cognitive or neurodegenerative disorders, such as Parkinson's disease (PD), Huntington's disease (HD), Alzheimer's disease, senile dementia, dementia of the Alzheimer's type, memory disorder, vascular dementia, and other dementias, for example, due to HIV disease, head trauma, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, or due to multiple aetiologies; movement disorders such as akinesias, dyskinesias, including familial paroxysmal dyskinesias, spasticities, Tourette's syndrome, Scott syndrome, PALSYS and akinetic-rigid syndrome; extra-pyramidal movement disorders such as medication-induced movement disorders, for example, neuroleptic-induced Parkinsonism, neuroleptic malignant syndrome, neuroleptic-induced acute dystonia, neuroleptic-induced acute akathisia, neuroleptic-induced tardive dyskinesia and medication-induced postural tremour; Down's syndrome; demyelinating diseases such as multiple sclerosis (MS) and amylolateral sclerosis (ALS), peripheral neuropathy, for example diabetic and chemotherapy-induced-neuropathy, and postherpetic neuralgia, trigeminal neuralgia, segmental or intercostal neuralgia and other neuralgias; and cerebral vascular disorders due to acute

or chronic cerebrovascular damage such as cerebral infarction, subarachnoid haemorrhage or cerebral oedema. The method comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound of formula I, II, III, IV, V or VI, or a pharmaceutically acceptable salt thereof.

This invention also provides for improving cognition in mammals, including humans, having AD, PD, and fibromyalgia by enhancing the amount and the quality of sleep. The method comprises administering to a mammal in need of improved cognition a therapeutically effective amount of a compound of formula I, II, III, IV, V or VI, or a pharmaceutically acceptable salt thereof.

This invention also provides a method of treating pain in a mammal, including a human, the method comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of formula I, II, III, IV, V or VI, or a pharmaceutically acceptable salt thereof. Pain refers to acute as well as chronic pain. Acute pain is usually short-lived and is associated with hyperactivity of the sympathetic nervous system. Examples are postoperative pain and allodynia. Chronic pain is usually defined as pain persisting from three to six months and includes somatogenic pain and psychogenic pain. Other pain is nociceptive.

Examples of the types of pain that can be treated with the compounds of formula I, II, III, IV, V or VI, and their pharmaceutically acceptable salts, include pain resulting from soft tissue and peripheral damage, such as acute trauma, pain associated with osteoarthritis and rheumatoid arthritis, musculo-skeletal pain, such as pain experienced after trauma; spinal pain, dental pain, myofascial pain syndromes, episiotomy pain, and pain resulting from burns; deep and visceral pain, such as heart pain, muscle pain, eye pain, orofacial pain, for example, odontalgia, abdominal pain, gynaecological pain, for example, dysmenorrhoea, labour pain and pain associated with endometriosis; pain associated with nerve and root damage, such as pain associated with peripheral nerve disorders, for example, nerve entrapment and brachial plexus avulsions, amputation, peripheral neuropathies, tic

douloureux, atypical facial pain, nerve root damage, trigeminal neuralgia, neuropathic lower back pain, HIV related neuropathic pain, cancer related neuropathic pain, diabetic neuropathic pain, and arachnoiditis; neuropathic and non-neuropathic pain associated with carcinoma, often referred to as cancer pain; central nervous system pain, such as pain due to spinal cord or brain stem damage; lower back pain; sciatica; phantom limb pain, headache, including migraine and other vascular headaches, acute or chronic tension headache, cluster headache, temperomandibular pain and maxillary sinus pain; pain resulting from ankylosing spondylitis and gout; pain caused by increased bladder contractions; post operative pain; scar pain; and chronic non-neuropathic pain such as pain associated with fibromyalgia, HIV, rheumatoid and osteoarthritis, anthralgia and myalgia, sprains, strains and trauma such as broken bones; and post surgical pain.

Still other pain is caused by injury or infection of peripheral sensory nerves. It includes, but is not limited to pain from peripheral nerve trauma, herpes virus infection, diabetes mellitus, fibromyalgia, causalgia, plexus avulsion, neuroma, limb amputation, and vasculitis. Neuropathic pain is also caused by nerve damage from chronic alcoholism, human immunodeficiency virus infection, hypothyroidism, uremia, or vitamin deficiencies. Neuropathic pain includes, but is not limited to pain caused by nerve injury such as, for example, the pain diabetics suffer from.

Psychogenic pain is that which occurs without an organic origin such as low back pain, atypical facial pain, and chronic headache.

Other types of pain include inflammatory pain, osteoarthritic pain, trigeminal neuralgia, cancer pain, diabetic neuropathy, restless leg syndrome, acute herpetic and postherpetic neuralgia, causalgia, brachial plexus avulsion, occipital neuralgia, gout, phantom limb, burn, and other forms of neuralgia, neuropathic and idiopathic pain syndrome.

This invention also provides a method of treating depression, which comprises administering to a mammal, including a human, in need of such treatment a therapeutically effective amount of a compound of formula I, II, III, IV, V or VI, or a pharmaceutically acceptable salt thereof. Depression can be

the result of organic disease, secondary to stress associated with personal loss, or idiopathic in origin. There is a strong tendency for familial occurrence of some forms of depression suggesting a mechanistic cause for at least some forms of depression. The diagnosis of depression is made primarily by quantification of alterations in patients' mood. These evaluations of mood are generally performed by a physician or quantified by a neuropsychologist using validated rating scales, such as the Hamilton Depression Rating Scale or the Brief Psychiatric Rating Scale. Numerous other scales have been developed to quantify and measure the degree of mood alterations in patients with depression, such as insomnia, difficulty with concentration, lack of energy, feelings of worthlessness, and guilt. The standards for diagnosis of depression as well as all psychiatric diagnoses are collected in *Diagnostic and Statistical Manual of Mental Disorders* (4th ed., 1994), which is referred to as the DSM-IV-R Manual, and is published by the American Psychiatric Association.

This invention also provides a method of treating a disorder or condition in a mammal, including a human, the disorder or condition selected from the group consisting of mood disorders, such as depression, or more particularly, depressive disorders, for example, single episodic or recurrent major depressive disorders, dysthymic disorders, depressive neurosis and neurotic depression, melancholic depression, including anorexia, weight loss, including weight loss associated with anorexia, cancer, old age and/or frailty, insomnia, early morning waking and psychomotor retardation, atypical depression (or reactive depression), including increased appetite, hypersomnia, psychomotor agitation or irritability, seasonal affective disorder and pediatric depression; or bipolar disorders or manic depression, for example, bipolar I disorder, bipolar II disorder and cyclothymic disorder; conduct disorder and disruptive behavior disorder; anxiety disorders, such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobias, for example, specific animal phobias, social anxiety disorder, social phobia, fear of flying, obsessive-compulsive disorder, stress disorders, including post-traumatic stress disorder and acute stress

disorder, and generalized anxiety disorders; borderline personality disorder; schizophrenia and other psychotic disorders, for example, schizophreniform disorders, schizoaffective disorders, delusional disorders, brief psychotic disorders, shared psychotic disorders, psychotic disorders with delusions or hallucinations, psychotic episodes of anxiety, anxiety associated with psychosis, psychotic mood disorders such as severe major depressive disorder; mood disorders associated with psychotic disorders such as acute mania and depression associated with bipolar disorder, mood disorders associated with schizophrenia; behavioral disturbances associated with mental retardation, autistic disorder, and conduct disorder. The method comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound of formula I, II, III, IV, V or VI, or a pharmaceutically acceptable salt thereof.

The compounds of the invention are also useful in the treatment of sleep disorders. Sleep disorders are disturbances that affect the ability to fall and/or stay asleep, that involve sleeping too much, or that result in abnormal behavior associated with sleep. The disorders include, for example, insomnia, drug-associated sleeplessness, hypersomnia, narcolepsy, sleep apnea syndromes, parasomnias, restless leg syndrome, jet lag, periodic limb movement disorder, and altered sleep architecture.

This invention also provides a method of treating a disorder or condition in a mammal, including a human, the disorder or condition selected from the group consisting of sleep disorders (e.g., insomnia, drug-associated sleeplessness, REM sleep disorders, hypersomnia, narcolepsy, sleep-wake cycle disorders, sleep apnea syndromes, parasomnias, and sleep disorders associated with shift work and irregular work hours). The method comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound of formula I, II, III, IV, V or VI, or a pharmaceutically acceptable salt thereof.

Compounds of formulas I, II, III, IV, V or VI contain at least one stereogenic (chiral) center and therefore may exist in different enantiomeric and diastereomeric forms. This invention includes all stereoisomers, including

optical isomers, of the compounds of formula I, II, III, IV, V or VI. Samples of the compounds may exist as racemic mixtures, as individual enantiomers and diastereoisomers, and as mixtures thereof. The invention also includes all pharmaceutical compositions and methods of treatment defined above that contain or employ stereoisomers of the compounds of formula I, II, III, IV, V or VI.

Compounds with one stereogenic center may exist as a racemic (equimolar) mixture, as a non-equimolar mixture of isomers, and as pure enantiomers having S- or R-stereoconfiguration. Compounds with two stereogenic centers may exist as a racemic mixture, as a non-equimolar mixture of isomers, and as pure enantiomers having SS, RR, SR or RS stereoconfiguration. Compounds with three stereogenic centers may exist as a racemic mixture, as a non-equimolar mixture of isomers, and as pure enantiomers having RRR, SSS, SRR, RSS, RSR, SRS, RRS or SSR stereoconfiguration. Individual isomers may be obtained by known methods, such as optical resolution, optically selective reaction, or chromatographic separation in the preparation of the final product or its intermediate. Individual enantiomers of the compounds of this invention may have advantages, as compared with racemic mixtures of these compounds, in the treatment of various disorders or conditions.

The present invention also includes isotopically labeled compounds, which are identical to those recited in formula I, II, III, IV, V, or VI but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine and chlorine, such as ^{2}H, ^{3}H, ^{13}C, ^{11}C, ^{14}C, ^{15}N, ^{18}O, ^{17}O, ^{31}P, ^{32}P, ^{35}S, ^{18}F, and ^{36}Cl, respectively. Compounds of the present invention, prodrugs thereof, and pharmaceutically acceptable salts of said compounds or of said prodrugs which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention. Certain isotopically labeled compounds of the present

invention, for example those into which radioactive isotopes such as ^{3}H and ^{14}C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., ^{3}H, and carbon-14, i.e., ^{14}C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium, i.e., ^{2}H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased *in vivo* half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically labeled compounds of formula I, II, III, IV, V, or VI of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples and Preparations below, by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.

Unless otherwise indicated, this disclosure uses definitions provided below. Some of the definitions and formulae may include a "-" (dash) to indicate a bond between atoms or a point of attachment to a named or unnamed atom or group of atoms. Other definitions and formulae may include an "=" (equal sign) or "≡" (identity sign) to indicate a double bond or a triple bond, respectively. Certain formulae may also include an "*" (asterisk) to indicate a stereogenic (chiral) center. Such formulae may refer to the racemate or to individual enantiomers, which may or may not be substantially pure.

The term "substituted" when used in connection with a compound, substituent, or moiety, indicates that one or more hydrogen atoms have been replaced with one or more non-hydrogen atoms or groups, provided that valence requirements are met and that a chemically stable compound results from the substitution.

The term "alkyl" refers to straight chain and branched saturated hydrocarbon groups, generally having a specified number of carbon atoms; i.e., $(C_1\text{-}C_6)$alkyl refers to an alkyl group having 1, 2, 3, 4, 5, or 6 carbon atoms. Examples of alkyl groups include, without limitation, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, i-butyl, t-butyl, pent-1-yl, pent-2-yl, pent-3-yl,

3-methylbut-1-yl, 3-methylbut-2-yl, 2-methylbut-2-yl, 2,2,2-trimethyleth-1-yl, n-hexyl, 3-ethylbutyl, and the like.

The term "cycloalkyl" refers to saturated monocyclic and bicyclic hydrocarbon rings, generally having a specified number of carbon atoms that comprise the ring; i.e., (C_3-C_6)cycloalkyl refers to a cycloalkyl group having 3, 4, 5, or 6 carbon atoms as ring members. The cycloalkyl may be attached to a parent group or to a substrate at any ring atom, unless such attachment would violate valence requirements. Likewise, the cycloalkyl groups may include one or more non-hydrogen substituents unless such substitution would violate valence requirements. Useful substituents include, without limitation, alkyl, as defined above, and hydroxy, mercapto, nitro, halogen, and amino.

Examples of monocyclic cycloalkyl groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like. Examples of bicyclic cycloalkyl groups include, without limitation, bicyclo[1.1.0]butyl, bicyclo[1.1.1]pentyl, bicyclo[2.1.0]pentyl, bicyclo[2.1.1]hexyl, bicyclo[3.1.0]hexyl, bicyclo[2.2.1]heptyl, bicyclo[3.2.0]heptyl, bicyclo[3.1.1]heptyl, bicyclo[4.1.0]heptyl, bicyclo[2.2.2]octyl, bicyclo[3.2.1]octyl, bicyclo[4.1.1]octyl, bicyclo[3.3.0]octyl, bicyclo[4.2.0]octyl, bicyclo[3.3.1]nonyl, bicyclo[4.2.1]nonyl, bicyclo[4.3.0]nonyl, bicyclo[3.3.2]decyl, bicyclo[4.2.2]decyl, bicyclo[4.3.1]decyl, bicyclo[4.4.0]decyl, bicyclo[3.3.3]undecyl, bicyclo[4.3.2]undecyl, bicyclo[4.3.3]dodecyl, and the like.

The term "alkoxy" refers to alkyl-O-, where alkyl is defined above. Examples of alkoxy groups include, without limitation, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, n-pentoxy, s-pentoxy, and the like.

The term "treating" refers to reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or preventing one or more symptoms of such condition or disorder. The term "treatment," as used herein, refers to the act of treating, as "treating" is defined immediately above.

The phrase "leaving group" refers to any group that leaves a molecule during a fragmentation process, including substitution reactions, elimination reactions, and addition-elimination reactions. Leaving groups may be nucleofugal, in which the group leaves with a pair of electrons that formerly served as the bond between the leaving group and the molecule, or may be electrofugal, in which the group leaves without the pair of electrons. The ability of a nucleofugal leaving group to leave depends on its base strength, with the strongest bases being the poorest leaving groups. Common nucleofugal leaving groups include nitrogen (e.g., from diazonium salts), sulfonates (including tosylates, brosylates, nosylates, and mesylates), triflates, nonaflates, tresylates, halide ions, carboxylate anions, phenolate ions, and alkoxides. Some stronger bases, such as NH_2^- and OH- can be made better leaving groups by treatment with an acid. Common electrofugal leaving groups include the proton, CO_2, and metals.

The phrase "enantiomeric excess" or "ee" is a measure, for a given sample, of the excess of one enantiomer over a racemic sample of a chiral compound and is expressed as a percentage. Enantiomeric excess is defined as 100 x (er - 1) / (er + 1), where "er" is the ratio of the more abundant enantiomer to the less abundant enantiomer.

The term "enantioselectivity" refers to a given reaction (e.g., hydrogenation) that yields more of one enantiomer than another.

The phrase "high level of enantioselectivity" refers to a given reaction that yields product with an ee of at least about 80 %.

The phrase "enantiomerically enriched" refers to a sample of a chiral compound, which has more of one enantiomer than another. The degree of enrichment is measured by er or ee.

The phrase "substantially pure enantiomer" or "substantially enantiopure" refers to a sample of an enantiomer having an ee of about 90 % or greater.

The phrase "enantiomerically pure" or "enantiopure" refers to a sample of an enantiomer having an ee of about 99 % or greater.

The phrase "opposite enantiomer" refers to a molecule that is a non-superimposable mirror image of a reference molecule, which may be obtained by inverting all of the stereogenic centers of the reference molecule. For example, if the reference molecule has S absolute stereochemical configuration, then the opposite enantiomer has R absolute stereochemical configuration. Likewise, if the reference molecule has S,S absolute stereochemical configuration, then the opposite enantiomer has R,R stereochemical configuration, and so on.

The phrase "pharmaceutically acceptable salts, esters, amides, and prodrugs" refers to acid or base addition salts, esters, amides, zwitterionic forms, where possible, and prodrugs of claimed and disclosed compounds, which are within the scope of sound medical judgment, suitable for use in contact with the tissues of patients without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use.

Because amino acids are amphoteric, pharmacologically compatible salts can be salts of appropriate inorganic or organic acids, for example, hydrochloric, sulfuric, phosphoric, acetic, oxalic, lactic, citric, malic, salicylic, malonic, maleic, succinic, and ascorbic. Starting from corresponding hydroxides or carbonates, salts with alkali metals or alkaline earth metals, for example, sodium, potassium, magnesium, or calcium are formed. Salts with quaternary ammonium ions can also be prepared with, for example, the tetramethyl-ammonium ion.

The effectiveness of an orally administered drug is dependent upon the drug's efficient transport across the mucosal epithelium and its stability in entero-hepatic circulation. Drugs that are effective after parenteral administration but less effective orally, or whose plasma half-life is considered too short, may be chemically modified into a prodrug form.

A prodrug is a drug that has been chemically modified and may be biologically inactive at its site of action, but which may be degraded or modified by one or more enzymatic or other in vivo processes to the parent bioactive form.

This chemically modified drug, or prodrug, should have a different pharmacokinetic profile than the parent drug, enabling easier absorption across the mucosal epithelium, better salt formulation, improved solubility, enhanced systemic stability (for an increase in plasma half-life, for example), and the like. These chemical modifications include, but are not limited to (1) ester or amide derivatives which may be cleaved by, for example, esterases or lipases; (2) peptides, which may be recognized by specific or nonspecific proteinases; (3) derivatives that accumulate at a site of action through membrane selection of a prodrug form or modified prodrug form; and (4) any combination of (1) to (3). The ester or amides prodrugs may be derived from the carboxylic acid moiety of the parent drug molecule or from the carboxylic acid moiety or the amine moiety of the parent drug molecule, respectively, by known means. In addition, the peptide prodrug may be coupled to the parent drug molecule via amide bond formation with the amine or carboxylic acid moiety of the parent drug molecule using known techniques.

Current research in animal experiments has shown that the oral absorption of certain drugs may be increased by the preparation of "soft" quaternary salts. The quaternary salt is termed a "soft" quaternary salt since, unlike normal quaternary salts, *e.g.*, $R\text{-}N^{+}(CH_3)_3$, it can release the active drug upon hydrolysis.

Soft quaternary salts have useful physical properties compared with the basic drug or its salts. Water solubility may be increased compared with other salts, such as the hydrochloride, but more important there may be an increased absorption of the drug from the intestine. Increased absorption is probably due to the fact that the soft quaternary salt has surfactant properties and is capable of forming micelles and unionized ion pairs with bile acids, etc., which are able to penetrate the intestinal epithelium more effectively. The prodrug, after absorption, is rapidly hydrolyzed with release of the active parent drug.

Prodrugs of compounds of formula I, II, III, IV, V or VI are included within the scope of this invention. For a discussion of prodrugs and soft drugs, see E. Palomino, *Drugs of the Future* 15(4):361-68 (1990). See also,

T. Higuchi and V. Stella, "Pro-drugs as Novel Delivery Systems," *ACS Symposium Series* 14 (1975); E.B. Roche (ed.), *Bioreversible Carriers in Drug Design* (1987); and H. Bundgaar, *Design of Prodrugs* (1985).

Certain of the compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms, including hydrated forms, are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention.

DETAILED DESCRIPTION

The compounds of this invention can be prepared as described below. In the reaction schemes and discussion that follow, structural formulas I, II, III, IV, V, or VI, and the radicals R_1, R_2, R_3, R_4, R_5 and R_6, unless otherwise indicated, are as defined above.

In some of the reaction schemes and examples below, certain compounds can be prepared using protecting groups, which prevent undesirable chemical reaction at otherwise reactive sites. Protecting groups may also be used to enhance solubility or otherwise modify physical properties of a compound. For a discussion of protecting group strategies, a description of materials and methods for installing and removing protecting groups, and a compilation of useful protecting groups for common functional groups, including amines, carboxylic acids, alcohols, ketones, aldehydes, and the like, see T. W. Greene and P.G. Wuts, *Protecting Groups in Organic Chemistry* (1999) and P. Kocienski, *Protective Groups* (2000).


In addition, some of the schemes and examples below may omit details of common reactions, including oxidations, reductions, and so on, which are known to persons of ordinary skill in the art of organic chemistry. The details of such reactions can be found in a number of treatises, including Richard Larock, *Comprehensive Organic Transformations* (1999), and the multi-volume series edited by Michael B. Smith and others, *Compendium of Organic Synthetic Methods* (1974-2003). Generally, starting materials and reagents may be obtained from commercial sources.

Generally, the chemical transformations described throughout the specification may be carried out using substantially stoichiometric amounts of reactants, though certain reactions may benefit from using an excess of one or more of the reactants. Additionally, many of the reactions disclosed throughout the specification may be carried out at about RT, but particular reactions may require the use of higher or lower temperatures, depending on reaction kinetics, yields, and the like. Furthermore, many of the chemical transformations may employ one or more compatible solvents, which depending on the nature of the reactants, may be polar protic solvents, polar aprotic solvents, non-polar solvents, or some combination. Although the choice of solvent or solvents may influence the reaction rate and yield, such solvents are generally considered to be inert (unreactive). Any references in the disclosure to a concentration range, a temperature range, a pH range, a catalyst loading range, and so on, whether expressly using the word "range" or not, includes the indicated endpoints.

Diverse methods exist for the preparation of chiral and racemic β-amino acids. Such methods can be found in Eusebio Juaristi (editor), *Enantioselective Synthesis of β-Amino Acids* (1997).

The methods described below are illustrative of methods that can be utilized for the preparation of such compounds but are not limiting in scope.

Method A



The use of chiral amine additions to α,β-unsaturated systems as a synthetic approach to β-amino acids, as illustrated in Method A above, has been described previously. See, e.g., S. G. Davies *et al, J. Chem. Soc. Chem. Commun.* 1153 (1993); S. G. Davies, *Synlett* 117 (1994); Ishikawa *et*

al, Synlett 1291 (1998); and Hawkins, *J. Org. Chem.* 51:2820 (1985).

Referring to Method A above, compounds of formula I can be prepared from the corresponding compounds of formula 4, wherein PG represents a suitable ester protecting group that can be removed by hydrolysis or hydrogenolysis, using conditions well known to those of skill in the art. See T. W. Greene and P. G. M. Wuts, *Protective groups in organic synthesis* (1991) for a detailed description for the formation and removal of suitable protecting groups). For example, this reaction can be conducted under hydrolytic conditions by treatment with an appropriate acid, such as hydrochloric acid or sulfuric acid, at a temperature from about room temperature to about the reflux temperature of the reaction mixture, preferably at the reflux temperature, or by treatment with an appropriate inorganic base, such as sodium hydroxide, potassium hydroxide, or lithium hydroxide, preferably sodium hydroxide, at a temperature from about room temperature to about the reflux temperature, preferably at about room temperature. This reaction is preferably carried out using hydrochloric acid at the reflux temperature. When PG is t-butyl, however, the reaction is preferably carried out in trifluoroacetic acid (TFA). When PG is a basic group, the hydrolysis can be carried out under basic conditions, using methods well known to those of skill in the art, for example, using sodium or potassium hydroxide.

Compounds of formula 4 can be prepared from the corresponding compounds of formula 3 using hydrogenolysis conditions that are well known to those of skill in the art. For example, this reaction can be carried out by treating the compounds of formula 3 with a palladium metal catalyst, such as, for example, palladium hydroxide on carbon, or palladium on carbon, or with Raney Nickel, in a solvent such as, for example, methanol, ethanol or tetrahydrofuran, under an atmosphere of hydrogen (between about 1 and 5 atmospheres of pressure) to give the desired compound of formula 4. Preferably, the reaction is carried out using palladium on carbon in ethanol under about 1 atmosphere of hydrogen.

Compounds of formula 3 can be prepared by treating the corresponding compounds of formula 2 with an appropriate amine such as

(R)-(+)-N-benzyl-α-methylbenzylamine, (S)-(-)-N-benzyl-α–methylbenzylamine after treatment with an appropriate base such as lithium diisopropylamide, n-butyl lithium, or lithium or potassium bis(trimethylsilyl)amide, in a solvent such as ethyl ether, or, preferably, tetrahydrofuran (THF), at a temperature from about –80°C to about 25°C, and then adding the appropriate compound of formula 2. The stereochemistry about the nitrogen of the amine will determine the stereochemistry about the nitrogen of the final product. Preferably, this reaction is carried out using either (R)-(+)-N-benzyl- α-methylbenzylamine, (S)-(-)-N-benzyl- α-methylbenzylamine, after deprotonation with n-butyl-lithium in tetrahydrofuran, at a temperature of about -78 °C, according to method described by S. D. Bull et al., *J. Chem. Soc., Perkin Trans. 1* 22:2931-38 (2001). Preferably, this reaction is carried out using either (R)-(+)-N-benzyl- α-methylbenzylamine, or (S)-(-)-N-benzyl- α-methylbenzylamine, after deprotonation with n-butyl-lithium in tetrahydrofuran, at a temperature of about -78 °C, according to method described by S. D. Bull et al., *J. Chem. Soc., Perkin Trans. 1* 22:2931-38 (2001).

Compounds of formula 2 can be prepared from the corresponding compounds of formula 1 by treating them with an appropriate phosphonate ester in the presence of a suitable base such as sodium hydride, lithium diisopropylamide, or triethyl amine and either lithium chloride or lithium bromide, in a solvent such as ether or THF. Preferably, the compound of formula 1 is reacted with a phosphonate ester (ALK = methyl, ethyl, isopropyl, benzyl or the like) in the presence of lithium bromide and triethylamine in tetrahydrofuran at about room temperature. Compounds of formula 1 can be prepared from commercially available materials using methods well known to those of skill in the art. It will be appreciated that compounds of formula I may possess one or more stereogenic centers. Using the above-described method, compounds with specific stereochemical configurations can be prepared.


Compounds that can be made by this method include, but are not limited to the following:

3-Amino-4,5-dimethyl-hexanoic acid;
3-Amino-4,5-dimethyl-heptanoic acid;
3-Amino-4,5-dimethyl-octanoic acid;
3-Amino-4,5-dimethyl-nonanoic acid;
3-Amino-4-ethyl-5-methyl-heptanoic acid;
3-Amino-4-ethyl-5-methyl-octanoic acid;
3-Amino-4-ethyl-5-methyl-nonanoic acid;
3-Amino-4-ethyl-5,6-dimethyl-heptanoic acid;
3-Amino-4-ethyl-5,7-dimethyl-octanoic acid;
3-Amino-4-ethyl-5,8-dimethyl-nonanoic acid;
(3R,4R)-3-Amino-4,5-dimethyl-hexanoic acid;
(3R,4R,5R)-3-Amino-4,5-dimethyl-heptanoic acid;
(3R,4R,5R)-3-Amino-4,5-dimethyl-octanoic acid;
(3R,4R,5R)-3-Amino-4,5-dimethyl-nonanoic acid;
(3R,4R,5R)-3-Amino-4,5-dimethyl- decanoic acid;
3-Amino-4,6-dimethyl-heptanoic acid;
3-Amino-4,6-dimethyl-octanoic acid;
3-Amino-4,6-dimethyl-nonanoic acid;
3-Amino-4,6-dimethyl-decanoic acid;
3-Amino-4,6,7-trimethyl-octanoic acid;
3-Amino-4,6,8-trimethyl-nonanoic acid;
3-Amino-4,6,9-trimethyl-decanoic acid;
3-Amino-6-cyclopropyl-4-methyl-heptanoic acid;
3-Amino-6-cyclobutyl-4-methyl-heptanoic acid;
3-Amino-6-cyclopentyl-4-methyl-heptanoic acid;
3-Amino-6-cyclohexyl-4-methyl-heptanoic acid;
3-Amino-7-cyclopropyl-4,6-dimethyl-heptanoic acid;
3-Amino-7-cyclobutyl-4,6-dimethyl-heptanoic acid;
3-Amino-7-cyclopentyl-4,6-dimethyl-heptanoic acid;
3-Amino-7-cyclohexyl-4,6-dimethyl-heptanoic acid;


3-Amino-8-cyclopropyl-4,6-dimethyl-octanoic acid;
3-Amino-8-cyclobutyl-4,6-dimethyl-octanoic acid;
3-Amino-8-cyclopentyl-4,6-dimethyl-octanoic acid;
3-Amino-8-cyclohexyl-4,6-dimethyl-octanoic acid;
3-Amino-6-(3-chloro-phenyl)-4-methyl-heptanoic acid;
3-Amino-6-(3,4-dichloro-phenyl)-4-methyl-heptanoic acid;
3-Amino-4-methyl-6-(3-trifluoromethyl-phenyl)-heptanoic acid;
3-Amino-4-methyl-6-(4-trifluoromethyl-phenyl)-heptanoic acid;
3-Amino-7-(3-chloro-phenyl)-4,6-dimethyl-heptanoic acid;
3-Amino-7-(3,4-dichloro-phenyl)-4,6-dimethyl-heptanoic acid;
3-Amino-4,6-dimethyl-7-(3-trifluoromethyl-phenyl)-heptanoic acid;
3-Amino-4,6-dimethyl-7-(4-trifluoromethyl-phenyl)-heptanoic acid;
3-Amino-8-(3-chloro-phenyl)-4,6-dimethyl-octanoic acid;
3-Amino-8-(3,4-dichloro-phenyl)-4,6-dimethyl-octanoic acid;
3-Amino-4,6-dimethyl-8-(3-trifluoromethyl-phenyl)-octanoic acid;
3-Amino-4,6-dimethyl-8-(4-trifluoromethyl-phenyl)-octanoic acid;
3-Amino-4-ethyl-6-methyl-octanoic acid;
3-Amino-4-ethyl-6-methyl-nonanoic acid;
3-Amino-4-ethyl-6-methyl-decanoic acid;
3-Amino-4-ethyl-6,7-dimethyl-octanoic acid;
3-Amino-4-ethyl-6,8-dimethyl-nonanoic acid;
3-Amino-4-ethyl-6,9-dimethyl-decanoic acid;
3-Amino-6-cyclopropyl-4-ethyl-heptanoic acid;
3-Amino-6-cyclobutyl-4-ethyl-heptanoic acid;
3-Amino-6-cyclopentyl-4-ethyl-heptanoic acid;
3-Amino-6-cyclohexyl-4-ethyl-heptanoic acid;
3-Amino-7-cyclopropyl-4-ethyl-6-methyl-heptanoic acid;
3-Amino-7-cyclobutyl-4-ethyl-6-methyl-heptanoic acid;
3-Amino-7-cyclopentyl-4-ethyl-6-methyl-heptanoic acid;
3-Amino-7-cyclohexyl-4-ethyl-6-methyl-heptanoic acid;
3-Amino-8-cyclopropyl-4-ethyl-6-methyl-octanoic acid;
3-Amino-8-cyclobutyl-4-ethyl-6-methyl-octanoic acid;

3-Amino-8-cyclopentyl-4-ethyl-6-methyl-octanoic acid;
3-Amino-8-cyclohexyl-4-ethyl-6-methyl-octanoic acid;
3-Amino-6-(3-chloro-phenyl)-4-ethyl-heptanoic acid;
3-Amino-6-(3,4-dichloro-phenyl)-4-ethyl-heptanoic acid;
3-Amino-4-ethyl-6-(3-trifluoromethyl-phenyl)-heptanoic acid;
3-Amino-4-ethyl-6-(4-trifluoromethyl-phenyl)-heptanoic acid;
3-Amino-7-(3-chloro-phenyl)-4-ethyl-6-methyl-heptanoic acid;
3-Amino-7-(3,4-dichloro-phenyl)-4-ethyl-6-methyl-heptanoic acid;
3-Amino-4-ethyl-6-methyl-7-(3-trifluoromethyl-phenyl)-heptanoic acid;
3-Amino-4-ethyl-6-methyl-7-(4-trifluoromethyl-phenyl)-heptanoic acid;
3-Amino-8-(3-chloro-phenyl)-4-ethyl-6-methyl-octanoic acid;
3-Amino-8-(3,4-dichloro-phenyl)-4-ethyl-6-methyl-octanoic acid;
3-Amino-4-ethyl-6-methyl-8-(3-trifluoromethyl-phenyl)-octanoic acid; and
3-Amino-4-ethyl-6-methyl-8-(4-trifluoromethyl-phenyl)-octanoic acid.


Method B



5




6




7

Base, PGO_2CCH_2LG




8

Hydrolysis




9

DPPA, alcohol



10

Hydrolysis



I

* = chiral center

The diastereoselective alkylation of imides such as those of formula 7 to afford chiral succinate analogs such as those of formula 8 has been previously described as an approach to preparing β-amino acids. See, e.g., Evans *et al, J. Org. Chem.* 64:6411 (1999); Sibi and Deshpande, *J. Chem. Soc. Perkin Trans 1* 1461 (2000); and Arvanitis *et al, J. Chem. Soc. Perkin Trans 1* 521 (1998).

Compounds of formula 8 can be prepared from compounds of formula 7 in the presence of a suitably derived ester (PG as defined above, LG = Br or I or Cl) such as, for example, t-butyl bromoacetate, benzyl bromoacetate with an organometallic base such as, for example, lithium diisopropylamide or lithium bis(trimethylsilyl)amide or sodium bis(trimethylsilyl)amide and the like in a solvent such as, for example, tetrahydrofuran, ether, and the like. The reaction can be carried out using sodium bis(trimethylsilyl)amide in tetrahydrofuran at -78°C and treatment of the resultant anion intermediate with t-butyl bromoacetate at -78°C to -30°C.

Compounds of formula 9 can be prepared by hydrolyzing the corresponding compounds of formula 8 in the presence of lithium hydroxide and hydrogen peroxide in a solvent such as water or THF, at a temperature from about 0°C to about room temperature. Preferably, this reaction is carried out using hydrogen peroxide and lithium hydroxide in aqueous tetrahydrofuran at about 0°C according to the method described in the literature. See P.-W. Yuen et al., *Bioorganic and Medicinal Chem. Lett.* 4(6):823-26 (1994).

Treatment of the compound of formula 9 with diphenylphosphorylazide (DPPA) followed by treatment with a suitable alcohol such as t-butanol, benzyl alcohol or p-methoxybenzyl alcohol, in a suitable solvent such as toluene, benzene, MTBE, or THF, at a temperature from about 50°C to about the reflux temperature of the reaction mixture yields the corresponding compound of formula 10, wherein R_7 is methyl, ethyl, t-butyl, benzyl, or p-methoxybenzyl. R_7 is dependent on the choice of the alcohol used. Preferably, this reaction is carried out using a toluene solvent in the presence of p-methoxybenzyl alcohol under refluxing conditions.

Compounds of formula 10 can be converted into the desired compounds of formula I by hydrolysis or hydrogenolysis, using conditions well known to those of skill in the art. See T. W. Greene and P. G. M. Wuts, *Protective groups in organic synthesis* (1991) for a detailed description for the formation and removal of suitable protecting groups. For example, this reaction can be conducted under hydrolytic conditions by treatment with an appropriate acid, such as hydrochloric acid or sulfuric acid, at a temperature from about room temperature to about the reflux temperature of the reaction mixture, preferably at the reflux temperature, or by treatment with an appropriate inorganic base, such as sodium hydroxide, potassium hydroxide, or lithium hydroxide, preferably sodium hydroxide, at a temperature from about room temperature to about the reflux temperature, preferably at about room temperature. This reaction is preferably carried out using hydrochloric acid at the reflux temperature. When PG is t-butyl, however, the reaction is preferably carried out in trifluoroacetic acid (TFA). When PG is a basic group, the hydrolysis can be carried out under basic conditions, using methods well known to those of skill in the art, for example, using sodium or potassium hydroxide.

Compounds of formula 7 can be prepared by treating the corresponding compounds of formula 5 with an amine base such as triethylamine, in the presence of trimethylacetylchloride, in an ethereal solvent such as THF, and then treating the intermediates formed by this reaction (in situ) with a chiral oxazolidinone of formula 6. Examples of other oxazolidinones that can be used in this method are: (4S)-(-)-4-isopropyl-2-oxazolidinone; (S)-(-)-4-benzyl-2-oxazolidinone; (4S,5R)-(-)-4-methyl-5-phenyl-2-oxazolidinone; (R)-(+)-4-benzyl-2-oxazolidinone, (S)-(+)-4-phenyl-2-oxazolidinone; (R)-(-)-4-phenyl-2-oxazolidinone; (R)-4-isopropyl-2-oxazolidinone; and (4R,5S)-(+)-4-methyl-5-phenyl-2-oxazolidinone)) and lithium chloride. Preferably, this reaction is carried out by treating an acid of formula 5 with trimethylacetylchloride and triethylamine in tetrahydrofuran at about -20°C, followed by treatment of the intermediate formed in such reaction with an oxazolidinone of formula 6 and lithium chloride at about room


temperature according to literature procedures. See G.-J. Ho and D. J. Mathre, *J. Org. Chem.* 60:2271-73 (1995).

Alternatively, compounds of formula 7 can be prepared by treating the corresponding compounds of formula 6 with an acid chloride derived from treatment of the corresponding compound of formula 5 with oxalyl chloride, in a solvent such as dichloromethane, in the presence of dimethylformamide (DMF). Acids of formula 5 can be prepared from commercially available materials using methods well known to those of skill in the art. These acids may possess one or more stereogenic centers.

Alternatively, referring to Method C below, compounds of formula 8 can be treated with an appropriate acid (for example, trifluoroacetic acid (TFA) when the t-butyl ester is used) to yield the corresponding compounds of formula 12, which can then be subjected to a Curtius rearrangement (where R_7 is defined as above) to yield the corresponding compounds of formula 13. See Arvanitis *et al, J. Chem. Soc. Perkin Trans 1* 521 (1998) for a description of this approach. Further hydrolysis of the imide group yields the corresponding compound of formula 14; hydrolysis of the resulting carbamate group in formula 14 gives the desired β-amino acids of formula V.

Compounds of formula 13 may be converted to compounds of formula 14 in a manner similar to the method for converting compounds of formula 8 into compounds of formula 9 (Method B). Furthermore, compounds of formula 14 may be converted to compounds of formula II through treatment with a strong acid, such as hydrochloric acid or the like, or a strong base, such as sodium or potassium hydroxide or, if R_7 is benzyl or p-methoxybenzyl, through hygrogenolytic conditions, using palladium on carbon in ethanol or THF under a hydrogen atmosphere. This approach, which preserves the stereochemistry about the stereogenic center in the compounds of formula 8 and formula II, is utilized in Example 4 below.


Method C



8 12 13 14 V


Other alternative approaches to synthesizing α-substituted β-amino acids that can be utilized for preparing the compounds of this invention. See, e.g., Juaristi et al., *Tetrahedron Asymm.* 7(8):2233 (1996); Seebach et al., *Eur. J. Org. Chem.* 335 (1999); Nagula et al., *Org, Lett,* 2:3527 (2000); Arvanitis et al., *J. Chem. Soc. Perkin Trans 1* 521 (1998); and Hintermann et al., *Helv. Chim.* Acta 81:2093 (1998), as shown in Method D below.

Method D



The use of chiral sulfimines to afford β-amino acids, as illustrated in Method E below, has been described previously. See, e.g., T. P. Tang and J. A. Ellman, *J. Org. Chem.* 64:12-13 (1999); Davis and McCoull, *J. Org. Chem.* 64:3396-97 (1999), and Davis et al., *J. Org. Chem.* 64:1403-06 (1999).

Method E



The final step in the above scheme (R_8 = *t*-butyl or *p*-tolyl, R_9 = a suitably derived ester such as methyl, ethyl or *t*-butyl) is a hydrolysis of both the sulfonamide and ester groups of a compound of formula 19 to give a compound of formula I. This reaction is generally carried out using a strong acid such as trifluoroacetic acid, hydrochloric acid, hydrobromic acid or sulfuric acid, in a solvent such as water or dioxane or a mixture of water and dioxane, at a temperature from about 20°C to about 100°C, preferably at about room temperature. The reaction may be carried out by treating compounds of formula 19 with an acid such as TFA in a solvent such as methanol then treating the product with TFA in a solvent such as dichloromethane to give a compound of formula I.

Compounds that can be made by this method include, but are not limited to the following:

3-Amino-4,5-dimethyl-hexanoic acid;

3-Amino-4,5-dimethyl-heptanoic acid;

3-Amino-4,5-dimethyl-octanoic acid;

3-Amino-4,5-dimethyl-nonanoic acid;

3-Amino-4-ethyl-5-methyl-heptanoic acid;

3-Amino-4-ethyl-5-methyl-octanoic acid;

3-Amino-4-ethyl-5-methyl-nonanoic acid;
3-Amino-4-ethyl-5-methyl- decanoic acid;
3-Amino-4-ethyl-5,6-dimethyl-heptanoic acid;
3-Amino-4-ethyl-5,7-dimethyl-octanoic acid;
3-Amino-4-ethyl-5,8-dimethyl-nonanoic acid;
3-Amino-5-ethyl-4-methyl-octanoic acid;
3-Amino-5-ethyl-4-methyl-nonanoic acid;
3-Amino-4,5-diethyl-heptanoic acid;
3-Amino-4,5-diethyl-octanoic acid;
3-Amino-4,5-diethyl-nonanoic acid;
3-Amino-5-ethyl-4,7-dimethyl-octanoic acid;
3-Amino-5-ethyl-4,8-dimethyl-nonanoic acid;
3-Amino-4,5-diethyl-6-methyl-heptanoic acid;
3-Amino-4,5-diethyl-7-methyl-octanoic acid;
3-Amino-4,5-diethyl-8-methyl-nonanoic acid;
3-Amino-4,5,6-trimethyl-heptanoic acid;
3-Amino-4,5,7-trimethyl-octanoic acid;
3-Amino-4,5,8-trimethyl-nonanoic acid;
3-Amino-4-ethyl-5-methyl-hexanoic acid;
3-Amino-5-ethyl-4-methyl-octanoic acid;
3-Amino-5-ethyl-4-methyl-heptanoic acid;
3-Amino-4-methyl-5-propyl-octanoic acid;
3-Amino-6-cyclopentyl-4,5-dimethyl-hexanoic acid;
3-Amino-7-cyclopentyl-4,5-dimethyl-heptanoic acid;
3-Amino-5-ethyl-4,6-dimethyl-heptanoic acid;
3-Amino-5-ethyl-4,7-dimethyl-octanoic acid;
3-Amino-5-ethyl-4,8-dimethyl-nonanoic acid;
(3R,4R)-3-Amino-4,5-dimethyl-hexanoic acid;
(3R,4R,5R)-3-Amino-4,5-dimethyl-heptanoic acid;
(3R,4R,5R)-3-Amino-4,5-dimethyl-octanoic acid;
(3R,4R,5R)-3-Amino-4,5-dimethyl-nonanoic acid;
(3R,4R,5R)-3-Amino-4,5-dimethyl- decanoic acid;

3-Amino-5-cyclopropyl-4-ethyl-hexanoic acid;
3-Amino-6-cyclopropyl-4-ethyl-5-methyl-hexanoic acid;
3-Amino-5-cyclobutyl-4-ethyl-hexanoic acid;
3-Amino-6-cyclobutyl-4-ethyl-5-methyl-hexanoic acid;
3-Amino-5-cyclopentyl-4-methyl-hexanoic acid;
3-Amino-6-cyclopentyl-4-ethyl-5-methyl-hexanoic acid;
3-Amino-5-cyclohexyl-4-ethyl-hexanoic acid;
3-Amino-6-cyclohexyl-4-ethyl-5-methyl-hexanoic acid;
3-Amino-5-cyclopropyl-4-methyl-hexanoic acid;
3-Amino-6-cyclopropyl-4,5-dimethyl-hexanoic acid;
3-Amino-5-cyclobutyl-4-methyl-hexanoic acid;
3-Amino-6-cyclobutyl-4,5-dimethyl-hexanoic acid;
3-Amino-5-cyclopentyl-4-methyl-hexanoic acid;
3-Amino-6-cyclopentyl-4,5-dimethyl-hexanoic acid;
3-Amino-5-cyclohexyl-4-methyl-hexanoic acid;
3-Amino-6-cyclohexyl-4,5-dimethyl-hexanoic acid;
3-Amino-8-cyclohexyl-4,5-dimethyl-octanoic acid;
3-Amino-8-cyclohexyl-4,5-dimethyl-octanoic acid;
3-Amino-4,6-dimethyl-heptanoic acid;
3-Amino-4,6-dimethyl-octanoic acid;
3-Amino-4,6-dimethyl-nonanoic acid;
3-Amino-4,6-dimethyl-decanoic acid;
3-Amino-4,6,7-trimethyl-octanoic acid;
3-Amino-4,6,8-trimethyl-nonanoic acid;
3-Amino-4,6,9-trimethyl-decanoic acid;
3-Amino-6-cyclopropyl-4-methyl-heptanoic acid;
3-Amino-6-cyclobutyl-4-methyl-heptanoic acid;
3-Amino-6-cyclopentyl-4-methyl-heptanoic acid;
3-Amino-6-cyclohexyl-4-methyl-heptanoic acid;
3-Amino-7-cyclopropyl-4,6-dimethyl-heptanoic acid;
3-Amino-7-cyclobutyl-4,6-dimethyl-heptanoic acid;
3-Amino-7-cyclopentyl-4,6-dimethyl-heptanoic acid;

96

3-Amino-7-cyclohexyl-4,6-dimethyl-heptanoic acid;
3-Amino-8-cyclopropyl-4,6-dimethyl-octanoic acid;
3-Amino-8-cyclobutyl-4,6-dimethyl-octanoic acid;
3-Amino-8-cyclopentyl-4,6-dimethyl-octanoic acid;
3-Amino-8-cyclohexyl-4,6-dimethyl-octanoic acid;
3-Amino-6-(3-chloro-phenyl)-4-methyl-heptanoic acid;
3-Amino-6-(3,4-dichloro-phenyl)-4-methyl-heptanoic acid;
3-Amino-4-methyl-6-(3-trifluoromethyl-phenyl)-heptanoic acid;
3-Amino-4-methyl-6-(4-trifluoromethyl-phenyl)-heptanoic acid;
3-Amino-7-(3-chloro-phenyl)-4,6-dimethyl-heptanoic acid;
3-Amino-7-(3,4-dichloro-phenyl)-4,6-dimethyl-heptanoic acid;
3-Amino-4,6-dimethyl-7-(3-trifluoromethyl-phenyl)-heptanoic acid;
3-Amino-4,6-dimethyl-7-(4-trifluoromethyl-phenyl)-heptanoic acid;
3-Amino-8-(3-chloro-phenyl)-4,6-dimethyl-octanoic acid;
3-Amino-8-(3,4-dichloro-phenyl)-4,6-dimethyl-octanoic acid;
3-Amino-4,6-dimethyl-8-(3-trifluoromethyl-phenyl)-octanoic acid;
3-Amino-4,6-dimethyl-8-(4-trifluoromethyl-phenyl)-octanoic acid;
3-Amino-4-ethyl-6-methyl-octanoic acid;
3-Amino-4-ethyl-6-methyl-nonanoic acid;
3-Amino-4-ethyl-6-methyl-decanoic acid;
3-Amino-4-ethyl-6,7-dimethyl-octanoic acid;
3-Amino-4-ethyl-6,8-dimethyl-nonanoic acid;
3-Amino-4-ethyl-6,9-dimethyl-decanoic acid;
3-Amino-6-cyclopropyl-4-ethyl-heptanoic acid;
3-Amino-6-cyclobutyl-4-ethyl-heptanoic acid;
3-Amino-6-cyclopentyl-4-ethyl-heptanoic acid;
3-Amino-6-cyclohexyl-4-ethyl-heptanoic acid;
3-Amino-7-cyclopropyl-4-ethyl-6-methyl-heptanoic acid;
3-Amino-7-cyclobutyl-4-ethyl-6-methyl-heptanoic acid;
3-Amino-7-cyclopentyl-4-ethyl-6-methyl-heptanoic acid;
3-Amino-7-cyclohexyl-4-ethyl-6-methyl-heptanoic acid;
3-Amino-8-cyclopropyl-4-ethyl-6-methyl-octanoic acid;

97

3-Amino-8-cyclobutyl-4-ethyl-6-methyl-octanoic acid;

3-Amino-8-cyclopentyl-4-ethyl-6-methyl-octanoic acid;

3-Amino-8-cyclohexyl-4-ethyl-6-methyl-octanoic acid;

3-Amino-6-(3-chloro-phenyl)-4-ethyl-heptanoic acid;

3-Amino-6-(3,4-dichloro-phenyl)-4-ethyl-heptanoic acid;

3-Amino-4-ethyl-6-(3-trifluoromethyl-phenyl)-heptanoic acid;

3-Amino-4-ethyl-6-(4-trifluoromethyl-phenyl)-heptanoic acid;

3-Amino-7-(3-chloro-phenyl)-4-ethyl-6-methyl-heptanoic acid;

3-Amino-7-(3,4-dichloro-phenyl)-4-ethyl-6-methyl-heptanoic acid;

3-Amino-4-ethyl-6-methyl-7-(3-trifluoromethyl-phenyl)-heptanoic acid;

3-Amino-4-ethyl-6-methyl-7-(4-trifluoromethyl-phenyl)-heptanoic acid;

3-Amino-8-(3-chloro-phenyl)-4-ethyl-6-methyl-octanoic acid;


3-Amino-8-(3,4-dichloro-phenyl)-4-ethyl-6-methyl-octanoic acid;

3-Amino-4-ethyl-6-methyl-8-(3-trifluoromethyl-phenyl)-octanoic acid;

and

3-Amino-4-ethyl-6-methyl-8-(4-trifluoromethyl-phenyl)-octanoic acid.

Method F




The synthesis of β-amino acids of formula V via the enantioselective alkylation of enantiopure 1-substituted-2-*tert*-butyl-3-methylperhydropyrimidine-4-one 21, as illustrated by Method F above, has been described previously. See, e.g., E. Juaristi, et al., *Tetrahedron: Asymmetry* 7:2233 (1996) and references cited therein. Referring to

Method F above, compounds of formula 22 can be prepared from corresponding compounds of formula 20 (HAL = Br, I, Cl or another suitable leaving group), wherein R_{10} represents a phenyl or methoxy group, preferably a methoxy group. The hydrolysis can be conducted under acidic conditions in a sealed tube, at reflux, or in a microwave. For instance, the method utilizing 6N HCl in a sealed tube heated at 90-100°C for 8 hr is described by E. Juaristi et al., *Tetrahedron: Asymmetry* 7:2233 (1996). Other preferred methods include heating a solution of compound 22 in a 1:1 mixture of dioxane:6N HCl in a microwave for 1-3 hrs or at reflux for several days to give a compound of formula V.

Compounds of formula 22 can be prepared from the corresponding compounds of formula 20 by treating them with an appropriate perhydropyrimidine-4-one of formula 21 after deprotonation with an appropriate base such as lithium diisopropylamide or lithium or sodium bis(trimethylsilyl)amide, in a solvent such as ethyl ether, or, preferably, tetrahydrofuran (THF), at a temperature from about –80°C to about 0°C, and then adding the appropriate compound of formula 20. The stereochemistry of the C5 center arises from approach of the electrophile from the opposite face of the enolate from the sterically congested axial disposition of the *tert*-butyl group at C2. Preferably, the compound 22 is prepared by the reaction of electrophiles 20 with compounds of formula 21, which have been deprotonated at –78°C with sodium bis(trimethylsilyl)amide in THF, at –78°C to –10°C. The synthesis of enantiopure compound 21 (R_{10} = Ph) from L-asparagine is described by E. Juaristi et al., *Tetrahedron: Asymmetry* 7:2233 (1996).

99

Method G



* = chiral center

In a like manner, Method G shows the synthesis of α-substituted, β-amino acids of formula V via the enantioselective alkylation of enantiopure 3-amino-N-(2-hydroxy-1-methyl-2-phenyl-ethyl)-N-methyl-propionamide (formula 24). See, G. Nagula et al., *Organic Letters* 2:3527-29 (2000). The method includes alkylation of compound 24 using an appropriate alkylating agent 20, where HAL in formula 20 is Br, I, Cl or another suitable leaving group. The enolate alkylation is carried out in a polar aprotic solvent (THF) with excess LiCl at a temperature of about -5°C to about 0°C using a hindered base (e.g., lithium hexamethyldisilazide, lithium diisopropylamide, etc.) that is sufficiently strong to deprotonate the α-carbon of formula 24. Hydrolysis of the resulting alkylated amide 25 gives the desired β-amino acid of formula V.

The compound of formula 24 is prepared through N-acylation of a chiral auxiliary, (+)- or (-)-pseudoephedrine, using a mixed anhydride. The

mixed anhydride is obtained by reacting an N-terminal protected, 3-amino-propionic acid (e.g., 3-tert-butoxycarbonylamino-propionic acid 23) with trimethylacetyl chloride in the presence of triethylamine in methylene chloride. Following the coupling reaction, the protecting group is removed via known methods (e.g., treatment of the resulting Boc-protected amide with HCl and MeOH) to give the compound of formula 24. See A. Myers et al., *J. Am. Chem. Soc. 119*:656-73 (1997).

Compounds of formula 20 shown in Method F and Method G can be prepared from commercially available materials using methods well known to those of skill in the art. It will be appreciated that compounds of formula 20 may possess one or more stereogenic centers. Using the above-described method, compounds with specific stereochemical configurations can be prepared.

The preparation of compounds of this invention that are not specifically described in the foregoing experimental section can be accomplished using combinations of the reactions described above that will be apparent to those skilled in the art.

In each of the reactions discussed or illustrated above, pressure is not critical unless otherwise indicated. Pressures from about 0.5 atmospheres to about 5 atmospheres are generally acceptable, and ambient pressure, i.e., about 1 atmosphere, is preferred as a matter of convenience.

The compounds of formula I, II, III, IV, V, and VI, and the intermediates shown in the above reaction schemes can be isolated and purified by conventional procedures, such as recrystallization or chromatographic separation.

The ability of compounds of the present invention to bind to the α2δ-subunit of a calcium channel can be determined using the following binding assay.

The radioligand binding assay using [^{3}H]-gabapentin and the α2δ-subunit derived from porcine brain tissue was used. See Nicolas S. Gee *et al.*, *"The novel anticonvulsant drug, gabapentin (Neurontin), binds to the α2δ*

subunit of a calcium channel," J. Biol. Chem. 271(10):5768-76 (1996). Compounds of the invention bind with nanomolar to micromolar affinity for the α2δ protein. For example, 2-aminomethyl-5-ethyl-nonanoic acid binds with 75 nM affinity to the α2δ protein; (S)-3-amino-5-ethyl-3-methyl-heptanoic acid binds with 149 nM affinity to the α2δ protein; and (3S,5R)-3-amino-3,5-dimethyl-heptanoic acid binds with 236 nM affinity to the α2δ protein.

The in vivo activity of compounds of this invention can be determined in animal models. For animal models related to hyperalgesia, see, e.g., K. Sluka et al., "Unilateral intramuscular injections of acidic saline produce a bilateral, long-lasting hyperalgesia," *Muscle Nerve* 24:37-46 (2001); W. Dixon, "Efficient analysis of experimental observations," *Ann. Rev. Pharmacol. Toxicol.* 20:441-62 (1980); L. O. Randall and J. J. Selitto, "A method for measurement of analgesic activity on inflamed tissue," *Arch. Int. Pharmacodyn* 4:409-19 (1957); K. Hargreaves et al., "A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia," *Pain* 32:77-88 (1988). Fir animal models related to anxiety, see J. R. Vogel et al., "A simple and reliable conflict procedure for testing anti-anxiety agents," *Psychopharmacologia* 21:1-7 (1971).

The compounds of the present invention, and their pharmaceutically acceptable salts, can be administered to mammals via either the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, buccal or intranasal routes.

The novel compounds of the present invention may be administered alone or in combination with pharmaceutically acceptable carriers or diluents by any of the routes previously indicated, and such administration may be carried out in single or multiple doses. More particularly, the novel therapeutic agents of this invention can be administered in a wide variety of different dosage forms; i.e., they may be combined with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, suppositories, jellies, gels, pastes, ointments, aqueous suspensions, injectable solutions, elixirs, syrups, and the like. Such carriers include solid diluents or

fillers, sterile aqueous media and various non-toxic organic solvents, etc. Moreover, oral pharmaceutical compositions can be suitably sweetened and/or flavored. In general, the weight ratio of the novel compounds of this invention to the pharmaceutically acceptable carrier will be in the range from about 1:6 to about 2:1, and preferably from about 1:4 to about 1:1.

For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch (and preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes. Solid compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.

For parenteral administration, solutions of a compound of the present invention in either sesame or peanut oil or in aqueous propylene glycol may be employed. The aqueous solutions should be suitably buffered (preferably pH greater than 8) if necessary and the liquid diluent first rendered isotonic. These aqueous solutions are suitable for intravenous injection purposes. The oily solutions are suitable for intra-articular, intra-muscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art.

For intranasal administration or administration by inhalation, the novel compounds of the invention are conveniently delivered in the form of a

103

solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant, *e.g.*, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurized container or nebulizer may contain a solution or suspension of the active compound. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch. Formulations of the active compounds of this invention for treatment of the conditions referred to above in the average adult human are preferably arranged so that each metered dose or "puff" of aerosol contains 20 μg to 1000 μg of active compound. The overall daily dose with an aerosol will be within the range 100 μg to 10 mg. Administration may be several times daily, for example 2, 3, 4 or 8 times, giving for example, 1, 2 or 3 doses each time.

The compounds of the present invention can be prepared and administered in a wide variety of oral and parenteral dosage forms. Thus, the compounds of the present invention can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally. Also, the compounds of the present invention can be administered by inhalation, for example, intranasally. Additionally, the compounds of the present invention can be administered transdermally. It will be obvious to those skilled in the art that the following dosage forms may comprise as the active component, either a compound of formulas I to VI or a corresponding pharmaceutically acceptable salt of such compound.

For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one

or more substances that may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material. In powders, the carrier is a finely divided solid, which is in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

The powders and tablets preferably contain from five or ten to about seventy percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.

For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.

Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water propylene glycol solutions. For parenteral injection liquid preparations can be formulated in solution in aqueous polyethylene glycol solution. Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing and thickening agents as desired. Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.

Also included are solid form preparations that are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

The pharmaceutical preparation is preferably in unit dosage form. In such form the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsules, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

The quantity of active component in a unit dose preparation may be varied or adjusted from 0.01 mg to 1 g according to the particular application and the potency of the active component. In medical use the drug may be administered three times daily as, for example, capsules of 100 or 300 mg. The composition can, if desired, also contain other compatible therapeutic agents.

In therapeutic use, the compounds utilized in the pharmaceutical method of this invention are administered at the initial dosage of about 0.1 mg to about 1g daily. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages that are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day, if desired.

The following Examples illustrate the preparation of the compounds of the present invention. They are not meant to be limiting in scope. Melting

points are uncorrected. NMR data are reported in parts per million and are referenced to the deuterium lock signal from the sample solvent.

Example 1

(4S,5R)-4-Methyl-3-pentanoyl-5-phenyl-oxazolidin-2-one

To a 0°C stirred solution of valeric acid (3.83 mL, 35.2 mmol) and Et_3N (14.7 mL, 106 mmol) in dry THF (175 mL) was added trimethylacetyl chloride (5.29 mL, 42.3 mmol) dropwise. The mixture was stirred at 0°C for 1 hour and (4S,5R)-(-)-4-methyl-5-phenyl-2-oxazolidinone (7.50 g, 42.3 mmol) was added followed by LiCl (1.79 g, 42.3 mmol). The reaction was warmed to room temperature overnight with good stirring. The mixture was filtered and the filtrate was concentrated under reduced pressure. Et_2O (75 mL) was added to the residue, which was washed with sat. $NaHCO_3$ (3 x 40 mL), 1N HCl (3 x 40 mL), and brine (2 x 40 mL). The organic phase was dried over $MgSO_4$, filtered and concentrated under reduced pressure to give a quantitative yield of crude product.

(4S,5R)-3-((S)-2-Ethyl-pentanoyl)-4-methyl-5-phenyl-oxazolidin-2-one

To a –78°C stirred solution of the (4S,5R)-4-Methyl-3-pentanoyl-5-phenyl-oxazolidin-2-one (9.20 g, 35.2 mmol) in dry THF (150 mL) was added NaHMDS (42.2 mL, 1.0 M in THF) dropwise. After 1 hour, ethyl trifluoromethanesulfonate (5.93 mL, 45.7 mmol) was added dropwise and the reaction was stirred at –78°C for an additional 2 hours. The reaction was warmed to –30°C for 30 minutes and quenched with sat. NH_4Cl. The layers were separated and the aqueous layer was extracted with EtOAc (3 x 40 mL). The organic extracts were combined and washed with brine (2 x 40 mL). The organic phase was dried over $MgSO_4$, filtered, and concentrated under reduced pressure to yield 8.05 g of crude product.

(S)-2-Ethyl-pentan-1-ol

To a room temperature solution of the (4S,5R)-3-((S)-2-ethyl-pentanoyl)-4-methyl-5-phenyl-oxazolidin-2-one (8.05 g, 27.8 mmol) in THF

(200 mL) was added a solution of $NaBH_4$ (4.21 g, 111 mmol) in H_2O (90 mL). The reaction was allowed to stir overnight at room temperature, was quenched with 2N HCl (75 mL) and the layers were separated. The aqueous layer was extracted with EtOAc (4 x 40 mL), and the organic extracts were combined and washed with brine (2 x 30 mL). The organic phase was dried over $MgSO_4$, filtered and concentrated under reduced pressure. The residue was triturated with *n*-hexanes (2 x 20 mL) to remove the oxazolidinone side product. After filtering off the oxazolidinone, the filtrate was concentrated under reduced pressure to yield 2.56 g of crude product.

Methanesulfonic acid (S)-2-ethyl-pentyl ester

To a –10°C stirred solution of (S)-2-ethyl-pentan-1-ol (1.30 g, 11.2 mmol) in dry CH_2Cl_2 (35 mL) was added Et_3N (2.33 mL, 16.8 mmol). The reaction was stirred at this temperature for 15 minutes and methansulfonyl chloride (0.952 mL, 12.3 mmol) was added. The reaction was allowed to warm to room temperature overnight with good stirring. The reaction was washed with 1N HCl (3 x 30 mL), sat. $NaHCO_3$ (3 x 30 mL), and brine (2 x 30 mL). The organic phase was dried over $MgSO_4$, filtered and concentrated under reduced pressure to give a quantitative yield of crude product.

(S)-3-Iodomethyl-hexane

To a stirred solution of methanesulfonic acid (S)-2-ethyl-pentyl ester (2.18 g, 11.2 mmol) in acetone (35 mL) was added NaI (3.36 g, 22.4 mmol) and the reaction was heated to reflux overnight with good stirring. The reaction was allowed to cool to room temperature and the mixture was filtered. The salts were washed with acetone (3 x 15 mL) and H_2O (60 mL) was added to the filtrate. The aqueous phase was extracted with hexanes (4 x 30 mL) and the organic extracts were combined and washed with brine (2 x 30 mL). The organic phase was dried over $MgSO_4$, filtered and concentrated under reduced pressure. The residue was purified by chromatography using hexanes (100%) to yield 1.24 g (49%) of pure product.

(2S,5R)-2-tert-Butyl-5-((S)-2-ethyl-pentyl)-3-methyl-4-oxo-tetrahydro-pyrimidine-1-carboxylic acid methyl ester

To a –78°C stirred solution of (S)-2-tert-butyl-3-methyl-4-oxo-tetrahydro-pyrimidine-1-carboxylic acid methyl ester (1.04 g, 4.57 mmol) in dry THF (15 mL) was added NaHMDS (5.03 mL, 1.0 M in THF) dropwise. The reaction was stirred at –78°C for 1 hour and then a solution of (S)-3-Iodomethyl-hexane (1.24g, 5.48 mmol) in dry THF (5 mL) was added dropwise. The reaction was stirred at this temperature for 2 hours and than was placed in a –10°C refrigerator overnight. The reaction was quenched with sat. NH_4Cl (20 mL) and was allowed to warm to room temperature. The layers were separated and the aqueous layer was extracted with EtOAc (3 x 15 mL). The organic extracts were combined and washed with brine (2 x 15 mL). The organic phase was dried over $MgSO_4$, filtered and concentrated under reduced pressure. The product was purified by chromatography using hexanes/EtOAc (10->20%) to yield 0.185 g (12%) of pure product. ^1H NMR (400 MHz, CD_3OD) δ ppm 0.9 (m, 6 H), 1.3 (m, 5 H), 1.4 (m, 3 H), 1.7 (m, 1 H), 2.5 (m, 1 H), 2.9 (d, J=6.6 Hz, 2 H). MS: M+1 (328).

(2R,4S)-2-Aminomethyl-4-ethyl-heptanoic acid

A stirred solution of (2S,5R)-2-tert-butyl-5-((S)-2-ethyl-pentyl)-3-methyl-4-oxo-tetrahydro-pyrimidine-1-carboxylic acid methyl ester (0.185 g, 0.567 mmol) in a 1:1 mixture of 6N HCl/dioxane (8 mL) was heated at 105°C for 6 days. The reaction was cooled to room temperature and concentrated under reduced pressure. The product was dissolved in 1:1 MeOH/H_2O and loaded onto an ion exchange chromatography column (Varian SCX-Prepacked 10g, 60 mL) and eluted with 1:1 MeOH/H_2O (95%) + NH_4OH. The fractions containing product were collected and concentrated under reduced pressure to yield 0.06 g (57%) of product. ^1H NMR (400 MHz, CD_3OD) δ ppm 0.9 (m, 6 H), 1.3 (m, 5 H), 1.4 (m, 3 H) 1.7 (m, 1 H), 2.5 (m, 1 H), 2.9 (d, J=6.6 Hz, 2 H). MS: M+1 (188).

Using the above methodology the following compounds were also made:

Compound Name	MS, APCI$^+$	^{1}H NMR, 400 MHz, δ, PPM, CD_3OD
(4R)-2-Aminomethyl-4-ethyl-heptanoic acid	188 (M+1)	0.9 (s, 6 H), 1.3 (m, 5 H), 1.4 (m, 3 H), 1.7 (s, 1 H), 2.5 (m, 1 H), 2.9 (d, J=6.1 Hz, 2 H)
(2R,4S)-2-Aminomethyl-4-7-dimethyl-octanoic acid	202 (M+1)	0.9 (d, J=6.6 Hz, 6 H), 0.9 (d, J=6.6 Hz, 3 H), 1.2 (m, 4 H), 1.2 (m, 1 H), 1.4 (m, 1 H), 1.5 (m, 2 H), 1.7 (m, 1 H), 2.5 (m, 1 H), 2.9 (d, 2 H)
(2S,4S)-2-Aminomethyl-4-ethyl-8-methylnonanoic acid	230 (M+1)	2.93(d,2H), 2.47(5-line m,1H),1.72(m,1H), 1.54(7-line m, 1H), 1.42-1.11(m,10H), 0.85(d,3H)
(2R/S,4S)-2-Aminomethyl-8-methyl-4-propyl-nonanoic acid	257 (M+1)	2.93(d,2H), 2.44(5-line m, 1H), 1.72(m,1H), 1.55(7-line m,1H), 1.44(m,1H), 1.40-1.10(m, 11H), 0.89(d,3H)
(2S,4S)-2-Aminomethyl-4-ethyl-6-methyl-heptanoic acid.	202 (M+1)	2.93 (d, 2 H), 2.43 (m, 1 H), 1.71 (m, 1 H), 1.63 (m, 1 H), 1.42 (m, 1 H), 1.36 (m, 2H), 1.22 (m, 1 H), 1.06 (m, 2 H), 0.85 (m, 9 H)
(2R,4S)-2-Aminomethyl-4-ethyl-6-methyl-heptanoic acid	202 (M+1)	2.89 (d, 2 H), 2.43 (m, 1 H), 1.62 (m, 2 H), 1.44 (m, 1 H), 1.34 (m, 1 H), 1.22 (m, 2 H), 1.12 (m, 1 H), 1.05 (m, 1 H), 0.80 (m, 9 H)
(2R,4R)-2-Aminomethyl-4-ethyl-6-methyl-heptanoic acid	202.1 (M+1)	2.90 (d, 2 H), 2.43 (m, 1 H), 1.68 (m, 1 H), 1.61 (m, 1 H), 1.42 (m, 1 H), 1.32 (m, 2 H), 1.21 (m, 1 H), 1.11 (m, 2 H), 0.80 (m, 9 H)

Compound Name	MS, APCI$^+$	^{1}H NMR, 400 MHz, δ, PPM, CD_3OD
(2S,4R)-2-Aminomethyl-4-ethyl-6-methyl-heptanoic acid	202 (M+1)	2.94 (d, 2 H), 2.23 (m, 1 H), 1.62 (m, 2 H), 1.44 (m, 1 H), 1.42 (m, 1 H), 1.22 (m, 2 H), 1.13 (m, 1 H), 1.03 (m, 1 H), 0.85 (m, 9 H)

Example 2

(R)-3-((R)-3-Methyl-hexanoyl)-4-phenyl-oxazolidin-2-one

To the copper (1) bromide dimethylsulfide complex (13.34g, 64.87mmol) in dry THF (150ml) at -30°C under Nitrogen was added a 2M ether solution of Propylmagnesiumchloride (64.87ml, 129.7mmol) and stirred for 20min. (R)-3-But-2-enoyl-4-phenyl-oxazolidin-2-one (15.0g, 64.87mmol) in THF (60ml) was added over a 15 min period at -35°C and let slowly warm up to room temperature over 4hr. The mixture was cooled to 0°C and quenched with saturated ammonium chloride solution. The suspension was extracted into ether, washed with 5% ammonium hydroxide solution and then with brine and dried over $MgSO_4$. The solution was concentrated under reduced pressure to afford the titled compound (13.34g; 100 %) as a white solid. ^{1}H NMR (400 MHz, $CDCl_3$) δ ppm 0.8 (m, 6 H) 1.2 (m, 3 H) 1.6 (s, 1 H) 2.0 (m, 1 H) 2.7 (dd, J=16.1, 8.5 Hz, 1 H) 3.0 (dd, J=15.9, 5.4 Hz, 1 H) 4.3 (dd, J=8.9, 3.8 Hz, 1 H) 4.7 (t, J=8.9 Hz, 1 H) 5.4 (dd, J=8.8, 3.9 Hz, 1 H) 5.4 (dd, J=8.8, 3.9 Hz, 1 H) 7.3 (m, 5 H). MS, m/z (relative intensity): 276 [M+1H, 100%].

(R)-3-((2R,3R)-2,3-Dimethyl-hexanoyl)-4-phenyl-oxazolidin-2-one

To a 1M THF solution of Sodium hexamethyldisylamide (16.2g, 88.3mmol) at -78°C was added via canular a 0°C solution of (R)-3-((R)-3-methyl-hexanoyl)-4-phenyl-oxazolidin-2-one (18.7g, 67.9mmol) in 70ml dry THF. The resulting solution was stirred at -78°C for 30 min. Methyl Iodide (48.2g, 339.5mmol) was added and stirring at -78°C was continued for 4hr. It was quenched with saturated ammonium chloride solution, extracted into

CH_2Cl_2 and washed with 1M sodium Bisulfite. The solution was dried over MgSO4, concentrated and Chromatographed in 10% ethylacetate in hexane to give the titled compound (11.1g, 56.5%) as an oil. MS, m/z (relative intensity): ^{1}H NMR (400 MHz, $CDCl_3$) δ ppm 0.8 (t, J=7.0 Hz, 3 H) 0.9 (d, J=6.6 Hz, 3 H) 1.0 (d, J=6.8 Hz, 3 H) 1.0 (d, J=8.5 Hz, 1 H) 1.1 (m, 1 H) 1.4 (m, 1 H) 1.7 (m, 1 H) 3.7 (m, 1 H) 4.2 (dd, J=8.8, 3.4 Hz, 1 H) 4.6 (t, J=8.7 Hz, 1 H) 5.4 (dd, J=8.7, 3.3 Hz, 1 H) 7.2 (m, 2 H) 7.3 (m, 3 H). MS, m/z (relative intensity):290 [M+1H, 100%].

(2R,3R)-2,3-Dimethyl-hexan-1-ol

A 1M THF solution of LAH (95.9ml, 95.9mmol) was added to (R)-3-((2R,3R)-2,3-dimethyl-hexanoyl)-4-phenyl-oxazolidin-2-one (in THF (300ml) under nitrogen at -78°C and stirred for 3 hr at that temperature. Water was added dropwise to quench the excess LAH and then poured into a mixture of ice and ether. The mixture was extracted into ether, washed with water and dried over $MgSO_4$. The solution was concentrated followed by the addition of excess hexane. The resulting white precipitate was filtered and washed with hexane. The filtrate was concentrated to afford the titled compound (5.05g, 100%) as an oil. ^{1}H NMR (400 MHz, $CDCl_3$) δ ppm 0.9 (m, 9 H) 1.0 (d, J=6.8 Hz, 1 H) 1.1 (m, 1 H) 1.2 (m, 3 H) 1.6 (m, 2 H) 3.4 (m, 1 H) 3.6 (m, 1 H).

(2R,3R)-2,3-Dimethyl-hexanal

Pyridinium chlorochromate (27.35g, 126.9mmol) and neutral alumina (96g, 3.5g per gram of pyridinium chlorochromate) in dry dichloromethane (200ml) was stirred under nitrogen for 0.25hr. (2R,3R)-2,3-Dimethyl-hexan-1-ol (5.0g, 38.46mmol) in dichloromethane (60ml) was added and the resulting dark slurry was stirred at room temperature for 3hr. The slurry was filtered through a short pad of silica eluting with excess dichloromethane. Evaporation of the solvent afforded the titled compound (4.1, 84%) as an oil. ^{1}H NMR (400 MHz, $CDCl_3$) δ ppm 0.8 (m, 3 H) 0.9 (d, J=6.6 Hz, 3 H) 1.0 (d, J=6.6 Hz, 3 H) 1.2 (m, 4 H) 1.8 (m, 1 H) 2.2 (m, 1 H) 9.6 (s, 1H).

112

4-Methyl-benzenesulfinic acid ((2R,3R)-2,3-dimethyl-hexylidene)-amide

Titanium(IV) ethoxide (5.16g, 22.6mmol) and (S)-(+)-p-toluenesulfinamide(7.02g, 45.2mmol) were added to (2R,3R)-2,3-dimethyl-hexanal (2.9g, 22.6mmol) in dry THF (30ml). The resulting mixture was stirred at room temperature for 18 hr and poured into a brine solution (40ml). The slurry was rapidly stirred for 10 minutes and filtered. The filtrate was extracted into ethyl acetate, washed with brine and dried over $MgSO_4$. The solvent was evaporated and the residue was filtered through a silica plug, eluting with 50/50 solution of hexane/ethyl acetate to afford the titled compound (3.1g, 51.6%) as an oil. ^1H NMR (400 MHz, $CDCl_3$) δ ppm 0.8 (m, 6H) 1.1 (m, 4H) 1.3 (m, 3H) 1.7 (m, 1 H) 2.4 (s, 3 H) 2.5 (m, 1H) 7.3 (d, J=8.3 Hz, 2 H) 7.5 (d, J=8.1 Hz, 2 H) 8.1 (d, J=5.4 Hz, 1 H). MS, m/z (relative intensity): 266 [M+1H, 100%].

(4R,5R)-4,5-Dimethyl-(R)-3-(toluene-4-sulfinylamino)-octanoic acid tert-butyl ester

Butyl lithium (26.3ml, 42.04mmol) was added to a solution of diisopropylamine (4.6g, 45.6mmol) in dry THF (40ml) under nitrogen at 0°C and stirred for 20 minutes. The solution was cooled to -78°C followed by the addition of t-butyl acetate (4.1g, 35.0mmol) and stirred at that temperature for 45 minutes. Chlorotitanium triisopropoxide (9.4g, 36.2mmol) was added dropwise and stirring was continued for 30 minutes at -78°C. A -50°C solution of 4-methyl-benzenesulfinic acid ((2R,3R)-2,3-dimethyl-hexylidene)-amide (3.1g, 11.7mmol) in dry THF (10ml) was added to the reaction and the resulting mixture was stirred at -78°C for 4hr. The reaction was quenched with a saturated solution of NaH_2PO_4 and extracted into ethyl acetate. The solution was dried over $MgSO_4$ and concentrated. The resulting residue was chromatographed on silica, eluting with 15% ethyl acetate in hexane to give the titled compound (2.4g, 53.9%) as white solid. 1H NMR (400 MHz, $CDCl_3$) δ ppm 0.9 (m, 6 H) 1.0 (d, J=6.6 Hz, 3 H) 1.1 (m, 1 H) 1.3 (m, 2 H) 1.4 (m, 9

H) 1.5 (m, 2 H) 2.4 (s, 3 H) 2.6 (m, 2 H) 3.8 (m, 1 H) 4.4 (d, J=10.0 Hz, 1 H) 7.3 (d, J=8.1 Hz, 2 H) 7.6 (d, J=8.1 Hz, 2 H). MS, m/z (relative intensity): 382 [M+1H, 100%], 326 [M+1H-C(CH_3)$_3$, 50%].

(3R,4R,5R)-3-Amino-4,5-dimethyl-octanoic acid

To the solution of (4R,5R)-4,5-dimethyl-(R)-3-(toluene-4-sulfinylamino)-octanoic acid tert-butyl ester (1.8g, 4.71mmol) in dry methanol (30ml) at 0°C under nitrogen was added excess trifluoroacetic acid (25ml) and stirred for 2 hr at that temperature. The solution was concentrated to dryness followed by the addition of dry dichloromethane (20ml) and trifluoroacetic acid (20ml). The resulting mixture was stirred for 2 hr under nitrogen and concentrated to dryness. The residue was applied to BondElute SCX ion exchange resin and eluted with water until the eluent was at constant pH of 6.5. The resin was then eluted with a 1:1 solution of methanol and with 10% ammonium hydroxide solution. The ammonium hydroxide solution was evaporated and the residue was crystallized with methanol-acetonitrile mixture to afford the titled compound (0.717g, 81.2%) as a white solid. ^{1}H NMR (400 MHz, CD3OD-D) δ ppm 0.9 (m, 11 H) 1.1 (m, 2 H) 1.3 (m, 1 H) 1.4 (m, 1 H) 1.6 (m, 1 H) 1.7 (m, 2 H) 2.3 (dd, J=16.6, 10.0 Hz, 1 H) 2.5 (dd, J=16.7, 3.5 Hz, 1 H) 3.3 (m, 1 H). MS, m/z (relative intensity): 188 [M+1H, 100%], 186 [M-1H, 100%].

Example 3

(S)-4-Methyl-hexan-2-one (2)

The Grignard reagent made from (S)-1-bromo-2-methyl-butane (10 g, 66.2 mmol) and Mg (1.77 g, 72.8 mmol) in Et_2O (65 ml) was added dropwise to a solution of acetic anhydride (8.1 g, 79.3 mmol) in Et_2O (65 ml) at –78°C in 1 h. Lots of white solid precipitated. The reaction mixture was stirred at -78°C for 1 h. Then the temperature was allowed to slowly rise to RT. The reaction was quenched with saturated NH_4Cl aqueous solution (150 ml). The ether phase was washed by 1 N NaOH (150 ml) and brine (150 ml). Stripped ether at 0°C. The residual oil was dissolved in hexane (50 ml). The solution was

dried by anhydrous Na_2SO4 and evaporated at 0°C under reduced pressure to give (S)-4-methyl-hexan-2-one (5.7 g, 75%) as a light orange oil. ^1H NMR ($CDCl_3$) δ2.26 (m, 2H), 2.08 (s, 3H), 1.86 (m, 1H), 1.21 (m, 2H), 0.83 (m, 6H); MS (APCI) $(M+1)^+$ 115.0.

(S)-2-Methyl-propane-2-sulfinic acid ((3S)-1,3-dimethyl-pentylidene)-amide.

A mixture of (S)-4-methyl-hexan-2-one (1.6 g, 14 mmol), (S)-2-methyl-propane-2-sulfinic acid amide (1.7 g, 14 mmol) and titanium(IV) ethoxide (6.4 g, 28 mmol) in THF (30 ml) was refluxed for 10 h. Then the reaction mixture was poured into brine (150 ml). The mixture was filtered. The filtrate was extracted by EtOAc (3x70 ml). Stripped EtOAc. The residue was purified by a silica gel column (Hexane/EtOAc 3:1) to give the titled compound (1.93 g, 63%) as a colorless oil. ^1H NMR ($CDCl_3$) δ2.24 (m, 2H), 2.27 (s, 3H), 1.85 (m, 1H), 1.22 (m, 2H), 1.20(s, 9H), 0.85 (m, 6H); MS (APCI) $(M+1)^+$ 218.1.

(3*S*,5*S*)-3,5-Dimethyl-3-((S)-2-methyl-propane-2-sulfinylamino)-heptanoic acid methyl ester

To a solution of diisopropylamine (3.1 ml, 22.2 mmol) in THF (40 ml) at -78°C was added butyllithium (14.4 ml, 1.6 M, 23 mmol) slowly. The mixture was stirred at 0°C for 25 min and subsequently cooled down to –78°C. Methyl acetate (1.76 ml, 22.2 mmol) in THF (7 ml) was added. After Stirring for 20 min, chlorotitaniumtriisopropoxide (11 ml, 46.2 mmol) in THF (10 ml) was added and the resulting mixture was stirred at –78°C for 20 min. (S)-2-Methyl-propane-2-sulfinic acid ((3S)-1,3-dimethyl-pentylidene)-amide (1.9 g, 8.9 mmol) in THF (10 ml) was added. The mixture was stirred at –78°C overnight. The reaction was quenched by NH_4Cl solution (50 ml). The mixture was filtered. The filtrate was extracted by EtOAc (3x70 ml). Stripped EtOAc. The residue was purified by a silica gel column (Hexane/EtOAc 1:1) to give the titled compound (1.61 g, 62%) as a colorless oil. ^1H NMR ($CDCl_3$) δ 3.64 (s, 3H), 2.60 (m, 2H), 1.47 (m, 2H), 1.44 (m, 1H), 1.36(s, 3H), 1.27 (m,

2H), 1.19 (s, 9H), 0.90 (d, J=6.4 Hz, 3H), 0.81 (t, J=7.6 Hz, 3H); MS (APCI) $(M+1)^+$ 292.2.

(3S,5S)-3-Amino-3,5-dimethyl-heptanoic acid

A mixture of (3*S*,5*S*)-3,5-dimethyl-3-((S)-2-methyl-propane-2-sulfinylamino)-heptanoic acid methyl ester (0.4 g, 1.37 mmol) and concentrated hydrochloric acid (7.6ml) in acetone (10 ml) was refluxed for 3 h. The solvents were stripped under reduced pressure. The residue was dissolved in water (10 ml) and extracted by EtOAc (2x15 ml). The aqueous phase was evaporated to dryness. The residue was dissolved in a mixture of water (10 ml) and triethylamine (0.5 ml). The mixture was stirred at 40°C for 20 min and then was evaporated to dryness. The residue was washed thoroughly with acetonitrile, filtered, and dried under vacuum to give the final product, (3S,5S)-3-Amino-3,5-dimethyl-heptanoic acid (0.182 g, 77%) as a white solid. m.p. 215-217°C. ^{1}H NMR ($CDCl_3$) δ4.85 (s, 3H), 2.38 (m, 2H), 1.75 (m, 1H), 1.39 (m, 4H), 1.35(s, 3H), 0.98 (d, J=6.6 Hz, 3H), 0.90 (t, J=7.5 Hz, 3H); MS (APCI) $(M+1)^+$ 174.1.

Using the above methodology the following compounds were also made.

Compound Name	MS, APCI$^+$	^{1}H NMR, 400 MHz, δ, PPM, CD_3OD
(3R,5S)-3-Amino-3,5-dimethyl-heptanoic acid	174 (M+1)	4.84 (s, 3H), 2.38 (m, 2H), 1.58 (m, 1H), 1.37 (m, 4H), 1.34(s, 3H), 0.98 (d, J=6.3 Hz, 3H), 0.91 (t, J=7.4 Hz, 3H)
(3S,5R)-3-Amino-3,5-dimethyl-heptanoic acid	174 (M+1)	4.84 (s, 3H), 2.38 (m, 2H), 1.58 (m, 1H), 1.37 (m, 4H), 1.34(s, 3H), 0.98 (d, J=6.3 Hz, 3H), 0.91 (t, J=7.4 Hz, 3H)

Compound Name	MS, APCI$^+$	^{1}H NMR, 400 MHz, δ, PPM, CD_3OD
(3R)-3-Amino-3,5-dimethyl- octanoic acid	188 (M+1)	4.84 (s, 3H), 2.39 (m, 2 H) 1.72 (m, 1H) 1.59 (s, 3 H) 1.38 (m, 6 H) 0.98 (d, J = 6.1Hz, 3H), 0.91 (m, 3H)
(3R, 4R/S)-3-Amino-4-methyl-heptanoic acid	160 (M+1)	0.98 (m, 6 H) 1.20 (m, 1H) 1.32 (m, 1 H) 1.43 (m, 2 H) 1.78 (m, 1 H), 2.32 (m, 1 H) 2.47 (m, 1 H) 3.30 (m, 1 H)
(3S,6R)-3-Amino-8-cyclohexyl-6-methyl-octanoic acid	256 (M+1)	0.87 (m, 2H) 0.88 (dd, J=15.86, 6.10 Hz, 3 H) 1.20 (m, 11 H) 1.39 (m, 4 H) 1.69 (m, 6 H) 2.53 (dd, J=17.32, 8.05 Hz, 1 H) 2.69 (m, 1 H) 3.44 (ddd, J=14.70, 6.89, 4.76 Hz, 1 H)

Example 4

(3R)-(3,7-Dimethyl-oct-6-enyl)-cyclohexane

A flask was charged with 100 mL dry THF and cooled to 0°C. To this flask was added 103 mL (205 mmol) 2 M cyclohexylmagnesium chloride in diethylether. Then 2.30 g (17 mmol) copper (II) chloride was taken up in 60 mL THF and added as a slurry to the Grignard reagent. To this mixture was added 0.73 g (17.1 mmol) lithium chloride, and the mixture was stirred at 0°C for 30 min. Then 13.5 mL (68.4 mmol) of (S)-citronellyl bromide was added, and the mixture was stirred 2 h at 0°C. The reaction mixture was allowed to warm to room temperature and stirred overnight. The reaction was quenched by the addition of sat. aq. NH_4Cl until bubbling ceased. The THF was removed under reduced pressure. The residue was taken up in water and extracted with diethyl ether. The combined ether layers were dried over $MgSO_4$. The drying agent was removed by filtration. The solvent was

117

removed under reduced pressure to yield 11.48 g (76%) of a clear oil. The crude long-chain alkyl was not readily characterized, and was carried on without further purification.

3-((R)-5-Cyclohexyl-3-methyl-pentyl)-2,2-dimethyl-oxirane

A flask was charged with 11.48 g (51.6 mmol) of crude (3R)-(3,7-Dimethyl-oct-6-enyl)-cyclohexane, 100 mL of dichloromethane, and 9.33 g (111 mmol) of sodium bicarbonate. The mixture was cooled in a 0°C bath. Slowly 11.6 mL (55.2 mmol) 32% peracetic acid was added. The mixture was stirred for 4 h at 0°C. Then 10% aqueous sodium sulfite was added slowly until bubbling ceased. The layers were separated, and the organic layer was washed twice with 10 % aqueous sodium sulfite and dried over magnesium sulfate. The drying agent was removed by filtration, and the solvent was removed under reduced pressure. The remaining residue was 10.65 g (87%) of a clear oil. ^{1}H NMR (400 MHz, $CDCl_3$) ppm 0.86 (m, 5 H) 1.00 (d, J=6.59 Hz, 2 H) 1.14 (m, 7 H) 1.25 (s, 3 H) 1.29 (s, 3 H) 1.35 (m, 2 H) 1.50 (m, 3 H) 1.65 (m, 5 H) 2.68 (td, J=6.16, 1.83 Hz, 1 H). MS (APCI) m+1/z = 239.

(R)-6-Cyclohexyl-4-methyl-hexanal

A flask was charged with 10.65 g (44.7 mmol) of 3-((R)-5-cyclohexyl-3-methyl-pentyl)-2,2-dimethyl-oxirane, 70 mL of acetone, 12.3 g (53.6 mmol) of potassium periodate, 70 mL of water, and 0.765 g (4 mmol) of tosic acid-monohydrate. The mixture was stirred for 46 h. The acetone was removed under reduced pressure, and the mixture was diluted with water. The aqueous layer was extracted with hexanes and dried with sodium sulfate. The drying agent was filtered off and solvent was removed under reduced pressure to get 7.12 g (81%) of a clear oil. ^{1}H NMR (400 MHz, $CDCl_3$) ppm 0.87 (m, 5 H) 1.13 (m, 3 H) 1.25 (m, 5 H) 1.66 (m, 8 H) 2.40 (m, 2 H) 9.75 (s, 1 H). MS (APCI) m+1/z is inconclusive.

(R)-6-Cyclohexyl-4-methyl-hexanoic acid

A flask was charged with 7.12 g (36.3 mmol) of (R)-6-cyclohexyl-4-methyl-hexanal, 40 mL water, 20 mL acetone, 4 mL acetic acid, and 6.18 g (39.9 mmol) potassium permanganate. The mixture was stirred vigorously overnight. The mixture was then treated with sat. aqueous sodium bisulfite until the liquid became clear. The liquid was extracted with hexanes. The combined hexane layers were washed with sat. aqueous sodium bisulfite until the hexane layer was clear. The hexane phases were dried with magnesium sulfate. The drying agent was filtered off and the solvent was removed under reduced pressure, which yielded 4.17 g (54%) of a clear oil. ^{1}H NMR (400 MHz, $CDCl_3$) ppm 0.89 (m, 5H), 1.13 (m, 3 H) 1.25 (m, 5 H) 1.66 (m, 8 H) 2.40 (m, 2 H). MS (APCI) m+1/z = 211.

(4R,5S)-3-((R)-6-Cyclohexyl-4-methyl-hexanoyl)-4-methyl-5-phenyl-oxazolidin-2-one

A flask was charged with 4.17 g (19.6 mmol) of (R)-6-cyclohexyl-4-methyl-hexanoic acid, 40 mL of THF, and 8.56 mL (61.4 mmol) of triethylamine. The mixture was cooled in a 0°C bath, and 2.41 mL (19.6 mmol) pivaloyl chloride was added. The mixture was stirred for 1 h at 0°C. Then 2.79 g (16.4 mmol) of (4R,5S)-4-methyl-5-phenyl-2-oxazolidinone and 0.823 g (19.6 mmol) of lithium chloride were added as solids. The mixture was allowed to warm to room temperature and stirred overnight. The resulting solids were filtered off. The solvent was stripped, and the residue was purified by column chromatography (eluent: 4:1 hexanes/ ethyl acetate) to give 6.09 g (quant.) of a clear oil. ^{1}H NMR (400 MHz, $CDCl_3$) δ ppm 0.89 (m, 8 H) 1.16 (m, 6 H) 1.68 (m, 9 H) 2.87 (m, 1 H) 2.99 (m, 1 H) 4.76 (qd, J=6.83, 6.59 Hz, 1 H) 5.66 (d, J=7.32 Hz, 1 H) 7.30 (m, 2 H) 7.40 (m, 3 H). MS (APCI) m+1/z = 372.

(5R,3S)-7-Cyclohexyl-5-methyl-3-((4R,5R)-4-methyl-2-oxo-5-phenyl-oxazolidine-3-carbonyl)-heptanoic acid tert-butyl ester

A dry flask was charged with 60 mL of THF, 2.87 mL (20.5 mmol) of diisopropyl amine, and the resulting solution was cooled in a –78°C bath. To this solution was added 13.3 mL (19.7 mmol) of 1.48 M n-butyl lithium solution. The mixture was allowed to warm to 0°C and was stirred for 30 min. at this temperature. The LDA solution was cooled again to –78°C, and 6.10 g (16.4 mmol) of (4R,5S)-3-((R)-6-cyclohexyl-4-methyl-hexanoyl)-4-methyl-5-phenyl-oxazolidin-2-one was added dropwise as a solution in 35 mL of THF. The mixture was stirred for 45 min. at –78°C, and was then allowed to warm slowly to –20°C over 2.5 h. The reaction mixture was quenched by the addition of sat. aq. ammonium chloride. The solvent was removed under reduced pressure, and the residue was partitioned between diethyl ether and water. The ether layer was collected and washed successively with sat. aq. ammonium chloride solution and sat. aq. sodium bicarbonate solution. The ether layer was dried with magnesium sulfate. The solvent was removed under reduced pressure, and the residue was purified by column chromatography (eluent 10:1 hexanes: ethyl acetate). This gave 4.13 g (52%) of a white solid. ^{1}H NMR (400 MHz, $CDCl_3$) δ ppm 0.88 (m, 8 H) 1.14 (m, 8 H) 1.39 (m, 12 H) 1.67 (m, 6 H) 2.41 (dd, *J*=16.47, 5.00 Hz, 1 H) 2.70 (dd, *J*=16.47, 9.64 Hz, 1 H) 4.31 (m, *J*=9.58, 7.29, 7.29, 5.12 Hz, 1 H) 4.75 (qd, *J*=6.75, 6.59 Hz, 1 H) 5.64 (d, *J*=7.08 Hz, 1 H) 7.31 (m, 2 H) 7.38 (m, 3 H). MS (APCI) m+1/z = 430 (loss of t-Bu group).

(S)-2-((R)-4-Cyclohexyl-2-methyl-butyl)-succinic acid 4-tert-butyl ester

A flask was charged with 4.13 g (8.50 mmol) of (5R,3S)-7-cyclohexyl-5-methyl-3-((4R,5R)-4-methyl-2-oxo-5-phenyl-oxazolidine-3-carbonyl)-heptanoic acid tert-butyl ester, 100 mL of THF, 25 mL of water, and the resulting mixture was cooled in a 0°C bath. To this solution was added 0.57 g (13.6 mmol) of lithium hydroxide monohydrate and 3.48 mL (34 mmol) of 30% hydrogen peroxide. The mixture was stirred 2.5 h. The reaction was quenched by the addition of 4.29 g (34 mmol) of sodium sulfite in 26 mL water. The mixture

was allowed to warm to room temperature and stirred overnight. The THF was removed under reduced pressure and the remaining material was further diluted with water. The water layer was made acidic by the slow addition of conc. HCl aq. The aqueous layer was extracted with dichloromethane. The organic layers were dried with magnesium sulfate. The resulting oil was purified by column chromatography (eluent 3:1 hexanes: ethyl acetate). This gave 2.19 g (79%) of a clear oil. ^{1}H NMR (400 MHz, $CDCl_3$) δ ppm 0.88 (m, 5 H) 1.17 (m, 10 H) 1.43 (s, 10 H) 1.68 (m, 7 H) 2.35 (dd, *J*=16.35, 5.37 Hz, 1 H) 2.60 (m, 1 H) 2.87 (m, *J*=9.09, 9.09, 5.61, 5.49 Hz, 1 H). MS (APCI) m+1/z is inconclusive.

(3S,5R)-3-Amino-7-cyclohexyl-5-methyl-heptanoic acid methyl ester

A flask was charged with 2.19 g (6.71 mmol) of (S)-2-((R)-4-cyclohexyl-2-methyl-butyl)-succinic acid 4-tert-butyl ester, 40 mL of toluene, 0.935 mL (6.71 mmol) of triethylamine, and 1.45 mL (6.71 mmol) of diphenylphosphorylazide. The mixture was stirred for 15 min. at room temperature and then heated to 110°C and stirred for 6 h. The toluene was removed under reduced pressure, and the residue was taken up in diethyl ether. The ether layer was washed with 3M HCl aq., water, and brine. The ether was removed under reduced pressure, and the crude isocyanate was taken up in 3 M HCl aq. and heated at reflux for 8 h. The water was removed under reduced pressure, and the residue was triturated with ether. This provided 1.45 g of an impure white solid. A portion of the white solid was dissolved in methanol, and HCl gas was bubbled through for 15 minutes. The acidic solution was stirred 2 hours. The methanol was removed under reduced pressure, and the crude ester was purified by column chromatography (4:1 dichloromethane: methanol). This gave 0.356 g of the pure ester. ^{1}H NMR (400 MHz, $CDCl_3$) δ ppm 0.85 (m, 2 H) 0.88 (d, *J*= 8.00 Hz, 3 H) 1.15 (m, 6 H) 1.26 (m, 1 H) 1.36 (ddd, *J*=13.73, 9.21, 4.64 Hz, 1 H) 1.51 (m, 1 H) 1.65 (m, 7 H) 2.28 (dd, *J*=15.86, 8.78 Hz, 1 H) 2.43 (dd, J= 16.0, 4.00 Hz, 1 H) 3.28 (m, *J*=8.97, 8.97, 4.39, 4.27 Hz, 1 H) 3.69 (s, 3 H). MS (APCI) m+1/z = 256.

(3S,5R)-3-Amino-7-cyclohexyl-5-methyl-heptanoic acid

A flask was charged with 0.356 g of (3S,5R)-3-amino-7-cyclohexyl-5-methyl-heptanoic acid methyl ester and 20 mL of 3 M HCl, and the mixture was heated at reflux overnight. The mixture was cooled to room temperature and the solvent was removed under reduced pressure. This provided 0.340 g (88%) of a white solid HCl salt. ^{1}H NMR (400 MHz, CD_3OD) δ ppm 0.87 (s, 2H) 0.95 (d, J=6.34 Hz, 3H) 1.21 (m, 6 H) 1.35 (m, 1 H) 1.43 (ddd, J=13.85, 8.24, 5.98 Hz, 1 H) 1.55 (ddd, J=12.81, 6.34, 6.22 Hz, 1 H) 1.64 (dd, J=8.30, 5.37 Hz, 2 H) 1.71 (m, 5 H) 2.57 (dd, J=17.45, 7.44 Hz, 1 H) 2.70 (m, 1H) 3.59 (m, J=7.72, 7.72, 5.73, 5.43 Hz, 1 H). MS (APCI) m+1/z = 242.

Example 5

(4R,5S)-3-[3-(2,4-Difluoro-phenyl)-propionyl]-4-methyl-5-phenyl-oxazolidin-2-one

A flask was charged with 29.5 g (158 mmol) of 3-(2,4-difluoro-phenyl)-propionic acid, 700 mL of THF, and 82.8 mL of triethylamine. The mixture was cooled to 0°C and 23.4 mL of trimethyl acetyl chloride was added slowly. The mixture was stirred cold for 1 h. Then 8.06 g (190 mmol) of LiCl and 28.1 g of (4S,5R)-4-methyl-5-phenyl-oxazolidin-2-one was added. The mixture was allowed to warm room temperature and stirred overnight. The solids were filtered off, and the solvent was removed under reduced pressure. The residue was taken up in diethyl ether and washed with sat. aq. ammonium chloride, sat. aq. sodium bicarbonate, and the solvent was removed under reduced pressure. The crude residue was purified by column chromatography (3:1 dichloromethane/ hexanes eluent) to give 54 g (99%) of the titled compound.

(4R,5S)-[(S)-2-(2,4-Difluoro-benzyl)-butyryl]-4-methyl-5-phenyl-oxazolidin-2-one

A flask was charged with 54 g (156 mmol) of (4R,5S)-3-[3-(2,4-difluoro-phenyl)-propionyl]-4-methyl-5-phenyl-oxazolidin-2-one and 300 mL of dry

THF, and the solution was cooled to –78°C. To this solution was added 172 mL (172 mmol) of 1 M NaHMDS in THF, and the mixture was stirred cold for 1 h. Then 30.6 g (172 mmol) of ethyl triflate was added dropwise to the enolate solution, and the reaction mixture was warmed to –40 to –30°C and stirred for 1.5 h. The reaction mixture was quenched by the addition of aqueous brine. The THF was removed under reduced pressure and the residue was partitioned between EtOAc and water. The organics were collected, and EtOAc was removed under reduced pressure. The resulting crude oil was purified by column chromatography (3:1 hexanes/ EtOAc eluent) to get 29.5 g of an impure oil that was used without further purification.

(S)-2-(2,4-Difluoro-benzyl)-butan-1-ol

A flask was charged with 29.5 g (~78.6 mmol) of (4R,5S)-[(S)-2-(2,4-difluoro-benzyl)-butyryl]-4-methyl-5-phenyl-oxazolidin-2-one and 200 mL dry THF, and the solution was cooled to 0°C. In a separate flask, 11.9 g (314 mmol) of sodium borohydride was taken up in 70 mL water and added dropwise over 15 minutes to the imide solution. The mixture was allowed to warm to room temperature and stirred overnight. The reaction mixture was quenched with conc. HCl until pH = 3 (keeping the reaction mixture temperature < 20°C). THF was removed under reduced pressure, and the residue was taken up in hexanes. The hexane layer was washed with sat. aq. sodium bicarbonate. The hexane layer was removed under reduced pressure, and the residue was purified by column chromatography (9:1 Hexanes/ EtOAc) which gave 7.2 g (46%) of (S)-2-(2,4-difluoro-benzyl)-butan-1-ol as a clear oil.

(2S)-Methanesulfonic acid 2-(2,4-difluoro-benzyl)-butyl ester

A flask was charged with 7.2 g (36 mmol) of (S)-2-(2,4-difluoro-benzyl)-butan-1-ol and 30 mL of dichloromethane, and the solution was cooled to 0°C. To this solution was added 7.53 mL (54 mmol) of triethylamine, and the mixture was stirred cold for 5 min. Then 3.1 mL (39.6 mmol) of methane sulfonyl chloride was added dropwise. The reaction mixture was stirred at

room temperature for 16 h. The dichloromethane was removed under reduced pressure, and the residue was partitioned between 1 N HCl aq. and diethyl ether. The ether layer was collected and washed with sat. aq. sodium bicarbonate, water, and brine. The ether layer was dried over sodium sulfate, filtered, and the ether was removed under reduced pressure. This procedure gave 9.54 g (95%) of (2S)-methanesulfonic acid 2-(2,4-difluoro-benzyl)-butyl ester as an orange oil. This material was used without further purification.

(S)-2,4-Difluoro-1-(2-iodomethyl-butyl)-benzene

A flask was charge with 9.54 g (34.3 mmol) of (2S)-methanesulfonic acid 2-(2,4-difluoro-benzyl)-butyl ester, 10.3 g (68.6 mmol) of sodium iodide, and 60 mL of acetone. The solution was heated at reflux for 30 h. The acetone was removed under reduced pressure. The residue was partitioned between water and hexanes. The organic layer was collected and washed with sodium bisulfite solution and brine. The hexane was removed under reduced pressure, and the crude oil was purified by column chromatography (hexanes eluent). This procedure gave 9.7 g (91%) of (S)-2,4-difluoro-1-(2-iodomethyl-butyl)-benzene as a clear oil.

2-tert-Butyl-5-[2-(2,4-difluoro-benzyl)-butyl]-3-methyl-4-oxo-tetrahydro-pyrimidine-1-carboxylic acid methyl ester

A flask was charged with 1.35 mL (9.64 mmol) diisopropyl amine and 15 mL dry THF. The solution was cooled to –78°C and 6.0 mL (9.64 mmol) 1.6 M n-butyl lithium solution in hexanes was added. The mixture was warmed to 0°C and stirred for 30 minutes. The mixture was cooled again to -78°C and 2.0 g (8.76 mmol) of (2S)-2-tert-butyl-3-methyl-4-oxo-tetrahydro-pyrimidine-1-carboxylic acid methyl ester was added as a solution in 10 mL of THF. This mixture was warmed to 0°C and stirred for 1 h. The anion solution was cooled again to –78°C and 2.99 g (9.64 mmol) of (S)-2,4-difluoro-1-(2-iodomethyl-butyl)-benzene was added as a solution in THF. The mixture was stirred at –78°C for 4 h. The reaction mixture was warmed to –21°C and stirred at that temperature for 5 days. The reaction mixture was quenched

with sat. aq. ammonium chloride solution. The crude reaction mixture was extracted with diethyl ether. The ether was removed under reduced pressure, and the crude residue was purified by column chromatography (9:1 hexanes/ EtOAc eluent) which gave 1.67 g (46%) of 2-tert-butyl-5-[2-(2,4-difluoro-benzyl)-butyl]-3-methyl-4-oxo-tetrahydro-pyrimidine-1-carboxylic acid methyl ester as a white solid.

(2R,4R)-2-Aminomethyl-4-(2,4-difluoro-benzyl)-hexanoic acid

A flask was charged with 0.5 g (1.2 mmol) of 2-tert-butyl-5-[2-(2,4-difluoro-benzyl)-butyl]-3-methyl-4-oxo-tetrahydro-pyrimidine-1-carboxylic acid methyl ester, 20 mL dioxane, and 20 mL of conc. HCl solution. The mixture was stirred and heated at 110°C for 4 days. The solvents were removed under reduced pressure. The residue was taken up in 20 mL water and 4 drops of conc. HCl solution. The aqueous layer was washed with dichloromethane. The aqueous layer was collected and the water was removed under reduced pressure. The residue was treated with 2 mL of triethylamine, and the excess triethylamine was removed under reduced pressure. The remaining solid was purified by column chromatography (1:8:27 NH_4OH, MeOH, dichloromethane eluent). The resulting white solid was washed with acetonitrile and dried under vacuum. This gave 80 mg (24%) of (2R,4R)-2-aminomethyl-4-(2,4-difluoro-benzyl)-hexanoic acid as a white solid.

It should be noted that, as used in this specification and the appended claims, singular articles such as "a," "an," and "the," may refer to a single object or to a plurality of objects unless the context clearly indicates otherwise. Thus, for example, reference to a composition containing "a compound" may include a single compound or two or more compounds.


It is to be understood that the above description is intended to be illustrative and not restrictive. Many embodiments will be apparent to those of skill in the art upon reading the above description. The scope of the invention should, therefore, be determined not with reference to the above description,

but should instead be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled.

CLAIMS

WHAT IS CLAIMED IS:

1. A compound of formula I



I

or a pharmaceutically acceptable salt thereof, wherein

R_1 is a hydrogen atom or $(C_1$-$C_6)$alkyl optionally substituted with from one to five fluorine atoms;

R_2 is a hydrogen atom or $(C_1$-$C_6)$alkyl optionally substituted with from one to five fluorine atoms; or

R_1 and R_2, together with the carbon to which they are attached, form a three- to six-membered cycloalkyl ring;

R_3 is a hydrogen atom, $(C_1$-$C_6)$alkyl, $(C_3$-$C_6)$cycloalkyl, $(C_3$-$C_6)$cycloalkyl-$(C_1$-$C_3)$alkyl, phenyl, phenyl-$(C_1$-$C_3)$alkyl, pyridyl, or pyridyl-$(C_1$-$C_3)$alkyl, wherein the alkyl and cycloalkyl moieties or substituents are optionally substituted with from one to five fluorine atoms, and the phenyl and pyridyl substituents and the phenyl and pyridyl moieties of the phenyl-$(C_1$-$C_3)$alkyl and the pyridyl-$(C_1$-$C_3)$alkyl substituents are optionally substituted with from one to five substituents independently selected from chloro, fluoro, amino, nitro, cyano, hydroxy, $(C_1$-$C_3)$alkylamino, $(C_1$-$C_3)$alkyl optionally substituted with from one to three fluorine atoms, and $(C_1$-$C_3)$alkoxy optionally substituted with from one to three fluorine atoms;

R_4 is a hydrogen atom or $(C_1$-$C_6)$alkyl optionally substituted with from one to five fluorine atoms;


R_5 is a hydrogen atom or $(C_1$-$C_6)$alkyl optionally substituted with from one to five fluorine atoms;

R_4 and R_5, together with the carbon to which they are attached, form a three- to six-membered cycloalkyl ring; and

R_6 is a hydrogen atom or $(C_1$-$C_6)$alkyl;

with the proviso that R_1, R_2, R_3, R_4, R_5, and R_6 are not simultaneously hydrogen atoms.


2. A compound of Claim 1 having a structure represented by formula II



II

or a pharmaceutically acceptable salt thereof, wherein R_1, R_3, and R_4 are defined as in Claim 1 with the proviso that R_1 is not a hydrogen atom.


3. A compound of Claim 1 having a structure represented by formula III



III

or a pharmaceutically acceptable salt thereof, wherein R_1 and R_3 are defined as in Claim 1 with the proviso that R_1 and R_3 are not hydrogen atoms.


4. A compound of Claim 3 having a structure represented by formula IV



IV

or a pharmaceutically acceptable salt thereof, wherein R_3 is defined as in Claim 1 with the proviso that R_3 is not a hydrogen atom.


5. A compound of Claim 1 having a structure represented by formula V



V

or a pharmaceutically acceptable salt thereof, wherein R_1, R_2, R_3, R_4, and R_5 are defined as in Claim 1 with the proviso that R_1, R_2, R_3, R_4, and R_5 are not simultaneously hydrogen atoms.

6. A compound of Claim 1 having a structure represented by formula VI



VI

or a pharmaceutically acceptable salt thereof, wherein R_3, R_4, and R_5 are defined as in Claim 1 with the proviso that R_3, R_4, and R_5 are not simultaneously hydrogen atoms.

7. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

8. A method of treating a disorder or condition in a mammal, including a human, the disorder or condition selected from:

epilepsy, faintness attacks, fibromyalgia, hypokinesia, cranial disorders, hot flashes, and essential tremor;

chemical dependencies and addictions to alcohol, amphetamines or amphetamine-like substances, caffeine, cannabis, cocaine, heroin, hallucinogens, tobacco, inhalants and aerosol propellants, nicotine, opioids, phenylglycidine derivatives, sedatives, hypnotics, benzodiazepines and other anxiolytics;

withdrawal symptoms associated with the dependencies, addictions, or addictive behaviors, including gambling; and

migraine, spasticity, muscle spasticity, hypotonia with paralysis, arthritis, irritable bowel syndrome, chronic pain, acute pain, neuropathic pain, post herpetic neuralgia, lower back pain, surgical pain, vascular headache, sinus headache, chronic headache, inflammatory disorders, rheumatoid arthritis, osteoarthritis, psoriasis, disease modification of osteoarthritis disease, diuresis, premenstrual syndrome, premenstrual dysphoric disorder, tinnitus, and gastric damage;

the method comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof.

9. A method of treating a disorder or condition in a mammal, including a human, the disorder or condition selected from:

delirium, dementia, and amnestic or other cognitive or neurodegenerative disorders, including Parkinson's disease, Huntington's disease, Alzheimer's disease, senile dementia, dementia of the Alzheimer's type, memory disorder, vascular dementia, and other dementias, including dementia due to HIV disease, head trauma, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, or due to multiple aetiologies;

movement disorders including akinesias, dyskinesias, including familial paroxysmal dyskinesias, spasticities, Tourette's syndrome, Scott syndrome, PALSYS and akinetic-rigid syndrome;

extra-pyramidal movement disorders including medication-induced movement disorders, including neuroleptic-induced Parkinsonism, neuroleptic malignant syndrome, neuroleptic-induced acute dystonia, neuroleptic-induced acute akathisia, neuroleptic-induced tardive dyskinesia and medication-induced postural tremour;

Down's syndrome;

demyelinating diseases including multiple sclerosis and amylolateral sclerosis, peripheral neuropathy, including diabetic and chemotherapy-induced-neuropathy, or postherpetic neuralgia, trigeminal neuralgia, segmental or intercostal neuralgia and other neuralgias; and

cerebral vascular disorders due to acute or chronic cerebrovascular damage including cerebral infarction, subarachnoid haemorrhage or cerebral oedema;

the method comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof.

10. A method of treating a disorder or condition in a mammal, including a human, the disorder or condition selected from sleep disorders, insomnia, drug-associated sleeplessness, REM sleep disorders, hypersomnia, narcolepsy, sleep-wake cycle disorders, sleep apnea syndromes, parasomnias, restless leg syndrome, jet lag, periodic limb movement disorder, altered sleep architecture, or sleep disorders associated with shift work and irregular work hours, the method comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof.

11. A method of treating a disorder or condition in a mammal, including a human, the disorder or condition selected from:

mood disorders, including depression or depressive disorders, including single episodic or recurrent major depressive disorders, dysthymic disorders, depressive neurosis and neurotic depression, melancholic

depression, including anorexia, weight loss, insomnia, early morning waking and psychomotor retardation, atypical depression or reactive depression, including increased appetite, hypersomnia, psychomotor agitation or irritability, seasonal affective disorder and pediatric depression;

bipolar disorders or manic depression, including bipolar I disorder, bipolar II disorder and cyclothymic disorder;

conduct disorder and disruptive behavior disorder;

anxiety disorders, including panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobias, including specific animal phobias, social anxiety, social phobia, obsessive-compulsive disorder, stress disorders, including post-traumatic stress disorder and acute stress disorder, and generalized anxiety disorders;

borderline personality disorder;

schizophrenia and other psychotic disorders, including schizophreniform disorders, schizoaffective disorders, delusional disorders, brief psychotic disorders, shared psychotic disorders, psychotic disorders with delusions or hallucinations, psychotic episodes of anxiety, anxiety associated with psychosis, psychotic mood disorders including severe major depressive disorder;

mood disorders associated with psychotic disorders including acute mania and depression associated with bipolar disorder, mood disorders associated with schizophrenia; and

behavioral disturbances associated with mental retardation, autistic disorder, and conduct disorder;

the method comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof.

12. A compound selected from the following compounds and their pharmaceutically acceptable salts:

3-Amino-4,5-dimethyl-hexanoic acid;

3-Amino-4,5-dimethyl-heptanoic acid;

3-Amino-4,5-dimethyl-octanoic acid;
3-Amino-4,5-dimethyl-nonanoic acid;
3-Amino-4,5-dimethyl-decanoic acid;
3-Amino-4-ethyl-5-methyl-heptanoic acid;
3-Amino-4-ethyl-5-methyl-octanoic acid;
3-Amino-4-ethyl-5-methyl-nonanoic acid;
3-Amino-4-ethyl-5,6-dimethyl-heptanoic acid;
3-Amino-4-ethyl-5,7-dimethyl-octanoic acid;
3-Amino-4-ethyl-5,8-dimethyl-nonanoic acid;
3-Amino-5-ethyl-4-methyl-octanoic acid;
3-Amino-5-ethyl-4-methyl-nonanoic acid;
3-Amino-4,5-diethyl-heptanoic acid;
3-Amino-4,5-diethyl-octanoic acid;
3-Amino-4,5-diethyl-nonanoic acid;
3-Amino-5-ethyl-4,7-dimethyl-octanoic acid;
3-Amino-5-ethyl-4,8-dimethyl-nonanoic acid;
3-Amino-4,5-diethyl-6-methyl-heptanoic acid;
3-Amino-4,5-diethyl-7-methyl-octanoic acid;
3-Amino-4,5-diethyl-8-methyl-nonanoic acid;
3-Amino-4,5,6-trimethyl-heptanoic acid;
3-Amino-4,5,7-trimethyl-octanoic acid;
3-Amino-4,5,8-trimethyl-nonanoic acid;
3-Amino-4-ethyl-5-methyl-hexanoic acid;
3-Amino-5-ethyl-4-methyl-octanoic acid;
3-Amino-5-ethyl-4-methyl-heptanoic acid;
3-Amino-4-methyl-5-propyl-octanoic acid;
3-Amino-4-methyl-6-ethyl-octanoic acid;
3-Amino-4-methyl-6-ethyl-nonanoic acid;
3-Amino-4,6-diethyl-octanoic acid;
3-Amino-4,6-diethyl-nonanoic acid;
3-Amino-6-cyclopentyl-4,5-dimethyl-hexanoic acid;
3-Amino-7-cyclopentyl-4,5-dimethyl-heptanoic acid;

3-Amino-5-ethyl-4,6-dimethyl-heptanoic acid;
3-Amino-5-ethyl-4,7-dimethyl-octanoic acid;
3-Amino-5-ethyl-4,8-dimethyl-nonanoic acid;
(3R,4R)-3-Amino-4,5-dimethyl-hexanoic acid;
(3R,4R,5R)-3-Amino-4,5-dimethyl-heptanoic acid;
(3R,4R,5R)-3-Amino-4,5-dimethyl-octanoic acid;
(3R,4R,5R)-3-Amino-4,5-dimethyl-nonanoic acid;
(3R,4R,5R)-3-Amino-4,5-dimethyl-decanoic acid;
3-Amino-5-cyclopropyl-4-ethyl-hexanoic acid;
3-Amino-6-cyclopropyl-4-ethyl-5-methyl-hexanoic acid;
3-Amino-5-cyclobutyl-4-ethyl-hexanoic acid;
3-Amino-6-cyclobutyl-4-ethyl-5-methyl-hexanoic acid;
3-Amino-5-cyclopentyl-4-methyl-hexanoic acid;
3-Amino-6-cyclopentyl-4-ethyl-5-methyl-hexanoic acid;
3-Amino-5-cyclohexyl-4-ethyl-hexanoic acid;
3-Amino-6-cyclohexyl-4-ethyl-5-methyl-hexanoic acid;
3-Amino-5-cyclopropyl-4-methyl-hexanoic acid;
3-Amino-6-cyclopropyl-4,5-dimethyl-hexanoic acid;
3-Amino-5-cyclobutyl-4-methyl-hexanoic acid;
3-Amino-6-cyclobutyl-4,5-dimethyl-hexanoic acid;
3-Amino-5-cyclopentyl-4-methyl-hexanoic acid;
3-Amino-6-cyclopentyl-4,5-dimethyl-hexanoic acid;
3-Amino-5-cyclohexyl-4-methyl-hexanoic acid;
3-Amino-6-cyclohexyl-4,5-dimethyl-hexanoic acid;
3-Amino-8-cyclohexyl-4,5-dimethyl-octanoic acid;
3-Amino-8-cyclohexyl-4,5-dimethyl-octanoic acid;
3-Amino-4,6-dimethyl-heptanoic acid;
3-Amino-4,6-dimethyl-octanoic acid;
3-Amino-4,6-dimethyl-nonanoic acid;
3-Amino-4,6-dimethyl-decanoic acid;
3-Amino-4,6,7-trimethyl-octanoic acid;
3-Amino-4,6,8-trimethyl-nonanoic acid;

3-Amino-4,6,9-trimethyl-decanoic acid;
3-Amino-6-cyclopropyl-4-methyl-heptanoic acid;
3-Amino-6-cyclobutyl-4-methyl-heptanoic acid;
3-Amino-6-cyclopentyl-4-methyl-heptanoic acid;
3-Amino-6-cyclohexyl-4-methyl-heptanoic acid;
3-Amino-7-cyclopropyl-4,6-dimethyl-heptanoic acid;
3-Amino-7-cyclobutyl-4,6-dimethyl-heptanoic acid;
3-Amino-7-cyclopentyl-4,6-dimethyl-heptanoic acid;
3-Amino-7-cyclohexyl-4,6-dimethyl-heptanoic acid;
3-Amino-8-cyclopropyl-4,6-dimethyl-octanoic acid;
3-Amino-8-cyclobutyl-4,6-dimethyl-octanoic acid;
3-Amino-8-cyclopentyl-4,6-dimethyl-octanoic acid;
3-Amino-8-cyclohexyl-4,6-dimethyl-octanoic acid;
3-Amino-6-(3-chloro-phenyl)-4-methyl-heptanoic acid;
3-Amino-6-(3,4-dichloro-phenyl)-4-methyl-heptanoic acid;
3-Amino-4-methyl-6-(3-trifluoromethyl-phenyl)-heptanoic acid;
3-Amino-4-methyl-6-(4-trifluoromethyl-phenyl)-heptanoic acid;
3-Amino-7-(3-chloro-phenyl)-4,6-dimethyl-heptanoic acid;
3-Amino-7-(3,4-dichloro-phenyl)-4,6-dimethyl-heptanoic acid;
3-Amino-4,6-dimethyl-7-(3-trifluoromethyl-phenyl)-heptanoic acid;
3-Amino-4,6-dimethyl-7-(4-trifluoromethyl-phenyl)-heptanoic acid;
3-Amino-8-(3-chloro-phenyl)-4,6-dimethyl-octanoic acid;
3-Amino-8-(3,4-dichloro-phenyl)-4,6-dimethyl-octanoic acid;
3-Amino-4,6-dimethyl-8-(3-trifluoromethyl-phenyl)-octanoic acid;
3-Amino-4,6-dimethyl-8-(4-trifluoromethyl-phenyl)-octanoic acid;
3-Amino-4-ethyl-6-methyl-octanoic acid;
3-Amino-4-ethyl-6-methyl-nonanoic acid;
3-Amino-4-ethyl-6-methyl-decanoic acid;
3-Amino-4-ethyl-6,7-dimethyl-octanoic acid;
3-Amino-4-ethyl-6,8-dimethyl-nonanoic acid;
3-Amino-4-ethyl-6,9-dimethyl-decanoic acid;
3-Amino-6-cyclopropyl-4-ethyl-heptanoic acid;

3-Amino-6-cyclobutyl-4-ethyl-heptanoic acid;
3-Amino-6-cyclopentyl-4-ethyl-heptanoic acid;
3-Amino-6-cyclohexyl-4-ethyl-heptanoic acid;
3-Amino-7-cyclopropyl-4-ethyl-6-methyl-heptanoic acid;
3-Amino-7-cyclobutyl-4-ethyl-6-methyl-heptanoic acid;
3-Amino-7-cyclopentyl-4-ethyl-6-methyl-heptanoic acid;
3-Amino-7-cyclohexyl-4-ethyl-6-methyl-heptanoic acid;
3-Amino-8-cyclopropyl-4-ethyl-6-methyl-octanoic acid;
3-Amino-8-cyclobutyl-4-ethyl-6-methyl-octanoic acid;
3-Amino-8-cyclopentyl-4-ethyl-6-methyl-octanoic acid;
3-Amino-8-cyclohexyl-4-ethyl-6-methyl-octanoic acid;
3-Amino-6-(3-chloro-phenyl)-4-ethyl-heptanoic acid;
3-Amino-6-(3,4-dichloro-phenyl)-4-ethyl-heptanoic acid;
3-Amino-4-ethyl-6-(3-trifluoromethyl-phenyl)-heptanoic acid;
3-Amino-4-ethyl-6-(4-trifluoromethyl-phenyl)-heptanoic acid;
3-Amino-7-(3-chloro-phenyl)-4-ethyl-6-methyl-heptanoic acid;
3-Amino-7-(3,4-dichloro-phenyl)-4-ethyl-6-methyl-heptanoic acid;
3-Amino-4-ethyl-6-methyl-7-(3-trifluoromethyl-phenyl)-heptanoic acid;
3-Amino-4-ethyl-6-methyl-7-(4-trifluoromethyl-phenyl)-heptanoic acid;
3-Amino-8-(3-chloro-phenyl)-4-ethyl-6-methyl-octanoic acid;
3-Amino-8-(3,4-dichloro-phenyl)-4-ethyl-6-methyl-octanoic acid;
3-Amino-4-ethyl-6-methyl-8-(3-trifluoromethyl-phenyl)-octanoic acid;
3-Amino-4-ethyl-6-methyl-8-(4-trifluoromethyl-phenyl)-octanoic acid;
3-Amino-4-methyl-heptanoic acid;
3-Amino-4,6-dimethyl-heptanoic acid;
3-Amino-4,7-dimethyl-octanoic acid;
3-Amino-4,8-dimethyl-nonanoic acid;
3-Amino-4-methyl-hexanoic acid;
3-Amino-4-methyl-heptanoic acid;
3-Amino-4-methyl-octanoic acid;
3-Amino-4-methyl-nonanoic acid;
3-Amino-5-cyclopropyl-4-methyl-pentanoic acid;

136

3-Amino-6-cyclopropyl-4-methyl-hexanoic acid;
3-Amino-7-cyclopropyl-4-methyl-heptanoic acid;
3-Amino-5-cyclobutyl-4-methyl-pentanoic acid;
3-Amino-6-cyclobutyl-4-methyl-hexanoic acid;
3-Amino-7-cyclobutyl-4-methyl-heptanoic acid;
3-Amino-5-cyclopentyl-4-methyl-pentanoic acid;
3-Amino-6-cyclopentyl-4-methyl-hexanoic acid;
3-Amino-7-cyclopentyl-4-methyl-heptanoic acid;
3-Amino-5-cyclohexyl-4-methyl-pentanoic acid;
3-Amino-6-cyclohexyl-4-methyl-hexanoic acid;
3-Amino-7-cyclohexyl-4-methyl-heptanoic acid;
3-Amino-5-cyclopropyl-4-ethyl-pentanoic acid;
3-Amino-6-cyclopropyl-4-ethyl-hexanoic acid;
3-Amino-7-cyclopropyl-4-ethyl-heptanoic acid;
3-Amino-5-cyclobutyl-4-ethyl-pentanoic acid;
3-Amino-6-cyclobutyl-4-ethyl-hexanoic acid;
3-Amino-7-cyclobutyl-4-ethyl-heptanoic acid;
3-Amino-5-cyclopentyl-4-ethyl-pentanoic acid;
3-Amino-6-cyclopentyl-4-ethyl-hexanoic acid;
3-Amino-7-cyclopentyl-4-ethyl-heptanoic acid;
3-Amino-5-cyclohexyl-4-ethyl-pentanoic acid;
3-Amino-6-cyclohexyl-4-ethyl-hexanoic acid;
3-Amino-7-cyclohexyl-4-ethyl-heptanoic acid;
3-Amino-4,4,5-trimethyl-heptanoic acid;
3-Amino-4,4,5-trimethyl-octanoic acid;
3-Amino-4,4,5-trimethyl-hexanoic acid;
3-Amino-4,5,5-trimethyl-heptanoic acid;
3-Amino-4,5,5-trimethyl-octanoic acid;
3-Amino-4,5,5-trimethyl-hexanoic acid;
3-Amino-4-methyl-5-phenyl-pentanoic acid;
3-Amino-4-methyl-6-phenyl-hexanoic acid;
3-Amino-4-methyl-7-phenyl-heptanoic acid;

3-Amino-5-(2-chloro-phenyl)-4-methyl-pentanoic acid;
3-Amino-5-(3-chloro-phenyl)-4-methyl-pentanoic acid;
3-Amino-5-(4-chloro-phenyl)-4-methyl-pentanoic acid;
3-Amino-5-(2,4-dichloro-phenyl)-4-methyl-pentanoic acid;
3-Amino-5-(3,4-dichloro-phenyl)-4-methyl-pentanoic acid;
3-Amino-4-(2-chloro-benzyl)-hexanoic acid;
3-Amino-4-(3-chloro-benzyl)-hexanoic acid;
3-Amino-4-(4-chloro-benzyl)-hexanoic acid;
3-Amino-4-(2,4-dichloro-benzyl)-hexanoic acid;
3-Amino-4-(3,4-dichloro-benzyl)-hexanoic acid;
3-Amino-6-(2-chloro-phenyl)-4-methyl-hexanoic acid;
3-Amino-6-(3-chloro-phenyl)-4-methyl-hexanoic acid;
3-Amino-6-(4-chloro-phenyl)-4-methyl-hexanoic acid;
3-Amino-6-(2,4-dichloro-phenyl)-4-methyl-hexanoic acid;
3-Amino-6-(3,4-dichloro-phenyl)-4-methyl-hexanoic acid;
3-Amino-6-(2-chloro-phenyl)-4-ethyl-hexanoic acid;
3-Amino-6-(3-chloro-phenyl)-4-ethyl-hexanoic acid;
3-Amino-6-(4-chloro-phenyl)-4-ethyl-hexanoic acid;
3-Amino-6-(2,4-dichloro-phenyl)-4-ethyl-hexanoic acid;
3-Amino-6-(3,4-dichloro-phenyl)-4-ethyl-hexanoic acid;
3-Amino-7-(2-chloro-phenyl)-4-methyl-heptanoic acid;
3-Amino-7-(3-chloro-phenyl)-4-methyl-heptanoic acid;
3-Amino-7-(4-chloro-phenyl)-4-methyl-heptanoic acid;
3-Amino-7-(2,4-dichloro-phenyl)-4-methyl-heptanoic acid;
3-Amino-7-(3,4-dichloro-phenyl)-4-methyl-heptanoic acid;
3-Amino-7-(2-chloro-phenyl)-4-ethyl-heptanoic acid;
3-Amino-7-(3-chloro-phenyl)-4-ethyl-heptanoic acid;
3-Amino-7-(4-chloro-phenyl)-4-ethyl-heptanoic acid;
3-Amino-7-(2,4-dichloro-phenyl)-4-ethyl-heptanoic acid; and
3-Amino-7-(3,4-dichloro-phenyl)-4-ethyl-heptanoic acid.
2-Aminomethyl-4-(2-fluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3-fluoro-phenyl)-pentanoic acid;

2-Aminomethyl-4-(4-fluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3-difluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,4-difluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,5-difluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,6-difluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3,4-difluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3,5-difluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,4-trifluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,5-trifluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,6-trifluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,4,6-trifluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,4,5-tetrafluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,4,6-tetrafluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,5,6-tetrafluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-pentafluorophenyl-pentanoic acid;
2-Aminomethyl-4-(2-fluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3-fluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(4-fluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3-difluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,4-difluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,5-difluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,6-difluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3,4-difluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3,5-difluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,4-trifluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,5-trifluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,6-trifluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,4,6-trifluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,4,5-tetrafluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,4,6-tetrafluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,5,6-tetrafluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-pentafluorophenyl-hexanoic acid;

2-Aminomethyl-5-(2-fluoro-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3-fluoro-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(4-fluoro-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,3-difluoro-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,4-difluoro-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,5-difluoro-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,6-difluoro-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3,4-difluoro-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3,5-difluoro-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4-trifluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5-trifluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,6-trifluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,4,6-trifluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4,5-tetrafluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4,6-tetrafluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5,6-tetrafluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-pentafluorophenyl-pentanoic acid;
2-Aminomethyl-5-(2-fluoro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3-fluoro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(4-fluoro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,3-difluoro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,4-difluoro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,5-difluoro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,6-difluoro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3,4-difluoro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3,5-difluoro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4-trifluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5-trifluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,6-trifluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,4,6-trifluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4,5-tetrafluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4,6-tetrafluoro-phenyl)-hexanoic acid;

2-Aminomethyl-4-methyl-5-(2,3,5,6-tetrafluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-pentafluorophenyl-hexanoic acid;
2-Aminomethyl-6-(2-fluoro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3-fluoro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(4-fluoro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,3-difluoro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,4-difluoro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,5-difluoro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,6-difluoro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3,4-difluoro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3,5-difluoro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,4-trifluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,5-trifluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,6-trifluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,4,6-trifluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,4,5-tetrafluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,4,6-tetrafluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,5,6-tetrafluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-pentafluorophenyl-hexanoic acid;
2-Aminomethyl-5-(2-fluoro-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3-fluoro-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(4-fluoro-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,3-difluoro-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,4-difluoro-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,5-difluoro-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,6-difluoro-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3,4-difluoro-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3,5-difluoro-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4-trifluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,5-trifluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,6-trifluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,4,6-trifluoro-phenyl)-pentanoic acid;

2-Aminomethyl-4-ethyl-5-(2,3,4,5-tetrafluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4,6-tetrafluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,5,6-tetrafluoro-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-pentafluorophenyl-pentanoic acid;
2-Aminomethyl-6-(2-fluoro-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3-fluoro-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(4-fluoro-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,3-difluoro-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,4-difluoro-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,5-difluoro-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,6-difluoro-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3,4-difluoro-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3,5-difluoro-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,4-trifluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,5-trifluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,6-trifluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,4,6-trifluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,4,5-tetrafluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,4,6-tetrafluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,5,6-tetrafluoro-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-pentafluorophenyl-hexanoic acid;
2-Aminomethyl-7-(2-fluoro-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3-fluoro-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(4-fluoro-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,3-difluoro-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,4-difluoro-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,5-difluoro-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,6-difluoro-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3,4-difluoro-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3,5-difluoro-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,4-trifluoro-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,5-trifluoro-phenyl)-heptanoic acid;

2-Aminomethyl-4-methyl-7-(2,3,6-trifluoro-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,4,6-trifluoro-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,4,5-tetrafluoro-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,4,6-tetrafluoro-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,5,6-tetrafluoro-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-pentafluorophenyl-heptanoic acid;
2-Aminomethyl-7-(2-fluoro-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3-fluoro-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(4-fluoro-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,3-difluoro-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,4-difluoro-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,5-difluoro-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,6-difluoro-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3,4-difluoro-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3,5-difluoro-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,4-trifluoro-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,5-trifluoro-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,6-trifluoro-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,4,6-trifluoro-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,4,5-tetrafluoro-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,4,6-tetrafluoro-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,5,6-tetrafluoro-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-pentafluorophenyl-heptanoic acid;
2-Aminomethyl-4-(2-chloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3-chloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(4-chloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3-dichloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,4-dichloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,5-dichloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,6-dichloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3,4-dichloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3,5-dichloro-phenyl)-pentanoic acid;

2-Aminomethyl-4-(2,3,4-trichloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,5-trichloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,6-trichloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,4,6-trichloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,4,5-tetrachloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,4,6-tetrachloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,5,6-tetrachloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-pentachlorophenyl-pentanoic acid;
2-Aminomethyl-4-(2-chloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3-chloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(4-chloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3-dichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,4-dichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,5-dichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,6-dichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3,4-dichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3,5-dichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,4-trichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,5-trichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,6-trichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,4,6-trichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,4,5-tetrachloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,4,6-tetrachloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,5,6-tetrachloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-pentachlorophenyl-hexanoic acid;
2-Aminomethyl-5-(2-chloro-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3-chloro-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(4-chloro-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,3-dichloro-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,4-dichloro-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,5-dichloro-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,6-dichloro-phenyl)-4-methyl-pentanoic acid;

2-Aminomethyl-5-(3,4-dichloro-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3,5-dichloro-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4-trichloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5-trichloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,6-trichloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,4,6-trichloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4,5-tetrachloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4,6-tetrachloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5,6-tetrachloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-pentachlorophenyl-pentanoic acid;
2-Aminomethyl-5-(2-chloro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3-chloro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(4-chloro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,3-dichloro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,4-dichloro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,5-dichloro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,6-dichloro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3,4-dichloro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3,5-dichloro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4-trichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5-trichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,6-trichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,4,6-trichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4,5-tetrachloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4,6-tetrachloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5,6-tetrachloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-pentachlorophenyl-hexanoic acid;
2-Aminomethyl-5-(2-chloro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3-chloro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(4-chloro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,3-dichloro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,4-dichloro-phenyl)-4-methyl-hexanoic acid;

2-Aminomethyl-5-(2,5-dichloro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,6-dichloro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3,4-dichloro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3,5-dichloro-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4-trichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5-trichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,6-trichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,4,6-trichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4,5-tetrachloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4,6-tetrachloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5,6-tetrachloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-pentachlorophenyl-hexanoic acid;
2-Aminomethyl-5-(2-chloro-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3-chloro-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(4-chloro-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,3-dichloro-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,4-dichloro-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,5-dichloro-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,6-dichloro-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3,4-dichloro-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3,5-dichloro-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4-trichloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,5-trichloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,6-trichloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,4,6-trichloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4,5-tetrachloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4,6-tetrachloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,5,6-tetrachloro-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-pentachlorophenyl-pentanoic acid;
2-Aminomethyl-6-(2-chloro-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3-chloro-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(4-chloro-phenyl)-4-ethyl-hexanoic acid;

2-Aminomethyl-6-(2,3-dichloro-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,4-dichloro-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,5-dichloro-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,6-dichloro-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3,4-dichloro-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3,5-dichloro-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,4-trichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,5-trichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,6-trichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,4,6-trichloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,4,5-tetrachloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,4,6-tetrachloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,5,6-tetrachloro-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-pentachlorophenyl-hexanoic acid;
2-Aminomethyl-7-(2-chloro-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3-chloro-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(4-chloro-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,3-dichloro-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,4-dichloro-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,5-dichloro-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,6-dichloro-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3,4-dichloro-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3,5-dichloro-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,4-trichloro-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,5-trichloro-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,6-trichloro-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,4,6-trichloro-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,4,5-tetrachloro-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,4,6-tetrachloro-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,5,6-tetrachloro-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-pentachlorophenyl-heptanoic acid;
2-Aminomethyl-7-(2-chloro-phenyl)-4-ethyl-heptanoic acid;

2-Aminomethyl-7-(3-chloro-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(4-chloro-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,3-dichloro-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,4-dichloro-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,5-dichloro-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,6-dichloro-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3,4-dichloro-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3,5-dichloro-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,4-trichloro-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,5-trichloro-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,6-trichloro-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,4,6-trichloro-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,4,5-tetrachloro-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,4,6-tetrachloro-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,5,6-tetrachloro-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-pentachlorophenyl-heptanoic acid;
2-Aminomethyl-4-(2-methoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3-methoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(4-methoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3-dimethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,4-dimethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,5-dimethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,6-dimethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3,4-dimethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3,5-dimethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,4-trimethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,5-trimethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,6-trimethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,4,6-trimethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2-methoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3-methoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(4-methoxy-phenyl)-hexanoic acid;

2-Aminomethyl-4-(2,3-dimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,4-dimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,5-dimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,6-dimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3,4-dimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3,5-dimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,4-trimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,5-trimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,6-trimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,4,6-trimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-5-(2-methoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3-methoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(4-methoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,3-dimethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,4-dimethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,5-dimethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,6-dimethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3,4-dimethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3,5-dimethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4-trimethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5-trimethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,6-trimethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,4,6-trimethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-5-(2-methoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3-methoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(4-methoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,3-dimethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,4-dimethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,5-dimethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,6-dimethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3,4-dimethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3,5-dimethoxy-phenyl)-4-methyl-hexanoic acid;

2-Aminomethyl-4-methyl-5-(2,3,4-trimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5-trimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,6-trimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,4,6-trimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-6-(2-methoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3-methoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(4-methoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,3-dimethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,4-dimethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,5-dimethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,6-dimethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3,4-dimethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3,5-dimethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,4-trimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,5-trimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,6-trimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,4,6-trimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-5-(2-methoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3-methoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(4-methoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,3-dimethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,4-dimethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,5-dimethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,6-dimethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3,4-dimethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3,5-dimethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4-trimethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,5-trimethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,6-trimethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,4,6-trimethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4,5-tetramethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4,6-tetramethoxy-phenyl)-pentanoic acid;

2-Aminomethyl-4-ethyl-5-(2,3,5,6-tetramethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-pentamethoxyphenyl-pentanoic acid;
2-Aminomethyl-6-(2-methoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3-methoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(4-methoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,3-dimethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,4-dimethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,5-dimethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,6-dimethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3,4-dimethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3,5-dimethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,4-trimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,5-trimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,6-trimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,4,6-trimethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-7-(2-methoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3-methoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(4-methoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,3-dimethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,4-dimethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,5-dimethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,6-dimethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3,4-dimethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3,5-dimethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,4-trimethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,5-trimethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,6-trimethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,4,6-trimethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-7-(2-methoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3-methoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(4-methoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,3-dimethoxy-phenyl)-4-ethyl-heptanoic acid;

2-Aminomethyl-7-(2,4-dimethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,5-dimethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,6-dimethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3,4-dimethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3,5-dimethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,4-trimethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,5-trimethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,6-trimethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,4,6-trimethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-(2-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(4-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3-di-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,4-di-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,5-di-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,6-di-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3,4-di-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3,5-di-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,4-tri-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,5-tri-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,6-tri-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,4,6-tri-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(4-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3-di-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,4-di-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,5-di-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,6-di-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3,4-di-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3,5-di-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,4-tri-trifluoromethyl-phenyl)-hexanoic acid;

2-Aminomethyl-4-(2,3,5-tri-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,6-tri-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,4,6-tri-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-5-(2-trifluoromethyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3-trifluoromethyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(4-trifluoromethyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,3-di-trifluoromethyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,4-di-trifluoromethyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,5-di-trifluoromethyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,6-di-trifluoromethyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3,4-di-trifluoromethyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3,5-di-trifluoromethyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4-tri-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5-tri-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,6-tri-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,4,6-tri-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-5-(2-trifluoromethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3-trifluoromethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(4-trifluoromethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,3-di-trifluoromethyl-phenyl)-4-methyl-hexanoic acid;

2-Aminomethyl-5-(2,4-di-trifluoromethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,5-di-trifluoromethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,6-di-trifluoromethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3,4-di-trifluoromethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3,5-di-trifluoromethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4-tri-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5-tri-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,6-tri-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,4,6-tri-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-6-(2-trifluoromethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3-trifluoromethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(4-trifluoromethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,3-di-trifluoromethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,4-di-trifluoromethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,5-di-trifluoromethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,6-di-trifluoromethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3,4-di-trifluoromethyl-phenyl)-4-methyl-hexanoic acid;

2-Aminomethyl-6-(3,5-di-trifluoromethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,4-tri-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,5-tri-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,6-tri-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,4,6-tri-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-5-(2-trifluoromethyl-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3-trifluoromethyl-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(4-trifluoromethyl-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,3-di-trifluoromethyl-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,4-di-trifluoromethyl-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,5-di-trifluoromethyl-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,6-di-trifluoromethyl-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3,4-di-trifluoromethyl-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3,5-di-trifluoromethyl-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4-tri-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,5-tri-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,6-tri-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,4,6-tri-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4,5-tetra-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4,6-tetra-trifluoromethyl-phenyl)-pentanoic acid;

2-Aminomethyl-4-ethyl-5-(2,3,5,6-tetra-trifluoromethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-penta-trifluoromethylphenyl-pentanoic acid;
2-Aminomethyl-6-(2-trifluoromethyl-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3-trifluoromethyl-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(4-trifluoromethyl-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,3-di-trifluoromethyl-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,4-di-trifluoromethyl-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,5-di-trifluoromethyl-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,6-di-trifluoromethyl-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3,4-di-trifluoromethyl-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3,5-di-trifluoromethyl-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,4-tri-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,5-tri-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,6-tri-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,4,6-tri-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-7-(2-trifluoromethyl-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3-trifluoromethyl-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(4-trifluoromethyl-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,3-di-trifluoromethyl-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,4-di-trifluoromethyl-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,5-di-trifluoromethyl-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,6-di-trifluoromethyl-phenyl)-4-methyl-heptanoic acid;

156

2-Aminomethyl-7-(3,4-di-trifluoromethyl-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3,5-di-trifluoromethyl-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,4-tri-trifluoromethyl-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,5-tri-trifluoromethyl-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,6-tri-trifluoromethyl-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,4,6-tri-trifluoromethyl-phenyl)-heptanoic acid;
2-Aminomethyl-7-(2-trifluoromethyl-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3-trifluoromethyl-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(4-trifluoromethyl-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,3-di-trifluoromethyl-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,4-di-trifluoromethyl-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,5-di-trifluoromethyl-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,6-di-trifluoromethyl-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3,4-di-trifluoromethyl-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3,5-di-trifluoromethyl-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,4-tri-trifluoromethyl-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,5-tri-trifluoromethyl-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,6-tri-trifluoromethyl-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,4,6-tri-trifluoromethyl-phenyl)-heptanoic acid;
2-Aminomethyl-4-(2-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(4-trifluoromethoxy-phenyl)-pentanoic acid;

2-Aminomethyl-4-(2,3-di-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,4-di-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,5-di-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,6-di-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3,4-di-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3,5-di-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,4-tri-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,5-tri-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,6-tri-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,4,6-tri-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(4-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3-di-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,4-di-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,5-di-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,6-di-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3,4-di-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3,5-di-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,4-tri-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,5-tri-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,6-tri-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,4,6-tri-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-5-(2-trifluoromethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3-trifluoromethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(4-trifluoromethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,3-di-trifluoromethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,4-di-trifluoromethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,5-di-trifluoromethoxy-phenyl)-4-methyl-pentanoic acid;

2-Aminomethyl-5-(2,6-di-trifluoromethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3,4-di-trifluoromethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3,5-di-trifluoromethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4-tri-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5-tri-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,6-tri-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,4,6-tri-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-5-(2-trifluoromethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3-trifluoromethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(4-trifluoromethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,3-di-trifluoromethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,4-di-trifluoromethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,5-di-trifluoromethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,6-di-trifluoromethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3,4-di-trifluoromethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3,5-di-trifluoromethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4-tri-trifluoromethoxy-phenyl)-pentanoic acid;

2-Aminomethyl-4-ethyl-5-(2,3,5-tri-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,6-tri-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,4,6-tri-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4,5-tetra-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4,6-tetra-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,5,6-tetra-trifluoromethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-penta-trifluoromethoxyphenyl-pentanoic acid;
2-Aminomethyl-5-(2-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(4-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,3-di-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,4-di-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,5-di-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,6-di-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3,4-di-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3,5-di-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4-tri-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5-tri-trifluoromethoxy-phenyl)-hexanoic acid;

2-Aminomethyl-4-methyl-5-(2,3,6-tri-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,4,6-tri-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-6-(2-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(4-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,3-di-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,4-di-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,5-di-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,6-di-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3,4-di-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3,5-di-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,4-tri-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,5-tri-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,6-tri-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,4,6-tri-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-6-(2-trifluoromethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3-trifluoromethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(4-trifluoromethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,3-di-trifluoromethoxy-phenyl)-4-ethyl-hexanoic acid;

2-Aminomethyl-6-(2,4-di-trifluoromethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,5-di-trifluoromethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,6-di-trifluoromethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3,4-di-trifluoromethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3,5-di-trifluoromethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,4-tri-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,5-tri-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,6-tri-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,4,6-tri-trifluoromethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-7-(2-trifluoromethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3-trifluoromethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(4-trifluoromethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,3-di-trifluoromethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,4-di-trifluoromethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,5-di-trifluoromethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,6-di-trifluoromethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3,4-di-trifluoromethoxy-phenyl)-4-methyl-heptanoic acid;

2-Aminomethyl-7-(3,5-di-trifluoromethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,4-tri-trifluoromethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,5-tri-trifluoromethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,6-tri-trifluoromethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,4,6-tri-trifluoromethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-7-(2-trifluoromethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3-trifluoromethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(4-trifluoromethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,3-di-trifluoromethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,4-di-trifluoromethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,5-di-trifluoromethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,6-di-trifluoromethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3,4-di-trifluoromethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3,5-di-trifluoromethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,4-tri-trifluoromethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,5-tri-trifluoromethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,6-tri-trifluoromethoxy-phenyl)-heptanoic acid;

2-Aminomethyl-4-ethyl-7-(2,4,6-tri-trifluoromethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-(2-ethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3-ethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(4-ethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3-diethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,4-diethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,5-diethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,6-diethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3,4-diethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3,5-diethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,4-triethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,5-triethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,6-triethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,4,6-triethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2-ethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3-ethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(4-ethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3-diethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,4-diethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,5-diethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,6-diethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3,4-diethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3,5-diethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,4-triethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,5-triethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,6-triethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,4,6-triethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-5-(2-ethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3-ethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(4-ethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,3-diethoxy-phenyl)-4-methyl-pentanoic acid;

16R

2-Aminomethyl-5-(2,4-diethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,5-diethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,6-diethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3,4-diethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3,5-diethoxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4-triethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5-triethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,6-triethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,4,6-triethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-5-(2-ethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3-ethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(4-ethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,3-diethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,4-diethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,5-diethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,6-diethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3,4-diethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3,5-diethoxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4-triethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,5-triethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,6-triethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,4,6-triethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4,5-tetraethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4,6-tetraethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,5,6-tetraethoxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-pentaethoxyphenyl-pentanoic acid;
2-Aminomethyl-5-(2-ethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3-ethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(4-ethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,3-diethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,4-diethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,5-diethoxy-phenyl)-4-methyl-hexanoic acid;

2-Aminomethyl-5-(2,6-diethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3,4-diethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3,5-diethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4-triethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5-triethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,6-triethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,4,6-triethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-6-(2-ethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3-ethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(4-ethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,3-diethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,4-diethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,5-diethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,6-diethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3,4-diethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3,5-diethoxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,4-triethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,5-triethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,6-triethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,4,6-triethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-6-(2-ethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3-ethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(4-ethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,3-diethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,4-diethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,5-diethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,6-diethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3,4-diethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3,5-diethoxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,4-triethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,5-triethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,6-triethoxy-phenyl)-hexanoic acid;

2-Aminomethyl-4-ethyl-6-(2,4,6-triethoxy-phenyl)-hexanoic acid;
2-Aminomethyl-7-(2-ethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3-ethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(4-ethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,3-diethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,4-diethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,5-diethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,6-diethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3,4-diethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3,5-diethoxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,4-triethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,5-triethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,6-triethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,4,6-triethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-7-(2-ethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3-ethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(4-ethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,3-diethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,4-diethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,5-diethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,6-diethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3,4-diethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3,5-diethoxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,4-triethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,5-triethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,6-triethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,4,6-triethoxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-(2-methyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3-methyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(4-methyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3-dimethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,4-dimethyl-phenyl)-pentanoic acid;

2-Aminomethyl-4-(2,5-dimethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,6-dimethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3,4-dimethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3,5-dimethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,4-trimethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,5-trimethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,6-trimethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,4,6-trimethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2-methyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3-methyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(4-methyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3-dimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,4-dimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,5-dimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,6-dimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3,4-dimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3,5-dimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,4-trimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,5-trimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,6-trimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,4,6-trimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-5-(2-methyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3-methyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(4-methyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,3-dimethyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,4-dimethyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,5-dimethyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,6-dimethyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3,4-dimethyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3,5-dimethyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4-trimethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5-trimethyl-phenyl)-pentanoic acid;

2-Aminomethyl-4-methyl-5-(2,3,6-trimethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,4,6-trimethyl-phenyl)-pentanoic acid;
2-Aminomethyl-5-(2-methyl-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3-methyl-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(4-methyl-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,3-dimethyl-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,4-dimethyl-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,5-dimethyl-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,6-dimethyl-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3,4-dimethyl-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3,5-dimethyl-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4-trimethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,5-trimethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,6-trimethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,4,6-trimethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4,5-tetramethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4,6-tetramethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,5,6-tetramethyl-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-pentamethylphenyl-pentanoic acid;
2-Aminomethyl-5-(2-methyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3-methyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(4-methyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,3-dimethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,4-dimethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,5-dimethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,6-dimethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3,4-dimethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3,5-dimethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4-trimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5-trimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,6-trimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,4,6-trimethyl-phenyl)-hexanoic acid;

2-Aminomethyl-6-(2-methyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3-methyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(4-methyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,3-dimethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,4-dimethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,5-dimethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,6-dimethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3,4-dimethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3,5-dimethyl-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,4-trimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,5-trimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,6-trimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,4,6-trimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-6-(2-methyl-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3-methyl-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(4-methyl-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,3-dimethyl-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,4-dimethyl-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,5-dimethyl-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,6-dimethyl-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3,4-dimethyl-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3,5-dimethyl-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,4-trimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,5-trimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,6-trimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,4,6-trimethyl-phenyl)-hexanoic acid;
2-Aminomethyl-7-(2-methyl-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3-methyl-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(4-methyl-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,3-dimethyl-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,4-dimethyl-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,5-dimethyl-phenyl)-4-methyl-heptanoic acid;

2-Aminomethyl-7-(2,6-dimethyl-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3,4-dimethyl-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3,5-dimethyl-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,4-trimethyl-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,5-trimethyl-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,6-trimethyl-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,4,6-trimethyl-phenyl)-heptanoic acid;
2-Aminomethyl-7-(2-methyl-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3-methyl-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(4-methyl-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,3-dimethyl-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,4-dimethyl-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,5-dimethyl-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,6-dimethyl-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3,4-dimethyl-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3,5-dimethyl-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,4-trimethyl-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,5-trimethyl-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,6-trimethyl-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,4,6-trimethyl-phenyl)-heptanoic acid;
2-Aminomethyl-4-(2-hydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3-hydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(4-hydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3-dihydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,4-dihydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,5-dihydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,6-dihydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3,4-dihydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(3,5-dihydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,4-trihydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,5-trihydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2,3,6-trihydroxy-phenyl)-pentanoic acid;

2-Aminomethyl-4-(2,4,6-trihydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-(2-hydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3-hydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(4-hydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3-dihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,4-dihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,5-dihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,6-dihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3,4-dihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(3,5-dihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,4-trihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,5-trihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,3,6-trihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-(2,4,6-trihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-5-(2-hydroxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3-hydroxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(4-hydroxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,3-dihydroxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,4-dihydroxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,5-dihydroxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(2,6-dihydroxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3,4-dihydroxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(3,5-dihydroxy-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4-trihydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5-trihydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,6-trihydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-methyl-5-(2,4,6-trihydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-5-(2-hydroxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3-hydroxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(4-hydroxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,3-dihydroxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,4-dihydroxy-phenyl)-4-methyl-hexanoic acid;

2-Aminomethyl-5-(2,5-dihydroxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(2,6-dihydroxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3,4-dihydroxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-5-(3,5-dihydroxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,4-trihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,5-trihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,3,6-trihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-5-(2,4,6-trihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-6-(2-hydroxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3-hydroxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(4-hydroxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,3-dihydroxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,4-dihydroxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,5-dihydroxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(2,6-dihydroxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3,4-dihydroxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-6-(3,5-dihydroxy-phenyl)-4-methyl-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,4-trihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,5-trihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,3,6-trihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-methyl-6-(2,4,6-trihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-5-(2-hydroxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3-hydroxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(4-hydroxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,3-dihydroxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,4-dihydroxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,5-dihydroxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(2,6-dihydroxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3,4-dihydroxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-5-(3,5-dihydroxy-phenyl)-4-ethyl-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4-trihydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,5-trihydroxy-phenyl)-pentanoic acid;

2-Aminomethyl-4-ethyl-5-(2,3,6-trihydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,4,6-trihydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4,5-tetrahydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,4,6-tetrahydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-(2,3,5,6-tetrahydroxy-phenyl)-pentanoic acid;
2-Aminomethyl-4-ethyl-5-pentahydroxyphenyl-pentanoic acid;
2-Aminomethyl-6-(2-hydroxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3-hydroxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(4-hydroxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,3-dihydroxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,4-dihydroxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,5-dihydroxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(2,6-dihydroxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3,4-dihydroxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-6-(3,5-dihydroxy-phenyl)-4-ethyl-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,4-trihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,5-trihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,3,6-trihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-4-ethyl-6-(2,4,6-trihydroxy-phenyl)-hexanoic acid;
2-Aminomethyl-7-(2-hydroxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3-hydroxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(4-hydroxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,3-dihydroxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,4-dihydroxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,5-dihydroxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(2,6-dihydroxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3,4-dihydroxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-7-(3,5-dihydroxy-phenyl)-4-methyl-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,4-trihydroxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,5-trihydroxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,3,6-trihydroxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-methyl-7-(2,4,6-trihydroxy-phenyl)-heptanoic acid;

2-Aminomethyl-7-(2-hydroxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3-hydroxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(4-hydroxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,3-dihydroxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,4-dihydroxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,5-dihydroxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(2,6-dihydroxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3,4-dihydroxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-7-(3,5-dihydroxy-phenyl)-4-ethyl-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,4-trihydroxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,5-trihydroxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,6-trihydroxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,4,6-trihydroxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,4,5-tetrahydroxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,4,6-tetrahydroxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-(2,3,5,6-tetrahydroxy-phenyl)-heptanoic acid;
2-Aminomethyl-4-ethyl-7-pentahydroxyphenyl-heptanoic acid;
(2R,4R)-2-Aminomethyl-4-(2,4-difluoro-benzyl)-hexanoic acid;
(2S,4R)-2-Aminomethyl-4-(2,4-difluoro-benzyl)-hexanoic acid;
(2R,4S)-2-Aminomethyl-7-(2,4-difluoro-phenyl)-4-ethyl-heptanoic acid;
(2S,4S)-2-Aminomethyl-7-(2,4-difluoro-phenyl)-4-ethyl-heptanoic acid;
(2R,4S)-2-Aminomethyl-4-(2,4-difluoro-benzyl)-hexanoic acid;
(2S,4S)-2-Aminomethyl-4-(2,4-difluoro-benzyl)-hexanoic acid;
(2S,4S)-2-Aminomethyl-4-(3,5-difluoro-benzyl)-hexanoic acid;
(2S,4S)-2-Aminomethyl-4-(2-fluoro-benzyl)-hexanoic acid;
(2S,4S)-2-Aminomethyl-5-(2,4-difluoro-phenyl)-4-methyl-pentanoic acid;
(2S)-2-Aminomethyl-5-(2,4-difluoro-phenyl)-pentanoic acid;
(2S,4S)-2-Aminomethyl-4-(2,6-difluoro-benzyl)-hexanoic acid;
(2S,4S)-2-Aminomethyl-4-(4-fluoro-benzyl)-hexanoic acid;
(2S,4S)-2-Aminomethyl-4-(2,5-difluoro-benzyl)-hexanoic acid;
(2S,4S)-2-Aminomethyl-4-(3-fluoro-benzyl)-hexanoic acid;

(2S,4S)-2-Aminomethyl-4-pentafluorophenylmethyl-hexanoic acid;
(2S,4R)-2-Aminomethyl-7-(2,4-difluoro-phenyl)-4-ethyl-heptanoic acid;
(2S,4S)-2-Aminomethyl-4-(4-trifluoromethyl-benzyl)-hexanoic acid;
2-Aminomethyl-4-(4-methoxy-2-methyl-benzyl)-hexanoic acid;
2-Aminomethyl-5-(4-methoxy-2-methyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-4-(4-methoxy-3-methyl-benzyl)-hexanoic acid;
2-Aminomethyl-5-(4-methoxy-3-methyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-4-ethyl-5-methyl-hexanoic acid;
2-Aminomethyl-4-ethyl-3-methyl-hexanoic acid;
2-Aminomethyl-3,4-dimethyl-hexanoic acid;
2-Aminomethyl-3-ethyl-4-methyl-hexanoic acid;
2-Aminomethyl-4-ethyl-3-methyl-heptanoic acid;
2-Aminomethyl-3,4-dimethyl-octanoic acid;
2-Aminomethyl-3-methyl-pentanoic acid;
2-Aminomethyl-3-methyl-hexanoic acid;
2-Aminomethyl-3-methyl-heptanoic acid;
2-Aminomethyl-3,4-dimethyl-pentanoic acid;
2-Aminomethyl-3,5-dimethyl-hexanoic acid;
2-Aminomethyl-3,6-dimethyl-heptanoic acid;
2-Aminomethyl-3,5,5-trimethyl-hexanoic acid;
2-Aminomethyl-3-cyclopropyl-butyric acid;
2-Aminomethyl-3-cyclopentyl-butyric acid;
2-Aminomethyl-3-cyclohexyl-butyric acid;
2-Aminomethyl-4-cyclohexyl-3-methyl-butyric acid;
2-Aminomethyl-5-cyclohexyl-3-methyl-pentanoic acid;
2-Aminomethyl-3-methyl-4-(4-methyl-cyclohexyl)-butyric acid;
2-Aminomethyl-3-ethyl-pentanoic acid;
2-Aminomethyl-3-ethyl-hexanoic acid;
2-Aminomethyl-3-ethyl-heptanoic acid;
2-Aminomethyl-3-ethyl-4-methyl-pentanoic acid;

2-Aminomethyl-3-cyclohexylmethyl-pentanoic acid;
2-Aminomethyl-5-(4-methoxy-cyclohexyl)-3-methyl-pentanoic acid;
2-Aminomethyl-5-(4-methoxy-phenyl)-3-methyl-pentanoic acid;
2-Aminomethyl-4-(2-methoxy-phenyl)-3-methyl-butyric acid;
2-Aminomethyl-4-(4-methoxy-phenyl)-3-methyl-butyric acid;
2-Aminomethyl-3-phenyl-butyric acid;
2-Aminomethyl-3-methyl-4-phenyl-butyric acid;
2-Aminomethyl-3-methyl-5-phenyl-pentanoic acid;
2-Aminomethyl-3-methyl-4-(3-trifluoromethyl-phenyl)-butyric acid;
2-Aminomethyl-3-(4-ethyl-phenyl)-butyric acid;
2-Aminomethyl-3-(2,5-dimethyl-phenyl)-butyric acid;
2-Aminomethyl-3-methyl-4-p-tolyl-butyric acid;
2-Aminomethyl-3-m-tolyl-butyric acid;
2-Aminomethyl-3-benzyl-pentanoic acid;
2-Aminomethyl-4-(4-fluoro-phenyl)-3-methyl-butyric acid;
2-Aminomethyl-5-cyclopropyl-hexanoic acid;
2-Aminomethyl-5-cyclobutyl-hexanoic acid;
2-Aminomethyl-5-cyclopentyl-hexanoic acid;
2-Aminomethyl-5-cyclohexyl-hexanoic acid;
2-Aminomethyl-5-phenyl-hexanoic acid;
2-Aminomethyl-5-(3-chloro-phenyl)-hexanoic acid;
2-Aminomethyl-5-(3-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-5-(4-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-5-cyclopropyl-heptanoic acid;
2-Aminomethyl-5-cyclobutyl-heptanoic acid;
2-Aminomethyl-5-cyclopentyl-heptanoic acid;
2-Aminomethyl-5-cyclohexyl-heptanoic acid;
2-Aminomethyl-5-phenyl-heptanoic acid;
2-Aminomethyl-5-(3-chloro-phenyl)-heptanoic acid;
2-Aminomethyl-5-(3-trifluoromethyl-phenyl)-heptanoic acid;
2-Aminomethyl-5-(4-trifluoromethyl-phenyl)-heptanoic acid;
2-Aminomethyl-5-methyl-6-phenyl-hexanoic acid;

2-Aminomethyl-6-(3-chloro-phenyl)-5-methyl-hexanoic acid;
2-Aminomethyl-5-methyl-6-(3-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-5-methyl-6-(4-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-5-cyclopropylmethyl-heptanoic acid;
2-Aminomethyl-5-cyclobutylmethyl-heptanoic acid;
2-Aminomethyl-5-cyclopentylmethyl-heptanoic acid;
2-Aminomethyl-5-cyclohexylmethyl-heptanoic acid;
2-Aminomethyl-5-benzyl-heptanoic acid;
2-Aminomethyl-5-(3-chloro-benzyl)-heptanoic acid;
2-Aminomethyl-5-(3-trifluoromethyl-benzyl)-heptanoic acid;
2-Aminomethyl-5-(4-trifluoromethyl-benzyl)-heptanoic acid;
2-Aminomethyl-5-methyl-7-phenyl-heptanoic acid;
2-Aminomethyl-7-(3-chloro-phenyl)-5-methyl-heptanoic acid;
2-Aminomethyl-5-methyl-7-(3-trifluoromethyl-phenyl)-heptanoic acid;
2-Aminomethyl-5-methyl-7-(4-trifluoromethyl-phenyl)-heptanoic acid;
2-Aminomethyl-7-cyclopropyl-5-ethyl-heptanoic acid;
2-Aminomethyl-7-cyclobutyl-5-ethyl-heptanoic acid;
2-Aminomethyl-7-cyclopentyl-5-ethyl-heptanoic acid;
2-Aminomethyl-7-cyclohexyl-5-ethyl-heptanoic acid;
2-Aminomethyl-5-ethyl-7-phenyl-heptanoic acid;
2-Aminomethyl-7-(3-chloro-phenyl)-5-ethyl-heptanoic acid;
2-Aminomethyl-5-ethyl-7-(3-trifluoromethyl-phenyl)-heptanoic acid;
2-Aminomethyl-5-ethyl-7-(4-trifluoromethyl-phenyl)-heptanoic acid;
2-Aminomethyl-5,5-dimethyl-heptanoic acid;
2-Aminomethyl-5,5-dimethyl-octanoic acid; and
2-Aminomethyl-5,5-dimethyl-nonanoic acid.

13. A compound selected from the following compounds and their pharmaceutically acceptable salts:

(3R,4R)-3-Amino-4,5-dimethyl-hexanoic acid;
(3S,4R)-3-Amino-4,5-dimethyl-hexanoic acid;
(3R,4R,5R)-3-Amino-4,5-dimethyl-heptanoic acid;

(3S,4R,5R)-3-Amino-4,5-dimethyl-heptanoic acid;
(3R,4S,5R)-3-Amino-4,5-dimethyl-heptanoic acid;
(3R,4R,5S)-3-Amino-4,5-dimethyl-heptanoic acid;
(3R,4R,5R)-3-Amino-4,5-dimethyl-octanoic acid;
(3S,4R,5R)-3-Amino-4,5-dimethyl-octanoic acid;
(3R,4S,5R)-3-Amino-4,5-dimethyl-octanoic acid;
(3R,4R,5S)-3-Amino-4,5-dimethyl-octanoic acid;
(3R,4R,5R)-3-Amino-4,5-dimethyl-nonanoic acid;
(3S,4R,5R)-3-Amino-4,5-dimethyl-nonanoic acid;
(3R,4S,5R)-3-Amino-4,5-dimethyl-nonanoic acid;
(3R,4R,5S)-3-Amino-4,5-dimethyl-nonanoic acid;
(3R,4R,5R)-3-Amino-4,5-dimethyl-decanoic acid;
(3S,4R,5R)-3-Amino-4,5-dimethyl-decanoic acid;
(3R,4S,5R)-3-Amino-4,5-dimethyl-decanoic acid;
(3R,4R,5S)-3-Amino-4,5-dimethyl-decanoic acid;
and opposite enantiomers thereof.

14. A compound selected from the following compounds and their pharmaceutically acceptable salts:
(3R,4R)-3-Amino-4,5-dimethyl-hexanoic acid;
(3R,4R,5R)-3-Amino-4,5-dimethyl-heptanoic acid;
(3R,4R,5R)-3-Amino-4,5-dimethyl-octanoic acid;
(3R,4R,5R)-3-Amino-4,5-dimethyl-nonanoic acid; and
(3R,4R,5R)-3-Amino-4,5-dimethyl-decanoic acid.

15. A compound selected from the following compounds and their pharmaceutically acceptable salts:
(2R,4R)-2-Aminomethyl-4-(2,4-difluoro-benzyl)-hexanoic acid;
(2S,4R)-2-Aminomethyl-4-(2,4-difluoro-benzyl)-hexanoic acid;
(2R,4S)-2-Aminomethyl-7-(2,4-difluoro-phenyl)-4-ethyl-heptanoic acid;
(2S,4S)-2-Aminomethyl-7-(2,4-difluoro-phenyl)-4-ethyl-heptanoic acid;
(2R,4S)-2-Aminomethyl-4-(2,4-difluoro-benzyl)-hexanoic acid;

(2S,4S)-2-Aminomethyl-4-(2,4-difluoro-benzyl)-hexanoic acid;
(2S,4S)-2-Aminomethyl-4-(3,5-difluoro-benzyl)-hexanoic acid;
(2S,4S)-2-Aminomethyl-4-(2-fluoro-benzyl)-hexanoic acid;
(2S,4S)-2-Aminomethyl-5-(2,4-difluoro-phenyl)-4-methyl-pentanoic acid;
(2S)-2-Aminomethyl-5-(2,4-difluoro-phenyl)-pentanoic acid;
(2S,4S)-2-Aminomethyl-4-(2,6-difluoro-benzyl)-hexanoic acid;
(2S,4S)-2-Aminomethyl-4-(4-fluoro-benzyl)-hexanoic acid;
(2S,4S)-2-Aminomethyl-4-(2,5-difluoro-benzyl)-hexanoic acid;
(2S,4S)-2-Aminomethyl-4-(3-fluoro-benzyl)-hexanoic acid;
(2S,4S)-2-Aminomethyl-4-pentafluorophenylmethyl-hexanoic acid;
(2S,4R)-2-Aminomethyl-7-(2,4-difluoro-phenyl)-4-ethyl-heptanoic acid; and
(2S,4S)-2-Aminomethyl-4-(4-trifluoromethyl-benzyl)-hexanoic acid.


AMINOÁCIDOS CON AFINIDAD POR LA PROTEÍNA α2δ

ANTECEDENTES DE LA INVENCIÓN

La presente invención se refiere a ciertos β-aminoácidos que se unen a la subunidad alfa-2-delta (α2δ) de un canal de calcio. Estos compuestos y sus sales farmacéuticamente aceptables son útiles en el tratamiento de diversos trastornos psiquiátricos, de dolor y otros.

SUMARIO DE LA INVENCIÓN

Esta invención proporciona compuestos de fórmula I



I

y sus sales farmacéuticamente aceptables, en la que

R_1 es un átomo de hidrógeno o alquilo (C_1-C_6) opcionalmente sustituido con uno a cinco átomos de flúor;

R_2 es un átomo de hidrógeno o alquilo (C_1-C_6) opcionalmente sustituido con uno a cinco átomos de flúor; o

R_1 y R_2, junto con el carbono al que están unidos, forman un anillo cicloalquilo de tres a seis miembros;

R_3 es un átomo de hidrógeno, alquilo (C_1-C_6), cicloalquilo (C_3-C_6), cicloalquil (C_3-C_6)-alquilo (C_1-C_3), fenilo, fenil-alquilo (C_1-C_3), piridilo o piridil-alquilo (C_1-C_3), donde los restos o sustituyentes alquilo y cicloalquilo están opcionalmente sustituidos con uno a cinco átomos de flúor, preferiblemente con cero a tres átomos de flúor y los sustituyentes fenilo y piridilo y los restos fenilo y

piridilo de los sustituyentes fenil-alquilo (C_1-C_3) y piridil-alquilo (C_1-C_3) están opcionalmente sustituidos con uno a cinco sustituyentes, preferiblemente con cero a dos sustituyentes, seleccionados independientemente entre cloro, fluoro, amino, nitro, ciano, hidroxi, alquilamino (C_1-C_3), alquilo (C_1-C_3) opcionalmente sustituido con uno a tres átomos de flúor y alcoxi (C_1-C_3) opcionalmente sustituido con uno a tres átomos de flúor;

R_4 es un átomo de hidrógeno o alquilo (C_1-C_6) opcionalmente sustituido con uno a cinco átomos de flúor;

R_5 es un átomo de hidrógeno o alquilo (C_1-C_6) opcionalmente sustituido con uno a cinco átomos de flúor;

R_4 y R_5, junto con el carbono al que están unidos, forman un anillo cicloalquilo de tres a seis miembros; y

R_6 es un átomo de hidrógeno o alquilo (C_1-C_6);

con la condición de que R_1, R_2, R_3, R_4, R_5 y R_6 no sean simultáneamente átomos de hidrógeno.

Los compuestos específicos de fórmula I incluyen los siguientes compuestos y sus sales farmacéuticamente aceptables:

Ácido 3-amino-4,5-dimetil-hexanoico;

Ácido 3-amino-4,5-dimetil-heptanoico;

Ácido 3-amino-4,5-dimetil-octanoico;

Ácido 3-amino-4,5-dimetil-nonanoico;

Ácido 3-amino-4,5-dimetil-decanoico;

Ácido 3-amino-4-etil-5-metil-heptanoico;

Ácido 3-amino-4-etil-5-metil-octanoico;

Ácido 3-amino-4-etil-5-metil-nonanoico;

Ácido 3-amino-4-etil-5,6-dimetil-heptanoico;

Ácido 3-amino-4-etil-5,7-dimetil-octanoico;

Ácido 3-amino-4-etil-5,8-dimetil-nonanoico;

Ácido 3-amino-5-etil-4-metil-octanoico;

Ácido 3-amino-5-etil-4-metil-nonanoico;

Ácido 3-amino-4,5-dietil-heptanoico;

Ácido 3-amino-4,5-dietil-octanoico;

Ácido 3-amino-4,5-dietil-nonanoico;

Ácido 3-amino-5-etil-4,7-dimetil-octanoico;

Ácido 3-amino-5-etil-4,8-dimetil-nonanoico;

Ácido 3-amino-4,5-dietil-6-metil-heptanoico;

Ácido 3-amino-4,5-dietil-7-metil-octanoico;

Ácido 3-amino-4,5-dietil-8-metil-nonanoico;

Ácido 3-amino-4,5,6-trimetil-heptanoico;

Ácido 3-amino-4,5,7-trimetil-octanoico;

Ácido 3-amino-4,5,8-trimetil-nonanoico;

Ácido 3-amino-4-etil-5-metil-hexanoico;

Ácido 3-amino-5-etil-4-metil-octanoico;

Ácido 3-amino-5-etil-4-metil-heptanoico;

Ácido 3-amino-4-metil-5-propil-octanoico;

Ácido 3-amino-4-metil-6-etil-octanoico;

Ácido 3-amino-4-metil-6-etil-nonanoico;

Ácido 3-amino-4,6-dietil-octanoico;

Ácido 3-amino-4,6-dietil-nonanoico;

Ácido 3-amino-6-ciclopentil-4,5-dimetil-hexanoico;

Ácido 3-amino-7-ciclopentil-4,5-dimetil-heptanoico;

Ácido 3-amino-5-etil-4,6-dimetil-heptanoico;

Ácido 3-amino-5-etil-4,7-dimetil-octanoico;

Ácido 3-amino-5-etil-4,8-dimetil-nonanoico;

Ácido (3*R*,4*R*)-3-amino-4,5-dimetil-hexanoico;

Ácido (3*R*,4*R*,5*R*)-3-amino-4,5-dimetil-heptanoico;

Ácido (3*R*,4*R*,5*R*)-3-amino-4,5-dimetil-octanoico;

Ácido (3*R*,4*R*,5*R*)-3-amino-4,5-dimetil-nonanoico;

Ácido (3*R*,4*R*,5*R*)-3-amino-4,5-dimetil-decanoico;

Ácido 3-amino-5-ciclopropil-4-etil-hexanoico;

Ácido 3-amino-6-ciclopropil-4-etil-5-metil-hexanoico;

Ácido 3-amino-5-ciclobutil-4-etil-hexanoico;

Ácido 3-amino-6-ciclobutil-4-etil-5-metil-hexanoico;

Ácido 3-amino-5-ciclopentil-4-metil-hexanoico;

Ácido 3-amino-6-ciclopentil-4-etil-5-metil-hexanoico;

Ácido 3-amino-5-ciclohexil-4-etil-hexanoico;

Ácido 3-amino-6-ciclohexil-4-etil-5-metil-hexanoico;

Ácido 3-amino-5-ciclopropil-4-metil-hexanoico;

Ácido 3-amino-6-ciclopropil-4,5-dimetil-hexanoico;

Ácido 3-amino-5-ciclobutil-4-metil-hexanoico;

Ácido 3-amino-6-ciclobutil-4,5-dimetil-hexanoico;

Ácido 3-amino-5-ciclopentil-4-metil-hexanoico;

Ácido 3-amino-6-ciclopentil-4,5-dimetil-hexanoico;

Ácido 3-amino-5-ciclohexil-4-metil-hexanoico;

Ácido 3-amino-6-ciclohexil-4,5-dimetil-hexanoico;

Ácido 3-amino-8-ciclohexil-4,5-dimetil-octanoico;

Ácido 3-amino-8-ciclohexil-4,5-dimetil-octanoico;

Ácido 3-amino-4,6-dimetil-heptanoico;

Ácido 3-amino-4,6-dimetil-octanoico;

Ácido 3-amino-4,6-dimetil-nonanoico;

Ácido 3-amino-4,6-dimetil-decanoico;

Ácido 3-amino-4,6,7-trimetil-octanoico;

Ácido 3-amino-4,6,8-trimetil-nonanoico;

Ácido 3-amino-4,6,9-trimetil-decanoico;

Ácido 3-amino-6-ciclopropil-4-metil-heptanoico;

Ácido 3-amino-6-ciclobutil-4-metil-heptanoico;

Ácido 3-amino-6-ciclopentil-4-metil-heptanoico;

Ácido 3-amino-6-ciclohexil-4-metil-heptanoico;

Ácido 3-amino-7-ciclopropil-4,6-dimetil-heptanoico;

Ácido 3-amino-7-ciclobutil-4,6-dimetil-heptanoico;

Ácido 3-amino-7-ciclopentil-4,6-dimetil-heptanoico;

Ácido 3-amino-7-ciclohexil-4,6-dimetil-heptanoico;

Ácido 3-amino-8-ciclopropil-4,6-dimetil-octanoico;

Ácido 3-amino-8-ciclobutil-4,6-dimetil-octanoico;

Ácido 3-amino-8-ciclopentil-4,6-dimetil-octanoico;

Ácido 3-amino-8-ciclohexil-4,6-dimetil-octanoico;

Ácido 3-amino-6-(3-cloro-fenil)-4-metil-heptanoico;

Ácido 3-amino-6-(3,4-dicloro-fenil)-4-metil-heptanoico;

Ácido 3-amino-4-metil-6-(3-trifluorometil-fenil)-heptanoico;

Ácido 3-amino-4-metil-6-(4-trifluorometil-fenil)-heptanoico;

Ácido 3-amino-7-(3-cloro-fenil)-4,6-dimetil-heptanoico;

Ácido 3-amino-7-(3,4-dicloro-fenil)-4,6-dimetil-heptanoico;

Ácido 3-amino-4,6-dimetil-7-(3-trifluorometil-fenil)-heptanoico;

Ácido 3-amino-4,6-dimetil-7-(4-trifluorometil-fenil)-heptanoico;

Ácido 3-amino-8-(3-cloro-fenil)-4,6-dimetil-octanoico;

Ácido 3-amino-8-(3,4-dicloro-fenil)-4,6-dimetil-octanoico;

Ácido 3-amino-4,6-dimetil-8-(3-trifluorometil-fenil)-octanoico;

Ácido 3-amino-4,6-dimetil-8-(4-trifluorometil-fenil)-octanoico;

Ácido 3-amino-4-etil-6-metil-octanoico;

Ácido 3-amino-4-etil-6-metil-nonanoico;

Ácido 3-amino-4-etil-6-metil-decanoico;

Ácido 3-amino-4-etil-6,7-dimetil-octanoico;

Ácido 3-amino-4-etil-6,8-dimetil-nonanoico;

Ácido 3-amino-4-etil-6,9-dimetil-decanoico;

Ácido 3-amino-6-ciclopropil-4-etil-heptanoico;

Ácido 3-amino-6-ciclobutil-4-etil-heptanoico;

Ácido 3-amino-6-ciclopentil-4-etil-heptanoico;

Ácido 3-amino-6-ciclohexil-4-etil-heptanoico;

Ácido 3-amino-7-ciclopropil-4-etil-6-metil-heptanoico;

Ácido 3-amino-7-ciclobutil-4-etil-6-metil-heptanoico;

Ácido 3-amino-7-ciclopentil-4-etil-6-metil-heptanoico;

Ácido 3-amino-7-ciclohexil-4-etil-6-metil-heptanoico;

Ácido 3-amino-8-ciclopropil-4-etil-6-metil-octanoico;

Ácido 3-amino-8-ciclobutil-4-etil-6-metil-octanoico;

Ácido 3-amino-8-ciclopentil-4-etil-6-metil-octanoico;

Ácido 3-amino-8-ciclohexil-4-etil-6-metil-octanoico;

Ácido 3-amino-6-(3-cloro-fenil)-4-etil-heptanoico;

Ácido 3-amino-6-(3,4-dicloro-fenil)-4-etil-heptanoico;

Ácido 3-amino-4-etil-6-(3-trifluorometil-fenil)-heptanoico;

Ácido 3-amino-4-etil-6-(4-trifluorometil-fenil)-heptanoico;

Ácido 3-amino-7-(3-cloro-fenil)-4-etil-6-metil-heptanoico;

Ácido 3-amino-7-(3,4-dicloro-fenil)-4-etil-6-metil-heptanoico;

Ácido 3-amino-4-etil-6-metil-7-(3-trifluorometil-fenil)-heptanoico;

Ácido 3-amino-4-etil-6-metil-7-(4-trifluorometil-fenil)-heptanoico;

Ácido 3-amino-8-(3-cloro-fenil)-4-etil-6-metil-octanoico;

Ácido 3-amino-8-(3,4-dicloro-fenil)-4-etil-6-metil-octanoico;

Ácido 3-amino-4-etil-6-metil-8-(3-trifluorometil-fenil)-octanoico;

Ácido 3-amino-4-etil-6-metil-8-(4-trifluorometil-fenil)-octanoico;

Ácido 3-amino-4-metil-heptanoico;

Ácido 3-amino-4,6-dimetil-heptanoico;

Ácido 3-amino-4,7-dimetil-octanoico;

Ácido 3-amino-4,8-dimetil-nonanoico;

Ácido 3-amino-4-metil-hexanoico;

Ácido 3-amino-4-metil-heptanoico;

Ácido 3-amino-4-metil-octanoico;

Ácido 3-amino-4-metil-nonanoico;

Ácido 3-amino-5-ciclopropil-4-metil-pentanoico;

Ácido 3-amino-6-ciclopropil-4-metil-hexanoico;

Ácido 3-amino-7-ciclopropil-4-metil-heptanoico;

Ácido 3-amino-5-ciclobutil-4-metil-pentanoico;

Ácido 3-amino-6-ciclobutil-4-metil-hexanoico;

Ácido 3-amino-7-ciclobutil-4-metil-heptanoico;

Ácido 3-amino-5-ciclopentil-4-metil-pentanoico;

Ácido 3-amino-6-ciclopentil-4-metil-hexanoico;

Ácido 3-amino-7-ciclopentil-4-metil-heptanoico;

Ácido 3-amino-5-ciclohexil-4-metil-pentanoico;

Ácido 3-amino-6-ciclohexil-4-metil-hexanoico;

Ácido 3-amino-7-ciclohexil-4-metil-heptanoico;

Ácido 3-amino-5-ciclopropil-4-etil-pentanoico;

Ácido 3-amino-6-ciclopropil-4-etil-hexanoico;

Ácido 3-amino-7-ciclopropil-4-etil-heptanoico;

Ácido 3-amino-5-ciclobutil-4-etil-pentanoico;

Ácido 3-amino-6-ciclobutil-4-etil-hexanoico;

Ácido 3-amino-7-ciclobutil-4-etil-heptanoico;

Ácido 3-amino-5-ciclopentil-4-etil-pentanoico;

Ácido 3-amino-6-ciclopentil-4-etil-hexanoico;

Ácido 3-amino-7-ciclopentil-4-etil-heptanoico;

Ácido 3-amino-5-ciclohexil-4-etil-pentanoico;

Ácido 3-amino-6-ciclohexil-4-etil-hexanoico;

Ácido 3-amino-7-ciclohexil-4-etil-heptanoico;

Ácido 3-amino-4,4,5-trimetil-heptanoico;

Ácido 3-amino-4,4,5-trimetil-octanoico;

Ácido 3-amino-4,4,5-trimetil-hexanoico;

Ácido 3-amino-4,5,5-trimetil-heptanoico;

Ácido 3-amino-4,5,5-trimetil-octanoico; y

Ácido 3-amino-4,5,5-trimetil-hexanoico;

Otros compuestos de fórmula I incluyen los siguientes compuestos y sus sales farmacéuticamente aceptables:

Ácido 3-amino-4-metil-5-fenil-pentanoico;

Ácido 3-amino-4-metil-6-fenil-hexanoico;

Ácido 3-amino-4-metil-7-fenil-heptanoico;

Ácido 3-amino-5-(2-cloro-fenil)-4-metil-pentanoico;

Ácido 3-amino-5-(3-cloro-fenil)-4-metil-pentanoico;

Ácido 3-amino-5-(4-cloro-fenil)-4-metil-pentanoico;

Ácido 3-amino-5-(2,4-dicloro-fenil)-4-metil-pentanoico;

Ácido 3-amino-5-(3,4-dicloro-fenil)-4-metil-pentanoico;

Ácido 3-amino-4-(2-cloro-bencil)-hexanoico;

Ácido 3-amino-4-(3-cloro-bencil)-hexanoico;

Ácido 3-amino-4-(4-cloro-bencil)-hexanoico;

Ácido 3-amino-4-(2,4-dicloro-bencil)-hexanoico;

Ácido 3-amino-4-(3,4-dicloro-bencil)-hexanoico;

Ácido 3-amino-6-(2-cloro-fenil)-4-metil-hexanoico;

Ácido 3-amino-6-(3-cloro-fenil)-4-metil-hexanoico;

Ácido 3-amino-6-(4-cloro-fenil)-4-metil-hexanoico;

Ácido 3-amino-6-(2,4-dicloro-fenil)-4-metil-hexanoico;

Ácido 3-amino-6-(3,4-dicloro-fenil)-4-metil-hexanoico;

Ácido 3-amino-6-(2-cloro-fenil)-4-etil-hexanoico;

Ácido 3-amino-6-(3-cloro-fenil)-4-etil-hexanoico;

Ácido 3-amino-6-(4-cloro-fenil)-4-etil-hexanoico;

Ácido 3-amino-6-(2,4-dicloro-fenil)-4-etil-hexanoico;

Ácido 3-amino-6-(3,4-dicloro-fenil)-4-etil-hexanoico;

Ácido 3-amino-7-(2-cloro-fenil)-4-metil-heptanoico;

Ácido 3-amino-7-(3-cloro-fenil)-4-metil-heptanoico;

Ácido 3-amino-7-(4-cloro-fenil)-4-metil-heptanoico;

Ácido 3-amino-7-(2,4-dicloro-fenil)-4-metil-heptanoico;

Ácido 3-amino-7-(3,4-dicloro-fenil)-4-metil-heptanoico;

Ácido 3-amino-7-(2-cloro-fenil)-4-etil-heptanoico;


Ácido 3-amino-7-(3-cloro-fenil)-4-etil-heptanoico;

Ácido 3-amino-7-(4-cloro-fenil)-4-etil-heptanoico;

Ácido 3-amino-7-(2,4-dicloro-fenil)-4-etil-heptanoico; y

Ácido 3-amino-7-(3,4-dicloro-fenil)-4-etil-heptanoico;

Esta invención también proporciona compuestos de fórmula II



II

y sus sales farmacéuticamente aceptables, en la que R_1, R_3 y R_4 son como se han definido anteriormente en la fórmula I, con la condición de que R_1 no sea un átomo de hidrógeno.

Los compuestos específicos de fórmula II incluyen los siguientes compuestos y sus sales farmacéuticamente aceptables:

Ácido 3-amino-4,5-dimetil-hexanoico;

Ácido 3-amino-4,5-dimetil-heptanoico;

Ácido 3-amino-4,5-dimetil-octanoico;

Ácido 3-amino-4,5-dimetil-nonanoico;

Ácido 3-amino-4-etil-5-metil-heptanoico;

Ácido 3-amino-4-etil-5-metil-octanoico;

Ácido 3-amino-4-etil-5-metil-nonanoico;

Ácido 3-amino-4-etil-5,6-dimetil-heptanoico;

Ácido 3-amino-4-etil-5,7-dimetil-octanoico;

Ácido 3-amino-4-etil-5,8-dimetil-nonanoico;

Ácido 3-amino-5-etil-4-metil-octanoico;

Ácido 3-amino-5-etil-4-metil-nonanoico;

Ácido 3-amino-4,5-dietil-heptanoico;

Ácido 3-amino-4,5-dietil-octanoico;

Ácido 3-amino-4,5-dietil-nonanoico;

Ácido 3-amino-5-etil-4,7-dimetil-octanoico;

Ácido 3-amino-5-etil-4,8-dimetil-nonanoico;

Ácido 3-amino-4,5-dietil-6-metil-heptanoico;

Ácido 3-amino-4,5-dietil-7-metil-octanoico;

Ácido 3-amino-4,5-dietil-8-metil-nonanoico;

Ácido 3-amino-4,5,6-trimetil-heptanoico;

Ácido 3-amino-4,5,7-trimetil-octanoico;

Ácido 3-amino-4,5,8-trimetil-nonanoico;

Ácido 3-amino-4-etil-5-metil-hexanoico;

Ácido 3-amino-5-etil-4-metil-octanoico;

Ácido 3-amino-5-etil-4-metil-heptanoico;

Ácido 3-amino-4-metil-5-propil-octanoico;

Ácido 3-amino-6-ciclopentil-4,5-dimetil-hexanoico;

Ácido 3-amino-7-ciclopentil-4,5-dimetil-heptanoico;

Ácido 3-amino-5-etil-4,6-dimetil-heptanoico;

Ácido 3-amino-5-etil-4,7-dimetil-octanoico;

Ácido 3-amino-5-etil-4,8-dimetil-nonanoico;

Ácido (3*R*,4*R*)-3-amino-4,5-dimetil-hexanoico;

Ácido (3*R*,4*R*,5*R*)-3-amino-4,5-dimetil-heptanoico;

Ácido (3*R*,4*R*,5*R*)-3-amino-4,5-dimetil-octanoico;

Ácido (3*R*,4*R*,5*R*)-3-amino-4,5-dimetil-nonanoico;

Ácido (3*R*,4*R*,5R)-3-amino-4,5-decanoico;

Ácido 3-amino-5-ciclopropil-4-etil-hexanoico;

Ácido 3-amino-6-ciclopropil-4-etil-5-metil-hexanoico;

Ácido 3-amino-5-ciclobutil-4-etil-hexanoico;

Ácido 3-amino-6-ciclobutil-4-etil-5-metil-hexanoico;

Ácido 3-amino-5-ciclopentil-4-metil-hexanoico;

Ácido 3-amino-6-ciclopentil-4-etil-5-metil-hexanoico;

Ácido 3-amino-5-ciclohexil-4-etil-hexanoico;

Ácido 3-amino-6-ciclohexil-4-etil-5-metil-hexanoico;

Ácido 3-amino-5-ciclopropil-4-metil-hexanoico;

Ácido 3-amino-6-ciclopropil-4,5-dimetil-hexanoico;

Ácido 3-amino-5-ciclobutil-4-metil-hexanoico;

Ácido 3-amino-6-ciclobutil-4,5-dimetil-hexanoico;

Ácido 3-amino-5-ciclopentil-4-metil-hexanoico;

Ácido 3-amino-6-ciclopentil-4,5-dimetil-hexanoico;


Ácido 3-amino-5-ciclohexil-4-metil-hexanoico;

Ácido 3-amino-6-ciclohexil-4,5-dimetil-hexanoico;

Ácido 3-amino-8-ciclohexil-4,5-dimetil-octanoico y

Ácido 3-amino-8-ciclohexil-4,5-dimetil-octanoico.;

Esta invención también proporciona compuestos de formula III



III

y sus sales farmacéuticamente aceptables, en la que R_1 y R_3 son como se han definido anteriormente en la fórmula I, con la condición de que R_1 y R_3 no sean átomos de hidrógeno.

Los compuestos específicos de fórmula III incluyen los siguientes compuestos y sus sales farmacéuticamente aceptables:

Ácido 3-amino-4,5-dimetil-hexanoico;

Ácido 3-amino-4,5-dimetil-heptanoico;

Ácido 3-amino-4,5-dimetil-octanoico;

Ácido 3-amino-4,5-dimetil-nonanoico;

Ácido 3-amino-4,5,6-trimetil-heptanoico;

Ácido 3-amino-4,5,7-trimetil-octanoico;

Ácido 3-amino-4,5,8-trimetil-nonanoico;

Ácido 3-amino-4-metil-5-propil-octanoico;

Ácido 3-amino-6-ciclopentil-4,5-dimetil-hexanoico;

Ácido 3-amino-7-ciclopentil-4,5-dimetil-heptanoico;

Ácido 3-amino-5-etil-4,6-dimetil-heptanoico;

Ácido 3-amino-5-etil-4,7-dimetil-octanoico;

Ácido 3-amino-5-etil-4,8-dimetil-nonanoico;

Ácido (3*R*,4*R*)-3-amino-4,5-dimetil-hexanoico;

Ácido (3*R*,4*R*,5*R*)-3-amino-4,5-dimetil-heptanoico;

Ácido (3*R*,4*R*,5*R*)-3-amino-4,5-dimetil-octanoico;

Ácido (3*R*,4*R*,5*R*)-3-amino-4,5-dimetil-nonanoico;

Ácido (3*R*,4*R*,5*R*)-3-amino-4,5-dimetil-decanoico;

Ácido 3-amino-5-ciclopentil-4-metil-hexanoico;

Ácido 3-amino-5-ciclopropil-4-metil-hexanoico;

Ácido 3-amino-6-ciclopropil-4,5-dimetil-hexanoico;

Ácido 3-amino-5-ciclobutil-4-metil-hexanoico;

Ácido 3-amino-6-ciclobutil-4,5-dimetil-hexanoico;

Ácido 3-amino-5-ciclopentil-4-metil-hexanoico;

Ácido 3-amino-6-ciclopentil-4,5-dimetil-hexanoico;


Ácido 3-amino-5-ciclohexil-4-metil-hexanoico;

Ácido 3-amino-6-ciclohexil-4,5-dimetil-hexanoico;

Ácido 3-amino-8-ciclohexil-4,5-dimetil-octanoico y

Ácido 3-amino-8-ciclohexil-4,5-dimetil-octanoico.

Esta invención también proporciona compuestos de formula IV



IV

y sus sales farmacéuticamente aceptables, en la que R_3 es como se ha definido anteriormente en la fórmula I, con la condición de que R_3 no sea un átomo de hidrógeno.

Los compuestos específicos de fórmula IV incluyen los siguientes compuestos y sus sales farmacéuticamente aceptables:

Ácido (3*R*,4*R*)-3-amino-4,5-dimetil-hexanoico;


Ácido (3*R*,4*R*,5*R*)-3-amino-4,5-dimetil-heptanoico;

Ácido (3*R*,4*R*,5*R*)-3-amino-4,5-dimetil-octanoico;

Ácido (3*R*,4*R*,5*R*)-3-amino-4,5-dimetil-nonanoico;

Ácido (3*R*,4*R*,5*R*)-3-amino-4,5-dimetil-decanoico.

Esta invención también se refiere a compuestos de formula V



V

y a sus sales farmacéuticamente aceptables, en la que R_1, R_2, R_3, R_4 y R_5 son como se han definido anteriormente en la fórmula I, con la condición de que R_1, R_2, R_3, R_4 y R_5 no sean átomos de hidrógeno simultáneamente.

Los compuestos específicos de fórmula V incluyen los siguientes compuestos y sus sales farmacéuticamente aceptables:

Ácido 2-aminometil-4-(2-fluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-(3-fluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-(4-fluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3-difluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,4-difluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,5-difluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,6-difluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-(3,4-difluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-(3,5-difluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,4-trifluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,5-trifluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,6-trifluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,4,6-trifluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,4,5-tetrafluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,4,6-tetrafluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,5,6-tetrafluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-pentafluorofenil-pentanoico;

Ácido 2-aminometil-4-(2-fluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-(3-fluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-(4-fluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3-difluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,4-difluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,5-difluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,6-difluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-(3,4-difluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-(3,5-difluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,4-trifluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,5-trifluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,6-trifluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,4,6-trifluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,4,5-tetrafluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,4,6-tetrafluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,5,6-tetrafluoro-fenil)-hexanoico;

196

Ácido 2-aminometil-4-pentafluorofenil-hexanoico;

Ácido 2-aminometil-5-(2-fluoro-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3-fluoro-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(4-fluoro-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,3-difluoro-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,4-difluoro-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,5-difluoro-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,6-difluoro-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3,4-difluoro-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3,5-difluoro-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4-trifluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5-trifluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,6-trifluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,4,6-trifluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4,5-tetrafluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4,6-tetrafluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5,6-tetrafluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-pentafluorofenil-pentanoico;

Ácido 2-aminometil-5-(2-fluoro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3-fluoro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(4-fluoro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,3-difluoro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,4-difluoro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,5-difluoro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,6-difluoro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3,4-difluoro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3,5-difluoro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4-trifluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5-trifluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,6-trifluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,4,6-trifluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4,5-tetrafluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4,6-tetrafluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5,6-tetrafluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-pentafluorofenil-hexanoico;

Ácido 2-aminometil-6-(2-fluoro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3-fluoro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(4-fluoro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,3-difluoro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,4-difluoro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,5-difluoro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,6-difluoro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3,4-difluoro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3,5-difluoro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,4-trifluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,5-trifluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,6-trifluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,4,6-trifluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,4,5-tetrafluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,4,6-tetrafluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,5,6-tetrafluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-pentafluorofenil-hexanoico;

Ácido 2-aminometil-5-(2-fluoro-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3-fluoro-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(4-fluoro-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,3-difluoro-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,4-difluoro-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,5-difluoro-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,6-difluoro-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3,4-difluoro-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3,5-difluoro-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4-trifluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,5-trifluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,6-trifluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,4,6-trifluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4,5-tetrafluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4,6-tetrafluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,5,6-tetrafluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-pentafluorofenil-pentanoico;

Ácido 2-aminometil-6-(2-fluoro-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3-fluoro-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(4-fluoro-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,3-difluoro-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,4-difluoro-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,5-difluoro-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,6-difluoro-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3,4-difluoro-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3,5-difluoro-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,4-trifluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,5-trifluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,6-trifluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,4,6-trifluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,4,5-tetrafluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,4,6-tetrafluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,5,6-tetrafluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-pentafluorofenil-hexanoico;

Ácido 2-aminometil-7-(2-fluoro-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3-fluoro-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(4-fluoro-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,3-difluoro-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,4-difluoro-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,5-difluoro-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,6-difluoro-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3,4-difluoro-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3,5-difluoro-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,4-trifluoro-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,5-trifluoro-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,6-trifluoro-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,4,6-trifluoro-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,4,5-tetrafluoro-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,4,6-tetrafluoro-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,5,6-tetrafluoro-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-pentafluorofenil-heptanoico;

Ácido 2-aminometil-7-(2-fluoro-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3-fluoro-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(4-fluoro-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,3-difluoro-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,4-difluoro-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,5-difluoro-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,6-difluoro-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3,4-difluoro-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3,5-difluoro-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,4-trifluoro-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,5-trifluoro-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,6-trifluoro-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,4,6-trifluoro-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,4,5-tetrafluoro-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,4,6-tetrafluoro-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,5,6-tetrafluoro-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-pentafluorofenil-heptanoico;

Ácido 2-aminometil-4-(2-cloro-fenil)-pentanoico;

Ácido 2-aminometil-4-(3-cloro-fenil)-pentanoico;

Ácido 2-aminometil-4-(4-cloro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3-dicloro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,4-dicloro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,5-dicloro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,6-dicloro-fenil)-pentanoico;

Ácido 2-aminometil-4-(3,4-dicloro-fenil)-pentanoico;

Ácido 2-aminometil-4-(3,5-dicloro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,4-tricloro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,5-tricloro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,6-tricloro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,4,6-tricloro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,4,5-tetracloro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,4,6-tetracloro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,5,6-tetracloro-fenil)-pentanoico;

Ácido 2-aminometil-4-pentaclorofenil-pentanoico;

Ácido 2-aminometil-4-(2-cloro-fenil)-hexanoico;

Ácido 2-aminometil-4-(3-cloro-fenil)-hexanoico;

Ácido 2-aminometil-4-(4-cloro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3-dicloro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,4-dicloro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,5-dicloro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,6-dicloro-fenil)-hexanoico;

Ácido 2-aminometil-4-(3,4-dicloro-fenil)-hexanoico;

Ácido 2-aminometil-4-(3,5-dicloro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,4-tricloro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,5-tricloro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,6-tricloro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,4,6-tricloro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,4,5-tetracloro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,4,6-tetracloro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,5,6-tetracloro-fenil)-hexanoico;

Ácido 2-aminometil-4-pentaclorofenil-hexanoico;

Ácido 2-aminometil-5-(2-cloro-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3-cloro-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(4-cloro-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,3-dicloro-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,4-dicloro-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,5-dicloro-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,6-dicloro-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3,4-dicloro-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3,5-dicloro-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4-tricloro-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5-tricloro-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,6-tricloro-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,4,6-tricloro-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4,5-tetracloro-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4,6-tetracloro-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5,6-tetracloro-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-pentaclorofenil-pentanoico;

Ácido 2-aminometil-5-(2-cloro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3-cloro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(4-cloro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,3-dicloro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,4-dicloro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,5-dicloro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,6-dicloro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3,4-dicloro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3,5-dicloro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4-tricloro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5-tricloro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,6-tricloro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,4,6-tricloro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4,5-tetracloro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4,6-tetracloro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5,6-tetracloro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-pentaclorofenil-hexanoico;

Ácido 2-aminometil-5-(2-cloro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3-cloro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(4-cloro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,3-dicloro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,4-dicloro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,5-dicloro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,6-dicloro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3,4-dicloro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3,5-dicloro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4-tricloro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5-tricloro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,6-tricloro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,4,6-tricloro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4,5-tetracloro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4,6-tetracloro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5,6-tetracloro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-pentaclorofenil-hexanoico;

Ácido 2-aminometil-5-(2-cloro-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3-cloro-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(4-cloro-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,3-dicloro-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,4-dicloro-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,5-dicloro-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,6-dicloro-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3,4-dicloro-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3,5-dicloro-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4-tricloro-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,5-tricloro-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,6-tricloro-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,4,6-tricloro-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4,5-tetracloro-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4,6-tetracloro-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,5,6-tetracloro-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-pentaclorofenil-pentanoico;

Ácido 2-aminometil-6-(2-cloro-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3-cloro-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(4-cloro-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,3-dicloro-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,4-dicloro-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,5-dicloro-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,6-dicloro-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3,4-dicloro-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3,5-dicloro-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,4-tricloro-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,5-tricloro-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,6-tricloro-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,4,6-tricloro-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,4,5-tetracloro-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,4,6-tetracloro-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,5,6-tetracloro-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-pentaclorofenil-hexanoico;

Ácido 2-aminometil-7-(2-cloro-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3-cloro-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(4-cloro-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,3-dicloro-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,4-dicloro-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,5-dicloro-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,6-dicloro-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3,4-dicloro-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3,5-dicloro-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,4-tricloro-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,5-tricloro-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,6-tricloro-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,4,6-tricloro-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,4,5-tetracloro-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,4,6-tetracloro-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,5,6-tetracloro-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-pentaclorofenil-heptanoico;

Ácido 2-aminometil-7-(2-cloro-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3-cloro-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(4-cloro-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,3-dicloro-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,4-dicloro-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,5-dicloro-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,6-dicloro-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3,4-dicloro-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3,5-dicloro-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,4-tricloro-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,5-tricloro-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,6-tricloro-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,4,6-tricloro-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,4,5-tetracloro-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,4,6-tetracloro-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,5,6-tetracloro-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-pentaclorofenil-heptanoico;

Ácido 2-aminometil-4-(2-metoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(3-metoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(4-metoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3-dimetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,4-dimetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,5-dimetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,6-dimetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(3,4-dimetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(3,5-dimetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,4-trimetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,5-trimetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,6-trimetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,4,6-trimetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2-metoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(3-metoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(4-metoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3-dimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,4-dimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,5-dimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,6-dimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(3,4-dimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(3,5-dimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,4-trimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,5-trimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,6-trimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,4,6-trimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-5-(2-metoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3-metoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(4-metoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,3-dimetoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,4-dimetoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,5-dimetoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,6-dimetoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3,4-dimetoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3,5-dimetoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4-trimetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5-trimetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,6-trimetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,4,6-trimetoxi-fenil)-pentanoico;

Ácido 2-aminometil-5-(2-metoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3-metoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(4-metoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,3-dimetoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,4-dimetoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,5-dimetoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,6-dimetoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3,4-dimetoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3,5-dimetoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4-trimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5-trimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,6-trimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,4,6-trimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-6-(2-metoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3-metoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(4-metoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,3-dimetoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,4-dimetoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,5-dimetoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,6-dimetoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3,4-dimetoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3,5-dimetoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,4-trimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,5-trimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,6-trimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,4,6-trimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-5-(2-metoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3-metoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(4-metoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,3-dimetoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,4-dimetoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,5-dimetoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,6-dimetoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3,4-dimetoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3,5-dimetoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4-trimetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,5-trimetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,6-trimetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,4,6-trimetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4,5-tetrametoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4,6-tetrametoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,5,6-tetrametoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-pentametoxifenil-pentanoico;

Ácido 2-aminometil-6-(2-metoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3-metoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(4-metoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,3-dimetoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,4-dimetoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,5-dimetoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,6-dimetoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3,4-dimetoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3,5-dimetoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,4-trimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,5-trimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,6-trimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,4,6-trimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-7-(2-metoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3-metoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(4-metoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,3-dimetoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,4-dimetoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,5-dimetoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,6-dimetoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3,4-dimetoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3,5-dimetoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,4-trimetoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,5-trimetoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,6-trimetoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,4,6-trimetoxi-fenil)-heptanoico;

Ácido 2-aminometil-7-(2-metoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3-metoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(4-metoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,3-dimetoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,4-dimetoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,5-dimetoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,6-dimetoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3,4-dimetoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3,5-dimetoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,4-trimetoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,5-trimetoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,6-trimetoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,4,6-trimetoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-(2-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-(3-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-(4-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3-di-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,4-di-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,5-di-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,6-di-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-(3,4-di-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-(3,5-di-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,4-tri-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,5-tri-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,6-tri-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,4,6-tri-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-(2-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-(3-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-(4-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3-di-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,4-di-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,5-di-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,6-di-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-(3,4-di-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-(3,5-di-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,4-tri-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,5-tri-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,6-tri-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,4,6-tri-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-5-(2-trifluorometil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3-trifluorometil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(4-trifluorometil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,3-di-trifluorometil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,4-di-trifluorometil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,5-di-trifluorometil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,6-di-trifluorometil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3,4-di-trifluorometil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3,5-di-trifluorometil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4-tri-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5-tri-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,6-tri-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,4,6-tri-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-5-(2-trifluorometil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3-trifluorometil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(4-trifluorometil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,3-di-trifluorometil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,4-di-trifluorometil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,5-di-trifluorometil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,6-di-trifluorometil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3,4-di-trifluorometil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3,5-di-trifluorometil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4-tri-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5-tri-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,6-tri-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,4,6-tri-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-6-(2-trifluorometil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3-trifluorometil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(4-trifluorometil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,3-di-trifluorometil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,4-di-trifluorometil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,5-di-trifluorometil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,6-di-trifluorometil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3,4-di-trifluorometil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3,5-di-trifluorometil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,4-tri-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,5-tri-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,6-tri-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,4,6-tri-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-5-(2-trifluorometil-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3-trifluorometil-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(4-trifluorometil-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,3-di-trifluorometil-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,4-di-trifluorometil-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,5-di-trifluorometil-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,6-di-trifluorometil-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3,4-di-trifluorometil-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3,5-di-trifluorometil-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4-tri-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,5-tri-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,6-tri-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,4,6-tri-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4,5-tetra-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4,6-tetra-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,5,6-tetra-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-penta-trifluorometilfenil-pentanoico;

Ácido 2-aminometil-6-(2-trifluorometil-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3-trifluorometil-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(4-trifluorometil-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,3-di-trifluorometil-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,4-di-trifluorometil-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,5-di-trifluorometil-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,6-di-trifluorometil-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3,4-di-trifluorometil-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3,5-di-trifluorometil-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,4-tri-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,5-tri-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,6-tri-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,4,6-tri-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-7-(2-trifluorometil-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3-trifluorometil-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(4-trifluorometil-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,3-di-trifluorometil-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,4-di-trifluorometil-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,5-di-trifluorometil-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,6-di-trifluorometil-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3,4-di-trifluorometil-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3,5-di-trifluorometil-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,4-tri-trifluorometil-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,5-tri-trifluorometil-fenil)-heptanoico;

216

Ácido 2-aminometil-4-metil-7-(2,3,6-tri-trifluorometil-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,4,6-tri-trifluorometil-fenil)-heptanoico;

Ácido 2-aminometil-7-(2-trifluorometil-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3-trifluorometil-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(4-trifluorometil-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,3-di-trifluorometil-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,4-di-trifluorometil-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,5-di-trifluorometil-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,6-di-trifluorometil-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3,4-di-trifluorometil-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3,5-di-trifluorometil-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,4-tri-trifluorometil-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,5-tri-trifluorometil-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,6-tri-trifluorometil-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,4,6-tri-trifluorometil-fenil)-heptanoico;

Ácido 2-aminometil-4-(2-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(3-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(4-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3-di-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,4-di-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,5-di-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,6-di-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(3,4-di-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(3,5-di-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,4-tri-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,5-tri-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,6-tri-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,4,6-tri-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(3-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(4-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3-di-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,4-di-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,5-di-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,6-di-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(3,4-di-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(3,5-di-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,4-tri-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,5-tri-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,6-tri-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,4,6-tri-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-5-(2-trifluorometoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3-trifluorometoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(4-trifluorometoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,3-di-trifluorometoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,4-di-trifluorometoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,5-di-trifluorometoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,6-di-trifluorometoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3,4-di-trifluorometoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3,5-di-trifluorometoxi-fenil)-4-metil-pentanoico;

218

Ácido 2-aminometil-4-metil-5-(2,3,4-tri-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5-tri-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,6-tri-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,4,6-tri-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-5-(2-trifluorometoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3-trifluorometoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(4-trifluorometoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,3-di-trifluorometoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,4-di-trifluorometoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,5-di-trifluorometoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,6-di-trifluorometoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3,4-di-trifluorometoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3,5-di-trifluorometoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4-tri-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,5-tri-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,6-tri-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,4,6-tri-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4,5-tetrafluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4,6-tetrafluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,5,6-tetrafluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-penta-trifluorometoxifenil-pentanoico;

Ácido 2-aminometil-5-(2-trifluorometoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3-trifluorometoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(4-trifluorometoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,3-di-trifluorometoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,4-di-trifluorometoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,5-di-trifluorometoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,6-di-trifluorometoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3,4-di-trifluorometoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3,5-di-trifluorometoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4-tri-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5-tri-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,6-tri-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,4,6-tri-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-6-(2-trifluorometoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3-trifluorometoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(4-trifluorometoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,3-di-trifluorometoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,4-di-trifluorometoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,5-di-trifluorometoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,6-di-trifluorometoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3,4-di-trifluorometoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3,5-di-trifluorometoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,4-tri-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,5-tri-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,6-tri-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,4,6-tri-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-6-(2-trifluorometoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3-trifluorometoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(4-trifluorometoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,3-di-trifluorometoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,4-di-trifluorometoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,5-di-trifluorometoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,6-di-trifluorometoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3,4-di-trifluorometoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3,5-di-trifluorometoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,4-tri-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,5-tri-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,6-tri-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,4,6-tri-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-7-(2-trifluorometoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3-trifluorometoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(4-trifluorometoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,3-di-trifluorometoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,4-di-trifluorometoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,5-di-trifluorometoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,6-di-trifluorometoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3,4-di-trifluorometoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3,5-di-trifluorometoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,4-tri-trifluorometoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,5-tri-trifluorometoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,6-tri-trifluorometoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,4,6-tri-trifluorometoxi-fenil)-heptanoico;

Ácido 2-aminometil-7-(2-trifluorometoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3-trifluorometoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(4-trifluorometoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,3-di-trifluorometoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,4-di-trifluorometoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,5-di-trifluorometoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,6-di-trifluorometoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3,4-di-trifluorometoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3,5-di-trifluorometoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,4-tri-trifluorometoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,5-tri-trifluorometoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,6-tri-trifluorometoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,4,6-tri-trifluorometoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-(2-etoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(3-etoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(4-etoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3-dietoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,4-dietoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,5-dietoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,6-dietoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(3,4-dietoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(3,5-dietoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,4-trietoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,5-trietoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,6-trietoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,4,6-trietoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2-etoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(3-etoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(4-etoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3-dietoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,4-dietoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,5-dietoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,6-dietoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(3,4-dietoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(3,5-dietoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,4-trietoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,5-trietoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,6-trietoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,4,6-trietoxi-fenil)-hexanoico;

Ácido 2-aminometil-5-(2-etoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3-etoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(4-etoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,3-dietoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,4-dietoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,5-dietoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,6-dietoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3,4-dietoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3,5-dietoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4-trietoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5-trietoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,6-trietoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,4,6-trietoxi-fenil)-pentanoico;

Ácido 2-aminometil-5-(2-etoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3-etoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(4-etoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,3-dietoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,4-dietoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,5-dietoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,6-dietoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3,4-dietoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3,5-dietoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4-trietoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,5-trietoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,6-trietoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,4,6-trietoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4,5-tetraetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4,6-tetraetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,5,6-tetraetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-pentaetoxifenil-pentanoico;

Ácido 2-aminometil-5-(2-etoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3-etoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(4-etoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,3-dietoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,4-dietoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,5-dietoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,6-dietoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3,4-dietoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3,5-dietoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4-trietoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5-trietoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,6-trietoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,4,6-trietoxi-fenil)-hexanoico;

Ácido 2-aminometil-6-(2-etoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3-etoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(4-etoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,3-dietoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,4-dietoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,5-dietoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,6-dietoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3,4-dietoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3,5-dietoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,4-trietoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,5-trietoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,6-trietoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,4,6-trietoxi-fenil)-hexanoico;

Ácido 2-aminometil-6-(2-etoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3-etoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(4-etoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,3-dietoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,4-dietoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,5-dietoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,6-dietoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3,4-dietoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3,5-dietoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,4-trietoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,5-trietoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,6-trietoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,4,6-trietoxi-fenil)-hexanoico;

Ácido 2-aminometil-7-(2-etoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3-etoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(4-etoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,3-dietoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,4-dietoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,5-dietoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,6-dietoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3,4-dietoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3,5-dietoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,4-trietoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,5-trietoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,6-trietoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,4,6-trietoxi-fenil)-heptanoico;

Ácido 2-aminometil-7-(2-etoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3-etoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(4-etoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,3-dietoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,4-dietoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,5-dietoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,6-dietoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3,4-dietoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3,5-dietoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,4-trietoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,5-trietoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,6-trietoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,4,6-trietoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-(2-metil-fenil)-pentanoico;

Ácido 2-aminometil-4-(3-metil-fenil)-pentanoico;

Ácido 2-aminometil-4-(4-metil-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3-dimetil-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,4-dimetil-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,5-dimetil-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,6-dimetil-fenil)-pentanoico;

Ácido 2-aminometil-4-(3,4-dimetil-fenil)-pentanoico;

Ácido 2-aminometil-4-(3,5-dimetil-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,4-trimetil-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,5-trimetil-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,6-trimetil-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,4,6-trimetil-fenil)-pentanoico;

Ácido 2-aminometil-4-(2-metil-fenil)-hexanoico;

Ácido 2-aminometil-4-(3-metil-fenil)-hexanoico;

Ácido 2-aminometil-4-(4-metil-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3-dimetil-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,4-dimetil-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,5-dimetil-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,6-dimetil-fenil)-hexanoico;

Ácido 2-aminometil-4-(3,4-dimetil-fenil)-hexanoico;

Ácido 2-aminometil-4-(3,5-dimetil-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,4-trimetil-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,5-trimetil-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,6-trimetil-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,4,6-trimetil-fenil)-hexanoico;

Ácido 2-aminometil-5-(2-metil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3-metil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(4-metil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,3-dimetil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,4-dimetil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,5-dimetil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,6-dimetil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3,4-dimetil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3,5-dimetil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4-trimetil-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5-trimetil-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,6-trimetil-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,4,6-trimetil-fenil)-pentanoico;

Ácido 2-aminometil-5-(2-metil-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3-metil-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(4-metil-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,3-dimetil-fenil)-4-etil-pentanoico;

228

Ácido 2-aminometil-5-(2,4-dimetil-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,5-dimetil-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,6-dimetil-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3,4-dimetil-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3,5-dimetil-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4-trimetil-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,5-trimetil-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,6-trimetil-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,4,6-trimetil-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4,5-tetrametil-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4,6-tetrametil-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,5,6-tetrametil-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-pentametilfenil-pentanoico;

Ácido 2-aminometil-5-(2-metil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3-metil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(4-metil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,3-dimetil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,4-dimetil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,5-dimetil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,6-dimetil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3,4-dimetil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3,5-dimetil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4-trimetil-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5-trimetil-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,6-trimetil-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,4,6-trimetil-fenil)-hexanoico;

Ácido 2-aminometil-6-(2-metil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3-metil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(4-metil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,3-dimetil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,4-dimetil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,5-dimetil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,6-dimetil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3,4-dimetil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3,5-dimetil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,4-trimetil-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,5-trimetil-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,6-trimetil-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,4,6-trimetil-fenil)-hexanoico;

Ácido 2-aminometil-6-(2-metil-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3-metil-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(4-metil-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,3-dimetil-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,4-dimetil-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,5-dimetil-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,6-dimetil-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3,4-dimetil-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3,5-dimetil-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,4-trimetil-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,5-trimetil-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,6-trimetil-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,4,6-trimetil-fenil)-hexanoico;

Ácido 2-aminometil-7-(2-metil-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3-metil-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(4-metil-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,3-dimetil-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,4-dimetil-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,5-dimetil-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,6-dimetil-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3,4-dimetil-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3,5-dimetil-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,4-trimetil-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,5-trimetil-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,6-trimetil-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,4,6-trimetil-fenil)-heptanoico;

Ácido 2-aminometil-7-(2-metil-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3-metil-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(4-metil-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,3-dimetil-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,4-dimetil-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,5-dimetil-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,6-dimetil-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3,4-dimetil-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3,5-dimetil-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,4-trimetil-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,5-trimetil-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,6-trimetil-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,4,6-trimetil-fenil)-heptanoico;

Ácido 2-aminometil-4-(2-hidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(3-hidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(4-hidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3-dihidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,4-dihidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,5-dihidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,6-dihidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(3,4-dihidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(3,5-dihidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,4-trihidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,5-trihidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,6-trihidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,4,6-trihidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2-hidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(3-hidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(4-hidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3-dihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,4-dihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,5-dihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,6-dihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(3,4-dihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(3,5-dihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,4-trihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,5-trihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,6-trihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,4,6-trihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-5-(2-hidroxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3-hidroxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(4-hidroxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,3-dihidroxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,4-dihidroxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,5-dihidroxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,6-dihidroxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3,4-dihidroxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3,5-dihidroxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4-trihidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5-trihidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,6-trihidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,4,6-trihidroxi-fenil)-pentanoico;

Ácido 2-aminometil-5-(2-hidroxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3-hidroxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(4-hidroxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,3-dihidroxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,4-dihidroxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,5-dihidroxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,6-dihidroxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3,4-dihidroxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3,5-dihidroxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4-trihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5-trihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,6-trihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,4,6-trihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-6-(2-hidroxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3-hidroxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(4-hidroxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,3-dihidroxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,4-dihidroxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,5-dihidroxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,6-dihidroxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3,4-dihidroxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3,5-dihidroxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,4-trihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,5-trihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,6-trihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,4,6-trihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-5-(2-hidroxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3-hidroxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(4-hidroxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,3-dihidroxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,4-dihidroxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,5-dihidroxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,6-dihidroxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3,4-dihidroxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3,5-dihidroxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4-trihidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,5-trihidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,6-trihidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,4,6-trihidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4,5-tetrahidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4,6-tetrahidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,5,6-tetrahidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-pentahidroxifenil-pentanoico;

Ácido 2-aminometil-6-(2-hidroxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3-hidroxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(4-hidroxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,3-dihidroxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,4-dihidroxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,5-dihidroxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,6-dihidroxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3,4-dihidroxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3,5-dihidroxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,4-trihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,5-trihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,6-trihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,4,6-trihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-7-(2-hidroxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3-hidroxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(4-hidroxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,3-dihidroxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,4-dihidroxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,5-dihidroxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,6-dihidroxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3,4-dihidroxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3,5-dihidroxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,4-trihidroxi-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,5-trihidroxi-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,6-trihidroxi-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,4,6-trihidroxi-fenil)-heptanoico;

Ácido 2-aminometil-7-(2-hidroxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3-hidroxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(4-hidroxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,3-dihidroxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,4-dihidroxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,5-dihidroxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,6-dihidroxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3,4-dihidroxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3,5-dihidroxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,4-trihidroxi-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,5-trihidroxi-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,6-trihidroxi-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,4,6-trihidroxi-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,4,5-tetrahidroxi-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,4,6-tetrahidroxi-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,5,6-tetrahidroxi-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-pentahidroxifenil-heptanoico;

Ácido (2*R*,4*R*)-2-aminometil-4-(2,4-difluoro-bencil)-hexanoico;

Ácido (2*S*,4*R*)-2-aminometil-4-(2,4-difluoro-bencil)-hexanoico;

Ácido (2*R*,4*S*)-2-aminometil-7-(2,4-difluoro-fenil)-4-etil-heptanoico;

Ácido (2*S*,4*S*)-2-aminometil-7-(2,4-difluoro-fenil)-4-etil-heptanoico;

Ácido (2*R*,4*S*)-2-aminometil-4-(2,4-difluoro-bencil)-hexanoico;

Ácido (2*S*,4*S*)-2-aminometil-4-(2,4-difluoro-bencil)-hexanoico;

Ácido (2*S*,4*S*)-2-aminometil-4-(3,5-difluoro-bencil)-hexanoico;

Ácido (2*S*,4*S*)-2-aminometil-4-(2-fluoro-bencil)-hexanoico;

Ácido (2*S*,4*S*)-2-aminometil-5-(2,4-difluoro-fenil)-4-metil-pentanoico

Ácido (2*S*)-2-aminometil-5-(2,4-difluoro-fenil)-pentanoico

Ácido (2*S*,4*S*)-2-aminometil-4-(2,6-difluoro-bencil)-hexanoico

Ácido (2*S*,4*S*)-2-aminometil-4-(4-fluoro-bencil)-hexanoico

Ácido (2*S*,4*S*)-2-aminometil-4-(2,5-difluoro-bencil)-hexanoico

Ácido (2*S*,4*S*)-2-aminometil-4-(3-fluoro-bencil)-hexanoico

Ácido (2*S*,4*S*)-2-aminometil-4-pentafluorofenilmetil-hexanoico

Ácido (2*S*,4*R*)-2-aminometil-7-(2,4-difluoro-fenil)-4-etil-heptanoico;

Ácido (2*S*,4*S*)-2-aminometil-4-(4-trifluorometil-bencil)-hexanoico;

Ácido 2-aminometil-4-(4-metoxi-2-metil-bencil)-hexanoico;

Ácido 2-aminometil-5-(4-metoxi-2-metil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-4-(4-metoxi-3-metil-bencil)-hexanoico; y

Ácido 2-aminometil-5-(4-metoxi-3-metil-fenil)-4-metil-pentanoico.

Otros compuestos de fórmula V incluyen los siguientes compuestos y sus

sales farmacéuticamente aceptables:

Ácido 2-aminometil-4-etil-5-metil-hexanoico;

Ácido 2-aminometil-4-etil-3-metil-hexanoico;

Ácido 2-aminometil-3,4-dimetil-hexanoico;

Ácido 2-aminometil-3-etil-4-metil-hexanoico;

Ácido 2-aminometil-4-etil-3-metil-heptanoico;

Ácido 2-aminometil-3,4-dimetil-octanoico;

Ácido 2-aminometil-3-metil-pentanoico;

Ácido 2-aminometil-3-metil-hexanoico;

Ácido 2-aminometil-3-metil-heptanoico;

Ácido 2-aminometil-3,4-dimetil-pentanoico;

Ácido 2-aminometil-3,5-dimetil-hexanoico;

Ácido 2-aminometil-3,5-dimetil-heptanoico;

Ácido 2-aminometil-3,5,5-trimetil-hexanoico;

Ácido 2-aminometil-3-ciclopropil-butírico;

Ácido 2-aminometil-3-ciclopentil-butírico;

Ácido 2-aminometil-3-ciclohexil-butírico;

Ácido 2-aminometil-4-ciclohexil-3-metil-butírico;

Ácido 2-aminometil-5-ciclohexil-3-metil-pentanoico;

Ácido 2-aminometil-3-metil-4-(4-metil-ciclohexil)-butírico;

Ácido 2-aminometil-3-etil-pentanoico;

Ácido 2-aminometil-3-etil-hexanoico;

Ácido 2-aminometil-3-etil-heptanoico;

Ácido 2-aminometil-3-etil-4-metil-pentanoico;

Ácido 2-aminometil-3-ciclohexilmetil-pentanoico;

Ácido 2-aminometil-5-(4-metoxi-ciclohexil)-3-metil-pentanoico;

Ácido 2-aminometil-5-(4-metoxi-fenil)-3-metil-pentanoico;

Ácido 2-aminometil-4-(2-metoxi-fenil)-3-metil-butírico;

Ácido 2-aminometil-4-(4-metoxi-fenil)-3-metil-butírico;

Ácido 2-aminometil-3-fenil-butírico;

Ácido 2-aminometil-3-metil-4-fenil-butírico;

Ácido 2-aminometil-3-metil-5-fenil-pentanoico;

Ácido 2-aminometil-3-metil-4-(3-trifluorometil-fenil)-butírico;

Ácido 2-aminometil-3-(4-etil-fenil)-butírico;

Ácido 2-aminometil-3-(2,5-dimetil-fenil)-butírico;


Ácido 2-aminometil-3-metil-4-p-tolil-butírico;

Ácido 2-aminometil-3-m-tolil-butírico;

Ácido 2-aminometil-3-bencil-pentanoico; y

Ácido 2-aminometil-4-(4-fluoro-fenil)-3-metil-butírico.

Esta invención también proporciona compuestos de formula VI



VI

y sus sales farmacéuticamente aceptables, en la que R_3, R_4 y R_5 son como se han definido anteriormente en la fórmula I, con la condición de que R_3, R_4 y R_5 no sean átomos de hidrógeno simultáneamente.

Los compuestos específicos de fórmula VI incluyen los siguientes compuestos y sus sales farmacéuticamente aceptables:

Ácido 2-aminometil-5-ciclopropil-hexanoico;

Ácido 2-aminometil-5-ciclobutil-hexanoico;

Ácido 2-aminometil-5-ciclopentil-hexanoico;

Ácido 2-aminometil-5-ciclohexil-hexanoico;

Ácido 2-aminometil-5-fenil-hexanoico;

Ácido 2-aminometil-5-(3-cloro-fenil)-hexanoico;

Ácido 2-aminometil-5-(3-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-5-(4-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-5-ciclopropil-heptanoico;

Ácido 2-aminometil-5-ciclobutil-heptanoico;

Ácido 2-aminometil-5-ciclopentil-heptanoico;

Ácido 2-aminometil-5-ciclohexil-heptanoico;

Ácido 2-aminometil-5-fenil-heptanoico;

Ácido 2-aminometil-5-(3-cloro-fenil)-heptanoico;

Ácido 2-aminometil-5-(3-trifluorometil-fenil)-heptanoico;

Ácido 2-aminometil-5-(4-trifluorometil-fenil)-heptanoico;

Ácido 2-aminometil-5-metil-6-fenil-hexanoico;

Ácido 2-aminometil-6-(3-cloro-fenil)-5-metil-hexanoico;

Ácido 2-aminometil-5-metil-6-(3-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-5-metil-6-(4-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-5-ciclopropilmetil-heptanoico;

Ácido 2-aminometil-5-ciclobutilmetil-heptanoico;

Ácido 2-aminometil-5-ciclopentilmetil-heptanoico;

Ácido 2-aminometil-5-ciclohexilmetil-heptanoico;

Ácido 2-aminometil-5-bencil-heptanoico;

Ácido 2-aminometil-5-(3-cloro-bencil)-heptanoico;

Ácido 2-aminometil-5-(3-trifluorometil-bencil)-heptanoico;

Ácido 2-aminometil-5-(4-trifluorometil-bencil)-heptanoico;

Ácido 2-aminometil-5-metil-7-fenil-heptanoico;

Ácido 2-aminometil-7-(3-cloro-fenil)-5-metil-heptanoico;

Ácido 2-aminometil-5-metil-7-(3-trifluorometil-fenil)-heptanoico;

Ácido 2-aminometil-5-metil-7-(4-trifluorometil-fenil)-heptanoico;

Ácido 2-aminometil-7-ciclopropil-5-etil-heptanoico;

Ácido 2-aminometil-7-ciclobutil-5-etil-heptanoico;

Ácido 2-aminometil-7-ciclopentil-5-etil-heptanoico;

Ácido 2-aminometil-7-ciclohexil-5-etil-heptanoico;

Ácido 2-aminometil-5-etil-7-fenil-heptanoico;

Ácido 2-aminometil-7-(3-cloro-fenil)-5-etil-heptanoico;

Ácido 2-aminometil-5-etil-7-(3-trifluorometil-fenil)-heptanoico;

Ácido 2-aminometil-5-etil-7-(4-trifluorometil-fenil)-heptanoico;

Ácido 2-aminometil-5,5-dimetil-heptanoico;

Ácido 2-aminometil-5,5-dimetil-octanoico; y

Ácido 2-aminometil-5,5-dimetil-nonanoico.

Esta invención también proporciona composiciones farmacéuticas que comprenden una cantidad terapéuticamente eficaz de un compuesto de fórmula I, II, III, IV, V o VI, o una sal farmacéuticamente aceptable del mismo y un vehículo farmacéuticamente aceptable.

Esta invención también proporciona un procedimiento para tratar un trastorno o afección en un mamífero, incluyendo un ser humano, seleccionándose el trastorno o afección entre epilepsia, ataques de desmayos, fibromialgia, hipoquinesia, trastornos craneales, sofocos, temblor esencial, dependencias y

adicciones a productos químicos (por ejemplo, dependencias o adicciones al alcohol, anfetaminas (o sustancias similares a las anfetaminas), cafeína, cannabis, cocaína, heroína, alucinógenos, tabaco, inhalantes y propulsores de aerosol, nicotina, opioides, derivados de la fenilglicidina, sedantes, hipnóticos, benzodiazepinas y otros ansiolíticos) y síndrome de abstinencia asociado con tales dependencias o adicciones, comportamientos adictivos tales como juegos de azar; migrañas, espasticidad incluyendo espasticidad muscular e hipotonia con parálisis, artritis, síndrome del intestino irritable (IBS), dolor crónico, dolor agudo, dolor neuropático, neuralgia post herpética, dolor lumbar, dolor quirúrgico, dolor de cabeza vascular, dolor de cabeza crónico, cefalea sinusal, trastornos inflamatorios (por ejemplo, artritis reumatoide, osteoartritis, modificación de la enfermedad de la enfermedad de osteoartritis, psoriasis), diuresis, síndrome premenstrual, trastorno disfórico premenstrual, tinnitus y lesión gástrica. El procedimiento comprende administrar a un mamífero en necesidad de tal tratamiento una cantidad terapéuticamente eficaz de un compuesto de fórmula I, II, III, IV, V o VI, o una sal farmacéuticamente aceptable del mismo.

La presente invención también proporciona un procedimiento para tratar trastornos neurodegenerativos denominados lesión cerebral aguda. Estos incluyen, pero sin limitación, apoplejía, traumatismo craneal y asfixia. El término apoplejía se refiere a una enfermedad cerebral vascular y también se puede denominar incidente cerebral vascular (CVA) e incluye apoplejía tromboembólica aguda. Las apoplejías incluyen tanto isquemia focal como global. Además, se incluyen apoplejías isquémicas cerebrales transitorias y otros problemas vasculares cerebrales acompañados de isquemia cerebral, tales como los que se producen en pacientes que se someten a endarterectomía de la carótida u otros

procedimientos quirúrgicos cerebrovasculares o vasculares, o procedimientos diagnósticos vasculares incluyendo angiografía cerebral y similares.

Los compuestos de fórmula I, II, III, IV, V o VI también son útiles en el tratamiento de traumatismo craneal, traumatismo de la médula espinal o lesión por anoxia general, hipoxia, hipoglucemia, hipotensión así como lesiones similares observadas durante procedimientos de embolia, hiperfusión e hipoxia. También son útiles para prevenir la lesión neuronal que se produce durante la revascularización quirúrgica cardiaca, en incidentes de hemorragia intracraneal, en asfixia perinatal, en paradas cardíacas y estados epilépticos.

Esta invención también proporciona un procedimiento para tratar un trastorno o afección en un mamífero, incluyendo un ser humano, seleccionando el trastorno o afección entre el grupo compuesto por delirio, demencia y trastornos amnésicos u otros trastornos cognitivos o neurodegenerativos, tales como enfermedad de Parkinson (PD), enfermedad de Huntington (HD), enfermedad de Alzheimer, demencia senil, demencia del tipo de la enfermedad de Alzheimer, trastorno de memoria, demencia vascular y otras demencias, por ejemplo, debidas a la enfermedad por VIH, traumatismo craneal, enfermedad de Parkinson, enfermedad de Huntington, enfermedad de Pick, enfermedad de Creutzfeldt-Jakob, o debido a múltiples etiologías; trastornos de movimiento tales como aquinesias, disquinesias, incluyendo disquinesias paroxísticas familiares, espasticidades, síndrome de Tourette, síndrome de Scott, parálisis y síndrome acinético rígido; trastornos de movimiento extrapiramidales tales como trastornos de movimiento inducidos por medicación, por ejemplo, Parkinsonismo inducido por neurolépticos, síndrome maligno neuroléptico, distonia aguda inducida por neurolépticos, acatisia aguda inducida por neurolépticos, disquinesia tardía

inducida por neurolépticos y temblor postural inducido por medicación; síndrome de Down; enfermedades desmielinizantes tales como esclerosis múltiple (MS) y esclerosis lateral amiotrófica (ALS), neuropatía periférica, por ejemplo neuropatía diabética e inducida por quimioterapia y neuralgia postherpética, neuralgia del trigémino, neuralgia segmental o intercostal y otras neuralgias; y trastornos cerebrales vasculares debidos a lesión cerebrovascular aguda o crónica tal como infarto cerebral, hemorragia subaracnoidea o edema cerebral. El procedimiento comprende administrar a un mamífero en necesidad de tal tratamiento una cantidad terapéuticamente eficaz de un compuesto de fórmula I, II, III, IV, V o VI, o una sal farmacéuticamente aceptable del mismo.

Esta invención también proporciona una mejora de la cognición en mamíferos, incluyendo seres humanos, que padecen AD, PD y fibromialgia potenciando la cantidad y calidad del sueño. El procedimiento comprende administrar a un mamífero en necesidad de una cognición mejorada una cantidad terapéuticamente eficaz de un compuesto de fórmula I, II, III, IV, V o VI, o una sal farmacéuticamente aceptable del mismo.

Esta invención también proporciona un procedimiento para tratar el dolor en un mamífero, incluyendo un ser humano, comprendiendo el procedimiento administrar a un mamífero en necesidad de tal tratamiento una cantidad terapéuticamente eficaz de un compuesto de fórmula I, II, III, IV, V o VI o una sal farmacéuticamente aceptable del mismo. El término dolor se refiere a dolor agudo así como a dolor crónico. El dolor agudo es normalmente de corta duración y se asocia con hiperactividad del sistema nervioso simpático. Son ejemplos dolor postoperatorio y alodinia. El dolor crónico se define normalmente como dolor que persiste de tres a seis meses e incluye dolor somatogénico y dolor psicogénico.

Otro tipo de dolor es el dolor nociceptivo.

Los ejemplos de los tipos de dolor que pueden tratarse con los compuestos de fórmula I, II, III, IV, V o VI y sus sales farmacéuticamente aceptables incluyen dolor como consecuencia de una lesión periférica y del tejido suave, tal como traumatismo agudo, dolor asociado con osteoartritis y artritis reumatoide, dolor musculo-esquelético tal como el dolor experimentado después del traumatismo; dolor espinal, dolor dental, síndromes de dolor miofascial, dolor de episiotomía y dolor como consecuencia de quemaduras; dolor profundo y visceral tal como dolor cardíaco, dolor muscular, dolor ocular, dolor orofacial, por ejemplo, odontalgia, dolor abdominal, dolor ginecológico, por ejemplo dismenorrea, dolor en el parto y dolor asociado con endometriosis; dolor asociado con lesión en nervio y raíz tal como dolor asociado con trastornos en nervios periféricos, por ejemplo, pinzamiento nervioso y avulsiones del plexo braquial, amputación, neuropatías periféricas, tic doloroso, dolor facial atípico, daño en la raíz del nervio, neuralgia del trigémino, dolor lumbar neuropático, dolor neuropático relacionado con el VIH, dolor neuropático relacionado con cáncer, dolor neuropático diabético y aracnoiditis; dolor neuropático y no neuropático asociado con carcinoma, denominado habitualmente dolor de cáncer; dolor del sistema nervioso central tal como dolor por lesión de la médula espinal o en el tronco cerebral; dolor lumbar; ciática; dolor en miembro fantasma, dolor de cabeza, incluyendo migraña y otros dolores de cabeza vasculares, dolor de cabeza agudo o crónico producido por tensión, cefalea acumulada, dolor temporomandibular y dolor sinusal maxilar; dolor como consecuencia de espondilitis anquilosante y gota; dolor causado por mayores contracciones de vejiga; dolor post operatorio; dolor de cicatrices; y dolor crónico no neuropático tal

como dolor asociado con fibromialgia, VIH, artritis reumatoide y osteoartritis, antralgia y mialgia, torceduras, esguinces y traumatismos tales como huesos rotos; y dolor post-quirúrgico.

Otro dolor más es el causado por lesión o infección de los nervios sensoriales periféricos. Esto incluye, pero sin limitación, dolor procedente de traumatismo de nervios periféricos, infección por herpesvirus, diabetes mellitus, fibromialgia, causalgia, avulsión del plexo, neuroma, amputación de miembros y vasculitis. El dolor neuropático también está causado por lesiones nerviosas como consecuencia del alcoholismo crónico, infección por virus de inmunodeficiencia humana, hipotiroidismo, uremia o deficiencias vitamínicas. El dolor neuropático incluye, pero sin limitación, dolor causado por lesiones nerviosas tales como, por ejemplo, el dolor que sufren los diabéticos.

El dolor psicogénico es aquel que se produce sin un origen orgánico tal como dolor lumbar, dolor facial atípico y dolor de cabeza crónico.

Otros tipos de dolor incluyen dolor inflamatorio, dolor osteoartrítico, neuralgia del trigémino, dolor de cáncer, neuropatía diabética, síndrome de las piernas inquietas, neuralgia herpética y postherpética aguda, causalgia, avulsión del plexo braquial, neuralgia occipital, gota, miembro fantasma, quemaduras y otras formas de neuralgia y síndrome de dolor neuropático e idiopático.

Esta invención también proporciona un procedimiento para tratar la depresión, que comprende administrar a un mamífero, incluyendo un ser humano, en necesidad de tal tratamiento, una cantidad terapéuticamente eficaz de un compuesto de fórmula I, II, III, IV, V o VI, o una sal farmacéuticamente aceptable del mismo. La depresión puede ser el resultado de una enfermedad orgánica, secundaria a estrés asociado con una pérdida personal o puede ser de

origen idiopático. Hay una gran tendencia a la aparición familiar de algunas formas de depresión lo que sugiere una causa mecánica para al menos algunas formas de depresión. El diagnóstico de la depresión se realiza principalmente por cuantificación de las alteraciones en el estado emocional de los pacientes. Estas evaluaciones del estado emocional las realiza generalmente un médico o las cuantifica un neuropsicólogo usando escalas de evaluación validadas, tales como la Escala de Evaluación de Depresión de Hamilton o la Escala de Evaluación Psiquiátrica Breve. Se han desarrollado otras numerosas escalas para cuantificar y medir el grado de alteraciones en el estado emocional de pacientes con depresión tales como insomnio, dificultad de concentración, falta de energía, sensación de inutilidad y sentimiento de culpa. Los patrones para el diagnóstico de la depresión así como todos los diagnósticos psiquiátricos se recogen en *Diagnostic and Statistical Manual of Mental Disorders* (4ª Ed, 1994), al que se denomina Manual DSM-IV-R y está publicado por la American Psychiatric Association.

Esta invención también proporciona un procedimiento para tratar un trastorno o afección en un mamífero, incluyendo un ser humano, seleccionándose el trastorno o afección entre el grupo compuesto por trastornos del estado emocional tales como depresión o, más particularmente, trastornos depresivos, por ejemplo, trastornos depresivos graves de un único episodio o recurrentes, trastornos distímicos, neurosis depresiva y depresión neurótica, depresión melancólica, incluyendo anorexia, pérdida de peso incluyendo pérdida de peso asociada con anorexia, cáncer, envejecimiento y/o fragilidad, insomnio, despertar vespertino y retardo psicomotor, depresión atípica (o depresión reactiva), incluyendo aumento del apetito, hipersomnia, agitación psicomotora o irritabilidad,

trastorno afectivo estacional y depresión pediátrica; o trastornos bipolares o depresión maniaca, por ejemplo, trastorno bipolar I, trastorno bipolar II y trastorno ciclotímico; trastornos de la conducta y trastorno perjudicial del comportamiento; trastornos de ansiedad, tales como trastorno del pánico con o sin agorafobia, agorafobia sin historial de trastorno del pánico, fobias específicas, por ejemplo, fobias a animales específicos, trastornos de ansiedad social, fobia social, miedo a volar, trastorno obsesivo-compulsivo, trastornos por estrés incluyendo trastorno por estrés post-traumático y trastorno por estrés agudo y trastornos de ansiedad generalizados; trastorno de personalidad fronteriza; esquizofrenia y otros trastornos psicóticos, por ejemplo, trastornos esquizofreniformes, trastornos esquizoafectivos, trastornos de delirio, trastornos psicóticos breves, trastornos psicóticos compartidos, trastornos psicóticos con delirios o alucinaciones, episodios psicóticos de ansiedad, ansiedad asociada con psicosis, trastornos psicóticos del estado emocional tales como trastorno depresivo grave; trastornos del estado emocional asociados con trastornos psicóticos tales como manía aguda y depresión asociada con trastorno bipolar, trastornos del estado emocional asociados con esquizofrenia; trastornos del comportamiento asociados con un retraso mental, trastorno autístico y trastornos de la conducta. El procedimiento comprende administrar a un mamífero en necesidad de tal tratamiento una cantidad terapéuticamente eficaz de un compuesto de fórmula I, II, III, IV, V o VI o una sal farmacéuticamente aceptable del mismo.

Los compuestos de la invención también son útiles en el tratamiento de trastornos del sueño. Los trastornos del sueño son trastornos que afectan a la capacidad de dormirse y/o permanecer dormido, que implican dormir demasiado, o que tienen como resultado un comportamiento anormal asociado al sueño. Los

trastornos incluyen, por ejemplo, insomnio, insomnio asociado a drogas, hipersomnia, narcolepsia, síndromes de la apnea del sueño, parasomnias, síndrome de las piernas inquietas, jet lag, trastorno de movimiento periódico del miembro y arquitectura del sueño alterada.

Esta invención también proporciona un procedimiento para tratar un trastorno o afección en un mamífero, incluyendo un ser humano, seleccionando el trastorno o afección entre el grupo compuesto por trastornos del sueño (por ejemplo, insomnio, insomnio asociado a drogas, trastornos del sueño REM, hipersomnia, narcolepsia, trastornos de un ciclo de sueño-vigilia, síndromes de apnea del sueño, parasomnias y trastornos del sueño asociados con el turno de trabajo y horas de trabajo irregulares). El procedimiento comprende administrar a un mamífero en necesidad de tal tratamiento una cantidad terapéuticamente eficaz de un compuesto de fórmula I, II, III, IV, V o VI, o una sal farmacéuticamente aceptable del mismo.

Los compuestos de fórmulas I, II, III, IV, V o VI contienen al menos un centro estereogénico (quiral) y por lo tanto pueden existir en diferentes formas enantioméricas y diastereoméricas. Esta invención incluye todos los estereoisómeros, incluyendo isómeros ópticos, de los compuestos de fórmula I, II, III, IV, V o VI. Las muestras de los compuestos pueden existir en forma de mezclas racémicas, como enantiómeros y diastereoisómeros individuales y como mezclas de los mismos. La invención también incluye todas las composiciones farmacéuticas y procedimientos de tratamiento definidos anteriormente que contienen o emplean estereoisómeros de los compuestos de fórmula I, II, III, IV, V o VI.

Los compuestos con un centro estereogénico pueden existir en forma de

una mezcla racémica (equimolar), como mezcla no equimolar de isómeros y como enantiómeros puros con una estereoconfiguración S- o R-. Los compuestos con dos centros estereogénicos pueden existir en forma de mezcla racémica, como mezcla no equimolar de isómeros y como enantiómeros puros que tienen estereconfiguración SS, RR, SR o RS. Los compuestos con tres centros estereogénicos pueden existir en forma de una mezcla racémica, como una mezcla no equimolar de isómeros y como enantiómeros puros que tienen estereconfiguración RRR, SSS, SRR, RSS, RSR, SRS, RRS o SSR. Pueden obtenerse isómeros individuales por procedimientos conocidos tales como resolución óptica, reacción ópticamente selectiva o separación cromatográfica en la preparación del producto final o sus intermedios. Los enantiómeros individuales de los compuestos de esta invención pueden tener ventajas, en comparación con mezclas racémicas de estos compuestos, en el tratamiento de diversos trastornos o afecciones.

La presente invención también incluye compuestos marcados isotópicamente, que son idénticos a los descritos en la fórmula I, II, III, IV, V o VI excepto por el hecho de que uno o más átomos están sustituidos con un átomo que tiene una masa atómica o número másico distinto de la masa atómica o número másico que se encuentra normalmente en la naturaleza. Los ejemplos de isótopos que pueden incorporarse en compuestos de la presente invención incluyen isótopos de hidrógeno, carbono, nitrógeno, oxígeno, fósforo, azufre, flúor y cloro, tales como, ^{2}H, ^{3}H, ^{13}C, ^{11}C ^{14}C, ^{15}N, ^{18}O, ^{17}O, ^{31}P, ^{32}P, ^{35}S, ^{18}F y ^{36}Cl, respectivamente.

Los compuestos de la presente invención, profármacos de los mismos y sales farmacéuticamente aceptables de dichos compuestos o de dichos

profármacos que contienen los isótopos mencionados anteriormente y/u otros isótopos de otros átomos están dentro del alcance de esta invención. Ciertos compuestos marcados isotópicamente de la presente invención, por ejemplo aquellos en los que se incorporan isótopos radiactivos tales como ^{3}H y ^{14}C, son útiles en ensayos de distribución tisular del fármaco y/o sustrato. Se prefieren particularmente isótopos tritio, es decir, ^{3}H y carbono-14, es decir, ^{14}C, por su fácil preparación y detectabilidad. Además, la sustitución con isótopos más pesados tales como deuterio, es decir, ^{2}H, puede proporcionar ciertas ventajas terapéuticas como resultado de una mayor estabilidad metabólica, por ejemplo, aumento de la semivida *in vivo* o disminución de los requerimientos de dosificación y, por tanto, pueden preferirse en algunas circunstancias. Los compuestos marcados isotópicamente de fórmula I, II, III, IV, V o VI de esta invención y profármacos de los mismos pueden prepararse generalmente realizando los procedimientos descritos en los Esquemas y/o Ejemplos y Preparaciones que se muestran más adelante, sustituyendo un reactivo no marcado isotópicamente con un reactivo marcado isotópicamente fácilmente disponible.

A menos que se indique otra cosa, esta descripción usa las definiciones que se proporcionan más adelante. Algunas de las definiciones y fórmulas pueden incluir un "-" (guión) para indicar un enlace entre átomos o un punto de unión a un átomo o grupo de átomos con o sin nombre. Otras definiciones y fórmulas pueden incluir un "=" (signo de igual) o "≡" (signo de identidad) para indicar un doble enlace o un triple enlace, respectivamente. Ciertas fórmulas pueden incluir también un "*" (asterisco) para indicar un centro estereogénico (quiral). Tales fórmulas pueden hacer referencia al racemato o a enantiómeros

251

individuales, que pueden o no ser sustancialmente puros.

El término "sustituido" cuando se usa con relación a un compuesto, sustituyente o resto, indica que uno o más átomos de hidrógeno se han reemplazado con uno o más átomos o grupos que no son hidrógeno, con la condición de que se cumplan los requerimientos de valencia y que se obtenga como resultado de la sustitución un compuesto químicamente estable.

El término "alquilo" se refiere a grupos hidrocarburo saturados de cadena lineal y ramificada que tienen generalmente un número especificado de átomos de carbono; es decir, alquilo (C_1-C_6) se refiere a un grupo alquilo que tiene 1, 2, 3, 4, 5 ó 6 átomos de carbono. Los ejemplos de grupos alquilo incluyen, pero sin limitación, metilo, etilo, *n*-propilo, *i*-propilo, *n*-butilo, *s*-butilo, *i*-butilo, *t*-butilo, pent-1-ilo, pent-2-ilo, pent-3-ilo, 3-metilbut-1-ilo, 3-metilbut-2-ilo, 2-metilbut-2-ilo, 2,2,2-trimetilet-1-ilo, *n*-hexilo, 3-etilbutilo y similares.

El término "cicloalquilo" se refiere a anillos de hidrocarburo saturados monocíclicos y bicíclicos, que tienen generalmente un número de átomos de carbono especificado que comprenden el anillo; es decir, cicloalquilo (C_3-C_6) se refiere a un grupo cicloalquilo que tiene 3, 4, 5 ó 6 átomos de carbono como miembros del anillo. El cicloalquilo puede estar unido a un grupo parental o a un sustrato en cualquier átomo del anillo, a menos que tal unión viole los requerimientos de valencia. Asimismo, los grupos cicloalquilo pueden incluir uno o más sustituyentes que no son hidrógeno a menos que tal sustitución viole los requerimientos de valencia. Los sustituyentes útiles incluyen, pero sin limitación, alquilo, como se ha definido anteriormente e hidroxi, mercapto, nitro, halógeno y amino.

Los ejemplos de grupos cicloalquilo monocíclicos incluyen, pero sin

252

limitación, ciclopropilo, ciclobutilo, ciclopentilo, ciclohexilo y similares. Los ejemplos de grupos cicloalquilo bicíclicos incluyen, pero sin limitación, biciclo[1.1.0]butilo, biciclo[1.1.1]pentilo, biciclo[2.1.0]pentilo, biciclo[2.1.1]hexilo, biciclo[3.1.0]hexilo, biciclo[2.2.1]heptilo, biciclo[3.2.0]heptilo, biciclo[3.1.1]heptilo, biciclo[4.1.0]heptilo, biciclo[2.2.2]octilo, biciclo[3.2.1]octilo, biciclo[4.1.1.]octilo, biciclo[3.3.0]octilo, biciclo[4.2.0]octilo, biciclo[3.3.1]nonilo, biciclo[4.2.1]nonilo, biciclo[4.3.0]nonilo, biciclo[3.3.2]decilo, biciclo[4.2.2]decilo, biciclo[4.3.1]decilo, biciclo[4.4.0]decilo, biciclo[3.3.3]undecilo, biciclo[4.3.2]undecilo, biciclo[4.3.3]dodecilo y similares.

El término "alcoxi" se refiere a alquil-O-, donde alquil es como se ha definido anteriormente. Los ejemplos de grupos alcoxi incluyen, sin limitación, metoxi, etoxi, *n*-propoxi, *i*-propoxi, *n*-butoxi, *s*-butoxi, *t*-butoxi, *n*-pentoxi, *s*-pentoxi y similares.

El término "tratar", se refiere a invertir, aliviar, inhibir el desarrollo de o prevenir el trastorno o afección al que se aplica tal término o prevenir uno o más síntomas de tal trastorno o afección. El término "tratamiento", como se usa en este documento, se refiere al acto de tratar, tal y como se acaba de definir "tratar".

La fase "grupo saliente" se refiere a cualquier grupo que deja una molécula durante un procedimiento de fragmentación incluyendo reacciones de sustitución, reacciones de eliminación y reacciones de adición-eliminación. Los grupos salientes pueden ser nucleófugo, donde el grupo sale con un par de electrones que servían anteriormente como enlace entre el grupo saliente y la molécula o pueden ser electrófugos, donde el grupo sale sin el par de electrones. La capacidad de un grupo saliente nucleófugo para salir de la molécula depende de

su fortaleza como base, siendo las bases más fuertes los grupos salientes más pobres. Los grupos salientes nucleófugos comunes incluyen nitrógeno (por ejemplo, de sales diazonio), sulfonatos (incluyendo tosilatos, brosilatos, nosilatos y mesilatos), triflatos, nonaflatos, tresilatos, iones de haluro, aniones carboxilato, iones fenolato y alcóxidos. Algunas bases más fuertes, tales como NH_2- y OH- pueden hacerse mejores grupos salientes mediante tratamiento con un ácido. Los grupos salientes electrófugos comunes incluyen el protón, CO_2 y metales.

La frase "exceso enantiomérico" o "ee" es un medida, para una muestra dada, del exceso de un enantiómero sobre una muestra racémica de un compuesto quiral y se expresa en porcentaje. El exceso enantiomérico se define como 100 x (er -1) / (er + 1), donde "er" es la relación entre el enantiómero más abundante y el enantiómero menos abundante.

El término "enantioselectividad" se refiere a una reacción dada (por ejemplo, hidrogenación) que produce más de un enantiómero que de otro.

La fase "alto nivel de enantioselectividad" se refiere a una reacción dada que da lugar a un producto con un ee de al menos aproximadamente el 80%.

La frase "enantioméricamente enriquecido" se refiere a una muestra de un compuesto quiral, que tiene más de un enantiómero que de otro. El grado de enriquecimiento se mide por er o ee.

La frase "enantiómero sustancialmente puro" o "sustancialmente enantiopuro" se refiere a una muestra de un enantiómero que tiene un ee de aproximadamente el 90% o mayor.

La frase "enantioméricamente puro" o "enantiopuro" se refiere a una muestra de un enantiómero que tiene un ee de aproximadamente el 99% o mayor.

La frase "enantiómero opuesto" se refiere a una molécula que es una imagen especular que no se puede superponer de una molécula de referencia, que puede obtenerse invirtiendo todos los centros estereogénicos de la molécula de referencia. Por ejemplo, si la molécula de referencia tiene una configuración estereoquímica absoluta S, entonces el enantiómero opuesto tiene una configuración estereoquímica absoluta R. Asimismo, si la molécula de referencia tiene una configuración estereoquímica absoluta S,S, entonces el enantiómero opuesto tiene una configuración estereoquímica absoluta R,R, etc.

La frase "sales, ésteres, amidas y profármacos farmacéuticamente aceptables" se refiere a sales de adición de ácidos o bases, ésteres, amidas, formas bipolares, cuando sea posible, y profármacos de los compuestos descritos y reivindicados, que están dentro del alcance del juicio médico, adecuados para uso en contacto con los tejidos de pacientes sin toxicidad, irritación, respuesta alérgica y similares, indebidas en proporción a una relación beneficio/riesgo razonable y eficaces para su uso pretendido.

Como los aminoácidos son anfóteros, las sales farmacológicamente compatibles pueden ser sales de ácidos orgánicos o inorgánicos apropiados, por ejemplo, clorhídrico, sulfúrico, fosfórico, acético, oxálico, láctico, cítrico, málico, salicílico, malónico, maleico, succínico y ascórbico. Partiendo de los correspondientes hidróxidos o carbonatos, se forman sales con metales alcalinos o alcalinotérreos, por ejemplo, sodio, potasio, magnesio o calcio. También se pueden preparar sales con iones amónicos cuaternarios, por ejemplo, con el ión tetrametil-amonio.

La eficacia de un fármaco administrado por vía oral depende del transporte eficaz del fármaco a través del epitelio de la mucosa y de su estabilidad en la

circulación entero-hepática. Pueden modificarse químicamente para dar una forma de profármaco, fármacos que son eficaces después de la administración parenteral pero menos eficaces por vía oral, o cuya semivida en plasma se considera demasiado corta.

Un profármaco es un fármaco que se ha modificado químicamente y puede ser biológicamente inactivo en su sitio de acción pero que puede degradarse o modificarse mediante uno o más procesos enzimáticos u otros procedimientos *in vivo* en la forma parental bioactiva.

Este fármaco químicamente modificado, o profármaco, debe tener un perfil farmacocinético distinto del fármaco parental, permitiendo una absorción más fácil a través del epitelio de la mucosa, una mejor formulación de la sal, una mejor solubilidad, una mejor estabilidad sistémica (para aumentar la semivida en plasma, por ejemplo), y similar. Estas modificaciones químicas incluyen, pero sin limitación, (1) derivados éster o amida que pueden escindirse, por ejemplo, con estearasas o lipasas; (2) péptidos, que pueden reconocerse mediante proteinasas específicas o no específicas; (3) derivados que se acumulan en el sitio de acción mediante la selección de membrana de una forma profármaco o forma profármaco modificada; y (4) cualquier combinación de (1) a (3). Los profármacos éster o amida pueden derivarse del resto de ácido carboxílico de la molécula del fármaco parental o del resto ácido carboxílico o el resto amina de la molécula del fármaco parental, respectivamente, por medios conocidos. Además, el profármaco peptídico puede unirse a la molécula del fármaco parental mediante la formación de un enlace amida con el resto amina o ácido carboxílico de la molécula del fármaco parental usando técnicas conocidas.

La investigación actual en experimentos animales ha demostrado que la

absorción oral de ciertos fármacos puede aumentarse mediante la preparación de sales cuaternarias "blandas". Una sal cuaternaria se denomina sal cuaternaria "blanda" ya que, a diferencia de las sales cuaternarias normales, por ejemplo, R-$N^+(CH_3)_3$, puede liberar el fármaco activo tras la hidrólisis.

Las sales cuaternarias blandas tienen propiedades físicas útiles en comparación con el fármaco básico o sus sales. La solubilidad en agua puede aumentarse en comparación con otras sales, tales como la sal clorhidrato, pero puede ser más importante una mayor absorción del fármaco en el intestino. Una mayor absorción se debe probablemente al hecho de que la sal cuaternaria blanda tiene propiedades tensioactivas y puede formar micelas y pares iónicos no ionizados con ácidos biliares, etc., que pueden penetrar el epitelio intestinal de forma más eficaz. El profármaco, después de la absorción, se hidroliza rápidamente con la liberación del fármaco parental activo.

Los profármacos de compuestos de fórmula I, II, III, IV, V o VI se incluyen dentro del alcance de esta invención. Para un análisis de profármacos y fármacos blandos, véase E. Palomino, *Drugs of the Future* 15(4):361-68 (1990). Véase también T. Higuchi y V. Stella, "Pro-Drugs as Novel Delivery Systems", *ACS Symposium Series* 14 (1975); E.B. Roche (ed.), *Bioreversible Carriers in Drug Design* (1987); y H. Bundgaar, *Design of Prodrugs* (1985).

Ciertos compuestos de la presente invención pueden existir en formas no solvatadas así como en formas solvatadas, incluyendo formas hidratadas. En general, las formas solvatadas, incluyendo formas hidratadas, equivalen a las formas no solvatadas y se pretende que estén incluidas dentro del alcance de la presente invención.

DESCRIPCIÓN DETALLADA

227

Los compuestos de esta invención pueden prepararse como se describe a continuación. En los esquemas de reacción y en la discusión que se proporciona más adelante, las fórmulas estructurales I, II, III, IV, V o VI y los radicales R_1, R_2, R_3, R_4, R_5 y R_6, a menos que se indique otra cosa, son como se han definido anteriormente.

En algunos de los esquemas de reacción y ejemplos que se proporcionan más adelante, pueden prepararse ciertos compuestos usando grupos protectores, lo que evita ciertas reacciones químicas no deseables en sitios, por lo demás, reactivos. Los grupos protectores también pueden usarse para mejorar la solubilidad o modificar de otra forma las propiedades físicas de un compuesto. Para un análisis de estrategias en grupos protectores, una descripción de materiales y procedimientos para instalar y retirar grupos protectores y una compilación de grupos protectores útiles para grupos funcionales comunes, incluyendo aminas, ácidos carboxílicos, alcoholes, cetonas, aldehídos y similares, véase T.W. Greene y P.G. Wuts, *Protecting Groups in Organic Chemistry* (1999) y P. Kocienski, *Protective Groups* (2000).


Además, algunos de los esquemas y ejemplos que se proporcionan más adelante pueden omitir detalles de reacciones comunes, incluyendo oxidaciones, reducciones, etc., que son conocidas para los especialistas habituales en la técnica de la química orgánica. Los detalles de tales reacciones pueden encontrarse en varios tratados, incluyendo Richard Larock, *Comprehensive Organic Transformations* (1999) y la serie multivolumen editada por Michael B. Smith y otros, *Compendium of Organic Synthetic Methods* (1974-2003). Generalmente los materiales y reactivos de partida pueden obtenerse a partir de fuentes comerciales.

Generalmente, las transformaciones químicas descritas a lo largo de esta memoria descriptiva pueden realizarse usando cantidades sustancialmente estequiométricas de reactivos, aunque ciertas reacciones pueden beneficiarse del uso de un exceso de uno o más de los reactivos. Además, muchas de las reacciones descritas a lo largo de esta memoria descriptiva pueden realizarse a aproximadamente la temperatura ambiente, pero algunas reacciones particulares pueden requerir el uso de temperaturas mayores o inferiores, dependiendo de la cinética de reacción, los rendimientos y similares. Además, muchas de las transformaciones químicas pueden emplear uno o más disolventes compatibles que, dependiendo de la naturaleza de los reactivos, pueden ser disolventes próticos polares, disolventes apróticos polares, disolventes no polares o alguna combinación. Aunque la elección del disolvente o disolventes pueden influir en la velocidad y rendimiento de reacción, tales disolventes se consideran generalmente inertes (no reactivos). Cualquier referencia en la descripción a un intervalo de concentración, un intervalo de temperatura, un intervalo de pH, un intervalo de carga de catalizador, etc., usando expresamente la palabra "intervalo" o no, incluye los extremos indicados.

Existen diversos procedimientos para la preparación de β-aminoácidos quirales y racémicos. Tales procedimientos pueden encontrarse en Eusebio Juaristi (editor), *Enantioselective Synthesis of β-Amino-Acids* (1997).

Los procedimientos descritos a continuación ilustran los procedimientos que pueden utilizarse para la preparación de tales compuestos pero no limitan su alcance.

Procedimiento A



1 2 5 3 4 I

El uso de adiciones de amina quiral a sistemas α,β-insaturados como enfoque sintético a los β-aminoácidos, como se ilustra en el Procedimiento A anterior, se ha descrito previamente. Véase, por ejemplo, S.G. Davies *y col., J.*

Chem. Soc. Chem. Commun. 1153 (1993); S.G. Davies, *Synlett* 117 (1994); Ishikawa *y col., Synlett* 1291 (1988); y Hawkins, *J. Org. Chem.* 51:2820 (1985).

Con referencia al Procedimiento A anterior, los compuestos de fórmula I pueden prepararse a partir de los correspondientes compuestos de fórmula 4, en la que PG representa un grupo protector éster adecuado que puede retirarse por hidrólisis o hidrogenolisis, usando condiciones bien conocidas para los especialistas en la técnica. Véase T.W. Greene y P.G.M. Wuts, *Protective groups in organic synthesis* (1991) para una descripción detallada de la formación y retirada de grupos protectores adecuados. Por ejemplo, esta reacción puede realizarse en condiciones de hidrólisis por tratamiento con un ácido apropiado, tal como ácido clorhídrico o ácido sulfúrico, a una temperatura de aproximadamente la temperatura ambiente a aproximadamente la temperatura de reflujo de la mezcla de reacción, preferiblemente a la temperatura de reflujo, o por tratamiento con una base inorgánica apropiada tal como hidróxido sódico, hidróxido potásico o hidróxido de litio, preferiblemente hidróxido sódico, a una temperatura de aproximadamente la temperatura ambiente a aproximadamente la temperatura de reflujo, preferiblemente a aproximadamente la temperatura ambiente. Esta reacción se realiza preferiblemente usando ácido clorhídrico a la temperatura de reflujo. Sin embargo, cuando PG es *t*-butilo, la reacción se realiza preferiblemente en ácido trifluoroacético (TFA). Cuando PG es un grupo básico, la hidrólisis puede realizarse en condiciones básicas, usando procedimientos bien conocidos para los especialistas en la técnica, por ejemplo, usando hidróxido sódico o potásico.

Los compuestos de fórmula 4 pueden prepararse a partir de los correspondientes compuestos de fórmula 3 usando condiciones de

hidrogenolisis que son bien conocidas para los especialistas en la técnica. Por ejemplo, esta reacción puede realizarse tratando los compuestos de fórmula 3 con un catalizador de metal paladio tal como, por ejemplo, hidróxido de paladio sobre carbono, o paladio sobre carbono, o con níquel Raney, en un disolvente tal como, por ejemplo, metanol, etanol o tetrahidrofurano, en una atmósfera de hidrógeno (entre aproximadamente 1 (101,33 kPa) y 5 atmósferas (506,63 kPa)de presión) dando el compuesto deseado de fórmula 4. Preferiblemente, la reacción se realiza usando paladio sobre carbono en etanol bajo aproximadamente 1 atmósfera (101,33 kPa) de hidrógeno.

Los compuestos de fórmula 3 pueden prepararse tratando los correspondientes compuestos de fórmula 2 con una amina apropiada tal como (*R*)-(+)-*N*-bencil-α-metilbencilamina, (*S*)-(-)-*N*-bencil-α-metilbencilamina después del tratamiento con una base apropiada tal como diisopropilamiduro de litio, *n*-butil litio o bis(trimetilsilil)amiduro de litio o potasio en un disolvente tal como éter etílico o, preferiblemente, tetrahidrofurano (THF) a una temperatura de aproximadamente -80°C a aproximadamente 25°C y añadiendo después el compuesto apropiado de fórmula 2. La estereoquímica del nitrógeno de la amina determinará la estereoquímica sobre el nitrógeno del producto final. Preferiblemente, esta reacción se realiza usando (*R*)-(+)-*N*-bencil-α-metilbencilamina, (*S*)-(-)-*N*-bencil-α-metilbencilamina, después de la desprotonación con *n*-butil litio en tetrahidrofurano, a una temperatura de aproximadamente -78°C, de acuerdo con el procedimiento descrito por S.D. Bull y col., *J. Chem. Soc., Perkin Trans. 1* 22:2931-38 (2001). Preferiblemente, esta reacción se realiza usando (*R*)-(+)-*N*-bencil-α-metilbencilamina o (*S*)-(-)-*N*-bencil-α-metilbencilamina, después de la desprotonación con *n*-butil litio en

tetrahidrofurano, a una temperatura de aproximadamente -78°C, de acuerdo con el procedimiento descrito por S.D. Bull y col., *J. Chem. Soc., Perkin Trans. 1* 22:2931-38 (2001).

Los compuestos de fórmula 2 pueden prepararse a partir de los correspondientes compuestos de fórmula 1 tratándolos con un éster fosfonato apropiado en presencia de una base adecuada tal como hidruro sódico, diisopropilamiduro de litio o trietilamina y cloruro de litio o bromuro de litio en un disolvente tal como éter o THF. Preferiblemente, el compuesto de fórmula 1 se hace reaccionar con un éster fosfonato (ALK = metilo, etilo, isopropilo, bencilo o similares) en presencia de bromuro de litio y trietilamina en tetrahidrofurano a aproximadamente la temperatura ambiente. Los compuestos de fórmula 1 pueden prepararse a partir de materiales disponibles en el mercado usando procedimientos bien conocidos para los especialista en la técnica. Se apreciará que los compuestos de fórmula I pueden tener uno o más centros estereogénicos. Usando el procedimiento descrito anteriormente, pueden prepararse compuestos con configuraciones estereoquímicas específicas.

Los compuestos que pueden prepararse con este procedimiento incluyen, pero sin limitación, los siguientes:

Ácido 3-amino-4,5-dimetil-hexanoico;

Ácido 3-amino-4,5-dimetil-heptanoico;

Ácido 3-amino-4,5-dimetil-octanoico;

Ácido 3-amino-4,5-dimetil-nonanoico;

Ácido 3-amino-4-etil-5-metil-heptanoico;

Ácido 3-amino-4-etil-5-metil-octanoico;

Ácido 3-amino-4-etil-5-metil-nonanoico;

Ácido 3-amino-4-etil-5,6-dimetil-heptanoico;

Ácido 3-amino-4-etil-5,7-dimetil-octanoico;

Ácido 3-amino-4-etil-5,8-dimetil-nonanoico;

Ácido (3*R*,4*R*)-3-amino-4,5-dimetil-hexanoico;

Ácido (3*R*,4*R*,5*R*)-3-amino-4,5-dimetil-heptanoico;

Ácido (3*R*,4*R*,5*R*)-3-amino-4,5-dimetil-octanoico;

Ácido (3*R*,4*R*,5*R*)-3-amino-4,5-dimetil-nonanoico;

Ácido (3*R*,4*R*,5*R*)-3-amino-4,5-dimetil-decanoico;

Ácido 3-amino-4,6-dimetil-heptanoico;

Ácido 3-amino-4,6-dimetil-octanoico;

Ácido 3-amino-4,6-dimetil-nonanoico;

Ácido 3-amino-4,6-dimetil-decanoico;

Ácido 3-amino-4,6,7-trimetil-octanoico;

Ácido 3-amino-4,6,8-trimetil-nonanoico;

Ácido 3-amino-4,6,9-trimetil-decanoico;

Ácido 3-amino-6-ciclopropil-4-metil-heptanoico;

Ácido 3-amino-6-ciclobutil-4-metil-heptanoico;

Ácido 3-amino-6-ciclopentil-4-metil-heptanoico;

Ácido 3-amino-6-ciclohexil-4-metil-heptanoico;

Ácido 3-amino-7-ciclopropil-4,6-dimetil-heptanoico;

Ácido 3-amino-7-ciclobutil-4,6-dimetil-heptanoico;

Ácido 3-amino-7-ciclopentil-4,6-dimetil-heptanoico;

Ácido 3-amino-7-ciclohexil-4,6-dimetil-heptanoico;

Ácido 3-amino-8-ciclopropil-4,6-dimetil-octanoico;

Ácido 3-amino-8-ciclobutil-4,6-dimetil-octanoico;

Ácido 3-amino-8-ciclopentil-4,6-dimetil-octanoico;

Ácido 3-amino-8-ciclohexil-4,6-dimetil-octanoico;

Ácido 3-amino-6-(3-cloro-fenil)-4-metil-heptanoico;

Ácido 3-amino-6-(3,4-dicloro-fenil)-4-metil-heptanoico;

Ácido 3-amino-4-metil-6-(3-trifluorometil-fenil)-heptanoico;

Ácido 3-amino-4-metil-6-(4-trifluorometil-fenil)-heptanoico;

Ácido 3-amino-7-(3-cloro-fenil)-4,6-dimetil-heptanoico;

Ácido 3-amino-7-(3,4-dicloro-fenil)-4,6-dimetil-heptanoico;

Ácido 3-amino-4,6-dimetil-7-(3-trifluorometil-fenil)-heptanoico;

Ácido 3-amino-4,6-dimetil-7-(4-trifluorometil-fenil)-heptanoico;

Ácido 3-amino-8-(3-cloro-fenil)-4,6-dimetil-octanoico;

Ácido 3-amino-8-(3,4-dicloro-fenil)-4,6-dimetil-octanoico;

Ácido 3-amino-4,6-dimetil-8-(3-trifluorometil-fenil)-octanoico;

Ácido 3-amino-4,6-dimetil-8-(4-trifluorometil-fenil)-octanoico;

Ácido 3-amino-4-etil-6-metil-octanoico;

Ácido 3-amino-4-etil-6-metil-nonanoico;

Ácido 3-amino-4-etil-6-metil-decanoico;

Ácido 3-amino-4-etil-6,7-dimetil-octanoico;

Ácido 3-amino-4-etil-6,8-dimetil-nonanoico;

Ácido 3-amino-4-etil-6,9-dimetil-decanoico;

Ácido 3-amino-6-ciclopropil-4-etil-heptanoico;

Ácido 3-amino-6-ciclobutil-4-etil-heptanoico;

Ácido 3-amino-6-ciclopentil-4-etil-heptanoico;

Ácido 3-amino-6-ciclohexil-4-etil-heptanoico;

Ácido 3-amino-7-ciclopropil-4-etil-6-metil-heptanoico;

Ácido 3-amino-7-ciclobutil-4-etil-6-metil-heptanoico;

Ácido 3-amino-7-ciclopentil-4-etil-6-metil-heptanoico;

Ácido 3-amino-7-ciclohexil-4-etil-6-metil-heptanoico;

Ácido 3-amino-8-ciclopropil-4-etil-6-metil-octanoico;

Ácido 3-amino-8-ciclobutil-4-etil-6-metil-octanoico;

Ácido 3-amino-8-ciclopentil-4-etil-6-metil-octanoico;

Ácido 3-amino-8-ciclohexil-4-etil-6-metil-octanoico;

Ácido 3-amino-6-(3-cloro-fenil)-4-etil-heptanoico;

Ácido 3-amino-6-(3,4-dicloro-fenil)-4-etil-heptanoico;

Ácido 3-amino-4-etil-6-(3-trifluorometil-fenil)-heptanoico;

Ácido 3-amino-4-etil-6-(4-trifluorometil-fenil)-heptanoico;

Ácido 3-amino-7-(3-cloro-fenil)-4-etil-6-metil-heptanoico;

Ácido 3-amino-7-(3,4-dicloro-fenil)-4-etil-6-metil-heptanoico;

Ácido 3-amino-4-etil-6-metil-7-(3-trifluorometil-fenil)-heptanoico;

Ácido 3-amino-4-etil-6-metil-7-(4-trifluorometil-fenil)-heptanoico;


Ácido 3-amino-8-(3-cloro-fenil)-4-etil-6-metil-octanoico;

Ácido 3-amino-8-(3,4-dicloro-fenil)-4-etil-6-metil-octanoico;

Ácido 3-amino-4-etil-6-metil-8-(3-trifluorometil-fenil)-octanoico;

Ácido 3-amino-4-etil-6-metil-8-(4-trifluorometil-fenil)-octanoico;

Procedimiento B



La alquilación diastereoselectiva de imidas tales como las de fórmula 7 para producir análogos succinatos quirales tales como los de fórmula 8 se ha descrito previamente como enfoque para preparar β-aminoácidos. Véase, por ejemplo, Evans *y col., J. Org. Chem.* 64:6411 (1999); Sibi y Deshpande, *J. Chem. Soc. Perkin Trans 1* 1461 (2000); y Arvanitis *y col., J. Chem. Soc. Perkin Trans 1* 521 (1998).

Los compuestos de fórmula 8 pueden prepararse a partir de compuestos de fórmula 7 en presencia de un éster adecuadamente derivado (PG como se ha definido anteriormente, LG = Br o I o Cl) tal como, por ejemplo, bromoacetato de *t*-butilo, bromoacetato de bencilo con una base organometálica tal como, por ejemplo, diisopropilamiduro de litio o bis(trimetilsilil)amiduro de litio o bis(trimetilsilil)amiduro sódico y similares en un disolvente tal como, por ejemplo, tetrahidrofurano, éter y similares. La reacción puede realizarse usando bis(trimetilsilil)amiduro sódico en tetrahidrofurano a -78°C y tratamiento del anión intermedio resultante con bromoacetato de *t*-butilo a una temperatura de -78°C a -30°C.

Los compuestos de fórmula 9 pueden prepararse hidrolizando los correspondientes compuestos de fórmula 8 en presencia de hidróxido de litio y peróxido de hidrógeno en un disolvente tal como agua o THF a una temperatura de aproximadamente 0°C a aproximadamente la temperatura ambiente. Preferiblemente, esta reacción se realiza usando peróxido de hidrógeno e hidróxido de litio en tetrahidrofurano acuoso a aproximadamente 0°C de acuerdo con el procedimiento descrito en la bibliografía. Véase P.W. Yuen y col., *Bioorganic and Medicinal Chem Lett.* 4(6):823-26 (1994).

El tratamiento del compuesto de fórmula 9 con difenilfosforilazida

(DPPA) seguido de tratamiento con un alcohol adecuado tal como *t*-butanol, alcohol bencílico o alcohol de *p*-metoxibencilo en un disolvente adecuado tal como tolueno, benceno, MTBE o THF a una temperatura de aproximadamente 50°C a aproximadamente la temperatura de reflujo de la mezcla de reacción produce el correspondiente compuesto de fórmula 10, en la que R_7 es metilo, etilo, *t*-butilo, bencilo o *p*-metoxibencilo. R_7 depende de la elección de alcohol usado. Preferiblemente, esta reacción se realiza usando un disolvente de tolueno en presencia de alcohol de *p*-metoxibencilo en condiciones de reflujo.

Los compuestos de fórmula 10 pueden transformarse en los compuestos deseados de fórmula I por hidrólisis o hidrogenolisis, usando condiciones bien conocidas para los especialistas en la técnica. Véase T.W. Greene y P.G.M. Wuts, *Protective groups in organic synthesis* (1991) para una descripción detallada de la formación y retirada de grupos protectores adecuados. Por ejemplo, esta reacción puede realizarse en condiciones de hidrólisis por tratamiento con un ácido apropiado, tal como ácido clorhídrico o ácido sulfúrico, a una temperatura de aproximadamente la temperatura ambiente a aproximadamente la temperatura de reflujo de la mezcla de reacción, preferiblemente a la temperatura de reflujo, o por tratamiento con una base inorgánica apropiada tal como hidróxido sódico, hidróxido potásico o hidróxido de litio, preferiblemente hidróxido sódico, a una temperatura de aproximadamente la temperatura ambiente a aproximadamente la temperatura de reflujo, preferiblemente a aproximadamente la temperatura ambiente. Esta reacción se realiza preferiblemente usando ácido clorhídrico a la temperatura de reflujo. Sin embargo, cuando PG es *t*-butilo, la reacción se realiza preferiblemente en ácido trifluoroacético (TFA). Cuando PG es un grupo básico,

la hidrólisis puede realizarse en condiciones básicas, usando procedimientos bien conocidos para los especialistas en la técnica, por ejemplo, usando hidróxido sódico o potásico.

Los compuestos de fórmula 7 pueden prepararse tratando los correspondientes compuestos de fórmula 5 con una base amina tal como trietilamina, en presencia de cloruro de trimetilacetilo, en un disolvente etéreo tal como THF, y tratando después los intermedios formados por esta reacción (in situ) con una oxazolidinona quiral de fórmula 6. Son ejemplos de otras oxazolidinonas que pueden usarse en este procedimiento: (4*S*)-(-)-4-isopropil-2-oxazolidinona, (*S*)-(-)-4-bencil-2-oxazolidinona, (4*S*,5*R*)-(-)-4-metil-5-fenil-2-oxazolidinona; (*R*)-(+)-4-bencil-2-oxazolidinona, (*S*)-(+)-4-fenil-2-oxazolidinona; (*R*)-(-)-4-fenil-2-oxazolidinona; (*R*)-4-isopropil-2-oxazolidinona; y (4*R*,5*S*)-(+)-4-metil-5-fenil-2-oxazilidinona) y cloruro de litio. Preferiblemente, esta reacción se realiza tratando un ácido de fórmula 5 con cloruro de trimetilacetilo y trietilamina en tetrahidrofurano a aproximadamente -20°C, seguido del tratamiento del intermedio formado en tal reacción con una oxazolidinona de fórmula 6 y cloruro de litio a aproximadamente la temperatura ambiente de acuerdo con los procedimientos de la bibliografía. Véase G.J. Ho y D.J. Mathre, *J. Org. Chem.* 60:2271-73 (1995).


Como alternativa, los compuestos de fórmula 7 pueden prepararse tratando los correspondientes compuestos de fórmula 6 con un cloruro de ácido derivado del tratamiento del correspondiente compuesto de fórmula 5 con cloruro de oxalilo, en un disolvente tal como diclorometano, en presencia de dimetilformamida (DMF). Los ácidos de fórmula 5 pueden prepararse a partir de materiales disponibles en el mercado usando procedimientos bien conocidos

para los especialistas en la técnica. Estos ácidos pueden tener uno o más centros estereogénicos.

Como alternativa, con referencia al Procedimiento C posterior, los compuestos de fórmula 8 pueden tratarse con un ácido apropiado (por ejemplo, ácido trifluoroacético (TFA) cuando se usa el éster *t*-butílico) produciendo los correspondientes compuestos de fórmula 12, que pueden someterse después a una transposición de Curtius (donde R_7 es como se ha definido anteriormente) produciendo los correspondientes compuestos de fórmula 13. Véase Arvanitis *y col., J. Chem. Soc. Perkin Trans 1* 521 (1998) para una descripción de este enfoque. La hidrólisis posterior del grupo imida produce el correspondiente compuesto de fórmula 14; la hidrólisis del grupo carbamato resultante en la fórmula 14 da los β-aminoácidos deseados de fórmula V.

Los compuestos de fórmula 13 pueden convertirse en compuestos de fórmula 14 de una forma similar al procedimiento para convertir compuestos de fórmula 8 en compuestos de fórmula 9 (Procedimiento B). Además, los compuestos de fórmula 14 pueden convertirse en compuestos de fórmula II mediante tratamiento con un ácido fuerte tal como ácido clorhídrico o similar, o una base fuerte, tal como hidróxido sódico o potásico o, si R_7 es bencilo o *p*-metoxibencilo, mediante condiciones hidrogenolíticas, usando paladio sobre carbono en etanol o THF en una atmósfera de hidrógeno. Este enfoque, que conserva la estereoquímica del centro estereogénico en los compuestos de fórmula 8 y fórmula II, se utiliza en el Ejemplo 4 que se proporciona más adelante.

Procedimiento C




8 12 13 14 V

Existe otros enfoques alternativos para sintetizar β-aminoácidos α-sustituidos que pueden utilizarse para preparar los compuestos de esta invención. Véase, por ejemplo, Juaristi y col., *Tetrahedron Asymm.* 7(8):2233 (1996); Seebach y col., *Eur. J. Org. Chem.* 335 (1999); Nagula y col., *Org. Lett.*,

292


2:3527 (2000); Arvanitis y col., *J. Chem. Soc. Perkin Trans 1* 521 (1998); y Hintermann y col., *Helv. Chim. Acta* 81:2093 (1998), como se muestra a continuación en el Procedimiento D.

Procedimiento D



El uso de sulfiminas quirales para producir β-aminoácidos, como se ilustra a continuación en el procedimiento E, se ha descrito previamente. Véase, por ejemplo, T.P. Tang J.A. Ellman, *J. Org. Chem.* 64:12-13 (1999); Davis y McCoull, *J. Org. Chem.* 64:3396-97 (1999) y Davis y col., *J. Org. Chem.* 64:1403-06 (1999).

Procedimiento E



La etapa final en el esquema anterior (R_8 = *t*-butilo o *p*-tolilo, R_9 = un éster convenientemente derivado tal como metilo, etilo o *t*-butilo) es una hidrólisis de los grupos sulfonamida y de los grupos éster de un compuesto de fórmula 19 dando un compuesto de fórmula I. Esta reacción se realiza generalmente usando un ácido fuerte tal como ácido trifluoroacético, ácido clorhídrico, ácido bromhídrico o ácido sulfúrico, en un disolvente tal como agua o dioxano, o una mezcla de agua y dioxano a una temperatura de aproximadamente 20°C a aproximadamente 100°C, preferiblemente a aproximadamente la temperatura ambiente. La reacción puede realizarse tratando compuestos de fórmula 19 con un ácido tal como TFA en un disolvente tal como metanol y tratando después el producto con TFA en un disolvente tal como diclorometano dando un compuesto de fórmula I.

Los compuestos que pueden prepararse mediante este procedimiento

incluyen, pero sin limitación, los siguientes:

Ácido 3-amino-4,5-dimetil-hexanoico;

Ácido 3-amino-4,5-dimetil-heptanoico;

Ácido 3-amino-4,5-dimetil-octanoico;

Ácido 3-amino-4,5-dimetil-nonanoico;

Ácido 3-amino-4-etil-5-metil-heptanoico;

Ácido 3-amino-4-etil-5-metil-octanoico;

Ácido 3-amino-4-etil-5-metil-nonanoico;

Ácido 3-amino-4-etil-5-metil-decanoico;

Ácido 3-amino-4-etil-5,6-dimetil-heptanoico;

Ácido 3-amino-4-etil-5,7-dimetil-octanoico;

Ácido 3-amino-4-etil-5,8-dimetil-nonanoico;

Ácido 3-amino-5-etil-4-metil-octanoico;

Ácido 3-amino-5-etil-4-metil-nonanoico;

Ácido 3-amino-4,5-dietil-heptanoico;

Ácido 3-amino-4,5-dietil-octanoico;

Ácido 3-amino-4,5-dietil-nonanoico;

Ácido 3-amino-5-etil-4,7-dimetil-octanoico;

Ácido 3-amino-5-etil-4,8-dimetil-nonanoico;

Ácido 3-amino-4,5-dietil-6-metil-heptanoico;

Ácido 3-amino-4,5-dietil-7-metil-octanoico;

Ácido 3-amino-4,5-dietil-8-metil-nonanoico;

Ácido 3-amino-4,5,6-trimetil-heptanoico;

Ácido 3-amino-4,5,7-trimetil-octanoico;

Ácido 3-amino-4,5,8-trimetil-nonanoico;

Ácido 3-amino-4-etil-5-metil-hexanoico;

Ácido 3-amino-5-etil-4-metil-octanoico;

Ácido 3-amino-5-etil-4-metil-heptanoico;

Ácido 3-amino-4-metil-5-propil-octanoico;

Ácido 3-amino-6-ciclopentil-4,5-dimetil-hexanoico;

Ácido 3-amino-7-ciclopentil-4,5-dimetil-heptanoico;

Ácido 3-amino-5-etil-4,6-dimetil-heptanoico;

Ácido 3-amino-5-etil-4,7-dimetil-octanoico;

Ácido 3-amino-5-etil-4,8-dimetil-nonanoico;

Ácido (3*R*,4*R*)-3-amino-4,5-dimetil-hexanoico;

Ácido (3*R*,4*R*,5*R*)-3-amino-4,5-dimetil-heptanoico;

Ácido (3*R*,4*R*,5*R*)-3-amino-4,5-dimetil-octanoico;

Ácido (3*R*,4*R*,5*R*)-3-amino-4,5-dimetil-nonanoico;

Ácido (3*R*,4*R*,5*R*)-3-amino-4,5-dimetil-decanoico;

Ácido 3-amino-5-ciclopropil-4-etil-hexanoico;

Ácido 3-amino-6-ciclopropil-4-etil-5-metil-hexanoico;

Ácido 3-amino-5-ciclobutil-4-etil-hexanoico;

Ácido 3-amino-6-ciclobutil-4-etil-5-metil-hexanoico;

Ácido 3-amino-5-ciclopentil-4-metil-hexanoico;

Ácido 3-amino-6-ciclopentil-4-etil-5-metil-hexanoico;

Ácido 3-amino-5-ciclohexil-4-etil-hexanoico;

Ácido 3-amino-6-ciclohexil-4-etil-5-metil-hexanoico;

Ácido 3-amino-5-ciclopropil-4-metil-hexanoico;

Ácido 3-amino-6-ciclopropil-4,5-dimetil-hexanoico;

Ácido 3-amino-5-ciclobutil-4-metil-hexanoico;

Ácido 3-amino-6-ciclobutil-4,5-dimetil-hexanoico;

Ácido 3-amino-5-ciclopentil-4-metil-hexanoico;

Ácido 3-amino-6-ciclopentil-4,5-dimetil-hexanoico;

Ácido 3-amino-5-ciclohexil-4-metil-hexanoico;

Ácido 3-amino-6-ciclohexil-4,5-dimetil-hexanoico;

Ácido 3-amino-8-ciclohexil-4,5-dimetil-octanoico;

Ácido 3-amino-8-ciclohexil-4,5-dimetil-octanoico;

Ácido 3-amino-4,6-dimetil-heptanoico;

Ácido 3-amino-4,6-dimetil-octanoico;

Ácido 3-amino-4,6-dimetil-nonanoico;

Ácido 3-amino-4,6-dimetil-decanoico;

Ácido 3-amino-4,6,7-trimetil-octanoico;

Ácido 3-amino-4,6,8-trimetil-nonanoico;

Ácido 3-amino-4,6,9-trimetil-decanoico;

Ácido 3-amino-6-ciclopropil-4-metil-heptanoico;

Ácido 3-amino-6-ciclobutil-4-metil-heptanoico;

Ácido 3-amino-6-ciclopentil-4-metil-heptanoico;

Ácido 3-amino-6-ciclohexil-4-metil-heptanoico;

Ácido 3-amino-7-ciclopropil-4,6-dimetil-heptanoico;

Ácido 3-amino-7-ciclobutil-4,6-dimetil-heptanoico;

Ácido 3-amino-7-ciclopentil-4,6-dimetil-heptanoico;

Ácido 3-amino-7-ciclohexil-4,6-dimetil-heptanoico;

Ácido 3-amino-8-ciclopropil-4,6-dimetil-octanoico;

Ácido 3-amino-8-ciclobutil-4,6-dimetil-octanoico;

Ácido 3-amino-8-ciclopentil-4,6-dimetil-octanoico;

Ácido 3-amino-8-ciclohexil-4,6-dimetil-octanoico;

Ácido 3-amino-6-(3-cloro-fenil)-4-metil-heptanoico;

Ácido 3-amino-6-(3,4-dicloro-fenil)-4-metil-heptanoico;

Ácido 3-amino-4-metil-6-(3-trifluorometil-fenil)-heptanoico;

Ácido 3-amino-4-metil-6-(4-trifluorometil-fenil)-heptanoico;

Ácido 3-amino-7-(3-cloro-fenil)-4,6-dimetil-heptanoico;

Ácido 3-amino-7-(3,4-dicloro-fenil)-4,6-dimetil-heptanoico;

Ácido 3-amino-4,6-dimetil-7-(3-trifluorometil-fenil)-heptanoico;

Ácido 3-amino-4,6-dimetil-7-(4-trifluorometil-fenil)-heptanoico;

Ácido 3-amino-8-(3-cloro-fenil)-4,6-dimetil-octanoico;

Ácido 3-amino-8-(3,4-dicloro-fenil)-4,6-dimetil-octanoico;

Ácido 3-amino-4,6-dimetil-8-(3-trifluorometil-fenil)-octanoico;

Ácido 3-amino-4,6-dimetil-8-(4-trifluorometil-fenil)-octanoico;

Ácido 3-amino-4-etil-6-metil-octanoico;

Ácido 3-amino-4-etil-6-metil-nonanoico;

Ácido 3-amino-4-etil-6-metil-decanoico;

Ácido 3-amino-4-etil-6,7-dimetil-octanoico;

Ácido 3-amino-4-etil-6,8-dimetil-nonanoico;

Ácido 3-amino-4-etil-6,9-dimetil-decanoico;

Ácido 3-amino-6-ciclopropil-4-etil-heptanoico;

Ácido 3-amino-6-ciclobutil-4-etil-heptanoico;

Ácido 3-amino-6-ciclopentil-4-etil-heptanoico;

Ácido 3-amino-6-ciclohexil-4-etil-heptanoico;

Ácido 3-amino-7-ciclopropil-4-etil-6-metil-heptanoico;

Ácido 3-amino-7-ciclobutil-4-etil-6-metil-heptanoico;

Ácido 3-amino-7-ciclopentil-4-etil-6-metil-heptanoico;

Ácido 3-amino-7-ciclohexil-4-etil-6-metil-heptanoico;

Ácido 3-amino-8-ciclopropil-4-etil-6-metil-octanoico;

Ácido 3-amino-8-ciclobutil-4-etil-6-metil-octanoico;

Ácido 3-amino-8-ciclopentil-4-etil-6-metil-octanoico;

Ácido 3-amino-8-ciclohexil-4-etil-6-metil-octanoico;

Ácido 3-amino-6-(3-cloro-fenil)-4-etil-heptanoico;

Ácido 3-amino-6-(3,4-dicloro-fenil)-4-etil-heptanoico;

Ácido 3-amino-4-etil-6-(3-trifluorometil-fenil)-heptanoico;

Ácido 3-amino-4-etil-6-(4-trifluorometil-fenil)-heptanoico;

Ácido 3-amino-7-(3-cloro-fenil)-4-etil-6-metil-heptanoico;

Ácido 3-amino-7-(3,4-dicloro-fenil)-4-etil-6-metil-heptanoico;

Ácido 3-amino-4-etil-6-metil-7-(3-trifluorometil-fenil)-heptanoico;

Ácido 3-amino-4-etil-6-metil-7-(4-trifluorometil-fenil)-heptanoico;


Ácido 3-amino-8-(3-cloro-fenil)-4-etil-6-metil-octanoico;

Ácido 3-amino-8-(3,4-dicloro-fenil)-4-etil-6-metil-octanoico;

Ácido 3-amino-4-etil-6-metil-8-(3-trifluorometil-fenil)-octanoico;

Ácido 3-amino-4-etil-6-metil-8-(4-trifluorometil-fenil)-octanoico;

Procedimiento F




La síntesis de β-aminoácidos de fórmula V mediante la alquilación enantioselectiva de 2-*terc*-butil-3-metilperhidropirimidin-4-ona enantiopura 1-sustituida 21, como se ilustra en el Procedimiento F anterior, se ha descrito previamente. Véase, por ejemplo, E. Juaristi y col., *Tetrahedron Asymmetry* 7:2233 (1996) y las referencias citadas en ese documento.

Con referencia al Procedimiento F anterior, los compuestos de fórmula 22 pueden prepararse a partir de los compuestos correspondientes de fórmula 20 (HAL = Br, I, Cl u otro grupo saliente adecuado), en la que R_{10} representa un grupo fenilo o metoxi, preferiblemente un grupo metoxi. La hidrólisis puede realizarse en condiciones ácidas en un tubo cerrado herméticamente, a reflujo o en un microondas. Por ejemplo, el procedimiento que utiliza HCl 6 N en un tubo cerrado herméticamente a 90-100°C durante 8 horas se describe en E. Juaristi y col., *Tetrahedron: Asymmetry* 7:2233 (1996). Otros procedimientos preferidos incluyen calentar una solución del compuesto 22 en una mezcla 1:1 de dioxano:HCl 6 N en un microondas durante 1-3 horas o a reflujo durante varios días, dando un compuesto de fórmula V.

Los compuestos de fórmula 22 pueden prepararse a partir de los

compuestos correspondientes de fórmula 20 tratándolos con una perhidropirimidin-4-ona apropiada de fórmula 21 después de la desprotonación con una base apropiada tal como diisopropilamiduro de litio o bis(trimetilsilil)amiduro de litio o sódico, en un disolvente tal como éter etílico o, preferiblemente, tetrahidrofurano (THF), a una temperatura de aproximadamente -80°C a aproximadamente 0°C, y añadiendo después el compuesto apropiado de fórmula 20. La estereoquímica del centro C5 surge de la aproximación del electrófilo desde la cara opuesta del enolato de la disposición axial estéricamente congestionada del grupo *terc*-butilo en C2. Preferiblemente, el compuesto 22 se prepara por reacción de los electrófilos 20 con compuestos de fórmula 21, que se han desprotonado a -78°C con bis(trimetilsilil)amiduro sódico en THF a una temperatura de -78°C a -10°C. La síntesis del compuesto enantiopuro 21 (R_{10} = Ph) a partir de *L*-asparagina se describe en E. Juaristi y col., *Tetrahedron: Asymmetry* 7:2233 (1996).

Procedimiento G



De una manera similar, el Procedimiento G muestra la síntesis de β-aminoácidos α-sustituidos de fórmula V mediante alquilación enantioselectiva de 3-amino-N-(2-hidroxi-1-metil-2-fenil-etil)-N-metil-propionamida enantiopura (fórmula 24). Véase, G. Nagula y col., *Organic Letters* 2:3527-29 (2000). El procedimiento incluye la alquilación del compuesto 24 usando un agente alquilante apropiado 20, donde HAL en la fórmula 20 es Br, I, Cl u otro grupo saliente adecuado. La alquilación del enolato se realiza en un disolvente aprótico polar (THF) con LiCl en exceso a una temperatura de

aproximadamente -5°C a aproximadamente 0°C usando una base con impedimentos estéricos (por ejemplo, hexametildisilazida de litio, diisopropilamiduro de litio, etc) que sea suficientemente fuerte para desprotonar el carbono α de la fórmula 24. La hidrólisis de la amida alquilada 25 resultante da el β-aminoácido deseado de fórmula V.

El compuesto de fórmula 24 se prepara mediante *N*-acilación de un auxiliar quiral, (+)- o (-)-pseudoefedrina, usando un anhídrido mixto. El anhídrido mixto se obtiene haciendo reaccionar un ácido 3-amino-propiónico N-terminal protegido (por ejemplo, ácido 3-*terc*-butoxicarbonilamino-propiónico 23) con cloruro de trimetilacetilo en presencia de trietilamina en cloruro de metileno. Después de la reacción de acoplamiento, el grupo protector se retira por procedimientos conocidos (por ejemplo, tratamiento de la amida protegida con Boc resultante con HCl y MeOH) dando el compuesto de fórmula 24. Véase A. Myers y col., *J. Am. Chem. Soc. 119*:656-73 (1997).

Los compuestos de fórmula 20 mostrados en el Procedimiento F y Procedimiento G pueden prepararse a partir de materiales disponibles en el mercado usando procedimientos que conocen los especialistas en la técnica. Debe apreciarse que los compuestos de fórmula 20 pueden tener uno o más centros estereogénicos. Usando el procedimiento descrito anteriormente pueden prepararse compuestos con configuraciones estereoquímicas específicas.

La preparación de compuestos de esta invención que no se han descrito específicamente en la sección experimental precedente puede realizarse usando combinaciones de las reacciones descritas anteriormente que serán evidentes para los especialistas en la técnica.

En cada una de las reacciones descritas o ilustradas anteriormente, la presión no es crítica a menos que se indique lo contrario. Las presiones de aproximadamente 0,5 atmósferas (50,66 kPa) a aproximadamente 5 atmósferas (506,63 kPa) son generalmente aceptables y la presión ambiente, es decir, aproximadamente 1 atmósfera (101,33 kPa), se prefiere por razones de conveniencia.

Los compuestos de fórmula I, II, III, IV, V o VI y los intermedios mostrados en los esquemas de reacción anteriores pueden aislarse y purificarse por procedimientos convencionales tales como recristalización o separación cromatográfica.

La capacidad de los compuestos de la presente invención para unirse a la subunidad α2δ de un canal de calcio puede determinarse usando el siguiente ensayo de unión.

Se usó un ensayo de unión con radioligando que usa [^{3}H]-gabapentina y la subunidad α2δ derivada de tejido cerebral porcino. Véase Nicolas S. Gee y col., "*The novel anticonvulsant drug, gabapentin (Neurontin), binds to the α2δ subunit of a calcium channel*", *J. Biol. Chem.* 271(10):5768-76 (1996).

Los compuestos de la invención se unen con una afinidad nanomolar a micromolar a la proteína α2δ. Por ejemplo, el ácido 2-aminometil-5-etil-nonanoico se une con una afinidad 75 nM a la proteína α2δ; el ácido (*S*)-3-amino-5-etil-3-metil-heptanoico se une con una afinidad 149 nM a la proteína α2δ; y el ácido (3*S*,5*R*)-3-amino-3,5-dimetil-heptanoico se une con una afinidad 236 nM a la proteína α2δ.

La actividad in vivo de los compuestos de esta invención puede determinarse en modelos animales. Como referencia de modelos animales

relacionados con hiperalgesia, véase, por ejemplo, K. Sluka y col., "Unilateral intramuscular injections of acidic saline produce a bilateral long-lasting hyperalgesia," *Muscle Nerve* 24:37-46 (2001); W. Dixon, "Efficient analysis of experimental observations," *Ann. Rev. Pharmacol. Toxicol.* 20-441-62 (1980); L.O. Randall y J.J. Selitto, "A method for measurement of analgesic activity on inflamed tissue," *Arch. Int. Pharmacodyn* 4:409-19 (1957); K. Hargreaves y col., "A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia," *Pain* 32:77-88 (1988). Como referencia de modelos animales de ansiedad, véase J.R. Vogel y col., "A simple and reliable conflict procedure for testing anti-anxiety agents", *Psychopharmacologia* 21:1-7 (1971).

Los compuestos de la presente invención y sus sales farmacéuticamente aceptables pueden administrarse a mamíferos por vía oral, parenteral (tal como subcutánea, intravenosa, intramuscular, intraesternal y por técnicas de infusión), rectal, bucal o intranasal.

Los nuevos compuestos de la presente invención pueden administrarse solos o en combinación con vehículos o diluyentes farmacéuticamente aceptables por cualquiera de las vías indicadas anteriormente y tal administración puede realizarse en una o en múltiples dosis. Más particularmente, los nuevos agentes terapéuticos de la invención pueden administrarse en una amplia diversidad de formas de dosificación diferentes, es decir, pueden combinarse con diversos vehículos inertes farmacéuticamente aceptables en forma en comprimidos, cápsulas, grageas, trociscos, caramelos duros, supositorios, gelatinas, geles, pastas, pomadas, suspensiones acuosas, soluciones inyectables, elixires, jarabes y similares. Tales vehículos incluyen diluyentes sólidos o cargas, medios acuosos estériles y diversos disolventes

orgánicos no tóxicos, etc. Además, las composiciones farmacéuticas orales pueden edulcorante y/o aromatizarse de forma adecuada. En general, la relación en peso de los nuevos compuestos de esta invención respecto al vehículo farmacéuticamente aceptable estará en el intervalo de aproximadamente 1:6 a aproximadamente 2:1 y, preferiblemente, de aproximadamente 1:4 a aproximadamente 1:1.

Para la administración oral, pueden emplearse comprimidos que contienen diversos excipientes tales como celulosa microcristalina, citrato sódico, carbonato cálcico, fosfato dicálcico y glicina junto con diversos disgregantes tales como almidón (y preferiblemente, almidón de maíz, patata o tapioca), ácido algínico y ciertos silicatos complejos, junto con aglutinantes de granulación tales como polivinilpirrolidona, sacarosa, gelatina y goma arábiga. Adicionalmente, los agentes lubricantes tales como estearato de magnesio, lauril sulfato sódico y talco son habitualmente muy útiles para propósitos de formación de comprimidos. Las composiciones sólidas de un tipo similar también pueden emplearse como cargas en cápsulas de gelatina; los materiales preferidos en relación con esto incluyen lactosa o azúcar de la leche así como polietilenglicoles de alto peso molecular. Cuando se desean suspensiones aucosas y/o elixires para administración oral, el ingrediente activo puede combinarse con diversos agentes edulcorantes o aromatizantes, colorantes o pigmentos y, si se desea, también emulsionantes y/o agentes de suspensión, junto con diluyentes tales como agua, etanol, propilenglicol, glicerina y diversas combinaciones similares de los mismos.

Para administración parenteral, pueden emplearse las soluciones de un compuesto de la presente invención en aceite de sésamo o cacahuete o en

propilenglicol acuoso. Las soluciones acuosas deben estar convenientemente reguladas con un tampón (preferiblemente pH > 8) si es necesario y convertir primero el diluyente líquido en isotónico. Estas soluciones acuosas son adecuadas para propósitos de inyección intravenosa. Las soluciones oleosas son adecuadas para propósitos de inyección intraarticular, intramuscular y subcutánea. La preparación de todas estas soluciones en condiciones estériles se logra fácilmente con técnicas farmacéuticas convencionales que conocen bien los especialistas en la técnica.

Para administración intranasal o administración por inhalación, los nuevos compuestos de la invención se administran convencionalmente en forma de solución o suspensión en un recipiente nebulizador con bomba que el paciente aprieta o bombea o como presentación de nebulizador en aerosol en un recipiente presurizado o nebulizador, con el uso de un propulsor adecuado, por ejemplo, diclorodifluorometano, triclorofluorometano, diclorotetrafluoroetano, dióxido de carbono u otro gas adecuado. En el caso de un aerosol presurizado, la unidad de dosificación puede determinarse proporcionando con una válvula que administra una cantidad medida. El recipiente presurizado o nebulizador puede contener una solución o suspensión del compuesto activo. Las cápsulas y cartuchos (fabricadas, por ejemplo, con gelatina), para usar en un inhalador o insuflador pueden formularse para contener una mezcla en polvo del compuesto de la invención y una base en polvo adecuada tal como lactosa o almidón. Las formulaciones de los compuestos activos de esta invención para el tratamiento de las afecciones a las que se ha hecho referencia anteriormente en un ser humano adulto medio se disponen preferiblemente de tal forma que cada dosis medida o "descarga"

del aerosol contiene de 20 μg a 1000 μg del compuesto activo. La dosis diaria total con un aerosol estará en el intervalo de 100 μg a 10 mg. La administración puede realizarse varias veces al día, por ejemplo, 2, 3, 4 u 8 veces, dando por ejemplo 1, 2 ó 3 dosis cada vez.

Los compuestos de la presente invención pueden prepararse y administrarse en una amplia diversidad de formas de dosificación oral y parenteral. De esta forma, los compuestos de la presente invención pueden administrarse por inyección, es decir, de forma intravenosa, intramuscular, intracutánea, subcutánea, intraduodenal o intraperitoneal. También, los compuestos de la presente invención pueden administrarse por inhalación, por ejemplo, por vía intranasal. Además, los compuestos de la presente invención pueden administrarse por vía transdérmica. Será evidente para los especialistas en la técnica que las siguientes formas de dosificación pueden comprender como componente activo, un compuesto de fórmulas I a VI o la correspondiente sal farmacéuticamente aceptable de tal compuesto.

Para preparar composiciones farmacéuticas con los compuestos de la presente invención, los vehículos farmacéuticamente aceptables pueden ser sólidos o líquidos. Las preparaciones en forma sólida incluyen polvos, comprimidos, píldoras, cápsulas, sobres, supositorios y gránulos dispersables. Un vehículo sólido puede ser una o más sustancias que puede actuar también como diluyentes, aromatizantes, aglutinantes, conservantes, agentes de disgregación de comprimidos o material de encapsulación. En los polvos, el vehículo es un sólido finamente dividido, que está mezclado con el componente activo finamente dividido. En los comprimidos, el componente activo se mezcla con el vehículo que tiene las propiedades aglutinantes necesarias en

proporciones adecuadas y se compacta en la forma y tamaño deseados.

Los polvos y comprimidos contienen preferiblemente de cinco o diez a aproximadamente setenta por cierto de compuesto activo. Los vehículos adecuados son carbonato de magnesio, estearato de magnesio, talco, azúcar, lactosa, pectina, dextrina, almidón, gelatina, tragacanto, metilcelulosa, carboximetilcelulosa sódica, una cera con punto de fusión bajo, manteca de cacao y similares. El término "preparación" pretende incluir la formulación del compuesto activo con material de encapsulación como vehículo proporcionando una cápsula en la que el componente activo, con o sin otros excipientes, está rodeado por el vehículo, que está de este modo en asociación con él. Los comprimidos, polvos, cápsulas, píldoras, sobres y grageas pueden usarse como formas de dosificación sólida adecuadas para la administración oral.

Para preparar supositorios, primero se funde una cera con punto de fusión bajo, tal como una mezcla de glicéridos de ácidos grasos o manteca de cacao, y el componente activo se dispersa homogéneamente en la misma, por ejemplo por agitación. Después, la mezcla fundida homogénea se vierte en moldes de tamaño conveniente, se deja enfriar y por tanto solidifica.

Las preparaciones en forma líquida incluyen soluciones, suspensiones y emulsiones, por ejemplo, agua o soluciones acuosas de propilenglicol. Para la inyección parenteral, las preparaciones líquidas pueden formularse en solución en una solución acuosa de polietilenglicol. Las soluciones acuosas adecuadas para uso oral pueden prepararse disolviendo el componente activo en agua y añadiendo colorantes, aromas, agentes estabilizantes y espesantes adecuados como se desee. Las suspensiones acuosas adecuadas para el uso oral pueden

prepararse dispersando el componente activo finamente dividido en agua con material viscoso, tal como gomas naturales o sintéticas, resinas, metilcelulosa, carboximetilcelulosa sódica y otros agentes de suspensión conocidos.

También se incluyen preparaciones en forma sólida que se transforman, poco después de su uso, en preparaciones en forma líquida para administración oral. Tales formas líquidas incluyen soluciones, suspensiones y emulsiones. Estas preparaciones pueden contener, además del componente activo, colorantes, aromas, estabilizantes, tampones, edulcorantes artificiales y naturales, dispersantes, espesantes, agentes solubilizantes y similares.

La preparación farmacéutica está preferiblemente en forma de dosificación unitaria. En tal forma la preparación se subdivide en dosis unitarias que contienen cantidades apropiadas del componente activo. La forma de dosificación unitaria puede ser una preparación envasada, conteniendo el envase cantidades discretas de preparación, tal como comprimidos, cápsulas y polvos envasados en viales o ampollas. Además, la forma de dosificación unitaria puede ser solamente una cápsula, comprimido, sobre o gragea o un número apropiado de cualquiera de éstas en forma envasada.

La cantidad de componente activo en una preparación de dosis unitaria puede variarse o ajustarse de 0,01 mg a 1 g de acuerdo con la aplicación particular y la potencia del componente activo. En uso médico, el fármaco puede administrarse tres veces al día, por ejemplo, en cápsulas de 100 o 300 mg. La composición puede contener también, si se desea, otros agentes terapéuticos compatibles.

En el uso terapéutico, los compuestos utilizados en el procedimiento farmacéutico de esta invención se administran en la dosificación inicial de

aproximadamente 0,1 mg a aproximadamente 1 g diario. Sin embargo, las dosificaciones pueden variar dependiendo de los requerimientos del paciente, la gravedad de la afección que se esté tratando y el compuesto que se esté empleando. La determinación de la dosificación correcta para una situación particular está dentro de la práctica de la técnica. Generalmente, el tratamiento se inicia con dosificaciones más pequeñas que son menores que la dosis óptima del compuesto. Después, la dosificación se aumenta en pequeños incrementos hasta que se alcanza el efecto óptimo en esas circunstancias. Por conveniencia, si se desea, la dosificación total diaria puede dividirse y administrarse en porciones durante el día.

Los siguientes Ejemplos ilustran la preparación de compuestos de la presente invención. No pretenden limitar el alcance de la invención. Los puntos de fusión no están corregidos. Los datos de RMN se indican en partes por millón y hacen referencia a la señal de bloqueo del deuterio en el disolvente de muestra.

Ejemplo 1

(4*S*,5*R*)-4-Metil-3-pentanoil-5-fenil-oxazolidin-2-ona

A una solución agitada a 0°C de ácido valérico (3,83 ml, 35,2 mmol) y Et_3N (14,7 ml, 106 mmol) en THF seco (175 ml) se le añadió gota a gota cloruro de trimetilacetilo (5,29 ml, 42,3 mmol). La mezcla se agitó a 0°C durante 1 hora y se añadió (4*S*,5*R*)-(-)-4-metil-5-fenil-2-oxazolidinona (7,50 g, 42,3 mmol) seguido de LiCl (1,79 g, 42,3 mmol). La reacción se calentó a temperatura ambiente durante una noche con buena agitación. La mezcla se filtró y el filtrado se concentró a presión reducida. Se añadió Et_2O (75 ml) al residuo que se lavó con $NaHCO_3$ saturado (3 x 40 ml), HCl 1 N (3 x 40 ml) y

salmuera (2 x 40 ml). La fase orgánica se secó sobre $MgSO_4$, se filtró y se concentró a presión reducida dando un rendimiento cuantitativo del producto en bruto.

(4*S*,5*R*)-3-((*S*)-2-Etil-pentanoil)-4-metil-5-fenil-oxazolidin-2-ona

A una solución agitada a -78°C de la (4*S*,5*R*)-4-metil-3-pentanoil-5-fenil-oxazolidin-2-ona (9,20 g, 35,2 mmol) en THF seco (150 ml) se le añadió gota a gota NaHMDS (42,2 ml, 1,0 M en THF). Después de 1 hora, se añadió gota a gota trifluorometanosulfonato de etilo (5,93 ml, 45, 7 mmol) y la reacción se agitó a -78°C durante 2 horas más. La reacción se calentó a -30°C durante 30 minutos y se inactivó con NH_4Cl saturado. Las fases se separaron y la fase acuosa se extrajo con EtoAc (3 x 40 ml). Los extractos orgánicos se combinaron y se lavaron con salmuera (2 x 40 ml). La fase orgánica se secó sobre $MgSO_4$, se filtró y se concentró a presión reducida produciendo 8,05 g de producto en bruto.

(*S*)-2-Etil-pentan-1-ol

A una solución a temperatura ambiente de (4S,5R)-3-((*S*)-2-etil-pentanoil)-4-metil-5-fenil-oxazolidin-2-ona (8,05 g, 27,8 mmol) en THF (200 ml) se le añadió una solución de $NaBH_4$ (4,21 g, 111 mmol) en H_2O (90 ml). La reacción se dejó agitando durante una noche a temperatura ambiente, se inactivó con HCl 2 N (75 ml) y las fases se separaron. La fase acuosa se extrajo con EtOAc (4 x 40 ml) y los extractos orgánicos se combinaron y lavaron con salmuera (2 x 30 ml). La fase orgánica se secó sobre $MgSO_4$, se filtró y se concentró a presión reducida. El residuo se trituró con n-hexanos (2 x 20 ml) retirando el producto secundario oxazolidinona. Después de filtrar la oxazolidinona, el filtrado se concentró a presión reducida dando 2,56 g de

producto en bruto.

(*S*)-2-etil-pentil éster de ácido metanosulfónico

A una solución en agitación a -10°C de (*S*)-2-etil-pentan-1-ol (1,30 g, 11,2 mmol) en CH_2Cl_2 seco (35 ml) se le añadió Et_3N (2,33 ml, 16,8 mmol). La reacción se agitó a esta temperatura durante 15 minutos y se añadió cloruro de metanosulfonilo (0,952 ml, 12,3 mmol). La reacción se dejó calentar a temperatura ambiente durante una noche con buena agitación. La reacción se lavó con HCl 1 N (3 x 30 ml), $NaHCO_3$ sat. (3 x 30 ml) y salmuera (2 x 30 ml). La fase orgánica se secó sobre $MgSO_4$, se filtró y se concentró a presión reducida dando un rendimiento cuantitativo del producto en bruto.

(*S*)-3-Yodometil-hexano

A una solución agitada de (*S*)-2-etil-pentil éster de ácido metanosulfónico (2,18 g, 11,2 mmol) en acetona (35 ml) se le añadió NaI (3,36 g, 22,4 mmol) y la reacción se calentó a reflujo durante una noche con buena agitación. La reacción se dejó enfriar a temperatura ambiente y la mezcla se filtró. Las sales se lavaron con acetona (3 x 15 ml) y se añadió H_2O (60 ml) al filtrado. La fase acuosa se extrajo con hexanos (4 x 30 ml)) y los extractos orgánicos se combinaron y lavaron con salmuera (2 x 30 ml). La fase orgánica se secó sobre $MgSO_4$, se filtró y se concentró a presión reducida. El residuo se purificó por cromatografía usando hexanos (100%) produciendo 1,24 g (49%) del producto puro.

Éster metílico del ácido (2*S*,5*R*)-2-*terc*-butil-5-((*S*)-2-etil-pentil)-3-metil-4-oxo-tetrahidro-pirimidin-1-carboxílico

A una solución en agitación a -78°C de éster metílico de ácido (*S*)-2-*terc*-butil-3-metil-4-oxo-tetrahidro-pirimidin-1-carboxílico (1,04 g, 4,57 mmol) en THF

seco (15 ml) se le añadió gota a gota NaHMDS (5,03 ml, 1,0 M en THF). La reacción se agitó a -78°C durante 1 hora y después se añadió gota a gota una solución de (*S*)-3-yodometil-hexano (1,24 g, 5,48 mmol) en THF seco (5 ml). La reacción se agitó a esta temperatura durante 2 horas y después se introdujo en un refrigerador a -10°C durante una noche. La reacción se inactivó con NH_4Cl sat. (20 ml) y se dejó calentar a temperatura ambiente. Las fases se separaron y la fase acuosa se extrajo con EtOAc (3 x 15 ml). Los extractos orgánicos se combinaron y se lavaron con salmuera (2 x 15 ml). La fase orgánica se secó sobre $MgSO_4$, se filtró y se concentró a presión reducida. El producto se purificó por cromatografía usando hexanos/EtOAc (10->20%) produciendo 0,185 g (12%) de producto puro. ^{1}H-RMN (400 MHz, CD_3OD) δ ppm 0,9 (m, 6H), 1,3 (m, 5H), 1,4 (m, 3H), 1,7 (m, 1H), 2,5 (m, 1H), 2,9 (d, J = 6,6 Hz, 2H). EM: M+1 (328).

Ácido (2*R*,4*S*)-2-Aminometil-4-etil-heptanoico

Una solución agitada de éster metílico del ácido (2*S*,5*R*)-2-*terc*-butil-5-((*S*)-2-etil-pentil)-3-metil-4-oxo-tetrahidro-pirimidin-1-carboxílico (0,185 g, 0,567 mmol) en una mezcla 1:1 de HCl 6 N/dioxano (8 ml) se calentó a 105°C durante 6 días. La reacción se enfrió a temperatura ambiente y se concentró a presión reducida. El producto se disolvió en MeOH/H_2O 1:1 y se cargó en una columna de cromatografía de intercambio iónico (Varian SCX-Prepacked 10 g, 60 ml) y se eluyó con MeOH/H_2O 1:1 (95%) + NH_4OH. Las fracciones que contenían el producto se recogieron y concentraron a presión reducida produciendo 0,06 g (57%) de producto. ^{1}H RMN (400 MHz, CD_3OD) δ ppm 0,9 (m, 6H), 1,3 (m, 5H), 1,4 (m, 3H), 1,7 (m, 1H), 2,5 (m, 1H), 2,9 (d, J = 6,6 Hz, 2H).

EM: M+1 (188).

Usando la metodología anterior se prepararon también los siguientes compuestos:

Nombre de compuesto	EM, IQPA$^+$	^{1}H RMN (400 MHz, δ, PPM, CD_3OD)
Ácido (4*R*)-2-aminometil-4-etil-heptanoico	188 (M+1)	0,9 (s, 6H), 1,3 (m, 5H), 1,4 (m, 3H), 1,7 (s, 1H), 2,5 (m, 1H), 2,9 (d, J = 6,1 Hz, 2H)
Ácido (2*R*,4*S*)-2-aminometil-4,7-dimetil-octanoico	202 (M+1)	0,9 (d, J = 6,6 Hz, 6,H), 0,9 (d, J = 6,6 Hz, 3H), 1,2 (m, 4H), 1,2 (m, 1H), 1,4 (m, 1H), 1,5 (m, 2H), 1,7 (m, 1H), 2,5 (m, 1H), 2,9 (d, 2H)
Ácido (2*S*,4*S*)-2-aminometil-4-etil-8-metilnonanoico	230 (M+1)	2,93 (d, 2H), 2,47 (línea 5 m, 1H), 1,72 (m, 1H), 1,54 (línea 7 m, 1H), 1,42-1,11 (m, 10H), 0,85 (d, 3H)
Ácido (2*R*/*S*,4*S*)-2-aminometil-8-metil-4-propil-nonanoico	257 (M+1)	2,93 (d, 2H), 2,44 (línea 5 m, 1H), 1,72 (m, 1H), 1,55 (línea 7 m, 1H), 1,44 (m, 1H), 1,40-1,10 (m, 11H), 0,89 (d, 3H)
Ácido (2*S*,4*S*)-2-aminometil-4-etil-6-metil-heptanoico	202 (M+1)	2,93 (d, 2H), 2,43 (m, 1H), 1,71 (m, 1H), 1,63 (m, 1H), 1,42 (m, 1H), 1,36 (m, 2H), 1,22 (m, 1H), 1,06 (m, 2H), 0,85 (m, 9H)
Ácido (2*R*,4*S*)-2-aminometil-4-etil-6-metil-heptanoico	202 (M+1)	2,89 (d, 2H), 2,43 (m, 1H), 1,62 (m, 2H), 1,44 (m, 1H), 1,34 (m, 1H), 1,22 (m, 2H), 1,12 (m, 1H),1,05 (m, 1H), 0,80 (m, 9H)
Ácido (2*R*,4*R*)-2-aminometil-4-etil-6-metil-	202,1 (M+1)	2,90 (d, 2H), 2,43 (m, 1H), 1,68 (m, 1H), 1,61 (m, 1H), 1,42 (m, 1H), 1,32 (m, 2H),

heptanoico		1,21 (m, 1H), 1,11 (m, 2H), 0,80 (m, 9H)
Ácido (2*S*,4*R*)-2-aminometil-4-etil-6-metil-heptanoico	202 (M+1)	2,94 (d, 2H), 2,23 (m, 1H), 1,62 (m, 2H), 1,44 (m, 1H), 1,42 (m, 1H), 1,22 (m, 2H), 1,13 (m, 1H), 1,03 (m, 1H), 0,85 (m, 9H)

Ejemplo 2

(*R*)-3-((*R*)-3-Metil-hexanoil)-4-fenil-oxazolidin-2-ona

Al complejo de bromuro de cobre (1) dimetilsulfuro (13,34 g, 64,87 mmol) en THF seco (150 ml) a -30°C en una atmósfera de nitrógeno se le añadió una solución 2 M en éter de cloruro de propilmagnesio (64,87 ml, 129,7 mmol) y se agitó durante 20 minutos. Se añadió (*R*)-3-but-2-enoil-4-fenil-oxazolidin-2-ona (15,0 g, 64,87 mmol) en THF (60 ml) durante un periodo de 15 minutos a -35°C y se dejó calentar lentamente hasta temperatura ambiente durante 4 horas. La mezcla se enfrió a 0°C y se inactivó con una solución saturada de cloruro amónico. La suspensión se extrajo en éter, se lavó con una solución de hidróxido amónico al 5% y después con salmuera y se secó sobre $MgSO_4$. La solución se concentró a presión reducida produciendo el compuesto del título (13,34 g, 100%) en forma de un sólido blanco. ^{1}H-RMN (400 MHz, $CDCl_3$) δ ppm 0,8 (m, 6H), 1,2 (m, 3H), 1,6 (s, 1H), 2,0 (m, 1H), 2,7 (dd, J = 16,1, 8,5 Hz, 1H), 3,0 (dd, J = 15,9, 5,4 Hz, 1H), 4,3 (dd, J = 8,9, 3,8 Hz, 1H), 4,7 (t, J = 8,9 Hz, 1H), 5,4 (dd, J = 8,8, 3,9 Hz, 1H), 5,4 (dd, J = 8,8, 3,9 Hz, 1H), 7,3 (m, 5H). EM m/z (intensidad relativa): 276 [M+1H, 100%]

(*R*)-3-((2*R*,3*R*)-2,3-dimetil-hexanoil)-4-fenil-oxazolidin-2-ona

A una solución en THF 1 M de hexametildisilamida sódica (16,2 g, 88,3 mmol) a -78°C se le añadió con una cánula una solución a 0°C de (*R*)-3-((*R*)-3-metil-hexanoil)-4-fenil-oxazolidin-2-ona (18,7 g, 67,9 mmol) en 70 ml de THF

seco. La solución resultante se agitó a -78°C durante 30 minutos. Se añadió yoduro de metilo (48,2 g, 339,5 mmol) y se continuó agitando a -78°C durante 4 horas. Se inactivó con una solución saturada de cloruro amónico, se extrajo en CH_2Cl_2 y se lavó con bisulfito sódico 1 M. La solución se secó sobre $MgSO_4$, se concentró y se cromatografió en acetato de etilo al 10% en hexano dando el compuesto del título (11,1 g, 56,5%) en forma de un aceite. EM, m/z (intensidad relativa): ^{1}H RMN (400 MHz, $CDCl_3$) δ ppm 0,8 (t, J = 7,0 Hz, 3H), 0,9 (d, J = 6,6 Hz, 3H, 1,0 (d, J = 6,8 Hz, 3H), 1,0 (d, J = 8,5 Hz, 1H), 1,1 (m, 1H), 1,4 (m, 1H), 1,7 (m, 1H), 3,7 (m, 1H), 4,2 (dd, J = 8,8, 3,4 Hz, 1H), 4,6 (t, J = 8,7 Hz, 1H), 5,4 (dd, J = 8,7, 3,3 Hz, 1H), 7,2 (m, 2H), 7,3 (m, 3H). EM m/z (intensidad relativa): 290 [M+1H, 100%].

(2*R*,3*R*)-2,3-Dimetil-hexan-1-ol

Una solución 1 M en THF de LAH (95,9 ml, 95,9 mmol) se añadió a (*R*)-3-((2*R*,3*R*)-2,3-dimetil-hexanoil)-4-fenil-oxazolidin-2-ona (en THF (300 ml)) en una atmósfera de nitrógeno a -78°C y se agitó durante 3 horas a esta temperatura. Se añadió agua gota a gota para inactivar el exceso de LAH y después se vertió en una mezcla de hielo y éter. La mezcla se extrajo en éter, se lavó con agua y se secó sobre $MgSO_4$. La solución se concentró seguida de adición de un exceso de hexano. El precipitado blanco resultante se filtró y se lavó con hexano. El filtrado se concentró produciendo el compuesto del título (5,05 g, 100%) en forma de un aceite. ^{1}H RMN (400 MHz, $CDCl_3$) δ ppm 0,9 (m, 9H), 1,0 (d, J = 6,8 Hz, 1H), 1,1 (m, 1H), 1,2 (m, 3H), 1,6 (m, 2H), 3,4 (m, 1H), 3,6 (m, 1H).

(2*R*, 3*R*)-2,3-dimetil-hexanal

Se agitaron clorocromato de piridinio (27,35 g, 126,9 mmol) y alúmina

neutra (96 g, 3,5 g por gramo de clorocromato de piridinio) en diclorometano seco (200 ml) en una atmósfera de nitrógeno durante 0,25 horas. Se añadió (2*R*,3*R*)-2,3-dimetil-hexan-1-ol (5,0 g, 38,46 mmol) en diclorometano (60 ml) y la suspensión oscura resultante se agitó a temperatura ambiente durante 3 horas. La suspensión se filtró a través de un lecho corto de sílice eluyendo con un exceso de diclorometano. La evaporación del disolvente produjo el compuesto del título (4,1, 84%) en forma de un aceite. ^{1}H-RMN (400 MHz, $CDCl_3$) δ ppm 0,8 (m, 3H), 0,9 (d, J = 6,6 Hz, 3H), 1,0 (d, J = 6,6 Hz, 3H), 1,2 (m, 4H), 1,8 (m, 1H), 2,2 (m, 1H), 9,6 (s, 1H).

((2*R*,3*R*)-2,3-Dimetil-hexiliden)-amida del ácido 4-metil-bencenosulfínico

Se añadieron etóxido de titanio (IV) (5,16 g, 22,6 mmol) y (*S*)-(+)-p-toluenosulfinamida (7,02 g, 45,2 mmol) a (2R,3R)-2,3-dimetil-hexanal (2,9 g, 22,6 mmol) en THF seco (30 ml). La mezcla resultante se agitó a temperatura ambiente durante 18 horas y se vertió en una solución de salmuera (40 ml). La suspensión se agitó rápidamente durante 10 minutos y se filtró. El filtrado se extrajo en acetato de etilo, se lavó con salmuera y se secó sobre $MgSO_4$. El disolvente se evaporó y el residuo se filtró a través de un lecho de sílice, eluyendo con una solución 50/50 de hexano/acetato de etilo para dar el compuesto del título (3,1 g, 51,6%) en forma de un aceite. ^{1}H RMN (400 MHz, $CDCl_3$) δ ppm 0,8 (m, 6H), 1,1 (m, 4H), 1,3 (m, 3H), 1,7 (m, 1H), 2,4 (s, 3H), 2,5 (m, 1H), 7,3 (d, J = 8,3 Hz, 2H), 7,5 (d, J = 8,1 Hz, 2H), 8,1 (d, J = 5,4 Hz, 1H). EM, *m/z* (intensidad relativa): 266 [M+1H, 100%]

Éster *terc*-butílico de ácido (4*R*,5*R*)-4,5-dimetil-(*R*)-3-(toluen-4-sulfinilamino)-octanoico

Se añadió butillitio (26, 3 ml, 42,04 mmol) a una solución de

diisopropilamina (4,6 g, 45, 6 mmol) en THF seco (40 ml) en una atmósfera de nitrógeno a 0°C y se agitó durante 20 minutos. La solución se enfrió a -78°C seguido de la adición de acetato de *t*-butilo (4,1 g, 35,0 mmol) y se agitó a esta temperatura durante 45 minutos. Se añadió gota a gota triisopropóxido de clorotitanio (9,4 g, 36,2 mmol) y se continuó agitando durante 30 minutos a -78°C. Una solución a -50°C de ((2*R*,3*R*)-2,3-dimetil-hexiliden)amida del ácido 4-metil-bencenosulfínico (3,1 g, 11,7 mmol) en THF seco (10 ml) se añadió a la reacción y la mezcla resultante se agitó a -78°C durante 4 horas. La reacción se inactivó con una solución saturada de NaH_2PO_4 y se extrajo con acetato de etilo. La solución se secó sobre $MgSO_4$ y se concentró. El residuo resultante se cromatografió sobre sílice, eluyendo con acetato de etilo al 15% en hexano dando el compuesto del título (2,4 g, 53,9%) en forma de un sólido blanco. ^1H RMN (400 MHz, $CDCl_3$) δ ppm 0,9 (m, 6H), 1,0 (d, J = 6,6 Hz, 3H), 1,1 (m, 1H), 1,3 (m, 2H), 1,4 (m, 9H), 1,5 (m, 2H), 2,4 (s, 3H), 2,6 (m, 2H), 3,8 (m, 1H), 4,4 (d, J = 10,0 Hz, 1H), 7,3 (d, J = 8,1 Hz, 2H), 7,6 (d, J = 8,1 Hz, 2H). EM, m/z intensidad relativa: 382 [M+1H, 100%], 326 [M+1H-$C(CH_3)_3$, 50%].

Ácido (3*R*,4*R*,5*R*)-3-amino-4,5-dimetil-octanoico

A la solución de éster *terc*-butílico del ácido (4*R*,5*R*)-4,5-dimetil-(*R*)-3-(tolueno-4-sulfinilamino)-octanoico (1,8 g, 4,71 mmol) en metanol seco (30 ml) a 0°C en una atmósfera de nitrógeno se le añadió ácido trifluoroacético en exceso (25 ml) y se agitó durante 2 horas a temperatura ambiente. La solución se concentró a sequedad seguido de la adición de diclorometano seco (20 ml) y ácido trifluoroacético (20 ml). La mezcla resultante se agitó durante 2 horas en una atmósfera de nitrógeno y se concentró a sequedad. El residuo se aplicó a una resina de intercambio iónico BondElute SCX y se eluyó con agua hasta

que el eluyente tenía un pH constante de 6,5. Después, la resina se eluyó con una solución 1:1 de metanol y con una solución de hidróxido amónico al 10%. La solución de hidróxido amónico se evaporó y el residuo se cristalizó en una mezcla de metanol-acetonitrilo produciendo el compuesto del título (0,717 g, 81,2%) en forma de un sólido blanco. ^{1}H RMN (400 MHz, CD_3OD-D) δ ppm 0,9 (m, 11H), 1,1 (m, 2H), 1,3 (m, 1H), 1,4 (m, 1H), 1,6 (m, 1H), 1,7 (m, 2H), 2,3 (dd, J = 16,6, 10,0 Hz, 1H), 2,5 (dd, J = 16,7, 3,5 Hz, 1H), 3,3 (m, 1H), EM, m/z (intensidad relativa): 188 [M+1H, 100%], 186 [M-1H, 100%].

Ejemplo 3

(*S*)-4-Metil-hexan-2-ona (2)

El reactivo de Grignard preparado con (*S*)-1-bromo-2-metil-butano (10 g, 66,2 mmol) y Mg (1,77 g, 72,8 mmol) en Et_2O (65 ml) se añadió gota a gota a una solución de anhídrido acético (8,1 g, 79,3 mmol) en Et_2O (65 ml) a -78°C en 1 hora. Precipitó gran cantidad de sólido blanco. La mezcla de reacción se agitó a -78°C durante 1 hora. Después, la temperatura se dejó aumentar lentamente hasta la temperatura ambiente. La reacción se inactivó con una solución acuosa saturada de NH_4Cl (150 ml). La fase de éter se lavó con NaOH 1 N (150 ml) y salmuera (150 ml). El éter se extrajo a 0°C. El aceite residual se disolvió en hexano (50 ml). La solución se secó con Na_2SO_4 anhidro y se evaporó a 0°C a presión reducida dando (*S*)-4-metil-hexan-2-ona (5,7 g, 75%) en forma de un aceite naranja claro. ^{1}H-RMN ($CDCl_3$) δ 2,26 (m, 2H), 2,08 (s, 3H), 1,86 (m, 1H), 1,21 (m, 2H), 0,83 (m, 6H); EM (IQPA) $(M+1)^+$ 115,0.

((3*S*)-1,3-dimetil-pentiliden)-amida del ácido (*S*)-2-metil-propano-2-sulfínico

Una mezcla de (*S*)-4-metil-hexan-2-ona (1,6 g, 14 mmol), amida de ácido (*S*)-2-metil-propan-2-sulfínico (1,7 g, 14 mmol) y etóxido de titanio (IV) (6,4 g,

28 mmol) en THF (30 ml) se calentó a reflujo durante 10 horas. Después, la mezcla de reacción se vertió en salmuera (150 ml). La mezcla se filtró. El filtrado se extrajo con EtOAc (3 x 70 ml). Se extrajo el EtOAc. El residuo se purificó con una columna de gel de sílice (hexano/EtOAc 3:1) dando el compuesto del título (1,93 g, 63%) en forma de un aceite incoloro. ^{1}H RMN ($CDCl_3$) δ 2,24 (m, 2H), 2,27 (s, 3H), 1,85 (m, 1H), 1,22 (m, 2H), 1,20 (s, 9H), 0,85 (m, 6H); EM (IQPA) $(M+1)^+$ 218,1.

Éster metílico del ácido (3*S*,5*S*)-3,5-dimetil-3-((*S*)-2-metil-propan-2-sulfinilamino)-heptanoico

A una solución de diisopropilamina (3,1 ml, 22,2 mmol) en THF (40 ml) a -78°C se le añadió lentamente butillitio (14,4 ml, 1,6 M, 23 mmol). La mezcla se agitó a 0°C durante 25 minutos y posteriormente se enfrió a -78°C. Se añadió acetato de metilo (1,76 ml, 22,2 mmol) en THF (7 ml). Después de agitar durante 20 minutos, se añadió clorotitanioisopropóxido (11 ml, 46,2 mmol) en THF (10 ml) y la mezcla resultante se agitó a -78°C durante 20 minutos. Se añadió ((3*S*)-1,3-dimetil-pentiliden)-amida de ácido (*S*)-2-metil-propan-2-sulfínico (1,9 g, 8,9 mmol) en THF (10 ml). La mezcla se agitó a -78°C durante una noche. La reacción se inactivó con una solución de NH_4Cl (50 ml). La mezcla se filtró. El filtrado se extrajo con EtOAc (3 x 70 ml). Se extrajo el EtOAc. El residuo se purificó con una columna de gel de sílice (hexano/EtOAc 1:1) dando el compuesto del título (1,61 g, 62%) en forma de un aceite incoloro. ^{1}H RMN ($CDCl_3$) δ 3,64 (s, 3H), 2,60 (m, 2H), 1,47 (m, 2H), 1,44 (m, 1H), 1,36 (s, 3H), 1,27 (m, 2H), 1,19 (s, 9H), 0,90 d, J = 6,4 Hz, 3H), 0,81 (t, J = 7,6 Hz, 3H) EM (IQPA) $(M+1)^+$ 292,2

Ácido (3*S*,5*S*)-3-amino-3,5-dimetil-heptanoico

Una mezcla de éster metílico del ácido (3*S*,5*S*)-3,5-dimetil-3-((*S*)-2-metil-propan-2-sulfinilamino)-heptanoico (0,4 g, 1,37 mmol) y ácido clorhídrico concentrado (7,6 ml) en acetona (10 ml) se calentó a reflujo durante 3 horas. Los disolventes se retiraron a presión reducida. El residuo se disolvió en agua (10 ml) y se extrajo con EtOAc (2 x 15 ml). La fase acuosa se evaporó a sequedad. El residuo se disolvió en una mezcla de agua (10 ml) y trietilamina (0,5 ml). La mezcla se agitó a 40°C durante 20 minutos y después se evaporó a sequedad. El residuo se lavó meticulosamente con acetonitrilo, se filtró y se secó al vacío dando el producto final, ácido (3*S*,5*S*)-3-amino-3,5-dimetil-heptanoico (0,182 g, 77%) en forma de un sólido blanco. pf 215-217°C. ^{1}H RMN ($CDCl_3$) δ 4,85 (s, 3H), 2,38 (m, 2H), 1,75 (m, 1H), 1,39 (m, 4H), 1,35 (s, 3H), 0,98 (d, J = 6,6 Hz, 3H), 0,90 (t, J = 7,5 Hz, 3H); EM (IQPA) $(M+1)^+$ 174,1.

Los siguientes compuestos también se prepararon usando la metodología anterior

Nombre del compuesto	EM, IQPAI$^+$	^{1}H RMN, 400 MHz, δ, PPM, CD_3OD
Ácido (3*R*,5*S*)-3-amino-3,5-dimetil-heptanoico	174 (M+1)	4,84 (s, 3H), 2,38 (m, 2H), 1,58 (m, 1H), 1,37 (m, 4H), 1,34 (s, 3H), 0,98 (d, J = 6,3 Hz, 3H), 0,91 (t, J = 7,4 Hz, 3H).
Ácido (3*S*,5*R*)-3-amino-3,5-dimetil-heptanoico	174 (M+1)	4,84 (s, 3H), 2,38 (m, 2H), 1,58 (m, 1H), 1,37 (m, 4H), 1,34 (s, 3H), 0,98 (d, J = 6,3 Hz, 3H), 0,91 (t, J = 7,4 Hz, 3H).
Ácido (3*R*)-3-amino-3,5-dimetil-octanoico	188 (M+1)	4,84 (s, 3H), 2,39 (m, 2H), 1,72 (m, 1H), 1,59 (s, 3H), 1,38 (m, 6H), 0,98 (d, J = 6,1 Hz, 3H), 0,91 (m, 3H).

Ácido (3*R*,4*R*/*S*)-3-amino-4-metil-heptanoico	160 (M+1)	0,98 (m, 6H), 1,20 (m, 1H), 1,32 (m, 1H), 1,43 (m, 2H), 1,78 (m, 1H), 2,32 (m, 1H), 2,47 (m, 1H), 3,30 (m, 1H).
Ácido (3*S*,6*R*)-3-amino-8-ciclohexil-6-metil-octanoico	256 (M+1)	0,87 (m, 2H), 0,88 (dd, J = 15,86, 6,10 Hz, 3H), 1,20 (m, 11H), 1,39 (m, 4H), 1,69 (m, 6H), 2,53 (dd, J = 17,32, 8,05 Hz, 1H), 2,69 (m, 1H), 3,44 (ddd, J = 14,70, 6,89, 4,76 Hz, 1H).

Ejemplo 4

(3*R*)-(3,7-dimetil-oct-6-enil)-ciclohexano

Se cargó un matraz con 100 ml de THF seco y se refrigeró a 0°C. A este matraz se le añadieron 103 ml (205 mmol) de cloruro de ciclohexilmagnesio 2 M en éter dietílico. Después se recogieron 2,30 g (17 mmol) de cloruro de cobre (II) en 60 ml de THF y se añadieron como una suspensión al reactivo de Grignard. A esta mezcla se le añadieron 0,73 g (17,1 mmol) de cloruro de litio y la mezcla se agitó a 0°C durante 30 minutos. Después se añadieron 13,5 ml (68,4 mmol) de bromuro de (S)-citronelilo y la mezcla se agitó durante 2 horas a 0°C. La mezcla de reacción se dejó calentar a temperatura ambiente y se agitó durante una noche. La reacción se inactivó con la adición de NH_4Cl saturado acuoso hasta que cesó el burbujeo. El THF se retiró a presión reducida. El residuo se recogió en agua y se extrajo con éter dietílico. Las fases de éter combinadas se secaron sobre $MgSO_4$. El agente de secado se retiró por filtración. El disolvente se retiró a presión reducida produciendo 11,48 g (76%) de un aceite transparente. El alquilo de cadena larga en bruto no se caracterizó fácilmente y se usó sin purificación adicional.

3-((*R*)-5-ciclohexil-3-metil-pentil)-2,2-dimetil-oxirano

Se cargó un matraz con 11,48 g (51,6 mmol) de (3*R*)-(3,7-dimetil-oct-6-enil)-ciclohexano bruto, 100 ml de diclorometano y 9,33 g (111 mmol) de bicarbonato sódico. La mezcla se enfrió en un baño a 0°C. Se añadieron lentamente 11,6 ml (55,2 mmol) de ácido peracético al 32%. La mezcla se agitó durante 4 horas a 0°C. Después se añadió lentamente sulfito sódico acuoso al 10% hasta que cesó el burbujeo. Las fases se separaron y la fase orgánica se lavó dos veces con sulfito sódico acuoso al 10% y se secó sobre sulfato de magnesio. El agente de secado se retiró por filtración y el disolvente se retiró a presión reducida. El residuo restante fue 10,65 g (87%) de un aceite transparente. ^{1}H RMN (400 MHz, $CDCl_3$) ppm 0,86 (m, 5H), 1,00 (d, J = 6,59 Hz, 2H), 1,14 (m, 7H), 1,25 (s, 3H), 1,29 (s, 3H), 1,35 (m, 2H), 1,50 (m, 3H), 1,65 (m, 5H), 2,68 (td, J = 6,16, 1,83 Hz, 1H). EM (IQPA) m+1/z = 239.

(*R*)-6-Ciclohexil-4-metil-hexanal

Se cargó un matraz con 10,65 g (44,7 mmol) de 3-((*R*)-5-ciclohexil-3-metil-pentil)-2,2-dimetil-oxirano, 70 ml de acetona, 12,3 g (53,6 mmol) de peryodato potásico, 70 ml de agua y 0,765 g (4 mmol) de ácido tósico monohidrato. La mezcla se agitó durante 46 horas. La acetona se retiró a presión reducida y la mezcla se diluyó con agua. La fase acuosa se extrajo con hexanos y se secó sobre sulfato sódico. El agente de secado se retiró por filtración y el disolvente se retiró a presión reducida consiguiendo 7,12 g (81%) de un aceite transparente. ^{1}H RMN (400 MHz, $CDCl_3$) ppm 0,87 (m, 5H), 1,13 (m, 3H), 1,25 (m, 5H), 1,66 (m, 8H), 2,40 (m, 2H), 9,75 (s, 1H). EM (IQPA) m+1/z es poco concluyente.

Ácido (*R*)-6-ciclohexil-4-metil-hexanoico

Se cargó un matraz con 7,12 g (36,3 mmol) de (*R*)-6-ciclohexil-4-metil-

hexanal, 40 ml de agua, 20 ml de acetona, 4 ml de ácido acético y 6,18 g (39,9 mmol) de permanganato potásico. La mezcla se agitó enérgicamente durante una noche. Después, la mezcla se trató con bisulfito sódico acuoso saturado hasta que el líquido se volvió transparente. El líquido se extrajo con hexanos. Las fases de hexano combinadas se lavaron con bisulfito sódico acuoso saturado hasta que la fase de hexano se volvió transparente. Las fases de hexano se secaron con sulfato de magnesio. El agente de secado se filtró y el disolvente se retiró a presión reducida, lo que produjo 4,17 g (54%) de un aceite transparente. ^{1}H RMN (400 MHz, $CDCl_3$) ppm 0,89 (m, 5H), 1,13 (m, 3H), 1,25 (m, 5H), 1,66 (m, 8H), 2,40 (m, 2H). EM (IQPA) m+1/z = 211.

(4*R*,5*S*)-3-((*R*)-6-ciclohexil-4-metil-hexanoil)-4-metil-5-fenil-oxazolidin-2-ona

Se cargó un matraz con 4,17 g (19,6 mmol) de ácido (*R*)-6-ciclohexil-4-metil-hexanoico, 40 ml de THF y 8,56 ml (61,4 mmol) de trietilamina. La mezcla se enfrió en un baño a 0°C y se añadieron 2,41 ml (19,6 mmol) de cloruro de pivaloílo. La mezcla se agitó durante 1 hora a 0°C. Después se añadieron 2,79 g (16,4 mmol) de (4*R*,5*S*)-4-metil-5-fenil-2-oxazolidinona y 0,823 g (19,6 mmol) de cloruro de litio en forma de sólidos. La mezcla se dejó calentar a temperatura ambiente y se agitó durante una noche. Los sólidos resultantes se filtraron. El disolvente se retiró y el residuo se purificó por cromatografía en columna (eluyente: 4:1 hexanos/acetato de etilo) dando 6,09 g (cuant.) de un aceite transparente. ^{1}H RMN (400 MHz, $CDCl_3$) δ ppm 0,89 (m, 8H), 1,16 (m, 6H), 1,68 (m, 9H), 2,87 (m, 1H), 2,99 (m, 1H), 4,76 (cd, J = 6,83, 6,59 Hz, 1H), 5,66 (d, J = 7,32 Hz, 1H), 7,30 (m, 2H), 7,40 (m, 3H). EM (IQPA) m+1/z = 372.

Éster *terc*-butílico del ácido (5*R*,3*S*)-7-ciclohexil-5-metil-3-((4*R*,5*R*)-4-metil-2-oxo-5-fenil-oxazolidin-3-carbonil)-heptanoico

Se cargó un matraz seco con 60 ml de THF, 2,87 ml (20,5 mmol) de diisopropilamina y la solución resultante se refrigeró en un baño a -78°C. A esta solución se le añadieron 13,3 ml (19,7 mmol) de una solución de *n*-butil litio 1,48 M. La mezcla se dejó calentar a 0°C y se agitó durante 30 minutos a esta temperatura. La solución de LDA se enfrió otra vez a -78°C y se añadieron gota a gota 6,10 g (16,4 mmol) de (4*R*,5*S*)-3-((*R*)-6-ciclohexil-4-metil-hexanoil)-4-metil-5-fenil-oxazolidin-2-ona en forma de solución en 35 ml de THF. La mezcla se agitó durante 45 minutos a -78°C y después se dejó calentar lentamente a -20°C durante 2,5 horas. La mezcla de reacción se inactivó por adición de cloruro amónico acuoso saturado. El disolvente se retiró a presión reducida y el residuo se dividió entre éter dietílico y agua. La fase de éter se recogió y lavó sucesivamente con una solución acuosa saturada de cloruro amónico y solución acuosa saturada de bicarbonato sódico. La fase de éter se secó sobre sulfato de magnesio. El disolvente se retiró a presión reducida y el residuo se purificó por cromatografía en columna (eluyente 10:1 hexanos:acetato de etilo). Esto dio 4,13 g (52%) de un sólido blanco. ^{1}H RMN (400 MHz, $CDCl_3$) δ ppm 0,88 (m, 8H), 1,14 (m, 8H), 1,39 (m, 12H), 1,67 (m, 6H), 2,41 (dd, J = 16,47, 5,00 Hz, 1H), 2,70 (dd, J = 16,47, 9,64 Hz, 1H), 4,31 (m, J = 9,58, 7,29, 7,29, 5,12 Hz, 1H), 4,75 (cd, J = 6,75, 6,59 Hz, 1H), 5,64 (d, J = 7,08 Hz, 1H), 7,31 (m, 2H), 7,38 (m, 3H). EM (IQPA) m+1/z = 430 (pérdida del grupo t-Bu).

Éster 4-*terc*-butílico del ácido (*S*)-2-((*R*)-4-ciclohexil-2-metil-butil)-succínico

Se cargó un matraz con 4,13 g (8,50 mmol) de éster *terc*-butílico del ácido (5*R*,3*S*)-7-ciclohexil-5-metil-3-((4*R*,5*R*)-4-metil-2-oxo-5-fenil-oxazolidin-3-carbonil)-heptanoico, 100 ml de THF, 25 ml de agua y la mezcla resultante se refrigeró en un baño a 0°C. A esta solución se le añadieron 0,57 g (13,6 mmol)

de hidróxido de litio monohidrato y 3,48 ml (34 mmol) de peróxido de hidrógeno al 30%. La mezcla se agitó durante 2,5 horas. La mezcla de reacción se inactivó por adición de 4,29 g (34 mmol) de sulfito sódico en 26 ml de agua. La mezcla se dejó calentar a temperatura ambiente y se agitó durante una noche. El THF se retiró a presión reducida y el material restante se diluyó posteriormente con agua. La fase acuosa se volvió ácida por adición lenta de HCl acuoso concentrado. La fase acuosa se extrajo con diclorometano. Las fases orgánicas se secaron con sulfato de magnesio. El aceite resultante se purificó por cromatografía en columna (eluyente 3:1 hexanos:acetato de etilo). Esto dio 2,19 g (79%) de un aceite transparente. ^{1}H RMN (400 MHz, $CDCl_3$) δ ppm 0,88 (m, 5H), 1,17 (m, 10H), 1,43 (s, 10H), 1,68 (m, 7H), 2,35 (dd, J = 16,35, 5,37 Hz, 1H), 2,60 (m, 1H), 2,87 (m, J = 9,09, 9,09, 5,61, 5,49 Hz, 1H). EM (IQPA) m+1/z es poco concluyente.

Éster metílico del ácido (3*S*,5*R*)-3-amino-7-ciclohexil-5-metil-heptanoico

Se cargó un matraz con 2,19 g (6,71 mmol) de éster 4-*terc*-butílico del ácido (*S*)-2-((*R*)-4-ciclohexil-2-metil-butil)-succínico, 40 ml de tolueno, 0,935 ml (6,71 mmol) de trietilamina y 1,45 ml (6,71 mmol) de difenilfosforilazida. La mezcla se agitó durante 15 minutos a temperatura ambiente y después se calentó a 110°C y se agitó durante 6 horas. El tolueno se retiró a presión reducida y el residuo se recogió en éter dietílico. La fase de éter se lavó con HCl acuoso 3 M, agua y salmuera. El éter se retiró a presión reducida y el isocianato en bruto se recogió en HCl acuoso 3 M y se calentó a reflujo durante 8 horas. El agua se retiró a presión reducida y el residuo se trituró con éter. Esto proporcionó 1,45 g de un sólido blanco impuro. Una porción del sólido blanco se disolvió en metanol y se burbujeó gas HCl durante 15 minutos. La

solución ácida se agitó durante 2 horas. El metanol se retiró a presión reducida y el éster en bruto se purificó por cromatografía en columna (4:1 diclorometano: metanol). esto proporcionó 0,356 g del éster puro. ^{1}H RMN (400 MHz, $CDCl_3$) δ ppm 0,85 (m,2 H), 0,88 (d, J = 8,00 Hz, 3H), 1,15 (m, 6H), 1,26 (m, 1H), 1,36 (ddd, J = 13,73, 9,21, 4,64 Hz, 1H), 1,51 (m, 1H), 1,65 (m, 7H), 2,28 (dd, J = 15,86, 8,78 Hz, 1H), 2,43 (dd, J = 16,0, 4,00 Hz, 1H), 3,28 (m, J = 8,97, 8,97, 4,39, 4,27 Hz, 1H), 3,69 (s, 3H). EM (IQPA) m+1/z = 256.

Ácido (3S,5R)-3-amino-7-ciclohexil-5-metil-heptanoico

Se cargó un matraz con 0,356 g de éster metílico del ácido (3S,5R)-3-amino-7-ciclohexil-5-metil-heptanoico y 20 ml de HCl 3 M y la mezcla se calentó a reflujo durante una noche. La mezcla se enfrió a temperatura ambiente y el disolvente se retiró a presión reducida. Esto proporcionó 0,340 g (88%) de la sal HCl como sólido blanco. ^{1}H RMN (400 MHz, CD_3OD) δ ppm 0,87 (s, 2H), 0,95 (d, J = 6,34 Hz, 3H), 1,21 (m, 6H), 1,35 (m, 1H), 1,43 (ddd, J = 13,85, 8,24, 5,98 Hz, 1H), 1,55 (ddd, J = 12,81, 6,34, 6,22 Hz, 1H), 1,64 (dd, J = 8,30, 5,37 Hz, 2H), 1,71 (m, 5H), 2,57 (dd, J = 17,45, 7,44 Hz, 1H), 2,70 (m, 1H), 3,59 (m, J = 7,72, 7,72, 5,73, 5,43 Hz, 1H). EM (IQPA) m+1/z = 242.

Ejemplo 5

(4R,5S)-3-[3-(2,4-difluoro-fenil)-propionil]-4-metil-5-fenil-oxazolidin-2-ona

Se cargó un matraz con 29,5 g (158 mmol) de ácido 3-(2,4-difluorofenil)-propiónico, 700 ml de THF y 82,8 ml de trietilamina. La mezcla se enfrió a 0°C y se añadieron lentamente 23,4 ml de cloruro de trimetilacetilo. La mezcla se agitó en frío durante 1 hora. Después se añadieron 8,06 g (190 mmol) de LiCl y 28,1 g de (4S,5R)-4-metil-5-fenil-oxazolidin-2-ona. La mezcla se dejó calentar a temperatura ambiente y se agitó durante una noche. Los sólidos se filtraron y el

disolvente se retiró a presión reducida. El residuo se recogió en éter dietílico y se lavó con cloruro amónico acuoso saturado, bicarbonato sódico acuoso saturado y el disolvente se retiró a presión reducida. El residuo en bruto se purificó por cromatografía en columna (3:1 diclorometano/hexanos) dando 54 g (99%) del compuesto del título.

(4*R*,5*S*)-[(*S*)-2-(2,4-difluoro-bencil)-butiril]-4-metil-5-fenil-oxazolidin-2-ona

Se cargó un matraz con 54 g (156 mmol) de (4*R*,5*S*)-3-[3-(2,4-difluoro-fenil)-propionil]-4-metil-5-fenil-oxazolidin-2-ona y 300 ml de THF seco y la solución se enfrió a -78°C. A esta solución se le añadieron 172 ml (172 mmol) de NaHMDS 1 M en THF y la mezcla se agitó en frío durante 1 hora. Después se añadieron gota a gota 30,6 g (172 mmol) de triflato etílico a la solución del enolato y la mezcla de reacción se calentó de -40 a -30°C y se agitó durante 1,5 horas. La mezcla de reacción se inactivó por adición de salmuera acuosa. El THF se retiró a presión reducida y el residuo se dividió entre EtOAc y agua. Los materiales orgánicos se recogieron y el EtOAc se retiró a presión reducida. El aceite en bruto resultante se purificó por cromatografía en columna (3:1 hexanos/EtOAc) dando 29,5 g de un aceite impuro que se usó sin purificación adicional.

(*S*)-2-(2,4-difluoro-bencil)-butan-1-ol

Se cargó un matraz con 29,5 g (~78,6 mmol) de (4*R*,5*S*)-[(*S*)-2-(2,4-difluoro-bencil)-butiril]-4-metil-5-fenil-oxazolidin-2-ona y 200 ml de THF seco y la solución se enfrió a 0°C. En otro matraz, 11,9 g (314 mmol) de borohidruro sódico se recogieron en 70 ml de agua y se añadieron gota a gota durante 15 minutos a la solución de imida. La mezcla se dejó calentar a temperatura ambiente y se agitó durante una noche. La mezcla de reacción se inactivó con

HCl concentrado hasta pH = 3 (manteniendo la temperatura de la mezcla de reacción < 20°C). EL THF se retiró a presión reducida y el residuo se recogió en hexanos. La fase de hexano se lavó con bicarbonato sódico acuoso saturado. La fase de hexano se retiró a presión reducida y el residuo se purificó por cromatografía en columna (9:1 hexanos/EtOAc) lo que dio 7,2 g (46%) del (*S*)-2-(2,4-difluoro-bencil)-butan-1-ol en forma de un aceite transparente.

2-(2,4-Difluoro-bencil)-butil éster del ácido (2*S*)-metanosulfónico

Se cargó un matraz con 7,2 g (36 mmol) de (*S*)-2-(2,4-difluoro-bencil)-butan-1-ol y 30 ml de diclorometano y la solución se enfrió a 0°C. A esta solución se le añadieron 7,53 ml (54 mmol) de trietilamina y la mezcla se agitó en frío durante 5 minutos. Después se añadieron gota a gota 3,1 ml (39,6 mmol) de cloruro de metanosulfonilo. La mezcla de reacción se agitó a temperatura ambiente durante 16 horas. El diclorometano se retiró a presión reducida y el residuo se dividió entre HCl acuoso 1 N y éter dietílico. La fase de éter se recogió y lavó con bicarbonato sódico acuoso saturado, agua y salmuera. La fase de éter se secó sobre sulfato sódico, se filtró y el éter se retiró a presión reducida. Este procedimiento dio 9,54 g (95%) de 2-(2,4-difluoro-bencil)-butil éster del ácido (2*S*)-metanosulfónico en forma de un aceite naranja. Este material se usó sin purificación adicional.

(*S*)-2,4-difluoro-1-(2-yodometil-butil)benceno

Se cargó un matraz con 9,54 g (34,3 mmol) de 2-(2,4-difluoro-bencil)-butil éster de ácido (2*S*)-metanosulfónico, 10,3 g (68,6 mmol) de yoduro sódico y 60 ml de acetona. La solución se calentó a reflujo durante 30 horas. La acetona se retiró a presión reducida. El residuo se repartió entre agua y hexanos. La fase orgánica se recogió y se lavó con una solución de bisulfito

sódico y salmuera. El hexano se retiró a presión reducida y el aceite en bruto se purificó por cromatografía en columna (eluyente hexanos). Este procedimiento dio 9,7 g (91%) de (*S*)-2,4-difluoro-1-(2-yodometil-butil)benceno en forma de un aceite transparente.

Éster metílico de ácido 2-*terc*-butil-5-[2-(2,4-difluoro-bencil)-butil]-3-metil-4-oxo-tetrahidro-pirimidin-1-carboxílico

Se cargó un matraz con 1,35 ml (9,64 mmol) de diisopropilamina y 15 ml de THF seco. La solución se enfrió a -78°C y se añadieron 6,0 ml (9,64 mmol) de solución de n-butil litio 1,6 M en hexanos. La mezcla se calentó a 0°C y se agitó durante 30 minutos. La mezcla se enfrió otra vez a -78°C y se añadieron 2,0 g (8,76 mmol) de éster metílico de ácido (2*S*)-2-*terc*-butil-3-metil-4-oxo-tetrahidro-pirimidin-1-carboxílico como solución en 10 ml de THF. Esta mezcla se calentó a 0°C y se agitó durante 1 hora. La solución aniónica se enfrió otra vez a -78°C y se añadieron 2,99 g (9,64 mmol) de (*S*)-2,4-difluoro-1-(2-yodometil-butil)benceno en forma de solución en THF. La mezcla se agitó a -78°C durante 4 horas. La mezcla de reacción se calentó a -21°C y se agitó a esa temperatura durante 5 días. La mezcla de reacción se inactivó con una solución acuosa saturada de cloruro amónico. La mezcla de reacción bruta se extrajo con éter dietílico. El éter se retiró a presión reducida y el residuo en bruto se purificó por cromatografía en columna (eluyente 9:1 hexanos/EtOAc) lo que dio 1,67 g (46%) de éster metílico de ácido 2-*terc*-butil-5-[2-(2,4-difluoro-bencil)-butil]-3-metil-4-oxo-tetrahidro-pirimidin-1-carboxílico en forma de un sólido blanco.

Ácido (2*R*,4*R*)-2-aminometil-4-(2,4-difluoro-bencil)-hexanoico

Se cargó un matraz con 0,5 g (1,2 mmol) de éster metílico de ácido 2-

terc-butil-5-[2-(2,4-difluoro-bencil)-butil]-3-metil-4-oxo-tetrahidro-pirimidin-1-carboxílico, 20 ml de dioxano y 20 ml de solución de HCl conc. La mezcla se agitó y calentó a 110°C durante 4 días. Los disolventes se retiraron a presión reducida. El residuo se recogió en 20 ml de agua y 4 gotas de solución de HCl concentrado. La fase acuosa se lavó con diclorometano. La fase acuosa se recogió y el agua se retiró a presión reducida. El residuo se trató con 2 ml de trietilamina y el exceso de trietilamina se retiró a presión reducida. El sólido restante se purificó por cromatografía en columna (eluyente 1:8:27 NH_4OH, MeOH, diclorometano). El sólido blanco resultante se lavó con acetonitrilo y se secó al vacío. Esto dio 80 mg (24%) de ácido (2*R*,4*R*)-2-aminometil-4-(2,4-difluoro-bencil)-hexanoico en forma de un sólido blanco.


Debe apreciarse que, como se usa en esta memoria descriptiva y en las reivindicaciones adjuntas, los artículos singulares tales como "un", "uno", "una", "el" y "la" pueden referirse a un único objeto o a una diversidad de objetos a menos que el contexto indique claramente lo contrario. De esta forma, por ejemplo, la referencia a una composición que contiene "un compuesto" puede incluir un único compuesto o dos o más compuestos.

Debe apreciarse que la descripción anterior pretende ser ilustrativa y no restrictiva. Muchas realizaciones serán evidentes para los especialistas en la técnica tras la lectura de la descripción anterior. Por lo tanto, el alcance de la invención no debe determinarse en referencia a la descripción anterior sino con referencia a las reivindicaciones adjuntas, junto con el alcance total de los equivalentes a los que se refieren tales reivindicaciones.

Habiendo descrito la invención como antecede, se declara como propiedad lo contenido en las siguientes

REIVINDICACIONES

1. Un compuesto de fórmula I



I

o una sal farmacéuticamente aceptable del mismo, donde

R_1 es un átomo de hidrógeno o alquilo (C_1-C_6) opcionalmente sustituido con uno a cinco átomos de flúor;

R_2 es un átomo de hidrógeno o alquilo (C_1-C_6) opcionalmente sustituido con uno a cinco átomos de flúor; o

R_1 y R_2, junto con el carbono al que están unidos, forman un anillo cicloalquilo de tres a seis miembros;


R_3 es un átomo de hidrógeno, alquilo (C_1-C_6), cicloalquilo (C_3-C_6), cicloalquil (C_3-C_6)-alquilo (C_1-C_3), fenilo, fenil-alquilo (C_1-C_3), piridilo o piridil-alquilo (C_1-C_3), donde los restos o sustituyentes alquilo y cicloalquilo están opcionalmente sustituidos con uno a cinco átomos de flúor, y los sustituyentes fenilo y piridilo y los restos fenilo y piridilo de los sustituyentes fenil-alquilo (C_1-C_3) y piridil-alquilo (C_1-C_3) están opcionalmente sustituidos con uno a cinco sustituyentes, seleccionados independientemente entre cloro, fluoro, amino, nitro, ciano, hidroxi, alquilamino (C_1-C_3), alquilo (C_1-C_3) opcionalmente sustituido con

uno a tres átomos de flúor, y alcoxi (C_1-C_3) opcionalmente sustituido con uno a tres átomos de flúor;

R_4 es un átomo de hidrógeno o alquilo (C_1-C_6) opcionalmente sustituido con uno a cinco átomos de flúor;

R_5 es un átomo de hidrógeno o alquilo (C_1-C_6) opcionalmente sustituido con uno a cinco átomos de flúor;


2. Un compuesto de la reivindicación 1 que tiene una estructura representada por la fórmula II



II

o una sal farmacéuticamente aceptable del mismo, donde R_1, R_3 y R_4 son como se han definido en la reivindicación 1 con la condición de que R_1 no es un átomo de hidrógeno.


3. Un compuesto de la reivindicación 1 que tiene una estructura representada por la fórmula III



III

o una sal farmacéuticamente aceptable del mismo, donde R_1 y R_3 son como se han definido en la reivindicación 1 con la condición de que R_1 y R_3 no son átomos de hidrógeno.


4. Un compuesto de la reivindicación 3 que tiene una estructura representada por la fórmula IV



IV

o una sal farmacéuticamente aceptable del mismo, donde R_3 es como se ha definido en la reivindicación 1 con la condición de que R_3 no es un átomo de hidrógeno.


5. Un compuesto de la reivindicación 1 que tiene una estructura representada por la fórmula V



V

o una sal farmacéuticamente aceptable del mismo, donde R_1, R_2, R_3, R_4 y R_5 son como se han definido en la reivindicación 1 con la condición de que R_1, R_2, R_3, R_4 y R_5 no son simultáneamente átomos de hidrógeno.

6. Un compuesto de la reivindicación 1 que tiene una estructura representada por la fórmula VI



VI

o una sal farmacéuticamente aceptable del mismo, donde R_3, R_4 y R_5 son como se han definido en la reivindicación 1 con la condición de que R_3, R_4 y R_5 no son simultáneamente átomos de hidrógeno.

7. Una composición farmacéutica que comprende una cantidad terapéuticamente eficaz de un compuesto de la reivindicación 1, o una sal farmacéuticamente aceptable del mismo, y un vehículo farmacéuticamente aceptable.

8. Un procedimiento para tratar un trastorno o afección en un mamífero,

incluyendo un ser humano, seleccionando el trastorno o afección entre:

epilepsia, ataques de desmayos, fibromialgia, hipoquinesia, trastornos craneales, sofocos y temblor esencial;

dependencias y adicciones químicas al alcohol, anfetaminas o sustancias similares a las anfetaminas, cafeína, cannabis, cocaína, heroína, alucinógenos, tabaco, inhalantes y propulsores de aerosol, nicotina, opioides, derivados de fenilglicidina, sedantes, hipnóticos, benzodiazepinas y otros ansiolíticos;

síndrome de abstinencia asociado con dependencias, adicciones o comportamientos adictivos, incluyendo juegos de azar; y

migrañas, espasticidad, espasticidad muscular, hipotonia con parálisis, artritis, síndrome del intestino irritable (IBS), dolor crónico, dolor agudo, dolor neuropático, neuralgia post herpética, dolor lumbar, dolor quirúrgico, dolor de cabeza vascular, cefalea sinusal, dolor de cabeza crónico, trastornos inflamatorios, artritis reumatoide, osteoartritis, psoriasis, modificación de la enfermedad de la enfermedad osteoartritis, diuresis, síndrome premenstrual, trastorno disfórico premenstrual, tinnitus y lesión gástrica;

el procedimiento que comprende administrar a un mamífero en necesidad de tal tratamiento una cantidad terapéuticamente eficaz de un compuesto de la reivindicación 1 o una sal farmacéuticamente aceptable del mismo.

9. Un procedimiento para tratar un trastorno o afección en un mamífero, incluyendo un ser humano, seleccionando el trastorno o afección entre:

delirio, demencia y trastornos amnésicos u otros trastornos cognitivos o neurodegenerativos, incluyendo enfermedad de Parkinson, enfermedad de Huntington, enfermedad de Alzheimer, demencia senil, demencia del tipo de la

enfermedad de Alzheimer, trastorno de memoria, demencia vascular y otras demencias, incluyendo demencia debida a la enfermedad por VIH, traumatismo craneal, enfermedad de Parkinson, enfermedad de Huntington, enfermedad de Pick, enfermedad de Creutzfeldt-Jakob, o debido a múltiples etiologías;

trastornos de movimiento tales como aquinesias, disquinesias, incluyendo disquinesias paroxísticas familiares, espasticidades, síndrome de Tourette, síndrome de Scott, parálisis y síndrome acinético rígido;

trastornos de movimiento extrapiramidales incluyendo trastornos de movimiento inducidos por medicación, incluyendo, Parkinsonismo inducido por neurolépticos, síndrome maligno neuroléptico, distonía aguda inducida por neurolépticos, acatisia aguda inducida por neurolépticos, disquinesia tardía inducida por neurolépticos y temblor postural inducido por medicación;

síndrome de Down;

enfermedades desmielinizantes incluyendo esclerosis múltiple y esclerosis lateral amiotrófica, neuropatía periférica, incluyendo neuropatía diabética e inducida por quimioterapia o neuralgia postherpética, neuralgia del trigémino, neuralgia segmental o intercostal y otras neuralgias; y

trastornos cerebrales vasculares debidos a lesión cerebrovascular aguda o crónica incluyendo infarto cerebral, hemorragia subaracnoidea o edema cerebral;

el procedimiento comprende administrar a un mamífero en necesidad de tal tratamiento una cantidad terapéuticamente eficaz de un compuesto de la reivindicación 1 o una sal farmacéuticamente aceptable del mismo.

10. Un procedimiento para tratar un trastorno o afección en un mamífero, incluyendo un ser humano, seleccionando el trastorno o afección, entre

trastornos del sueño, insomnio, insomnio asociado a fármacos, trastornos del sueño REM, hipersomnia, narcolepsia, trastornos de un ciclo de sueño-vigilia, síndromes de apnea del sueño, parasomnias, síndrome de las piernas inquietas, jet lag, trastorno de movimiento periódico del miembro, arquitectura del sueño alterada, o trastornos del sueño asociados con el turno de trabajo y horas de trabajo irregulares, comprendiendo el procedimiento administrar a un mamífero en necesidad de tal tratamiento una cantidad terapéuticamente eficaz de un compuesto de la reivindicación 1 o una sal farmacéuticamente aceptable del mismo.

11. Un procedimiento para tratar un trastorno o afección en un mamífero, incluyendo un ser humano, seleccionando el trastorno o afección entre:

trastornos del estado emocional, incluyendo depresión o trastornos depresivos, incluyendo trastornos depresivos graves de un único episodio o recurrentes, trastornos distímicos, neurosis depresiva y depresión neurótica, depresión melancólica, incluyendo anorexia, pérdida de peso, insomnio, despertar vespertino y retardo psicomotor, depresión atípica o depresión reactiva, incluyendo aumento del apetito, hipersomnia, agitación psicomotora o irritabilidad, trastorno afectivo estacional y depresión pediátrica;

trastornos bipolares o depresión maniaca, incluyendo trastorno bipolar I, trastorno bipolar II y trastorno ciclotímico;

trastorno de la conducta y trastorno perjudicial del comportamiento;

trastornos de ansiedad, incluyendo trastorno del pánico con o sin agorafobia, agorafobia sin historial de trastorno del pánico, fobias específicas, incluyendo fobias a animales específicos, ansiedad social, fobia social, trastorno

obsesivo-compulsivo, trastornos por estrés incluyendo trastorno por estrés post-traumático y trastorno por estrés agudo y trastornos de ansiedad generalizados;

trastorno de personalidad fronteriza;

esquizofrenia y otros trastornos psicóticos, incluyendo trastornos esquizofreniformes, trastornos esquizoafectivos, trastornos de delirio, trastornos psicóticos breves, trastornos psicóticos compartidos, trastornos psicóticos con delirios o alucinaciones, episodios psicóticos de ansiedad, ansiedad asociada con psicosis, trastornos psicóticos del estado emocional incluyendo trastorno depresivo grave;

trastornos del estado emocional asociados con trastornos psicóticos incluyendo manía aguda y depresión asociada con trastorno bipolar, trastornos del estado emocional asociados con esquizofrenia; y

trastornos del comportamiento asociados con un retraso mental, trastorno autístico y trastornos de la conducta.

el procedimiento comprende administrar a un mamífero en necesidad de tal tratamiento una cantidad terapéuticamente eficaz de un compuesto de la reivindicación 1 o una sal farmacéuticamente aceptable del mismo.

12. Un compuesto seleccionado entre los siguientes compuestos y sus sales farmacéuticamente aceptables:

Ácido 3-amino-4,5-dimetil-hexanoico;

Ácido 3-amino-4,5-dimetil-heptanoico;

Ácido 3-amino-4,5-dimetil-octanoico;

Ácido 3-amino-4,5-dimetil-nonanoico;

Ácido 3-amino-4,5-dimetil-decanoico;

Ácido 3-amino-4-etil-5-metil-heptanoico;

Ácido 3-amino-4-etil-5-metil-octanoico;

Ácido 3-amino-4-etil-5-metil-nonanoico;

Ácido 3-amino-4-etil-5,6-dimetil-heptanoico;

Ácido 3-amino-4-etil-5,7-dimetil-octanoico;

Ácido 3-amino-4-etil-5,8-dimetil-nonanoico;

Ácido 3-amino-5-etil-4-metil-octanoico;

Ácido 3-amino-5-etil-4-metil-nonanoico;

Ácido 3-amino-4,5-dietil-heptanoico;

Ácido 3-amino-4,5-dietil-octanoico;

Ácido 3-amino-4,5-dietil-nonanoico;

Ácido 3-amino-5-etil-4,7-dimetil-octanoico;

Ácido 3-amino-5-etil-4,8-dimetil-nonanoico;

Ácido 3-amino-4,5-dietil-6-metil-heptanoico;

Ácido 3-amino-4,5-dietil-7-metil-octanoico;

Ácido 3-amino-4,5-dietil-8-metil-nonanoico;

Ácido 3-amino-4,5,6-trimetil-heptanoico;

Ácido 3-amino-4,5,7-trimetil-octanoico;

Ácido 3-amino-4,5,8-trimetil-nonanoico;

Ácido 3-amino-4-etil-5-metil-hexanoico;

Ácido 3-amino-5-etil-4-metil-octanoico;

Ácido 3-amino-5-etil-4-metil-heptanoico;

Ácido 3-amino-4-metil-5-propil-octanoico;

Ácido 3-amino-4-metil-6-etil-octanoico;

Ácido 3-amino-4-metil-6-etil-nonanoico;

Ácido 3-amino-4,6-dietil-octanoico;

Ácido 3-amino-4,6-dietil-nonanoico;

Ácido 3-amino-6-ciclopentil-4,5-dimetil-hexanoico;

Ácido 3-amino-7-ciclopentil-4,5-dimetil-heptanoico;

Ácido 3-amino-5-etil-4,6-dimetil-heptanoico;

Ácido 3-amino-5-etil-4,7-dimetil-octanoico;

Ácido 3-amino-5-etil-4,8-dimetil-nonanoico;

Ácido (3*R*,4*R*)-3-amino-4,5-dimetil-hexanoico;

Ácido (3*R*,4*R*,5*R*)-3-amino-4,5-dimetil-heptanoico;

Ácido (3*R*,4*R*,5*R*)-3-amino-4,5-dimetil-octanoico;

Ácido (3*R*,4*R*,5*R*)-3-amino-4,5-dimetil-nonanoico;

Ácido (3*R*,4*R*,5*R*)-3-amino-4,5-dimetil-decanoico;

Ácido 3-amino-5-ciclopropil-4-etil-hexanoico;

Ácido 3-amino-6-ciclopropil-4-etil-5-metil-hexanoico;

Ácido 3-amino-5-ciclobutil-4-etil-hexanoico;

Ácido 3-amino-6-ciclobutil-4-etil-5-metil-hexanoico;

Ácido 3-amino-5-ciclopentil-4-metil-hexanoico;

Ácido 3-amino-6-ciclopentil-4-etil-5-metil-hexanoico;

Ácido 3-amino-5-ciclohexil-4-etil-hexanoico;

Ácido 3-amino-6-ciclohexil-4-etil-5-metil-hexanoico;

Ácido 3-amino-5-ciclopropil-4-metil-hexanoico;

Ácido 3-amino-6-ciclopropil-4,5-dimetil-hexanoico;

Ácido 3-amino-5-ciclobutil-4-metil-hexanoico;

Ácido 3-amino-6-ciclobutil-4,5-dimetil-hexanoico;

Ácido 3-amino-5-ciclopentil-4-metil-hexanoico;

Ácido 3-amino-6-ciclopentil-4,5-dimetil-hexanoico;

Ácido 3-amino-5-ciclohexil-4-metil-hexanoico;

Ácido 3-amino-6-ciclohexil-4,5-dimetil-hexanoico;

Ácido 3-amino-8-ciclohexil-4,5-dimetil-octanoico;

Ácido 3-amino-8-ciclohexil-4,5-dimetil-octanoico;

Ácido 3-amino-4,6-dimetil-heptanoico;

Ácido 3-amino-4,6-dimetil-octanoico;

Ácido 3-amino-4,6-dimetil-nonanoico;

Ácido 3-amino-4,6-dimetil-decanoico;

Ácido 3-amino-4,6,7-trimetil-octanoico;

Ácido 3-amino-4,6,8-trimetil-nonanoico;

Ácido 3-amino-4,6,9-trimetil-decanoico;

Ácido 3-amino-6-ciclopropil-4-metil-heptanoico;

Ácido 3-amino-6-ciclobutil-4-metil-heptanoico;

Ácido 3-amino-6-ciclopentil-4-metil-heptanoico;

Ácido 3-amino-6-ciclohexil-4-metil-heptanoico;

Ácido 3-amino-7-ciclopropil-4,6-dimetil-heptanoico;

Ácido 3-amino-7-ciclobutil-4,6-dimetil-heptanoico;

Ácido 3-amino-7-ciclopentil-4,6-dimetil-heptanoico;

Ácido 3-amino-7-ciclohexil-4,6-dimetil-heptanoico;

Ácido 3-amino-8-ciclopropil-4,6-dimetil-octanoico;

Ácido 3-amino-8-ciclobutil-4,6-dimetil-octanoico;

Ácido 3-amino-8-ciclopentil-4,6-dimetil-octanoico;

Ácido 3-amino-8-ciclohexil-4,6-dimetil-octanoico;

Ácido 3-amino-6-(3-cloro-fenil)-4-metil-heptanoico;

Ácido 3-amino-6-(3,4-dicloro-fenil)-4-metil-heptanoico;

Ácido 3-amino-4-metil-6-(3-trifluorometil-fenil)-heptanoico;

Ácido 3-amino-4-metil-6-(4-trifluorometil-fenil)-heptanoico;

Ácido 3-amino-7-(3-cloro-fenil)-4,6-dimetil-heptanoico;

Ácido 3-amino-7-(3,4-dicloro-fenil)-4,6-dimetil-heptanoico;

Ácido 3-amino-4,6-dimetil-7-(3-trifluorometil-fenil)-heptanoico;

Ácido 3-amino-4,6-dimetil-7-(4-trifluorometil-fenil)-heptanoico;

Ácido 3-amino-8-(3-cloro-fenil)-4,6-dimetil-octanoico;

Ácido 3-amino-8-(3,4-dicloro-fenil)-4,6-dimetil-octanoico;

Ácido 3-amino-4,6-dimetil-8-(3-trifluorometil-fenil)-octanoico;

Ácido 3-amino-4,6-dimetil-8-(4-trifluorometil-fenil)-octanoico;

Ácido 3-amino-4-etil-6-metil-octanoico;

Ácido 3-amino-4-etil-6-metil-nonanoico;

Ácido 3-amino-4-etil-6-metil-decanoico;

Ácido 3-amino-4-etil-6,7-dimetil-octanoico;

Ácido 3-amino-4-etil-6,8-dimetil-nonanoico;

Ácido 3-amino-4-etil-6,9-dimetil-decanoico;

Ácido 3-amino-6-ciclopropil-4-etil-heptanoico;

Ácido 3-amino-6-ciclobutil-4-etil-heptanoico;

Ácido 3-amino-6-ciclopentil-4-etil-heptanoico;

Ácido 3-amino-6-ciclohexil-4-etil-heptanoico;

Ácido 3-amino-7-ciclopropil-4-etil-6-metil-heptanoico;

Ácido 3-amino-7-ciclobutil-4-etil-6-metil-heptanoico;

Ácido 3-amino-7-ciclopentil-4-etil-6-metil-heptanoico;

Ácido 3-amino-7-ciclohexil-4-etil-6-metil-heptanoico;

Ácido 3-amino-8-ciclopropil-4-etil-6-metil-octanoico;

Ácido 3-amino-8-ciclobutil-4-etil-6-metil-octanoico;

Ácido 3-amino-8-ciclopentil-4-etil-6-metil-octanoico;

Ácido 3-amino-8-ciclohexil-4-etil-6-metil-octanoico;

Ácido 3-amino-6-(3-cloro-fenil)-4-etil-heptanoico;

Ácido 3-amino-6-(3,4-dicloro-fenil)-4-etil-heptanoico;

Ácido 3-amino-4-etil-6-(3-trifluorometil-fenil)-heptanoico;

Ácido 3-amino-4-etil-6-(4-trifluorometil-fenil)-heptanoico;

Ácido 3-amino-7-(3-cloro-fenil)-4-etil-6-metil-heptanoico;

Ácido 3-amino-7-(3,4-dicloro-fenil)-4-etil-6-metil-heptanoico;

Ácido 3-amino-4-etil-6-metil-7-(3-trifluorometil-fenil)-heptanoico;

Ácido 3-amino-4-etil-6-metil-7-(4-trifluorometil-fenil)-heptanoico;

Ácido 3-amino-8-(3-cloro-fenil)-4-etil-6-metil-octanoico;

Ácido 3-amino-8-(3,4-dicloro-fenil)-4-etil-6-metil-octanoico;

Ácido 3-amino-4-etil-6-metil-8-(3-trifluorometil-fenil)-octanoico;

Ácido 3-amino-4-etil-6-metil-8-(4-trifluorometil-fenil)-octanoico;

Ácido 3-amino-4-metil-heptanoico;

Ácido 3-amino-4,6-dimetil-heptanoico;

Ácido 3-amino-4,7-dimetil-octanoico;

Ácido 3-amino-4,8-dimetil-nonanoico;

Ácido 3-amino-4-metil-hexanoico;

Ácido 3-amino-4-metil-heptanoico;

Ácido 3-amino-4-metil-octanoico;

Ácido 3-amino-4-metil-nonanoico;

Ácido 3-amino-5-ciclopropil-4-metil-pentanoico;

Ácido 3-amino-6-ciclopropil-4-metil-hexanoico;

Ácido 3-amino-7-ciclopropil-4-metil-heptanoico;

Ácido 3-amino-5-ciclobutil-4-metil-pentanoico;

Ácido 3-amino-6-ciclobutil-4-metil-hexanoico;

Ácido 3-amino-7-ciclobutil-4-metil-heptanoico;

Ácido 3-amino-5-ciclopentil-4-metil-pentanoico;

Ácido 3-amino-6-ciclopentil-4-metil-hexanoico;

Ácido 3-amino-7-ciclopentil-4-metil-heptanoico;

Ácido 3-amino-5-ciclohexil-4-metil-pentanoico;

Ácido 3-amino-6-ciclohexil-4-metil-hexanoico;

Ácido 3-amino-7-ciclohexil-4-metil-heptanoico;

Ácido 3-amino-5-ciclopropil-4-etil-pentanoico;

Ácido 3-amino-6-ciclopropil-4-etil-hexanoico;

Ácido 3-amino-7-ciclopropil-4-etil-heptanoico;

Ácido 3-amino-5-ciclobutil-4-etil-pentanoico;

Ácido 3-amino-6-ciclobutil-4-etil-hexanoico;

Ácido 3-amino-7-ciclobutil-4-etil-heptanoico;

Ácido 3-amino-5-ciclopentil-4-etil-pentanoico;

Ácido 3-amino-6-ciclopentil-4-etil-hexanoico;

Ácido 3-amino-7-ciclopentil-4-etil-heptanoico;

Ácido 3-amino-5-ciclohexil-4-etil-pentanoico;

Ácido 3-amino-6-ciclohexil-4-etil-hexanoico;

Ácido 3-amino-7-ciclohexil-4-etil-heptanoico;

Ácido 3-amino-4,4,5-trimetil-heptanoico;

Ácido 3-amino-4,4,5-trimetil-octanoico;

Ácido 3-amino-4,4,5-trimetil-hexanoico;

Ácido 3-amino-4,5,5-trimetil-heptanoico;

Ácido 3-amino-4,5,5-trimetil-octanoico; y

Ácido 3-amino-4,5,5-trimetil-hexanoico;

Ácido 3-amino-4,5,5-trimetil-hexanoico;

Ácido 3-amino-4-metil-5-fenil-pentanoico;

Ácido 3-amino-4-metil-6-fenil-hexanoico;

Ácido 3-amino-4-metil-7-fenil-heptanoico;

Ácido 3-amino-5-(2-cloro-fenil)-4-metil-pentanoico;

Ácido 3-amino-5-(3-cloro-fenil)-4-metil-pentanoico;

Ácido 3-amino-5-(4-cloro-fenil)-4-metil-pentanoico;

Ácido 3-amino-5-(2,4-dicloro-fenil)-4-metil-pentanoico;

Ácido 3-amino-5-(3,4-dicloro-fenil)-4-metil-pentanoico;

Ácido 3-amino-4-(2-cloro-bencil)-hexanoico;

Ácido 3-amino-4-(3-cloro-bencil)-hexanoico;

Ácido 3-amino-4-(4-cloro-bencil)-hexanoico;

Ácido 3-amino-4-(2,4-dicloro-bencil)-hexanoico;

Ácido 3-amino-4-(3,4-dicloro-bencil)-hexanoico;

Ácido 3-amino-6-(2-cloro-fenil)-4-metil-hexanoico;

Ácido 3-amino-6-(3-cloro-fenil)-4-metil-hexanoico;

Ácido 3-amino-6-(4-cloro-fenil)-4-metil-hexanoico;

Ácido 3-amino-6-(2,4-dicloro-fenil)-4-metil-hexanoico;

Ácido 3-amino-6-(3,4-dicloro-fenil)-4-metil-hexanoico;

Ácido 3-amino-6-(2-cloro-fenil)-4-etil-hexanoico;

Ácido 3-amino-6-(3-cloro-fenil)-4-etil-hexanoico;

Ácido 3-amino-6-(4-cloro-fenil)-4-etil-hexanoico;

Ácido 3-amino-6-(2,4-dicloro-fenil)-4-etil-hexanoico;

Ácido 3-amino-6-(3,4-dicloro-fenil)-4-etil-hexanoico;

Ácido 3-amino-7-(2-cloro-fenil)-4-metil-heptanoico;

Ácido 3-amino-7-(3-cloro-fenil)-4-metil-heptanoico;

Ácido 3-amino-7-(4-cloro-fenil)-4-metil-heptanoico;

Ácido 3-amino-7-(2,4-dicloro-fenil)-4-metil-heptanoico;

Ácido 3-amino-7-(3,4-dicloro-fenil)-4-metil-heptanoico;

Ácido 3-amino-7-(2-cloro-fenil)-4-etil-heptanoico;

Ácido 3-amino-7-(3-cloro-fenil)-4-etil-heptanoico;

Ácido 3-amino-7-(4-cloro-fenil)-4-etil-heptanoico;

Ácido 3-amino-7-(2,4-dicloro-fenil)-4-etil-heptanoico;

Ácido 3-amino-7-(3,4-dicloro-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-4-(2-fluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-(3-fluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-(4-fluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3-difluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,4-difluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,5-difluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,6-difluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-(3,4-difluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-(3,5-difluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,4-trifluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,5-trifluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,6-trifluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,4,6-trifluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,4,5-tetrafluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,4,6-tetrafluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,5,6-tetrafluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-pentafluorofenil-pentanoico;

Ácido 2-aminometil-4-(2-fluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-(3-fluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-(4-fluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3-difluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,4-difluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,5-difluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,6-difluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-(3,4-difluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-(3,5-difluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,4-trifluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,5-trifluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,6-trifluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,4,6-trifluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,4,5-tetrafluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,4,6-tetrafluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,5,6-tetrafluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-pentafluorofenil-hexanoico;

Ácido 2-aminometil-5-(2-fluoro-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3-fluoro-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(4-fluoro-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,3-difluoro-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,4-difluoro-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,5-difluoro-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,6-difluoro-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3,4-difluoro-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3,5-difluoro-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4-trifluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5-trifluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,6-trifluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,4,6-trifluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4,5-tetrafluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4,6-tetrafluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5,6-tetrafluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-pentafluorofenil-pentanoico;

Ácido 2-aminometil-5-(2-fluoro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3-fluoro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(4-fluoro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,3-difluoro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,4-difluoro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,5-difluoro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,6-difluoro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3,4-difluoro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3,5-difluoro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4-trifluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5-trifluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,6-trifluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,4,6-trifluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4,5-tetrafluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4,6-tetrafluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5,6-tetrafluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-pentafluorofenil-hexanoico;

Ácido 2-aminometil-6-(2-fluoro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3-fluoro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(4-fluoro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,3-difluoro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,4-difluoro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,5-difluoro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,6-difluoro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3,4-difluoro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3,5-difluoro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,4-trifluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,5-trifluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,6-trifluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,4,6-trifluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,4,5-tetrafluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,4,6-tetrafluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,5,6-tetrafluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-pentafluorofenil-hexanoico;

Ácido 2-aminometil-5-(2-fluoro-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3-fluoro-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(4-fluoro-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,3-difluoro-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,4-difluoro-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,5-difluoro-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,6-difluoro-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3,4-difluoro-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3,5-difluoro-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4-trifluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,5-trifluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,6-trifluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,4,6-trifluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4,5-tetrafluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4,6-tetrafluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,5,6-tetrafluoro-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-pentafluorofenil-pentanoico;

Ácido 2-aminometil-6-(2-fluoro-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3-fluoro-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(4-fluoro-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,3-difluoro-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,4-difluoro-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,5-difluoro-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,6-difluoro-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3,4-difluoro-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3,5-difluoro-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,4-trifluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,5-trifluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,6-trifluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,4,6-trifluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,4,5-tetrafluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,4,6-tetrafluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,5,6-tetrafluoro-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-pentafluorofenil-hexanoico;

Ácido 2-aminometil-7-(2-fluoro-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3-fluoro-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(4-fluoro-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,3-difluoro-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,4-difluoro-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,5-difluoro-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,6-difluoro-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3,4-difluoro-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3,5-difluoro-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,4-trifluoro-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,5-trifluoro-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,6-trifluoro-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,4,6-trifluoro-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,4,5-tetrafluoro-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,4,6-tetrafluoro-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,5,6-tetrafluoro-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-pentafluorofenil-heptanoico;

Ácido 2-aminometil-7-(2-fluoro-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3-fluoro-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(4-fluoro-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,3-difluoro-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,4-difluoro-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,5-difluoro-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,6-difluoro-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3,4-difluoro-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3,5-difluoro-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,4-trifluoro-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,5-trifluoro-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,6-trifluoro-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,4,6-trifluoro-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,4,5-tetrafluoro-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,4,6-tetrafluoro-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,5,6-tetrafluoro-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-pentafluorofenil-heptanoico;

Ácido 2-aminometil-4-(2-cloro-fenil)-pentanoico;

Ácido 2-aminometil-4-(3-cloro-fenil)-pentanoico;

Ácido 2-aminometil-4-(4-cloro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3-dicloro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,4-dicloro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,5-dicloro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,6-dicloro-fenil)-pentanoico;

Ácido 2-aminometil-4-(3,4-dicloro-fenil)-pentanoico;

Ácido 2-aminometil-4-(3,5-dicloro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,4-tricloro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,5-tricloro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,6-tricloro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,4,6-tricloro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,4,5-tetracloro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,4,6-tetracloro-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,5,6-tetracloro-fenil)-pentanoico;

Ácido 2-aminometil-4-pentaclorofenil-pentanoico;

Ácido 2-aminometil-4-(2-cloro-fenil)-hexanoico;

Ácido 2-aminometil-4-(3-cloro-fenil)-hexanoico;

Ácido 2-aminometil-4-(4-cloro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3-dicloro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,4-dicloro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,5-dicloro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,6-dicloro-fenil)-hexanoico;

Ácido 2-aminometil-4-(3,4-dicloro-fenil)-hexanoico;

Ácido 2-aminometil-4-(3,5-dicloro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,4-tricloro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,5-tricloro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,6-tricloro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,4,6-tricloro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,4,5-tetracloro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,4,6-tetracloro-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,5,6-tetracloro-fenil)-hexanoico;

Ácido 2-aminometil-4-pentaclorofenil-hexanoico;

Ácido 2-aminometil-5-(2-cloro-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3-cloro-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(4-cloro-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,3-dicloro-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,4-dicloro-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,5-dicloro-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,6-dicloro-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3,4-dicloro-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3,5-dicloro-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4-tricloro-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5-tricloro-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,6-tricloro-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,4,6-tricloro-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4,5-tetracloro-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4,6-tetracloro-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5,6-tetracloro-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-pentaclorofenil-pentanoico;

Ácido 2-aminometil-5-(2-cloro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3-cloro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(4-cloro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,3-dicloro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,4-dicloro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,5-dicloro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,6-dicloro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3,4-dicloro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3,5-dicloro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4-tricloro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5-tricloro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,6-tricloro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,4,6-tricloro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4,5-tetracloro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4,6-tetracloro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5,6-tetracloro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-pentaclorofenil-hexanoico;

Ácido 2-aminometil-5-(2-cloro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3-cloro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(4-cloro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,3-dicloro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,4-dicloro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,5-dicloro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,6-dicloro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3,4-dicloro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3,5-dicloro-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4-tricloro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5-tricloro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,6-tricloro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,4,6-tricloro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4,5-tetracloro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4,6-tetracloro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5,6-tetracloro-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-pentaclorofenil-hexanoico;

Ácido 2-aminometil-5-(2-cloro-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3-cloro-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(4-cloro-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,3-dicloro-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,4-dicloro-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,5-dicloro-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,6-dicloro-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3,4-dicloro-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3,5-dicloro-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4-tricloro-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,5-tricloro-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,6-tricloro-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,4,6-tricloro-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4,5-tetracloro-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4,6-tetracloro-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,5,6-tetracloro-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-pentaclorofenil-pentanoico;

Ácido 2-aminometil-6-(2-cloro-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3-cloro-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(4-cloro-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,3-dicloro-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,4-dicloro-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,5-dicloro-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,6-dicloro-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3,4-dicloro-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3,5-dicloro-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,4-tricloro-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,5-tricloro-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,6-tricloro-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,4,6-tricloro-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,4,5-tetracloro-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,4,6-tetracloro-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,5,6-tetracloro-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-pentaclorofenil-hexanoico;

Ácido 2-aminometil-7-(2-cloro-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3-cloro-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(4-cloro-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,3-dicloro-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,4-dicloro-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,5-dicloro-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,6-dicloro-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3,4-dicloro-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3,5-dicloro-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,4-tricloro-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,5-tricloro-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,6-tricloro-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,4,6-tricloro-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,4,5-tetracloro-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,4,6-tetracloro-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,5,6-tetracloro-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-pentaclorofenil-heptanoico;

Ácido 2-aminometil-7-(2-cloro-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3-cloro-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(4-cloro-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,3-dicloro-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,4-dicloro-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,5-dicloro-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,6-dicloro-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3,4-dicloro-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3,5-dicloro-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,4-tricloro-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,5-tricloro-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,6-tricloro-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,4,6-tricloro-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,4,5-tetracloro-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,4,6-tetracloro-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,5,6-tetracloro-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-pentaclorofenil-heptanoico;

Ácido 2-aminometil-4-(2-metoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(3-metoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(4-metoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3-dimetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,4-dimetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,5-dimetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,6-dimetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(3,4-dimetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(3,5-dimetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,4-trimetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,5-trimetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,6-trimetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,4,6-trimetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2-metoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(3-metoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(4-metoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3-dimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,4-dimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,5-dimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,6-dimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(3,4-dimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(3,5-dimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,4-trimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,5-trimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,6-trimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,4,6-trimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-5-(2-metoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3-metoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(4-metoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,3-dimetoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,4-dimetoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,5-dimetoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,6-dimetoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3,4-dimetoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3,5-dimetoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4-trimetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5-trimetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,6-trimetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,4,6-trimetoxi-fenil)-pentanoico;

Ácido 2-aminometil-5-(2-metoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3-metoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(4-metoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,3-dimetoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,4-dimetoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,5-dimetoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,6-dimetoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3,4-dimetoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3,5-dimetoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4-trimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5-trimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,6-trimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,4,6-trimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-6-(2-metoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3-metoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(4-metoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,3-dimetoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,4-dimetoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,5-dimetoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,6-dimetoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3,4-dimetoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3,5-dimetoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,4-trimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,5-trimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,6-trimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,4,6-trimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-5-(2-metoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3-metoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(4-metoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,3-dimetoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,4-dimetoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,5-dimetoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,6-dimetoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3,4-dimetoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3,5-dimetoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4-trimetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,5-trimetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,6-trimetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,4,6-trimetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4,5-tetrametoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4,6-tetrametoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,5,6-tetrametoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-pentametoxifenil-pentanoico;

Ácido 2-aminometil-6-(2-metoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3-metoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(4-metoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,3-dimetoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,4-dimetoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,5-dimetoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,6-dimetoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3,4-dimetoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3,5-dimetoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,4-trimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,5-trimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,6-trimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,4,6-trimetoxi-fenil)-hexanoico;

Ácido 2-aminometil-7-(2-metoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3-metoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(4-metoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,3-dimetoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,4-dimetoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,5-dimetoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,6-dimetoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3,4-dimetoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3,5-dimetoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,4-trimetoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,5-trimetoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,6-trimetoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,4,6-trimetoxi-fenil)-heptanoico;

Ácido 2-aminometil-7-(2-metoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3-metoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(4-metoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,3-dimetoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,4-dimetoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,5-dimetoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,6-dimetoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3,4-dimetoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3,5-dimetoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,4-trimetoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,5-trimetoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,6-trimetoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,4,6-trimetoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-(2-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-(3-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-(4-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3-di-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,4-di-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,5-di-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,6-di-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-(3,4-di-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-(3,5-di-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,4-tri-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,5-tri-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,6-tri-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,4,6-tri-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-(2-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-(3-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-(4-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3-di-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,4-di-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,5-di-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,6-di-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-(3,4-di-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-(3,5-di-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,4-tri-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,5-tri-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,6-tri-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,4,6-tri-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-5-(2-trifluorometil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3-trifluorometil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(4-trifluorometil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,3-di-trifluorometil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,4-di-trifluorometil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,5-di-trifluorometil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,6-di-trifluorometil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3,4-di-trifluorometil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3,5-di-trifluorometil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4-tri-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5-tri-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,6-tri-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,4,6-tri-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-5-(2-trifluorometil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3-trifluorometil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(4-trifluorometil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,3-di-trifluorometil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,4-di-trifluorometil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,5-di-trifluorometil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,6-di-trifluorometil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3,4-di-trifluorometil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3,5-di-trifluorometil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4-tri-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5-tri-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,6-tri-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,4,6-tri-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-6-(2-trifluorometil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3-trifluorometil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(4-trifluorometil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,3-di-trifluorometil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,4-di-trifluorometil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,5-di-trifluorometil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,6-di-trifluorometil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3,4-di-trifluorometil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3,5-di-trifluorometil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,4-tri-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,5-tri-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,6-tri-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,4,6-tri-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-5-(2-trifluorometil-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3-trifluorometil-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(4-trifluorometil-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,3-di-trifluorometil-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,4-di-trifluorometil-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,5-di-trifluorometil-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,6-di-trifluorometil-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3,4-di-trifluorometil-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3,5-di-trifluorometil-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4-tri-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,5-tri-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,6-tri-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,4,6-tri-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4,5-tetra-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4,6-tetra-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,5,6-tetra-trifluorometil-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-penta-trifluorometilfenil-pentanoico;

Ácido 2-aminometil-6-(2-trifluorometil-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3-trifluorometil-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(4-trifluorometil-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,3-di-trifluorometil-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,4-di-trifluorometil-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,5-di-trifluorometil-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,6-di-trifluorometil-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3,4-di-trifluorometil-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3,5-di-trifluorometil-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,4-tri-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,5-tri-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,6-tri-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,4,6-tri-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-7-(2-trifluorometil-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3-trifluorometil-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(4-trifluorometil-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,3-di-trifluorometil-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,4-di-trifluorometil-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,5-di-trifluorometil-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,6-di-trifluorometil-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3,4-di-trifluorometil-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3,5-di-trifluorometil-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,4-tri-trifluorometil-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,5-tri-trifluorometil-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,6-tri-trifluorometil-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,4,6-tri-trifluorometil-fenil)-heptanoico;

Ácido 2-aminometil-7-(2-trifluorometil-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3-trifluorometil-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(4-trifluorometil-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,3-di-trifluorometil-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,4-di-trifluorometil-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,5-di-trifluorometil-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,6-di-trifluorometil-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3,4-di-trifluorometil-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3,5-di-trifluorometil-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,4-tri-trifluorometil-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,5-tri-trifluorometil-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,6-tri-trifluorometil-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,4,6-tri-trifluorometil-fenil)-heptanoico;

Ácido 2-aminometil-4-(2-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(3-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(4-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3-di-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,4-di-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,5-di-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,6-di-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(3,4-di-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(3,5-di-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,4-tri-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,5-tri-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,6-tri-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,4,6-tri-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(3-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(4-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3-di-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,4-di-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,5-di-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,6-di-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(3,4-di-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(3,5-di-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,4-tri-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,5-tri-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,6-tri-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,4,6-tri-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-5-(2-trifluorometoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3-trifluorometoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(4-trifluorometoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,3-di-trifluorometoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,4-di-trifluorometoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,5-di-trifluorometoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,6-di-trifluorometoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3,4-di-trifluorometoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3,5-di-trifluorometoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4-tri-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5-tri-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,6-tri-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,4,6-tri-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-5-(2-trifluorometoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3-trifluorometoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(4-trifluorometoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,3-di-trifluorometoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,4-di-trifluorometoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,5-di-trifluorometoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,6-di-trifluorometoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3,4-di-trifluorometoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3,5-di-trifluorometoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4-tri-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,5-tri-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,6-tri-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,4,6-tri-trifluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4,5-tetrafluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4,6-tetrafluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,5,6-tetrafluorometoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-penta-trifluorometoxifenil-pentanoico;

Ácido 2-aminometil-5-(2-trifluorometoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3-trifluorometoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(4-trifluorometoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,3-di-trifluorometoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,4-di-trifluorometoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,5-di-trifluorometoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,6-di-trifluorometoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3,4-di-trifluorometoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3,5-di-trifluorometoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4-tri-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5-tri-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,6-tri-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,4,6-tri-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-6-(2-trifluorometoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3-trifluorometoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(4-trifluorometoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,3-di-trifluorometoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,4-di-trifluorometoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,5-di-trifluorometoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,6-di-trifluorometoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3,4-di-trifluorometoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3,5-di-trifluorometoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,4-tri-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,5-tri-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,6-tri-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,4,6-tri-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-6-(2-trifluorometoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3-trifluorometoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(4-trifluorometoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,3-di-trifluorometoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,4-di-trifluorometoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,5-di-trifluorometoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,6-di-trifluorometoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3,4-di-trifluorometoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3,5-di-trifluorometoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,4-tri-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,5-tri-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,6-tri-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,4,6-tri-trifluorometoxi-fenil)-hexanoico;

Ácido 2-aminometil-7-(2-trifluorometoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3-trifluorometoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(4-trifluorometoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,3-di-trifluorometoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,4-di-trifluorometoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,5-di-trifluorometoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,6-di-trifluorometoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3,4-di-trifluorometoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3,5-di-trifluorometoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,4-tri-trifluorometoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,5-tri-trifluorometoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,6-tri-trifluorometoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,4,6-tri-trifluorometoxi-fenil)-heptanoico;

Ácido 2-aminometil-7-(2-trifluorometoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3-trifluorometoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(4-trifluorometoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,3-di-trifluorometoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,4-di-trifluorometoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,5-di-trifluorometoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,6-di-trifluorometoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3,4-di-trifluorometoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3,5-di-trifluorometoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,4-tri-trifluorometoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,5-tri-trifluorometoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,6-tri-trifluorometoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,4,6-tri-trifluorometoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-(2-etoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(3-etoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(4-etoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3-dietoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,4-dietoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,5-dietoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,6-dietoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(3,4-dietoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(3,5-dietoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,4-trietoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,5-trietoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,6-trietoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,4,6-trietoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2-etoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(3-etoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(4-etoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3-dietoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,4-dietoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,5-dietoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,6-dietoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(3,4-dietoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(3,5-dietoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,4-trietoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,5-trietoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,6-trietoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,4,6-trietoxi-fenil)-hexanoico;

Ácido 2-aminometil-5-(2-etoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3-etoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(4-etoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,3-dietoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,4-dietoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,5-dietoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,6-dietoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3,4-dietoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3,5-dietoxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4-trietoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5-trietoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,6-trietoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,4,6-trietoxi-fenil)-pentanoico;

Ácido 2-aminometil-5-(2-etoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3-etoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(4-etoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,3-dietoxi-fenil)-4-etil-pentanoico;

356

Ácido 2-aminometil-5-(2,4-dietoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,5-dietoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,6-dietoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3,4-dietoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3,5-dietoxi-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4-trietoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,5-trietoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,6-trietoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,4,6-trietoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4,5-tetraetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4,6-tetraetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,5,6-tetraetoxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-pentaetoxifenil-pentanoico;

Ácido 2-aminometil-5-(2-etoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3-etoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(4-etoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,3-dietoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,4-dietoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,5-dietoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,6-dietoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3,4-dietoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3,5-dietoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4-trietoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5-trietoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,6-trietoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,4,6-trietoxi-fenil)-hexanoico;

Ácido 2-aminometil-6-(2-etoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3-etoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(4-etoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,3-dietoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,4-dietoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,5-dietoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,6-dietoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3,4-dietoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3,5-dietoxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,4-trietoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,5-trietoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,6-trietoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,4,6-trietoxi-fenil)-hexanoico;

Ácido 2-aminometil-6-(2-etoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3-etoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(4-etoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,3-dietoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,4-dietoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,5-dietoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,6-dietoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3,4-dietoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3,5-dietoxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,4-trietoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,5-trietoxi-fenil)-hexanoico;

338

Ácido 2-aminometil-4-etil-6-(2,3,6-trietoxi-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,4,6-trietoxi-fenil)-hexanoico;

Ácido 2-aminometil-7-(2-etoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3-etoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(4-etoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,3-dietoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,4-dietoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,5-dietoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,6-dietoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3,4-dietoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3,5-dietoxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,4-trietoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,5-trietoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,6-trietoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,4,6-trietoxi-fenil)-heptanoico;

Ácido 2-aminometil-7-(2-etoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3-etoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(4-etoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,3-dietoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,4-dietoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,5-dietoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,6-dietoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3,4-dietoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3,5-dietoxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,4-trietoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,5-trietoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,6-trietoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,4,6-trietoxi-fenil)-heptanoico;

Ácido 2-aminometil-4-(2-metil-fenil)-pentanoico;

Ácido 2-aminometil-4-(3-metil-fenil)-pentanoico;

Ácido 2-aminometil-4-(4-metil-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3-dimetil-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,4-dimetil-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,5-dimetil-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,6-dimetil-fenil)-pentanoico;

Ácido 2-aminometil-4-(3,4-dimetil-fenil)-pentanoico;

Ácido 2-aminometil-4-(3,5-dimetil-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,4-trimetil-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,5-trimetil-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,6-trimetil-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,4,6-trimetil-fenil)-pentanoico;

Ácido 2-aminometil-4-(2-metil-fenil)-hexanoico;

Ácido 2-aminometil-4-(3-metil-fenil)-hexanoico;

Ácido 2-aminometil-4-(4-metil-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3-dimetil-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,4-dimetil-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,5-dimetil-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,6-dimetil-fenil)-hexanoico;

Ácido 2-aminometil-4-(3,4-dimetil-fenil)-hexanoico;

Ácido 2-aminometil-4-(3,5-dimetil-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,4-trimetil-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,5-trimetil-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,6-trimetil-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,4,6-trimetil-fenil)-hexanoico;

Ácido 2-aminometil-5-(2-metil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3-metil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(4-metil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,3-dimetil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,4-dimetil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,5-dimetil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,6-dimetil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3,4-dimetil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3,5-dimetil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4-trimetil-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5-trimetil-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,6-trimetil-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,4,6-trimetil-fenil)-pentanoico;

Ácido 2-aminometil-5-(2-metil-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3-metil-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(4-metil-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,3-dimetil-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,4-dimetil-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,5-dimetil-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(2,6-dimetil-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3,4-dimetil-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-5-(3,5-dimetil-fenil)-4-etil-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4-trimetil-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,5-trimetil-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,6-trimetil-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,4,6-trimetil-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4,5-tetrametil-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4,6-tetrametil-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,5,6-tetrametil-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-pentametilfenil-pentanoico;

Ácido 2-aminometil-5-(2-metil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3-metil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(4-metil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,3-dimetil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,4-dimetil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,5-dimetil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,6-dimetil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3,4-dimetil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3,5-dimetil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4-trimetil-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5-trimetil-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,6-trimetil-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,4,6-trimetil-fenil)-hexanoico;

Ácido 2-aminometil-6-(2-metil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3-metil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(4-metil-fenil)-4-metil-hexanoico;

362

Ácido 2-aminometil-6-(2,3-dimetil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,4-dimetil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,5-dimetil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,6-dimetil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3,4-dimetil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3,5-dimetil-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,4-trimetil-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,5-trimetil-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,6-trimetil-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,4,6-trimetil-fenil)-hexanoico;

Ácido 2-aminometil-6-(2-metil-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3-metil-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(4-metil-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,3-dimetil-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,4-dimetil-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,5-dimetil-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,6-dimetil-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3,4-dimetil-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3,5-dimetil-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,4-trimetil-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,5-trimetil-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,6-trimetil-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,4,6-trimetil-fenil)-hexanoico;

Ácido 2-aminometil-7-(2-metil-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3-metil-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(4-metil-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,3-dimetil-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,4-dimetil-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,5-dimetil-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,6-dimetil-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3,4-dimetil-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3,5-dimetil-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,4-trimetil-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,5-trimetil-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,6-trimetil-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,4,6-trimetil-fenil)-heptanoico;

Ácido 2-aminometil-7-(2-metil-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3-metil-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(4-metil-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,3-dimetil-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,4-dimetil-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,5-dimetil-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,6-dimetil-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3,4-dimetil-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3,5-dimetil-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,4-trimetil-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,5-trimetil-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,6-trimetil-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,4,6-trimetil-fenil)-heptanoico;

Ácido 2-aminometil-4-(2-hidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(3-hidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(4-hidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3-dihidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,4-dihidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,5-dihidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,6-dihidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(3,4-dihidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(3,5-dihidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,4-trihidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,5-trihidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,3,6-trihidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2,4,6-trihidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-(2-hidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(3-hidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(4-hidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3-dihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,4-dihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,5-dihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,6-dihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(3,4-dihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(3,5-dihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,4-trihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,5-trihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,3,6-trihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-(2,4,6-trihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-5-(2-hidroxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3-hidroxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(4-hidroxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,3-dihidroxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,4-dihidroxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,5-dihidroxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(2,6-dihidroxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3,4-dihidroxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-5-(3,5-dihidroxi-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4-trihidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5-trihidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,3,6-trihidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-metil-5-(2,4,6-trihidroxi-fenil)-pentanoico;

Ácido 2-aminometil-5-(2-hidroxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3-hidroxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(4-hidroxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,3-dihidroxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,4-dihidroxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,5-dihidroxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(2,6-dihidroxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3,4-dihidroxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-5-(3,5-dihidroxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,4-trihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,5-trihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-5-(2,3,6-trihidroxi-fenil)-hexanoico;

366

Ácido 2-aminometil-4-metil-5-(2,4,6-trihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-6-(2-hidroxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3-hidroxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(4-hidroxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,3-dihidroxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,4-dihidroxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,5-dihidroxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(2,6-dihidroxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3,4-dihidroxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-6-(3,5-dihidroxi-fenil)-4-metil-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,4-trihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,5-trihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,3,6-trihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-metil-6-(2,4,6-trihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-5-(2-hidroxi-fenil)-4-etil-hepanoico;

Ácido 2-aminometil-5-(3-hidroxi-fenil)-4-etil- hepanoico;

Ácido 2-aminometil-5-(4-hidroxi-fenil)-4-etil- hepanoico;

Ácido 2-aminometil-5-(2,3-dihidroxi-fenil)-4-etil-hepanoico;

Ácido 2-aminometil-5-(2,4-dihidroxi-fenil)-4-etil-hepanoico;

Ácido 2-aminometil-5-(2,5-dihidroxi-fenil)-4-etil-hepanoico;

Ácido 2-aminometil-5-(2,6-dihidroxi-fenil)-4-etil-hepanoico;

Ácido 2-aminometil-5-(3,4-dihidroxi-fenil)-4-etil-hepanoico;

Ácido 2-aminometil-5-(3,5-dihidroxi-fenil)-4-etil-hepanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4-trihidroxi-fenil)-hepanoico;

Ácido 2-aminometil-4-etil-5-(2,3,5-trihidroxi-fenil)-hepanoico;

Ácido 2-aminometil-4-etil-5-(2,3,6-trihidroxi-fenil)-hepanoico;

Ácido 2-aminometil-4-etil-5-(2,4,6-trihidroxi-fenil)-hepanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4,5-tetrahidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,4,6-tetrahidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-(2,3,5,6-tetrahidroxi-fenil)-pentanoico;

Ácido 2-aminometil-4-etil-5-pentahidroxifenil-pentanoico;

Ácido 2-aminometil-6-(2-hidroxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3-hidroxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(4-hidroxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,3-dihidroxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,4-dihidroxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,5-dihidroxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(2,6-dihidroxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3,4-dihidroxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-6-(3,5-dihidroxi-fenil)-4-etil-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,4-trihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,5-trihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,3,6-trihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-4-etil-6-(2,4,6-trihidroxi-fenil)-hexanoico;

Ácido 2-aminometil-7-(2-hidroxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3-hidroxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(4-hidroxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,3-dihidroxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,4-dihidroxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(2,5-dihidroxi-fenil)-4-metil-heptanoico;

368

Ácido 2-aminometil-7-(2,6-dihidroxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3,4-dihidroxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-7-(3,5-dihidroxi-fenil)-4-metil-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,4-trihidroxi-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,5-trihidroxi-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,3,6-trihidroxi-fenil)-heptanoico;

Ácido 2-aminometil-4-metil-7-(2,4,6-trihidroxi-fenil)-heptanoico;

Ácido 2-aminometil-7-(2-hidroxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3-hidroxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(4-hidroxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,3-dihidroxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,4-dihidroxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,5-dihidroxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(2,6-dihidroxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3,4-dihidroxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-7-(3,5-dihidroxi-fenil)-4-etil-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,4-trihidroxi-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,5-trihidroxi-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,6-trihidroxi-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,4,6-trihidroxi-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,4,5-tetrahidroxi-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,4,6-tetrahidroxi-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-(2,3,5,6-tetrahidroxi-fenil)-heptanoico;

Ácido 2-aminometil-4-etil-7-pentahidroxifenil-heptanoico;

Ácido (2*R*,4*R*)-2-aminometil-4-(2,4-difluoro-bencil)-hexanoico;

Ácido (2*S*,4*R*)-2-aminometil-4-(2,4-difluoro-bencil)-hexanoico;

Ácido (2*R*,4*S*)-2-aminometil-7-(2,4-difluoro-fenil)-4-etil-heptanoico;

Ácido (2*S*,4*S*)-2-aminometil-7-(2,4-difluoro-fenil)-4-etil-heptanoico;

Ácido (2*R*,4*S*)-2-aminometil-4-(2,4-difluoro-bencil)-hexanoico;

Ácido (2*S*,4*S*)-2-aminometil-4-(2,4-difluoro-bencil)-hexanoico;

Ácido (2*S*,4*S*)-2-aminometil-4-(3,5-difluoro-bencil)-hexanoico;

Ácido (2*S*,4*S*)-2-aminometil-4-(2-fluoro-bencil)-hexanoico;

Ácido (2*S*,4*S*)-2-aminometil-5-(2,4-difluoro-fenil)-4-metil-pentanoico

Ácido (2*S*)-2-aminometil-5-(2,4-difluoro-fenil)-pentanoico

Ácido (2*S*,4*S*)-2-aminometil-4-(2,6-difluoro-bencil)-hexanoico

Ácido (2*S*,4*S*)-2-aminometil-4-(4-fluoro-bencil)-hexanoico

Ácido (2*S*,4*S*)-2-aminometil-4-(2,5-difluoro-bencil)-hexanoico

Ácido (2*S*,4*S*)-2-aminometil-4-(3-fluoro-bencil)-hexanoico

Ácido (2*S*,4*S*)-2-aminometil-4-pentafluorofenilmetil-hexanoico;

Ácido (2*S*,4*R*)-2-aminometil-7-(2,4-difluoro-fenil)-4-etil-heptanoico;

Ácido (2*S*,4*S*)-2-aminometil-4-(4-trifluorometil-bencil)-hexanoico;

Ácido 2-aminometil-4-(4-metoxi-2-metil-bencil)-hexanoico;

Ácido 2-aminometil-5-(4-metoxi-2-metil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-4-(4-metoxi-3-metil-bencil)-hexanoico; y

Ácido 2-aminometil-5-(4-metoxi-3-metil-fenil)-4-metil-pentanoico;

Ácido 2-aminometil-4-etil-5-metil-hexanoico;

Ácido 2-aminometil-4-etil-3-metil-hexanoico;

Ácido 2-aminometil-3,4-dimetil-hexanoico;

Ácido 2-aminometil-3-etil-4-metil-hexanoico;

Ácido 2-aminometil-4-etil-3-metil-heptanoico;

Ácido 2-aminometil-3,4-dimetil-octanoico;

Ácido 2-aminometil-3-metil-pentanoico;

Ácido 2-aminometil-3-metil-hexanoico;

Ácido 2-aminometil-3-metil-heptanoico;

Ácido 2-aminometil-3,4-dimetil-pentanoico;

Ácido 2-aminometil-3,5-dimetil-hexanoico;

Ácido 2-aminometil-3,6-dimetil-heptanoico;

Ácido 2-aminometil-3,5,5-trimetil-hexanoico;

Ácido 2-aminometil-3-ciclopropil-butírico;

Ácido 2-aminometil-3-ciclopentil-butírico;

Ácido 2-aminometil-3-ciclohexil-butírico;

Ácido 2-aminometil-4-ciclohexil-3-metil-butírico;

Ácido 2-aminometil-5-ciclohexil-3-metil-pentanoico;

Ácido 2-aminometil-3-metil-4-(4-metil-ciclohexil)-butírico;

Ácido 2-aminometil-3-etil-pentanoico;

Ácido 2-aminometil-3-etil-hexanoico;

Ácido 2-aminometil-3-etil-heptanoico;

Ácido 2-aminometil-3-etil-4-metil-pentanoico;

Ácido 2-aminometil-3-ciclohexilmetil-pentanoico;

Ácido 2-aminometil-5-(4-metoxi-ciclohexil)-3-metil-pentanoico;

Ácido 2-aminometil-5-(4-metoxi-fenil)-3-metil-pentanoico;

Ácido 2-aminometil-4-(2-metoxi-fenil)-3-metil-butírico;

Ácido 2-aminometil-4-(4-metoxi-fenil)-3-metil-butírico;

Ácido 2-aminometil-3-fenil-butírico;

Ácido 2-aminometil-3-metil-4-fenil-butírico;

Ácido 2-aminometil-3-metil-5-fenil-pentanoico;

Ácido 2-aminometil-3-metil-4-(3-trifluorometil-fenil)-butírico;

Ácido 2-aminometil-3-(4-etil-fenil)-butírico;

Ácido 2-aminometil-3-(2,5-dimetil-fenil)-butírico;

Ácido 2-aminometil-3-metil-4-p-tolil-butírico;

Ácido 2-aminometil-3-m-tolil-butírico;

Ácido 2-aminometil-3-bencil-pentanoico;

Ácido 2-aminometil-4-(4-fluoro-fenil)-3-metil-butírico;

Ácido 2-aminometil-5-ciclopropil-hexanoico;

Ácido 2-aminometil-5-ciclobutil-hexanoico;

Ácido 2-aminometil-5-ciclopentil-hexanoico;

Ácido 2-aminometil-5-ciclohexil-hexanoico;

Ácido 2-aminometil-5-fenil-hexanoico;

Ácido 2-aminometil-5-(3-cloro-fenil)-hexanoico;

Ácido 2-aminometil-5-(3-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-5-(4-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-5-ciclopropil-heptanoico;

Ácido 2-aminometil-5-ciclobutil-heptanoico;

Ácido 2-aminometil-5-ciclopentil-heptanoico;

Ácido 2-aminometil-5-ciclohexil-heptanoico;

Ácido 2-aminometil-5-fenil-heptanoico;

Ácido 2-aminometil-5-(3-cloro-fenil)-heptanoico;

Ácido 2-aminometil-5-(3-trifluorometil-fenil)-heptanoico;

Ácido 2-aminometil-5-(4-trifluorometil-fenil)-heptanoico;

Ácido 2-aminometil-5-metil-6-fenil-hexanoico;

Ácido 2-aminometil-6-(3-cloro-fenil)-5-metil-hexanoico;

Ácido 2-aminometil-5-metil-6-(3-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-5-metil-6-(4-trifluorometil-fenil)-hexanoico;

Ácido 2-aminometil-5-ciclopropilmetil-heptanoico;

Ácido 2-aminometil-5-ciclobutilmetil-heptanoico;

Ácido 2-aminometil-5-ciclopentilmetil-heptanoico;

Ácido 2-aminometil-5-ciclohexilmetil-heptanoico;

Ácido 2-aminometil-5-bencil-heptanoico;

Ácido 2-aminometil-5-(3-cloro-bencil)-heptanoico;

Ácido 2-aminometil-5-(3-trifluorometil-bencil)-heptanoico;

Ácido 2-aminometil-5-(4-trifluorometil-bencil)-heptanoico;

Ácido 2-aminometil-5-metil-7-fenil-heptanoico;

Ácido 2-aminometil-7-(3-cloro-fenil)-5-metil-heptanoico;

Ácido 2-aminometil-5-metil-7-(3-trifluorometil-fenil)-heptanoico;

Ácido 2-aminometil-5-metil-7-(4-trifluorometil-fenil)-heptanoico;

Ácido 2-aminometil-7-ciclopropil-5-etil-heptanoico;

Ácido 2-aminometil-7-ciclobutil-5-etil-heptanoico;

Ácido 2-aminometil-7-ciclopentil-5-etil-heptanoico;

Ácido 2-aminometil-7-ciclohexil-5-etil-heptanoico;

Ácido 2-aminometil-5-etil-7-fenil-heptanoico;

Ácido 2-aminometil-7-(3-cloro-fenil)-5-etil-heptanoico;

Ácido 2-aminometil-5-etil-7-(3-trifluorometil-fenil)-heptanoico;

Ácido 2-aminometil-5-etil-7-(4-trifluorometil-fenil)-heptanoico;

Ácido 2-aminometil-5,5-dimetil-heptanoico;

Ácido 2-aminometil-5,5-dimetil-octanoico; y

Ácido 2-aminometil-5,5-dimetil-nonanoico;

13. Un compuesto seleccionado entre los siguientes compuestos y sus sales farmacéuticamente aceptables:

Ácido (3*R*,4*R*)-3-amino-4,5-dimetil-hexanoico;
Ácido (3*S*,4*R*)-3-amino-4,5-dimetil-hexanoico;
Ácido (3*R*,4*R*,5*R*)-3-amino-4,5-dimetil-heptanoico;
Ácido (3*S*,4*R*,5*R*)-3-amino-4,5-dimetil-heptanoico;
Ácido (3*R*,4*S*,5*R*)-3-amino-4,5-dimetil-heptanoico;
Ácido (3*R*,4*R*,5*S*)-3-amino-4,5-dimetil-heptanoico;
Ácido (3*R*,4*R*,5*R*)-3-amino-4,5-dimetil-octanoico;
Ácido (3*S*,4*R*,5*R*)-3-amino-4,5-dimetil-octanoico;
Ácido (3*R*,4*S*,5*R*)-3-amino-4,5-dimetil-octanoico;
Ácido (3*R*,4*R*,5*S*)-3-amino-4,5-dimetil-octanoico;
Ácido (3*R*,4*R*,5*R*)-3-amino-4,5-dimetil-nonanoico;
Ácido (3*S*,4*R*,5*R*)-3-amino-4,5-dimetil-nonanoico;
Ácido (3*R*,4*S*,5*R*)-3-amino-4,5-dimetil-nonanoico;
Ácido (3*R*,4*R*,5*S*)-3-amino-4,5-dimetil-nonanoico;
Ácido (3*R*,4*R*,5*R*)-3-amino-4,5-dimetil-decanoico;
Ácido (3*S*,4*R*,5*R*)-3-amino-4,5-dimetil-decanoico;
Ácido (3*R*,4*S*,5*R*)-3-amino-4,5-dimetil-decanoico;
Ácido (3*R*,4*R*,5*S*)-3-amino-4,5-dimetil-decanoico;
y los enantiómeros opuestos de los mismos.

14. Un compuesto seleccionado entre los siguientes compuestos y sus sales

374

farmacéuticamente aceptables:

Ácido (3*R*,4*R*)-3-amino-4,5-dimetil-hexanoico;

Ácido (3*R*,4*R*,5*R*)-3-amino-4,5-dimetil-heptanoico;

Ácido (3*R*,4*R*,5*R*)-3-amino-4,5-dimetil-octanoico;

Ácido (3*R*,4*R*,5*R*)-3-amino-4,5-dimetil-nonanoico; y

Ácido (3*R*,4*R*,5*R*)-3-amino-4,5-dimetil-decanoico;

15. Un compuesto seleccionado entre los siguientes compuestos y sus sales farmacéuticamente aceptables:

Ácido (2*R*,4*R*)-2-aminometil-4-(2,4-difluoro-bencil)-hexanoico;

Ácido (2*S*,4*R*)-2-aminometil-4-(2,4-difluoro-bencil)-hexanoico;

Ácido (2*R*,4*S*)-2-aminometil-7-(2,4-difluoro-fenil)-4-etil-heptanoico;

Ácido (2*S*,4*S*)-2-aminometil-7-(2,4-difluoro-fenil)-4-etil-heptanoico;

Ácido (2*R*,4*S*)-2-aminometil-4-(2,4-difluoro-bencil)-hexanoico;

Ácido (2*S*,4*S*)-2-aminometil-4-(2,4-difluoro-bencil)-hexanoico;

Ácido (2*S*,4*S*)-2-aminometil-4-(3,5-difluoro-bencil)-hexanoico;

Ácido (2*S*,4*S*)-2-aminometil-4-(2-fluoro-bencil)-hexanoico;

Ácido (2*S*,4*S*)-2-aminometil-5-(2,4-difluoro-fenil)-4-metil-pentanoico

Ácido (2*S*)-2-aminometil-5-(2,4-difluoro-fenil)-pentanoico

Ácido (2*S*,4*S*)-2-aminometil-4-(2,6-difluoro-bencil)-hexanoico

Ácido (2*S*,4*S*)-2-aminometil-4-(4-fluoro-bencil)-hexanoico

Ácido (2*S*,4*S*)-2-aminometil-4-(2,5-difluoro-bencil)-hexanoico

Ácido (2*S*,4*S*)-2-aminometil-4-(3-fluoro-bencil)-hexanoico

Ácido (2*S*,4*S*)-2-aminometil-4-pentafluorofenilmetil-hexanoico

Ácido (2*S*,4*R*)-2-aminometil-7-(2,4-difluoro-fenil)-4-etil-heptanoico;

Ácido (2*S*,4*S*)-2-aminometil-4-(4-trifluorometil-bencil)-hexanoico;

RESUMEN

Se describen ciertos β-aminoácidos que se unen a la subunidad alfa-2-delta (α2δ) de un canal de calcio. Estos compuestos y sus sales farmacéuticamente aceptables son útiles en el tratamiento de diversos trastornos psiquiátricos, del dolor y otros.

TRATADO DE C OPERACIÓN DE PATENTES
PCT
NOTIFICACIÓN DE TRANSMISIÓN DEL REPORTE DE EXAMEN PRELIMINAR INTERNACIONAL
(PCT Regla 71.1)
De: AUTORIDAD DE REVISION PRELIMINAR INTERNACIONAL

Para:
FULLER, Grover, F. Jr.
Pfizer Inc.
201 Tabor Road
Morris Plains, NJ 07950
Estados Unidos de América.

Sello de Recibido 6 de febrero 2006, MOPS IP GLBL SRVS.

Fecha de expedición: 31.01.2006
Referencia del expediente del solicitante o mandatario: PC26111A
Solicitud Internacional No.: PCT/IB2004/002985
Fecha de presentación internacional: 13.09.2004
Fecha de prioridad: 25.09.2003
Solicitante: WARNER-LAMBERT COMPANY LLC et. al.

1. Se notifica al solicitante que la Administración Encargada del Examen Preliminar Internacional ha emitido el informe de examen preliminar internacional para la solicitud internacional y se lo transmite adjunto, acompañado, si procede, de sus anexos.

2. Se transmite una copia del presente informe y, si procede, de sus anexos, a la Oficina Internacional para comunicación a todas las Oficinas elegidas.

3. Si alguna Oficina elegida lo exige, la Oficina Internacional realizará una traducción en inglés del informe (con exclusión de sus anexos) y la transmitirá a las Oficinas interesadas.

4. **RECORDATORIO**

Para iniciar la fase nacional ante cada Oficina elegida, el solicitante debe cumplir ciertos actos (presentación de la traducción y pago de las tasas nacionales) en el plazo de 30 meses desde la fecha de prioridad (o más tarde por lo que respecta a ciertas oficinas) (Artículo 39 (1)) (véase también el recordatorio enviado por la Oficina Internacional en el formulario PCT/IB/301).

Cuando deba entregarse una traducción de la solicitud internacional o una oficina elegida, se incluirá la traducción de cualquier anexo de informe de Examen Preliminar Internacional. Corresponde al

solicitante preparar la traducción en cuestión y entregarla directamente a cada Oficina elegida interesada

Para más amplios detalles en lo relativo a los plazos aplicables y las exigencias de las oficinas elegidas, véase el Volumen II de la guía del solicitante PCT.

Se llama la atención del solicitante sobre el Artículo 33(5) que prevé que los criterios de novedad, actividad inventiva y de aplicación industrial definidos en el Artículo 33(2) a (4) sólo servirán a los efectos del examen preliminar internacional, y que "todo Estado contratante puede aplicar criterios adicionales o diferentes al objeto de decidir, en ese Estado, si la invención es patentable o no" (véase también el Artículo 27(5)). Tales criterios adicionales pueden afectar, por ejemplo, a las excepciones de patentabilidad, requisitos específicos relativos a la divulgación, la claridad de las reivindicaciones.

Nombre y dirección postal de la Administración encargada del Examen Preliminar Internacional:
Oficina de Patentes Europea
D-80298 – Munich
Tel: +49-89 2399 - 0, Tx: 523656 epmu d
Fax· +49-89 2399 – 4465.

Funcionario Autorizado: Parriche, S
Tel: + 49 89 2399-7890

TRATADO DE COOPERACIÓN DE PATENTES
PCT
INFORME PRELIMINAR INTERNACIONAL SOBRE PATENTABILIDAD
(Capítulo II del Tratado de Cooperación en materia de Patentes)
(PCT Artículo 36 y Regla 70)

Referencia del expediente del solicitante o mandatario: PC26111A
Solicitud Internacional No.: PCT/IB2004/002985
Fecha de presentación internacional: 13.09.2004
Fecha de prioridad: 25.09.2003
Clasificación Internacional de Patentes (IPC) o la vez clasificación nacional e IPC: C07C 29/00.
Solicitante: WARNER LAMBERT COMPANY LLC et. al.

1. El reporte de examen preliminar internacional ha sido preparado por esta Autoridad de Revisión Preliminar Internacional bajo el Artículo 35 y es transmitido al solicitante según el Artículo 36

2. Este REPORTE consta de un total de 10 hojas, incluida la presente hoja de portada.

3 Este informe también contiene ANEXOS, que comprenden.

a ☒ (*remitido al solicitante y a la oficina internacional*) un total de 15 hojas, descritas a continuación:

☒ hojas de la descripción, las reivindicaciones y/o los dibujos que han sido modificadas y que sirven de base al presente informe, y/o de hojas que contienen rectificaciones autorizadas por esta Administración (véase la Regla 70.16 y la Instrucción Administrativa 607 del PCT).

☐ hojas que reemplazan a otras hojas anteriores, pero que esta Administración considera que contienen modificaciones que se extienden más allá de la divulgación de la invención tal como fue originalmente presentada, según se indica en el punto 4 del Reglamento I y en el Recuadro Suplementario.

b. ☐ (remitido únicamente a la Oficina Internacional) un total de (indicar tipo y soporte(s) electrónico(s)) , que contienen una lista de secuencias y/o tabla(s) relativa(s), solo en formato legible por ordenador, como se indica en el Recuadro Suplementario relativo a Listas de Secuencias (ver Instrucción Administrativa 802).

4. El presente informe contiene indicaciones relativas a los siguientes puntos:

☒	Recuadro I	Base de este informe
☐	Recuadro II	Prioridad
☒	Recuadro III	Ninguna formulación de opinión sobre la novedad, la actividad inventiva y la aplicación industrial
☒	Recuadro IV	Falta de unidad de Invención
☒	Recuadro V	Declaración motivada según el Artículo 35(2) sobre la novedad, la actividad inventiva y la aplicación industrial, citas y explicaciones en apoyo de esta declaración
☐	Recuadro VI	Ciertos documentos citados
☐	Recuadro VII	Defectos en la Solicitud Internacional
☐	Recuadro VIII	Observaciones relativas a la solicitud internacional

Fecha de radicación de la demanda: 19.10.2004
Fecha de elaboración de este reporte: 31.01.2006

Nombre y dirección postal de la Administración encargada del Examen Preliminar Internacional:
Oficina de Patentes Europea
D-80298 – Munich
Tel: +49-89 2399 - 0, Tx: 523656 epmu d
Fax: +49-89 2399 – 4465.

Funcionario Autorizado: Seufert, G
Tel: + 49 89 2399-8330

Recuadro I. Base de este informe

1. Por lo que respecta al **idioma**, este informe se ha establecido sobre la base de la solicitud internacional en el idioma en el cual se depositó, salvo indicación en contra señalada a continuación.

☐ Este informe está basado en una traducción del idioma original al siguiente idioma , que es el de una traducción proporcionada a los fines de:
- ☐ búsqueda internacional (según Reglas 12.3 y 23.1 (b))
- ☐ publicación de la solicitud internacional (según Regla 12.4)
- ☐ examen preliminar internacional (según Reglas 55.2 y/o 55 3)

2. Por lo que respecta a los **elementos*** de la solicitud internacional, esta opinión se ha establecido sobre la base de (*las hojas de reemplazo que hayan sido enviadas a la Oficina receptora en respuesta a un requerimiento según el Artículo 14 se las denomina en este informe como "inicialmente presentadas" y no se anexan al informe):*

Descripción, Páginas

1 – 58, 60, 62, 65 -109	tal como se presentaron inicialmente
59, 61, 63, 64, 110	recibido el 20.09.2005 con carta de fecha 20.09 2005

Reivindicaciones, Números

1 – 13	recibido el 04.11.2005 con carta de fecha 04.11.2005

☐ una lista de secuencias y/o tabla(s) relativa(s) – ver Recuadro Suplementario relativo a Listas de Secuencias

3. ☐ Las modificaciones ha ocasionado la cancelación de:

- ☐ la descripción, páginas
- ☐ las reivindicaciones, Nos.
- ☐ los dibujos, hojas/fig.
- ☐ la lista de secuencias (especificar):
- ☐ tabla(s) relativa(s) a la lista de secuencias (especificar):

4. ☐ El presente informe ha sido establecido como si no se hubiesen presentado (algunas de) las modificaciones anexadas a este informe y listadas abajo, ya que se ha considerado que iban más allá de la divulgación de la invención tal como fue

presentada, como se indica en el Recuadro Suplementario (Regla 70.2(c)).

☐ la descripción, páginas
☐ las reivindicaciones, Nos.
☐ los dibujos, hojas/fig.
☐ la lista de secuencias (especificar):
☐ tabla(s) relativa(s) a la lista de secuencias (especificar):

* Si se utiliza el punto 4, algunas o todas estas páginas pueden llevar el sello de "sustituida".

Recuadro No. III. Ninguna formulación de opinión sobre la novedad, la actividad inventiva y la aplicación industrial

1. Las preguntas con respecto a si el invento reivindicado parece ser novedoso, implica una actividad inventiva (no ser evidente), o ser susceptible de aplicación industrial, por lo que respecta.

☐ al conjunto de la solicitud internacional,
☒ a las reivindicaciones Nos. 4-8, (parte), 10-13 (parte) por aplicación industrial

debido a que:

☒ la solicitud internacional, o las reivindicaciones Nos. 10-13 (parte) en cuestión se refieren al objeto, respecto del cual no requiere examen preliminar internacional (especifique).

ver hoja separada

☐ a descripción, reivindicaciones, o los dibujos (indíquese cuales a continuación) o tales reivindicaciones Nos. en cuestión no son claras, de manera que no es posible formular una opinión significativa (especifique):

☐ las reivindicaciones, o las reivindicaciones Nos. en cuestión no son claras, de manera que no es posible formular una opinión significativa.

☐ no se ha emitido informe de búsqueda internacional para dichas reivindicaciones Nos.

☐ la lista de de secuencias nucleótidas y/o de aminoácidos no cumplen la norma estándar prevista en el Anexo C de las Instrucciones Administrativas por que:

La lista en papel ☐ no se presentó

☐ no cumple con la norma estándar

La lista en formato legible por ordenador

☐ no se presentó

☐ no cumple con la norma estándar

☐ las tablas relativas a las listas de secuencias de nucleótidas y/o de aminoácidos, si únicamente se han presentado en formato legible por ordenador, no cumplen con los requisitos técnicos previstos en el Anexo C-*bis* de las Instrucciones Administrativas.

☐ Ver recuadro suplementario para más detalles.

Recuadro No. IV Falta de unidad de Invención

1. ☒ En respuesta al requerimiento para limitar las reivindicaciones o pagar tasas adicionales, el solicitante:

   ☐ ha limitado las reivindicaciones
   ☐ ha pagado tasas adicionales
   ☐ ha pagado tasas adicionales bajo protesta
   ☒ no ha limitado las reivindicaciones ni pagado las tasas adicionales.

2. ☐ Esta Administración considera que no se cumple la exigencia de unidad de la invención por los motivos indicados a continuación, y con forme a la regla 68.1, decide no requerir al solicitante para limitar las reivindicaciones o pagar tasas adicionales.

3. Esta Administración considera que el requerimiento de unidad de invención según las reglas 13.1, 13.2 y 13.3·

   ☐ se cumple
   ☒ no se cumple por las siguientes razones:

Ver hoja adjunta

4. En consecuencia, el presente informe se ha establecido con relación a las partes siguientes de la solicitud internacional:

   ☐ todas las partes de la solicitud

☒ las partes relativas a la reivindicaciones Nos. 1-3, 9-13 (parte).

Recuadro No. V Declaración razonada según el Artículo 35 (2) con respecto a la novedad, nivel inventivo o aplicación industrial: anterioridades y explicaciones que soportan tal declaración

1. Declaración

Novedad (N)	Si:	Reivindicaciones 1, 2, 9-13 (parte)
	No:	Reivindicaciones 3
Nivel Inventivo (NI)	Si:	Reivindicaciones
	No:	Reivindicaciones 1-3, 9-13 (parte)
Aplicación Industrial (AI)	Si:	Reivindicaciones 1-3, 9 (parte)
	No:	Reivindicaciones

2. Citas y explicaciones (Regla 70.7)

ver hoja separada.

REPORTE DE EXÁMEN PRELIMINAR INTERNACIONAL
– HOJA SEPARADA
Solicitud Internacional No. PCT/IB2004/002985

Se hace referencia a los siguientes documentos:

D1: WO 98/40055 A

D2: BIOORG. MED. CHEM. Vol. 11. no. 1, 2 enero de 2003, páginas 113-122.

D3: DATABASE BEILSTEIN, BEILSTEIN INSTITUT ZUR FÖRDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE: Base de Datos de acceso No. BRN 7914440.

D13: WO 00/76958 A

D14: WO 98/17627 A

D15. WO 03/082807 A

III. No se establece ninguna opinión con respecto a novedad, nivel inventivo y aplicación industrial

Las Reivindicaciones 10-13 se refieren a la materia considerada por esta Autoridad que está cubierta por provisiones de la Regla 67.7 (iv) del PCT. En consecuencia, no se formulará ninguna opinión con respecto a la aplicación industrial de la materia de estas reivindicaciones (Artículo 34(4)(a)(I) del PCT).

La presente solicitud Internacional se considera que no satisface los requerimientos de la unidad de invención, ver tema IV de abajo. A continuación una invitación al solicitante para que restrinja o cancele los honorarios adicionales que no ha cancelado. Él igualmente presentó reivindicaciones modificadas, que no son restringidas. Dando respuesta a la invitación mencionada, junto con las reivindicaciones modificadas, el solicitante solicitó que el IPEA restrinja la presente solicitud, a los compuestos de la formula (III), sus compuestos estereos (formula (V)) y los compuestos de la reivindicación 3 así como las reivindicaciones correspondientes a composiciones farmacéuticas y métodos de tratamiento que comprende estos compuestos, el cual también corresponde a la primera materia mencionada en la invitación a cancelar honorarios adicionales. El IPEA no está en una posición de restringir una solicitud, pero si examinará la primer materia mencionada si la solicitud no ha restringido las reivindicaciones o cancelado los honorarios adicionales.

En consecuencia, este reporte esta limitado a los compuestos de formula (III), (VI) y a compuestos de la reivindicación 3, composiciones farmacéuticas que comprenden los mismos y sus usos, por ejemplo la materia de las reivindicaciones 1-3 y 9-13 (parte).

IV. CARENCIA DE UNIDAD DE INVENCIÓN

El conjunto de las reivindicaciones modificadas presentadas por el solicitante el 04-11-05 carecen de unidad de invención. Las reivindicaciones independientes 1, 4 y 7 no son consideradas para ser unidas por un simple concepto inventivo. Las razones son esencialmente las mismas que las mencionadas en conjunto de la Opinión Escrita de la Autoridad Internacional de Búsqueda y son mencionadas a continuación:

La Autoridad de Examen Preliminar Internacional considera que hay tres invenciones cubiertas bajo las reivindicaciones como se indica a continuación:

A: Las reivindicaciones 1-3, 9-13 (parcialmente) dirigidas a compuestos de formula (III), (IV) y explícitamente nombrados compuestos, composiciones farmacéuticas que comprenden los mismos y sus usos en el tratamiento de enfermedades/trastornos mencionados en las reivindicaciones 10-13.

B: Las reivindicaciones 4-6, 9-13 (parcialmente) dirigidas a compuestos de formula (V), composiciones farmacéuticas que comprenden los mismos y sus usos en el tratamiento de enfermedades/trastornos mencionadas en las reivindicaciones 10-13.

C: Las reivindicaciones 7-8, 9-13 (parcialmente) dirigidas a compuestos de formula (VI), composiciones farmacéuticas que comprenden los mismos y sus usos en el tratamiento de enfermedades/trastornos mencionadas en las reivindicaciones 10-13.

Las razones por las cuales las invenciones no son unidas a una simple forma de concepto inventivo, como es requerido por la regla 13.1 del PCT, como se detalla a continuación:

El problema fundamental de la presente invención es la provisión de los compuestos, los cuales son apropiados para el tratamiento de una variedad de desórdenes, tales como desordenes de epilepsia siquiátrica, dolor etc.

La solución propuesta a este problema es la provisión de derivados de beta-alanina de acuerdo con la formula (III), (IV), (V) y (VI), las cuales tienen la siguiente unidad estructural en común: NH2-CH-CH-COOH. Los compuestos con esta unidad estructural han sido divulgados en el

documento WO-A-9840055 por el mismo uso (por ejemplo epilepsia), ver ejemplo en la tabla 3, o reivindicaciones 16-21. La característica común así no es novedosa.

El problema fundamental de la invención puede ser por consiguiente definida como una provisión mas allá de los derivados de beta-alanina apropiados para el tratamiento de desordenes siquiátricas de epilepsia, dolor etc.

Las invenciones A - C mencionadas arriba son consideradas por ser soluciones diferentes para este problema. Por ejemplo, más allá del desarrollo de diferentes direcciones, las cuales no comparten una característica común novedosa.

Teniendo en cuenta que los compuestos que contienen la misma característica común para el mismo uso son conocidos y que no tiene otra característica técnica que pueda ser considerada como una característica técnica especial en el sentido de la regla 13.2 del PCT, el IPEA da su opinión que no hay un simple concepto inventivo fundamentando en los tres inventos reivindicados en la presente solicitud. Por consiguiente la solicitud carece de unidad (Regla 13.1, del PCT).

Es de reconocer que existe cierta relación entre los compuestos (VI) y (V). El área de relación es considerada como perteneciente a la segunda invención.

V. Declaración razonada bajo el Artículo 35 (2) con respecto a novedad, nivel inventivo o aplicación industrial.

Novedad

La reivindicación 1 de la presente solicitud se refiere a compuestos de fórmula (III) y la reivindicación 3 se refiere explícitamente a un número de compuestos mencionados. Estos compuestos son útiles en el tratamiento de varias enfermedades como dolor, epilepsia, trastornos psiquiátricos, etc.

El documento D3 divulga el compuesto ácido 3-animo-4-metil-heptanoico, el cual cabe dentro del concepto de la reivindicación 3, ver la presente solicitud, la reivindicación 3, página 114, líneas 11-12. La reivindicación 3 no es considerada por consiguiente que reúne el requisito del Artículo 33(2) del PCT.

Ninguno de los documento del arte anterior disponibles, se refieren a compuestos que caben dentro del ámbito de la reivindicación 1. La reivindicación 1 así como la dependiente reivindicación 2 (fórmula (IV)) y las reivindicaciones 9-13 se refieren a composiciones farmacéuticas y

métodos de tratamiento que comprende compuestos de la reivindicación 1 y 3 por consiguiente son considerados que reúnen el requisito del Artículo 33(2) del PCT.

Nivel Inventivo

La presente solicitud no reúne el requisito del Art. 33(3) del PCT por las siguientes razones:

Para ser considerado como invento, el problema técnico, el cual es la provisión de compuestos extensos para el tratamiento del dolor, epilepsia, trastornos psiquiátricos etc. tiene que ser resuelto como mínimo por todas las reivindicaciones.

La presente reivindicación 1 tiene compuestos limitados de la fórmula (III), sus compuestos estereos de la fórmula (IV) y compuestos específicos de acuerdo a la reivindicación 3 los cuales son sustituidos en la posición 4. Sin embargo, la solicitud no contiene ningún Dato Biológico, el cual se demuestra que el problema ha sido resuelto por esta clase de compuestos y tiene que ser resuelto como mínimo por todas las reivindicaciones. Solo para tres clases de compuestos para la afinidad a la proteína α2δ están presentes en la solicitud (ver página 87, líneas 2-7) y ninguna de ellas corresponden a un acido 3-aminocarboxilico con un sustituyente en posición 4, permite exclusivamente en posición 4 y 5.

La atención es así mismo marcada a la realidad con respecto a la técnica de D1 o D2 (ya los cambios pequeños llevan los compuestos inactivos, ver D1, tabla 3 en la página 62, últimos 4 compuestos, D2, tabla 2, compuestos 5 y 6) que aparenta ser muy dudoso que todos los compuestos reivindicados ahora resuelven el problema fundamental.

Sin suficientes datos de demostración, que el problema es resuelto por la clase de compuestos de acuerdo a las reivindicaciones 1-3 y tiene que ser resuelto como mínimo por todas las reivindicaciones, un nivel inventivo no puede ser reconocido.

Aplicación Industrial

Para la evaluación de las reivindicaciones 10-13 de la presente, sobre si son industrialmente aplicables, no existen criterios unificados en los Estados pertenecientes al PCT. La patentabilidad también puede depender de la formulación de las reivindicaciones. La EPO, por ejemplo, no reconoce como industrialmente aplicable aquella materia que reivindique el uso de un compuesto en tratamiento médico, pero permite, sin embargo, reivindicar sobre un compuesto conocido para primero uso en tratamiento médico y el uso de tal compuesto en la manufactura de un medicamento para un nuevo tratamiento médico.

No hay objeciones en contra de las reivindicaciones 1-3 y 9 en cuanto a la aplicación industrial le concierne.

Observaciones Adicionales:

A pesar que el documento D15 no se considera que forma parte del arte previo en lo estipulado en la Regla 64.1 para el propósito del Art. 33(2) y (3) del PCT, este documento se adelanta a la materia de las reivindicaciones 1 y 2, ver D15 página 10, línea 4 página 11, línea 13, página 13, línea 1.

Las reivindicaciones no son sustentadas por la descripción como lo es requerido por el Artículo 6 del PCT, por cuanto su alcance es más extenso a lo que justifica la descripción y los dibujos. Por consiguiente las razones son las siguientes: Las reivindicaciones aún comprenden una gran cantidad de compuestos, mientras sólo una parte pequeña es sustentada por los compuestos preparados explícitamente (ver los ejemplos). Los compuestos meramente mencionando por su nombre, que teóricamente se encuentran dentro del alcance de una fórmula, no se considera como un argumento suficiente. Además, ningún dato biológico es utilizable para sustentar la actividad reivindicada.

La reivindicación 3 se refiere independientemente a compuestos específicos, los cuales en cierta forma describen compuestos de acuerdo con la fórmula (III) y/o (IV). Estos compuestos deberían haber formado parte de las reivindicaciones dependientes (Regla 6.4 del PCT).

La reivindicación 3 aparentemente menciona algunos compuestos dos veces, ver página 113, líneas 5 y 6 o página 114 líneas 11 y 12.

Contrario a los requisitos de la Regla 5.1 (a) (ii) PCT, el arte de fondo pertinente divulgado en los documentos D1, D2, D13 y D14 no son mencionados en la descripción, pero estos documentos son identificados en esta.

isómeros ópticos, de los compuestos de fórmula I, II, III, IV, V ó VI. Las muestras de los compuestos pueden existir en forma de mezclas racémicas, como enantiomeros y diastereoisómeros individuales y como mezclas de los mismos La invención también incluye todas las composiciones farmacéuticas y procedimientos de tratamiento definidos anteriormente que contienen o emplean estereoisómeros de los compuestos de fórmula I, II, III, IV, V ó VI
Los compuestos con un centro estereogénico pueden existir en forma de una mezcla racemica (equimolar), como mezcla no equimolar de isómeros y como enantiomeros puros con una estereoconfiguración S- o R-. Los compuestos con dos centros estereogénicos pueden existir en forma de mezcla racemica, como mezcla no equimolar de isómeros y como enantiomeros puros que tienen estereoconfiguración SS, RR, SR o RS Los compuestos con tres centros estereogénicos pueden existir en forma de una mezcla racemica, como una mezcla no quimolar de isómeros y como enantiómeros puros que tienen estereoconfiguración RRR, SSS, SRR, RSS, RSR, SRS, RRS ó SSR Pueden obtenerse isómeros individuales por procedimientos conocidos tales como resolución óptica, reacción ópticamente selectiva o separación cromatográfica en la preparación del producto final o sus intermedios Los enantiomeros individuales de los compuestos de esta invención pueden tener ventajas, en comparación con mezclas racémicas de estos compuestos, en el tratamiento de diversos trastornos o afecciones.

La presente invención también incluye compuestos marcados isotópicamente, que son idénticos a los descritos en la fórmula I, II, III, IV, V ó VI excepto por el hecho de que uno o más átomos están sustituidos con un átomo que tiene una masa atómica o número másico distinto de la masa atómica o número másico que se encuentra normalmente en la naturaleza Los ejemplos de isótopos que pueden incorporarse en compuestos de la presente invención incluyen isótopos de hidrógeno, carbono, nitrógeno, oxígeno, flúor y cloro, tales como, ^{2}H, ^{3}H, ^{13}C, ^{11}C, ^{14}C, ^{15}N, ^{18}O, ^{17}O, ^{18}F y ^{36}Cl, respectivamente Los compuestos de la presente invención, profármacos de los mismos y sales farmaceuticamente aceptables de dichos compuestos o de dichos profármacos que contienen los isótopos mencionados anteriormente y/u otros isótopos de otros átomos están dentro del alcance de esta invención Ciertos compuestos marcados isotópicamente de la presente

3-metilbut-1-ilo, 3-metilbut-2-ilo, 2-metilbut-2-ilo, 2,2,2-trimetilet-1-ilo, *n*-hexilo, 3-etilbutilo y similares

El término "cicloalquilo" se refiere a anillos de hidrocarburos saturados monocíclicos y bicíclicos, que tienen generalmente un número de átomos de carbono especificado que comprenden el anillo, es decir, cicloalquilo (C_3-C_6) se refiere a un grupo cicloalquilo que tiene 3, 4, 5 ó 6 átomos de carbono como miembros del anillo. El cicloalquilo puede estar unido a un grupo parental o a un sustrato en cualquier átomo del anillo, a menos que tal unión viole los requerimientos de valencia

Los ejemplos de grupos cicloalquilo monocíclicos incluyen, pero sin limitación, ciclopropilo, ciclobutilo, ciclopentilo, ciclohexilo y similares Los ejemplos de grupos cicloalquilo bicíclicos incluyen, pero sin limitación, biciclo[1 1 0]butilo, biciclo[1.1 1]pentilo, biciclo[2 1 0]pentilo, biciclo[2 1.1]hexilo, biciclo[3 1 0]hexilo, biciclo[2 2 1]heptilo, biciclo[3 2 0]heptilo, biciclo[3 1 1]heptilo, biciclo[4.1.0]heptilo, biciclo[2 2 2]octilo, biciclo[3 2 1]octilo, biciclo[4 1 1]octilo, biciclo[3.3 0]octilo, biciclo[4 2 0]octilo, biciclo[3.3 1]nonilo, biciclo[4 2 1]nonilo, biciclo[4 3 0]nonilo, biciclo[3.3.2]decilo, biciclo[4 2 2]decilo, biciclo[4 3 1]decilo, bicilo[4 4 0]decilo, biciclo[3.3 3]undecilo, biciclo[4 3 2]undecilo, biciclo[4 3 3]dodecilo y similares

El término "alcoxi" se refiere a alquil-O-, donde alquil es como se ha definido anteriormente. Los ejemplos de grupos alcoxi incluyen, sin limitación, metoxi, etoxi, n-propoxi, i-propoxi, n-butoxi, s-butoxi, t-butoxi, n-pentoxi, s-pentoxi y similares

El término "tratar", se refiere a invertir, aliviar, inhibir el desarrollo de o prevenir el trastorno o afección al que se aplica tal término o prevenir uno o más síntomas de tal trastorno o afección. El término "tratamiento", como se usa en este documento, se refiere al acto de tratar, tal y como se acaba de definir "tratar".

La frase "enantiomero opuesto" se refiere a una molécula que es una imagen especular que no se puede superponer de una molécula de referencia, que puede obtenerse invirtiendo todos los centros estereogénicos de la molécula de referencia Por ejemplo, si la molécula de referencia tiene una configuración estereoquímica absoluta S, entonces el enantiomero opuesto tiene una configuración estereoquímica absoluta R Asimismo, si la molécula de referencia tiene una configuración estereoquímica absoluta S, S, entonces el enantiomero opuesto tiene una configuración estereoquímica absoluta R, R, etc

La frase "sales, farmaceuticamente aceptables" se refiere a sales de adición de ácidos o bases, formas bipolares, cuando sea posible, que están dentro del alcance del juicio médico, adecuados para uso en contacto con los tejidos de pacientes sin toxicidad, irritación, respuesta alérgica y similares, indebidas en proporción a una relación beneficio/riesgo razonable y eficaces para su uso pretendido

Como los aminoácidos son anfóteros, las sales farmacológicamente compatibles pueden ser sales de ácidos orgánicos o inorgánicos apropiados, por ejemplo, clorhídrico, sulfúrico, fosfórico, acético, oxálico, láctico, cítrico, málico, salicílico, malónico, maleico, succínico y ascórbico Partiendo de los correspondientes hidróxidos o carbonatos, se forman sales con metales alcalinos o alcalinotérreos, por ejemplo, sodio, potasio, magnesio o calcio También se pueden preparar sales con iones amónicos cuaternarios, por ejemplo, con el ión tetrametil-amonio.

La eficacia de un fármaco administrado por vía oral depende del transporte eficaz del fármaco a través del epitelio de la mucosa y de su estabilidad en la circulación entero-hepática Pueden modificarse químicamente para dar una forma de profármaco, fármacos que son eficaces después de la administración parenteral pero menos eficaces por vía oral, o cuya semivida en plasma se considera demasiado corta

Un profármaco es un fármaco que se ha modificado químicamente y puede ser biológicamente inactivo en su sitio de acción pero que puede degradarse o modificarse mediante uno o más procesos enzimáticos u otros procedimientos in vivo en la forma parental bioactiva

HOJA SUSTITUIDA

Este fármaco químicamente modificado, o profármaco, debe tener un perfil farmacocinético distinto del fármaco parental, permitiendo una absorción más fácil a través del epitelio de la mucosa, una mejor formulación de la sal, una mejor solubilidad, una mejor estabilidad sistémica (para aumentar la semivida en plasma, por ejemplo), y similar Estas modificaciones químicas incluyen, pero sin limitación, (1) derivados éster o amida que pueden escindirse, por ejemplo, con estearasas o lipasas, (2) péptidos, que pueden reconocerse mediante proteinasas específicas o no específicas, (3) derivados que se acumulan en el sitio de acción mediante la selección de membrana de una forma profármaco o forma profármaco modificada, y (4) cualquier combinación de (1) a (3) Los profármacos éster o amida pueden derivarse del resto de ácido carboxílico de la molécula del fármaco parental o del resto ácido carboxílico o el resto amina de la molécula del fármaco parental, respectivamente, por medios conocidos Además, el profármaco peptídico puede unirse a la molécula del fármaco parental mediante la formación de un enlace amida con el resto amina o ácido carboxilico de la molécula del fármaco parental usando técnicas conocidas.

La investigación actual en experimentos animales ha demostrado que la absorción oral de ciertos fármacos puede aumentarse mediante la preparación de sales cuaternarias "blandas" Una sal cuaternaria se denomina sal cuaternaria "blanda" ya que, a diferencia de las sales cuaternarias normales, por ejemplo, $R\text{-}N^{+}(CH_3)_3$, puede liberar el fármaco activo tras la hidrólisis

Las sales cuaternarias blandas tienen propiedades físicas útiles en comparación con el fármaco básico o sus sales La solubilidad en agua puede aumentarse en comparación con otras sales, tales como la sal clorhidrato, pero puede ser más importante una mayor absorción del fármaco en el intestino Una mayor absorción se debe probablemente al hecho de que la sal cuaternaria blanda tiene propiedades tensioactivas y puede formar micelas y pares iónicos no ionizados con ácidos biliares, etc , que pueden penetrar el epitelio intestinal de forma más eficaz El profármaco, después de la absorción, se hidroliza rápidamente con la liberación del fármaco parental activo

Para un análisis de profármacos y sales cuaternarias blandas, véase E Palomino, Drugs of the Future 15(4)·361-68 (1990) Véase también,

con una solución acuosa saturada de cloruro amónico La mezcla de reacción bruta se extrajo con éter dietílico El éter se retiró a presión reducida y el residuo en bruto se purificó por cromatografía en columna (eluyente 9.1 hexanos/EtOAc) lo que dio 1,67 g (46%) de éster metílico de ácido 2-terc-butil-5-[2-(2,4-difluoro- bencil)-butil]-3-metil-4-oxo-tetrahidro-pirimidin-1-carboxílico en forma de un sólido blanco

Ácido (2R,4R)-2-aminometil-4-(2,4-difluoro-bencil)-hexanoico

Se cargó un matraz con 0,5 g (1,2 mmol) de éster metílico de ácido 2-terc-butil-5-[2-(2,4-difluoro-bencil)-butil]-3-metil-4-oxo-tetrahidro-pirimidin-1 - carboxílico, 20 ml de dioxano y 20 ml de solución de HCl conc. La mezcla se agitó y calentó a 110°C durante 4 días Los disolventes se retiraron a presión reducida El residuo se recogió en 20 ml de agua y 4 gotas de solución de HCl concentrado La fase acuosa se lavó con diclorometano La fase acuosa se recogió y el agua se retiró a presión reducida. El residuo se trató con 2 ml de trietilamina y el exceso de trietilamina se retiró a presión reducida El sólido restante se purificó por cromatografía en columna (eluyente 1 8 27 NH_4OH, MeOH, diclorometano). El sólido blanco resultante se lavó con acetonitrilo y se secó al vacío. Esto dio 80 mg (24%) de ácido (2R, 4R)-2-aminometil-4-(2,4-difluoro-bencil)-hexanoico en forma de un sólido blanco


Debe apreciarse que, como se usa en esta memoria descriptiva y en las reivindicaciones adjuntas, los artículos singulares tales como "un", "uno", "una", "el" y 'la" pueden referirse a un único objeto o a una diversidad de objetos a menos que el contexto indique claramente lo contrario De esta forma, por ejemplo, la referencia a una composición que contiene "un compuesto" puede incluir un único compuesto o dos o más compuestos

Debe apreciarse que la descripción anterior pretende ser ilustrativa y no restrictiva Muchas realizaciones serán evidentes para los especialistas en la técnica tras la lectura de la descripción anterior Por lo tanto, el alcance de la invención no debe determinarse en referencia a la descripción anterior sino con referencia a las reivindicaciones adjuntas

HOJA SUSTITUIDA

REIVINDICACIONES

1 Un compuesto que tiene una estructura representada por la formula III




III

o una sal farmaceuticamente aceptable del mismo, donde

R_1 es alquilo (C_1-C_6) opcionalmente sustituido con uno o cinco átomos de fluor, y

R_3 es alquilo (C_1- C_6), cicloalquilo (C_3- C_6), cicloalquil (C_3- C_6) – alquilo (C_1- C_3), fenilo, fenil-alquilo (C_1- C_3), piridilo o piridil- alquilo (C_1- C_3), donde los restos o sustituyentes alquilo y cicloalquilo están opcionalmente sustituidos con uno a cinco átomos de flúor, y los sustituyentes fenilo y piridilo y los restos fenilo y piridilo de los sustituyentes fenil- alquilo (C_1- C_3) y piridil- alquilo (C_1- C_3) están opcionalmente sustituidos con uno a cinco sustituyentes, seleccionados independientemente entre cloro, fluoro, amino, nitro, ciano, hidroxi, alquilamino (C_1- C_3), alquilo (C_1- C_3) opcionalmente sustituido con uno a tres átomos de flúor, y alcoxi (C_1- C_3) opcionalmente sustituido con uno a tres átomos de flúor

2 Un compuesto como en la Reivindicación 1 que tiene la estructura representada por la formula IV



IV

o una sal farmaceuticamente aceptable del mismo, en donde R_3 es como se define en la Reivindicación 1

3 Un compuesto seleccionado entre los siguientes compuestos y sus sales farmaceuticamente aceptables

Acido 3- Amino- 4,5- dimetil- heptanoico,
Acido 3- Amino- 4,5- dimetil- octanoico,
Acido 3- Amino- 4,5- dimetil- nonanoico,
Acido 3- Amino- 4,5- dimetil- decanoico,
Acido 3- Amino- 4- etil- 5- metil- heptanoico,
Acido 3- Amino- 4- etil- 5- metil- octanoico,
Acido 3- Amino- 4- etil- 5- metil- nonanoico,
Acido 3- Amino- 4- etil- 5,6- dimetil- heptanoico,
Acido 3- Amino- 4- etil- 5,7- dimetil- octanoico;
Acido 3- Amino- 4- etil- 5,8- dimetil- nonanoico,
Acido 3- Amino- 5- etil- 4- metil- octanoico,
Acido 3- Amino- 5- etil- 4- metil- nonanoico,
Acido 3- Amino- 4,5- dietil- heptanoico;
Acido 3- Amino- 4,5- dietil- octanoico,
Acido 3- Amino- 4,5- dietil- nonanoico;
Acido 3- Amino- 5- etil- 4,7- dimetil- octanoico,
Acido 3- Amino- 5- etil- 4,8- dimetil- nonanoico,
Acido 3- Amino- 4,5- dietil- 6- metil- heptanoico,
Acido 3- Amino- 4,5- dietil- 7- metil- octanoico;
Acido 3- Amino- 4,5- dietil- 8- metil- nonanoico;
Acido 3- Amino- 4, 5,6- trimetil- heptanoico;
Acido 3- Amino- 4, 5,7- trimetil- octanoico,
Acido 3- Amino- 4, 5,8- trimetil- nonanoico,
Acido 3- Amino- 5- etil- 4- metil- octanoico,
Acido 3- Amino- 5- etil- 4- metil- heptanoico,
Acido 3- Amino- 4- metil- 5- propil- octanoico,
Acido 3- Amino- 4- metil- 6- etil- octanoico,

Acido 3- Amino- 4- metil- 6- etil- nonanoico,

Acido 3- Amino- 4,6- dietil- octanoico;

Acido 3- Amino- 4,6- dietil- nonanoico;

Acido 3- Amino- 7- ciclopentil- 4,5- dimetil- heptanoico,

Acido 3- Amino- 5- etil- 4,6- dimetil- heptanoico,

Acido 3- Amino- 5- etil- 4,7- dimetil- octanoico,

Acido 3- Amino- 5- etil- 4,8- dimetil- nonanoico,

Acido 3- Amino- 8- ciclohexil- 4,5- dimetil- octanoico,

Acido 3- Amino- 8- ciclohexil- 4,5- dimetil- octanoico;

Acido 3- Amino- 4,6- dimetil- octanoico;

Acido 3- Amino- 4,6- dimetil- nonanoico,

Acido 3- Amino- 4,6- dimetil- decanoico,

Acido 3- Amino- 4, 6,7- trimetil- octanoico,

Acido 3- Amino- 4, 6,8- trimetil- nonanoico,

Acido 3- Amino- 4, 6,9- trimetil- decanoico,

Acido 3- Amino- 6- ciclopropil- 4- metil- heptanoico,

Acido 3- Amino- 6- ciclobutil- 4- metil- heptanoico;

Acido 3- Amino- 6- ciclopentil- 4- metil- heptanoico,

Acido 3- Amino- 6- ciclohexil- 4- metil- heptanoico,

Acido 3- Amino- 7- ciclopropil- 4,6- dimetil- heptanoico,

Acido 3- Amino- 7- ciclobutil- 4,6- dimetil- heptanoico,

Acido 3- Amino- 7- ciclopentil- 4,6- dimetil- heptanoico,

Acido 3- Amino- 7- ciclohexil- 4,6- dimetil- heptanoico;

Acido 3- Amino- 8- ciclopropil- 4,6- dimetil- octanoico,

Acido 3- Amino- 8- ciclobutil- 4,6- dimetil- octanoico,

Acido 3- Amino- 8- ciclopentil- 4,6- dimetil- octanoico,

Acido 3- Amino- 8- ciclohexil- 4,6- dimetil- octanoico,

Acido 3- Amino- 4- etil- 6- metil- octanoico,

Acido 3- Amino- 4- etil- 6- metil- nonanoico,

Acido 3- Amino- 4- etil- 6- metil- decanoico,

Acido 3- Amino- 4- etil- 6,7- dimetil- octanoico,

Acido 3- Amino- 4- etil- 6,8- dimetil- nonanoico,

Acido 3- Amino- 4- etil- 6,9- dimetil- decanoico,

Acido 3- Amino- 6- ciclopropil- 4- etil- heptanoico,

Acido 3- Amino- 6- ciclobutil- 4- etil- heptanoico,

Acido 3- Amino- 6- ciclopentil- 4- etil- heptanoico,

Acido 3- Amino- 6- ciclohexil- 4- etil- heptanoico,

Acido 3- Amino- 7- ciclopropil- 4- etil- 6- metil- heptanoico;

Acido 3- Amino- 7- ciclobutil- 4- etil- 6- metil- heptanoico;

Acido 3- Amino- 7- ciclopentil- 4- etil- 6- metil- heptanoico,

Acido 3- Amino- 7- ciclohexil- 4- etil- 6- metil- heptanoico,

Acido 3- Amino- 8- ciclopropil- 4- etil- 6- metil- octanoico,

Acido 3- Amino- 8- ciclobutil- 4- etil- 6- metil- octanoico,

Acido 3- Amino- 8- ciclopentil- 4- etil- 6- metil- octanoico,

Acido 3- Amino- 8- ciclohexil- 4- etil- 6- metil- octanoico,

Acido 3- Amino- 4- metil- heptanoico,

Acido 3- Amino- 4- metil- heptanoico

Acido 3- Amino- 7- ciclopripil- 4- etil- heptanoico,

Acido 3- Amino- 7- ciclobutil- 4- etil- heptanoico,

Acido 3- Amino- 6- ciclopentil- 4- etil- hexanoico,

Acido 3- Amino- 7- ciclopentil- 4- etil- heptanoico,

Acido 3- Amino- 7- ciclohexil- 4- etil- heptanoico;

Acido 3- Amino- 4, 4, 5- trimetil- heptanoico,

Acido 3- Amino- 4, 4, 5- trimetil- octanoico,

Acido 3- Amino- 4, 5, 5- trimetil- heptanoico,

Acido 3- Amino- 4,5, 5- trimetil- octanoico, y

Acido (3R, 4R, 5R) - 3- Amino- 4, 5- dimetil- heptanoico;

Acido (3S, 4R, 5R) - 3- Amino- 4, 5- dimetil- heptanoico,

Acido (3R, 4S, 5R) - 3- Amino- 4, 5- dimetil- heptanoico;

Acido (3R, 4R, 5S) - 3- Amino- 4, 5- dimetil- heptanoico;

Acido (3R, 4R, 5R) - 3- Amino- 4, 5- dimetil- octanoico,

Acido (3S, 4R, 5R) - 3- Amino- 4, 5- dimetil- octanoico,

Acido (3R, 4S, 5R) - 3- Amino- 4, 5- dimetil- octanoico;

Acido (3R, 4R, 5S) - 3- Amino- 4, 5- dimetil- octanoico,

Acido (3R, 4R, 5R) - 3- Amino- 4, 5- dimetil- nonanoico;


Acido (3S, 4R, 5R) - 3- Amino- 4, 5- dimetil- nonanoico,

Acido (3R, 4S, 5R) - 3- Amino- 4, 5- dimetil- nonanoico,

Acido (3R, 4R, 5S) - 3- Amino- 4, 5- dimetil- nonanoico,

Acido (3R, 4R, 5R) - 3- Amino- 4, 5- dimetil- decanoico,
Acido (3S, 4R, 5R) - 3- Amino- 4, 5- dimetil- decanoico,
Acido (3R, 4S, 5R) - 3- Amino- 4, 5- dimetil- decanoico,
Acido (3R, 4R, 5S) - 3- Amino- 4, 5- dimetil- decanoico,
y enantiomeros opuestos de los mismos

4 Un compuesto que tiene la formula estructural representada por la fórmula V



V

o una sal farmaceuticamente aceptable del mismo, en donde

R_1, R_2, R_4 y R_5 son cada uno independientemente un átomo de hidrogeno o alquilo (C_1- C_8) opcionalmente sustituido con uno o cinco átomos de fluor, con la condición que R_1, R_2, R_4 y R_5 no son simultáneamente átomos de hidrogeno, y

R_3 es un fenil ó bencil, cada uno opcionalmente sustituido con uno a cinco sustituyentes seleccionados independientemente de cloro, fluoro, amino, nitro, ciano, hidroxi, alquilamino (C_1- C_3), alquilo (C_1- C_3) opcionalmente sustituido con uno a tres átomos de flúor, y alcoxi (C_1-C_3) opcionalmente sustituido con uno a tres átomos de flúor.


5 Un compuesto como en la Reivindicación 4, en donde R_4 y R_5 son juntos átomos de hidrógeno

6 Un compuesto como en la Reivindicación 4, seleccionado de los siguientes compuestos y sus sales farmaceuticamente aceptables:

Acido 2- Aminometil- 4- (4- metoxi- 2- metil- bencil) - hexanoico,
Acido 2- Aminometil- 5- (4- metoxi- 2- metil- fenil) - 4- metil- pentanoico;

Acido 2- Aminometil- 4- (4- metoxi- 3- metil- bencil) - hexanoico,
Acido 2- Aminometil- 5- (4- metoxi- 3- metil- fenil) - 4- metil- pentanoico,
Acido 2- Aminometil- 5- (4- metoxi- fenil) - 3- metil- pentanoico,
Acido 2- Aminometil- 4- (2- metoxi- fenil) - 3- metil- butirico;
Acido 2- Aminometil- 4- (4- metoxi- fenil) - 3- metil- butirico,
Acido 2- Aminometil- 3- metil- 4- fenil- butirico,
Acido 2- Aminometil- 3- metil- 5- fenil- pentanoico,
Acido 2- Aminometil- 3- metil- 4- (3- trifluorometil- fenil) - butirico,
Acido 2- Aminometil- 3- metil- 4- p- tolil- butirico,
Acido 2- Aminometil- 4- (4- fluoro- fenil) - 3- metil- butirico,
Acido (2R, 4R) - 2- Aminometil- 4- (2,4- difluoro- bencil) - hexanoico,
Acido (2S, 4R) - 2- Aminometil- 4- (2,4- difluoro- bencil) - hexanoico,
Acido (2R, 4S) - 2- Aminometil- 4- (2,4- difluoro- bencil) - hexanoico,
Acido (2S, 4S) - 2- Aminometil- 4- (2,4- difluoro- bencil) - hexanoico,
Acido (2S, 4S) - 2- Aminometil- 4- (3,5- difluoro- bencil) - hexanoico,
Acido (2S, 4S) - 2- Aminometil- 4- (2- fluoro- bencil) - hexanoico;
Acido (2S, 4S) - 2- Aminometil- 5- (2,4- difluoro- fenil) - 4- metil - pentanoico,
Acido (2S) - 2- Aminometil- 5- (2,4- difluoro- fenil) - - pentanoico,
Acido (2S, 4S) - 2- Aminometil- 4- (2,6- difluoro- bencil) - hexanoico,
Acido (2S, 4S) - 2- Aminometil- 4- (4- fluoro- bencill) - hexanoico,
Acido (2S, 4S) - 2- Aminometil- 4- (2,5- difluoro- bencil) - hexanoico,
Acido (2S, 4S) - 2- Aminometil- 4- (3- fluoro- bencil) - hexanoico;
Acido (2S, 4S) - 2- Aminometil- 4- pentafluorofenilmetil- hexanoico, y
Acido (2S, 4S) - 2- Aminometil- 4- (4- trifluorometil- bencil) - hexanoico

7 Un compuesto que tiene una estructura representada por la fórmula VI



VI

o una sal farmaceuticamente aceptable del mismo, en donde

R_3 es un fenil ó bencil, cada uno opcionalmente sustituido con uno a cinco sustituyentes seleccionados independientemente de cloro, fluoro, amino, nitro, ciano, hidroxi, alquilamino (C_1- C_3), alquilo (C_1- C_3) opcionalmente sustituido con uno a tres átomos de flúor, y alcoxi (C_1- C_3) opcionalmente sustituido con uno a tres átomos de flúor, y

R_4 y R_5 son cada uno independientemente un átomo de hidrogeno ó alquilo (C_1- C_6) opcionalmente sustituido con uno a cinco átomos de flúor, con la condición que R_4 y R_5 no son simultáneamente átomos de hidrogeno

8. Un compuesto como en la Reivindicación 7 seleccionado de los siguientes compuestos y sus sales farmaceuticamente aceptables

Acido 2- Aminometil- 5- fenil- hexanoico,

Acido 2- Aminometil- 5- (3- cloro- fenil) - hexanoico,

Acido 2- Aminometil- 5- (3- trifluorometil- fenil) - hexanoico,

Acido 2- Aminometil- 5- (4- trifluorometil- fenil) - hexanoico,

Acido 2- Aminometil- 5- (3- cloro- fenil) - heptanoico;

Acido 2- Aminometil- 5- (3- trifluorometil- fenil) - heptanoico,

Acido 2- Aminometil- 5- (4- trifluorometil- fenil) - heptanoico,

Acido 2- Aminometil- 5- metil- 6- fenil- hexanoico;

Acido 2- Aminometil- 6- (3- cloro- fenil) - 5- metil- hexanoico,

Acido 2- Aminometil- 5- metil- 6- (3- trifluorometil- fenil) - hexanoico,

Acido 2- Aminometil- 5- metil- 6- (4- trifluorometil- fenil) - hexanoico,

Acido 2- Aminometil- 5- bencil- heptanoico,

Acido 2- Aminometil- 5- (3- cloro- bencil) - heptanoico,

Acido 2- Aminometil- 5- (3- trifluorometil- bencil) - heptanoico; y

Acido 2- Aminometil- 5- (4- trifluorometil- bencil) - heptanoico;

9 Una composición farmacéutica que comprende

una cantidad terapéuticamente efectiva de un compuesto de acuerdo con cualquiera de las Reivindicaciones 1 a 8 ó una sal farmaceuticamente aceptable del mismo; y un vehículo farmaceuticamente aceptable

10 Un método para tratar un trastorno o afección en un mamífero, incluyendo un ser humano, seleccionando el trastorno o afección entre

epilepsia, ataques de desmayos, fibromialgia, hipoquinesia, trastornos craneales, sofocos y temblor esencial,

dependencias y adicciones químicas al alcohol, anfetaminas o sustancias similares a las anfetaminas, cafeina, cannabis, cocaina, heroína, alucinogenos, tabaco, inhalantes y propulsores de aerosol, nicotina, opiodes, derivados de fenilglicidina, sedantes, hipnoticos, benzodiazepinas y otros ansioliticos;

síndrome de abstinencia asociado con dependencias, adicciones o comportamientos adictivos, incluyendo juegos de azar, y

migrañas, espasticidad, espasticidad muscular, hipotonía con parálisis, artritis, síndrome del intestino irritable (IBS), dolor crónico, dolor agudo, dolor neuropático, neuralgia post herpética, dolor lumbar, dolor quirúrgico, dolor de cabeza vascular, cefalea sinusal, dolor de cabeza crónico, trastornos inflamatorios, artritis reumatoide, osteoartritis, psoriasis, modificación de la enfermedad de la enfermedad osteoartritis, diuresis, síndrome premenstrual, trastorno disfórico premenstrual, tinnitus y lesión gástrica,

el método que comprende administrar a un mamífero en necesidad de tal tratamiento una cantidad terapéuticamente eficaz de un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 8 o una sal farmaceuticamente aceptable del mismo

11. Un método para tratar un trastorno o afección en un mamífero, incluyendo un ser humano, seleccionando el trastorno o afección entre

delirio, demencia y trastornos amnésicos u otros trastornos cognitivos o neurodegenerativos, incluyendo enfermedad de Parkinson, enfermedad de Huntington, enfermedad de Alzheimer, demencia senil, demencia de tipo de la enfermedad de Alzheimer, trastorno de memoria, demencia vascular y otras demencias, incluyendo demencia debida a la enfermedad por VIH, traumatismo craneal, enfermedad de Parkinson, enfermedad de Huntington, enfermedad de Pick, enfermedad de Creutzfeldt- Jakob, o debido a múltiples etiologías,

trastornos de movimiento tales como aquinesias, disquinesias, incluyendo disquinesias paroxísticas familiares, espasticidades, síndrome de Tourette, síndrome de Scout, parálisis y síndrome acinético rígido,

trastornos de movimiento extrapiramidales incluyendo trastornos de movimiento inducidos por medicación, incluyendo Parkinsonismo, inducido por neurolépticos, síndrome maligno neuroléptico, distonía aguda inducida por neurolépticos, acatisia aguda inducida por neurolépticos, disquinesia tardía inducida por neurolépticos y temblor postural inducido por medicación; síndrome de Down,

enfermedades desmielinizantes incluyendo esclerosis múltiple y esclerosis lateral amiotrófica, neuropatía periférica, incluyendo neuropatía diabética e inducida por quimioterapia o neuralgia postherpetica, neuralgia del trigemino, neuralgia segmental o intercostal y otras neuralgias, y

trastornos cerebrales vasculares debidos a lesión cerebro vascular aguda o crónica incluyendo infarto cerebral, hemorragia subaracnoidea o edema cerebral,

el procedimiento comprende administrar a un mamífero en necesidad de tal tratamiento una cantidad terapéuticamente eficaz de un compuesto acuerdo con cualquiera de las reivindicaciones 1 a 8 o una sal farmaceuticamente aceptable del mismo

12 Un procedimiento para tratar un trastorno o afección en un mamífero, incluyendo un ser humano, seleccionando el trastorno o afección entre trastornos del sueño, insomnio, insomnio asociado a fármacos, trastornos del sueño REM hipersomnia, narcolepsia, trastornos de un ciclo de sueño-vigilia, síndromes de apnea del sueño, parasomnias, síndrome de las piernas inquietas, jet lag, trastorno de movimiento periódico del miembro, arquitectura del sueño alterada, o trastornos del sueño asociado con el turno de trabajo y horas de trabajo irregulares, comprendiendo el procedimiento administrar a un mamífero en necesidad de tal tratamiento una cantidad terapéuticamente eficaz de un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 8 o una sal farmaceuticamente aceptable del mismo

13. Un procedimiento para tratar un trastorno o afección en un mamífero, incluyendo un ser humano, seleccionando el trastorno o afección entre

trastornos del estado emocional, incluyendo depresión o trastornos depresivos, incluyendo trastornos depresivos graves de un único episodio o recurrentes, trastornos distímicos, neurosis depresiva y depresión neurótica, depresión melancólica, incluyendo anorexia, pérdida de peso, insomnio, despertar vespertino y retardo psicomotor, depresión atípica o depresión reactiva, incluyendo aumento del apetito, hipersomnia, agitación psicomotora o irritabilidad, trastorno afectivo estacional y depresión pediátrica,

trastornos bipolares o depresión maniaca, incluyendo trastorno bipolar I, trastorno bipolar II y trastorno ciclotímico,

trastorno de la conducta y trastorno perjudicial del comportamiento,

trastornos de ansiedad, incluyendo trastorno del pánico con o sin agorafobia, agorafobia sin historial de trastorno del pánico, fobias específicas, incluyendo fobias a animales específicos, ansiedad social, fobia social, trastorno obsesivo-compulsivo, trastornos por estrés incluyendo trastorno por estrés post- traumático y trastorno por estrés agudo y trastornos de ansiedad generalizados,

trastorno de personalidad fronteriza;

esquizofrenia y otros trastornos psicóticos, incluyendo trastornos esquizofreniformes, trastornos esquizoafectivos, trastornos de delirio, trastornos psicóticos breves, trastornos psicóticos compartidos, trastornos psicóticos con delirios o alucinaciones, episodios psicóticos de ansiedad, ansiedad asociada con psicosis, trastornos psicóticos del estado emocional incluyendo trastorno depresivo grave,

trastornos del estado emocional asociados con trastornos psicóticos incluyendo manía aguda y depresión asociada con trastorno bipolar, trastornos del estado emocional asociados con esquizofrenia, y

trastornos del comportamiento asociados con un retraso mental, trastorno autístico y trastornos de la conducta

el procedimiento comprende administrar a un mamífero en necesidad de tal tratamiento una cantidad terapéuticamente eficaz de un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 8 o una sal farmaceuticamente aceptable del mismo

PATENT COOPERATION TREATY

31 1905

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

FULLER, Grover, F., Jr.
Pfizer Inc.
201 Tabor Road
Morris Plains, NJ 07950
ETATS-UNIS D'AMERIQUE

RECEIVED
FEB 06 2006
MOPS IP GLBL SRVS

PCT

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY
(PCT Rule 71.1)

Date of mailing *(day/month/year)*	31.01.2006
Applicant's or agent's file reference: PC26111A	**IMPORTANT NOTIFICATION**

International application No.	International filing date *(day/month/year)*	Priority date *(day/month/year)*
PCT/IB2004/002985	13.09.2004	25.09.2003

Applicant
WARNER-LAMBERT COMPANY LLC et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary report on patentability and its annexes, if any, established on the international application.

2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.

3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. **REMINDER**

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary report on patentability. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

The applicant's attention is drawn to Article 33(5), which provides that the criteria of novelty, inventive step and industrial applicability described in Article 33(2) to (4) merely serve the purposes of international preliminary examination and that "any Contracting State may apply additional or different criteria for the purposes of deciding whether, in that State, the claimed inventions is patentable or not" (see also Article 27(5)). Such additional criteria may relate, for example, to exemptions from patentability, requirements for enabling disclosure, clarity and support for the claims.

Name and mailing address of the international preliminary examining authority:
European Patent Office
D-80298 Munich
Tel. +49 89 2399 - 0 Tx: 523656 epmu d
Fax: +49 89 2399 - 4465

Authorized Officer
Parriche, S
Tel. +49 89 2399-7890

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference PC26111A	FOR FURTHER ACTION	See Form PCT/IPEA/416
International application No. PCT/IB2004/002985	International filing date *(day/month/year)* 13.09.2004	Priority date *(day/month/year)* 25.09.2003
International Patent Classification (IPC) or national classification and IPC C07C29/00		
Applicant WARNER-LAMBERT COMPANY LLC et al.		

1. This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 10 sheets, including this cover sheet.
3. This report is also accompanied by ANNEXES, comprising:
   a. ☒ *sent to the applicant and to the International Bureau)* a total of 15 sheets, as follows:
      ☒ sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).
      ☐ sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.
   b. ☐ *(sent to the International Bureau only)* a total of (Indicate type and number of electronic carrier(s)) , containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).

4. This report contains indications relating to the following items:
   - ☒ Box No. I Basis of the opinion
   - ☐ Box No. II Priority
   - ☒ Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
   - ☒ Box No. IV Lack of unity of invention
   - ☒ Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
   - ☐ Box No. VI Certain documents cited
   - ☐ Box No. VII Certain defects in the international application
   - ☐ Box No. VIII Certain observations on the international application

Date of submission of the demand	Date of completion of this report
19.10.2004	31.01.2006
Name and mailing address of the international preliminary examining authority: European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized Officer Seufert, G Telephone No. +49 89 2399-8330

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.
PCT/IB2004/002985

Box No. I. Basis of the report

1. With regard to the **language**, this report is based on the international application in the language in which it was filed, unless otherwise indicated under this item.

   ☐ This report is based on translations from the original language into the following language , which is the language of a translation furnished for the purposes of:
   - ☐ international search (under Rules 12.3 and 23.1(b))
   - ☐ publication of the international application (under Rule 12.4)
   - ☐ international preliminary examination (under Rules 55.2 and/or 55.3)

2. With regard to the **elements*** of the international application, this report is based on *(replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report)*:

Description, Pages	
1-58, 60, 62, 65-109	as originally filed
59, 61, 63, 64, 110	received on 20.09.2005 with letter of 20.09.2005
Claims, Numbers	
1-13	received on 04.11.2005 with letter of 04.11.2005

   ☐ a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing

3. ☐ The amendments have resulted in the cancellation of:
   - ☐ the description, pages
   - ☐ the claims, Nos.
   - ☐ the drawings, sheets/figs
   - ☐ the sequence listing *(specify)*:
   - ☐ any table(s) related to sequence listing *(specify)*:

4. ☐ This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).
   - ☐ the description, pages
   - ☐ the claims, Nos.
   - ☐ the drawings, sheets/figs
   - ☐ the sequence listing *(specify)*:
   - ☐ any table(s) related to sequence listing *(specify)*:

* *If item 4 applies, some or all of these sheets may be marked "superseded."*

Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application,

☒ claims Nos. 4-8, 9(part), 10-13(part) for industrial applicability

because:

☒ the said international application, or the said claims Nos. 10-13(part) relate to the following subject matter which does not require an international preliminary examination (specify):

see separate sheet

☐ the description, claims or drawings *(indicate particular elements below)* or said claims Nos. are so unclear that no meaningful opinion could be formed *(specify)*:

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

☐ no international search report has been established for the said claims Nos.

☐ the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:

the written form	☐	has not been furnished
	☐	does not comply with the standard
the computer readable form	☐	has not been furnished
	☐	does not comply with the standard

☐ the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with the technical requirements provided for in Annex C-*bis* of the Administrative Instructions.

☐ See separate sheet for further details

Box No. IV Lack of unity of invention

1. ☒ In response to the invitation to restrict or pay additional fees, the applicant has:
   - ☐ restricted the claims.
   - ☐ paid additional fees.
   - ☐ paid additional fees under protest.
   - ☒ neither restricted nor paid additional fees.

2. ☐ This Authority found that the requirement of unity of invention is not complied with and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.

3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is

   ☐ complied with.

   ☐ not complied with for the following reasons:

4. Consequently, this report has been established in respect of the following parts of the international application:

   ☐ all parts.

   ☒ the parts relating to claims Nos. 1-3, 9-13(part) .

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	1, 2, 9-13(part)
	No:	Claims	3
Inventive step (IS)	Yes:	Claims	
	No:	Claims	1-3, 9-13(part)
Industrial applicability (IA)	Yes:	Claims	1-3, 9(part)
	No:	Claims	

2. Citations and explanations (Rule 70.7):

see separate sheet

Reference is made to the following documents:

D1 WO 98/40055 A
D2 BIOORG. MED. CHEM., vol. 11, no. 1, 2 January 2003, pages 113-122
D3 DATABASE BEILSTEIN, BEILSTEIN INSTITUT ZUR FÖRDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; Database accession no. BRN 7914440
D13 WO 00/76958 A
D14 WO 98/17627 A
D15 WO 03/082807 A

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

Claims 10-13 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(I) PCT).

The present international application is not considered to comply with the requirement of unity of invention, see item IV below. Following an invitation to restrict or pay additional fees the applicant has not paid additional fees. He also filed amended claims, which are not restricted. In reply to the aforementioned invitation submitted together with the amended claims the applicant requested that the IPEA restricts the application to compounds of formula (III), their stereo compounds (formula (IV)), and compounds of claim 3 as well as the corresponding claims to pharmaceutical compositions and methods of treatment comprising these compounds, which also corresponds to the first subject-matter mentioned in the invitation to pay additional fees. The IPEA is not in a position to restrict an application, but will examine the first mentioned subject-matter if the applicant has not restricted the claims or paid additional fees.
Consequently, this report is limited to compounds of formulae (III), (IV), and to compounds of claim 3, pharmaceutical compositions comprising them and their use,

i.e. the subject-matter of claims 1-3 and 9-13(part).

IV. Lack of unity of invention

The amended set of claims submitted by the applicant on 04.11.05 lacks unity of invention. Independent claims 1, 4 and 7 are not considered to be linked by a single inventive concept. The reasons are essentially the same as set out in the Written Opinion of the International Searching Authority and are mentioned below.

The International Preliminary Examining Authority considers that there are three inventions covered by the claims indicated as follows:

A: Claims 1-3, 9-13 (partially) directed to compounds of formula (III), (IV) and explicitly named compounds, pharmaceutical compositions comprising them and their use in the treatment of the diseases/disorders mentioned in claims 10-13.

B: Claims 4-6 and 9-13 (partially) directed to compounds of formula V, pharmaceutical compositions comprising them and their use in the treatment of the diseases/disorders mentioned in claims 10-13.

C: Claims 7-8 and 9-13 (partially) directed to compounds of formula (VI), pharmaceutical compositions comprising them and their use in the treatment of the diseases/disorders mentioned in claims 10-13.

The reasons for which the inventions are not so linked as to form a single general inventive concept, as required by Rule 13.1 PCT, are as follows:

The problem underlying the present invention is the provision of compounds, which are suitable in the treatment of a variety of disorders, like epilepsy psychiatric disorders, pain etc.

The proposed solution to this problem is the provision of beta-alanine derivatives according to formulae (III), (IV), (V) and (VI), which have the following structural unit *in common*: NH2-CH-CH-COOH. Compounds with this structural unit have already been disclosed in the document WO-A-9840055 for the same use (i.e. epilepsy), see for example table 3, or claims 16-21. The common structural feature is thus not novel.

The underlying problem of the invention can therefore be redefined as providing further beta-alanine derivatives suitable for the treatment of epilepsy, psychiatric disorders, pain, etc.

The inventions A - C mentioned above are considered to be different solutions to this problem, i.e. further developments in different directions, which do not share a common novel feature.

Taking into account that compounds having the same common structural feature for the same use are known and that no other technical feature can be regarded as special technical feature in the sense of Rule 13.2 PCT, the IPEA is of the opinion that there is no single inventive concept underlying the three inventions claimed in the present application. The application therefore lacks unity (Rule 13.1 PCT)

It is acknowledged that a certain overlap exists between the compounds (VI) and (V). The overlapping area is considered as belonging to the second invention.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability

Novelty

Claim 1 of the present application refers to compounds of formula (III) and claim 3 refers to a number of explicitly mentioned compounds. These compounds are useful in the treatment of various disorders like pain, epilepsy, psychiatric disorders, etc.

Document D3 discloses the compound 3-amino-4-methyl-heptanoic acid, which falls within the scope of claim 3, see present application, claim 3, page 114, lines 11-12. Claim 3 is therefore not considered to meet the requirement of Art. 33(2) PCT.

None of the available prior art documents refers to compounds falling within the scope of claim 1. Claim 1 as well as the dependent claim 2 (formula (IV)) and claims 9-13 referring to pharmaceutical compositions and methods of treatment comprising compounds of claim 1 and 3 are therefore considered to meet the requirement of Art. 33(2) PCT.

Inventive step

The present application does not meet the requirement of Art. 33(3) PCT for the following reasons:

To be considered inventive, the technical problem, which is the provision of further compounds for the treatment of pain, epilepsy, psychiatric disorders etc, has to be solved over basically the whole breadth of the claims.

The present claim 1 has been limited to compounds of formula (III), their stereo compounds of formula (IV) and specific compounds according to claim 3 which are all substituted in position 4. However, the application does not contain any biological data, which show that the problem has been solved by this type of compounds and over basically the whole breadth of the claims. Only for three compounds data for the affinity to the α2δ protein are present in the application (see page 87, lines 2-7) and none of them corresponds to a 3-aminocarboxylic acid with a substituent in position 4, let alone in position 4 and 5.
Attention is also drawn to the fact that with regard to the teaching of D1 or D2 (already small changes lead to inactive compounds, see D1, table 3 on page 62, last four compounds; D2, table 2, compounds 5 and 6), it appears to be highly doubtful that all the compounds now claimed solve the underlying problem.
Without sufficient data demonstrating that the problem is solved by the type of compounds according to claims 1-3 and basically over the whole breadth of these

claims, an inventive step cannot be acknowledged.

Industrial applicability

For the assessment of the present claims 10-13 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

There are no objections against claims 1-3 and 9 as far as industrial application is concerned.

Further remarks:

Although the document D15 is not considered to be part of the prior art in the sense of Rule 64.1 for the purpose of Art. 33(2) and (3) PCT, this document anticipates subject-matter of claims 1 and 2, see D15, page 10, line 4, page 11, line 13, page 13, line 1.

The claims are not supported by the description as required by Article 6 PCT, as their scope is broader than justified by the description and drawings. The reasons therefor are the following: The claims encompass still a large amount of compounds, while only a small part is supported by explicitly prepared compounds (see examples). Merely mentioning compounds by name, which theoretically fall within the scope of a formula is not considered as sufficient support. Furthermore, no biological data are available to support the claimed activity.

Independent claim 3 refers to specific compounds, which in part describe compounds according to formulae (III) and/or (IV). These compounds should have been part of a

dependent claim (Rule 6.4 PCT).

Claim 3 apparently mentions some compounds twice, see page 113, lines 5 and 6 or page 114, lines 11 and 12.

Contrary to the requirements of Rule 5.1(a)(ii) PCT, the relevant background art disclosed in the documents D1, D2, D13 and D14 is not mentioned in the description, are these documents identified therein.

optical isomers, of the compounds of formula I, II, III, IV, V or VI. Samples of the compounds may exist as racemic mixtures, as individual enantiomers and diastereoisomers, and as mixtures thereof. The invention also includes all pharmaceutical compositions and methods of treatment defined above that contain or employ stereoisomers of the compounds of formula I, II, III, IV, V or VI.

Compounds with one stereogenic center may exist as a racemic (equimolar) mixture, as a non-equimolar mixture of isomers, and as pure enantiomers having S- or R-stereoconfiguration. Compounds with two stereogenic centers may exist as a racemic mixture, as a non-equimolar mixture of isomers, and as pure enantiomers having SS, RR, SR or RS stereoconfiguration. Compounds with three stereogenic centers may exist as a racemic mixture, as a non-equimolar mixture of isomers, and as pure enantiomers having RRR, SSS, SRR, RSS, RSR, SRS, RRS or SSR stereoconfiguration. Individual isomers may be obtained by known methods, such as optical resolution, optically selective reaction, or chromatographic separation in the preparation of the final product or its intermediate. Individual enantiomers of the compounds of this invention may have advantages, as compared with racemic mixtures of these compounds, in the treatment of various disorders or conditions.

The present invention also includes isotopically labeled compounds, which are identical to those recited in formula I, II, III, IV, V, or VI but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, fluorine and chlorine, such as ^{2}H, ^{3}H, ^{13}C, ^{11}C, ^{14}C, ^{15}N, ^{18}O, ^{17}O, ^{18}F, and ^{36}Cl, respectively. Compounds of the present invention, prodrugs thereof, and pharmaceutically acceptable salts of said compounds or of said prodrugs which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention. Certain isotopically labeled compounds of the present

PC28111A

3-methylbut-1-yl, 3-methylbut-2-yl, 2-methylbut-2-yl, 2,2,2-trimethyleth-1-yl, n-hexyl, 3-ethylbutyl, and the like.

The term "cycloalkyl" refers to saturated monocyclic and bicyclic hydrocarbon rings, generally having a specified number of carbon atoms that comprise the ring; i.e., (C_3-C_8)cycloalkyl refers to a cycloalkyl group having 3, 4, 5, or 6 carbon atoms as ring members. The cycloalkyl may be attached to a parent group or to a substrate at any ring atom, unless such attachment would violate valence requirements.

Examples of monocyclic cycloalkyl groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like. Examples of bicyclic cycloalkyl groups include, without limitation, bicyclo[1.1.0]butyl, bicyclo[1.1.1]pentyl, bicyclo[2.1.0]pentyl, bicyclo[2.1.1]hexyl, bicyclo[3.1.0]hexyl, bicyclo[2.2.1]heptyl, bicyclo[3.2.0]heptyl, bicyclo[3.1.1]heptyl, bicyclo[4.1.0]heptyl, bicyclo[2.2.2]octyl, bicyclo[3.2.1]octyl, bicyclo[4.1.1]octyl, bicyclo[3.3.0]octyl, bicyclo[4.2.0]octyl, bicyclo[3.3.1]nonyl, bicyclo[4.2.1]nonyl, bicyclo[4.3.0]nonyl, bicyclo[3.3.2]decyl, bicyclo[4.2.2]decyl, bicyclo[4.3.1]decyl, bicyclo[4.4.0]decyl, bicyclo[3.3.3]undecyl, bicyclo[4.3.2]undecyl, bicyclo[4.3.3]dodecyl, and the like.

The term "alkoxy" refers to alkyl-O-, where alkyl is defined above. Examples of alkoxy groups include, without limitation, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, n-pentoxy, s-pentoxy, and the like.

The term "treating" refers to reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or preventing one or more symptoms of such condition or disorder. The term "treatment," as used herein, refers to the act of treating, as "treating" is defined immediately above.

PC26111A

The phrase "opposite enantiomer" refers to a molecule that is a non-superimposable mirror image of a reference molecule, which may be obtained by inverting all of the stereogenic centers of the reference molecule. For example, if the reference molecule has S absolute stereochemical configuration, then the opposite enantiomer has R absolute stereochemical configuration. Likewise, if the reference molecule has S,S absolute stereochemical configuration, then the opposite enantiomer has R,R stereochemical configuration, and so on.

The phrase "pharmaceutically acceptable salts" refers to acid or base addition salts and zwitterionic forms, where possible, which are within the scope of sound medical judgment, suitable for use in contact with the tissues of patients without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use.

Because amino acids are amphoteric, pharmacologically compatible salts can be salts of appropriate inorganic or organic acids, for example, hydrochloric, sulfuric, phosphoric, acetic, oxalic, lactic, citric, malic, salicylic, malonic, maleic, succinic, and ascorbic. Starting from corresponding hydroxides or carbonates, salts with alkali metals or alkaline earth metals, for example, sodium, potassium, magnesium, or calcium are formed. Salts with quaternary ammonium ions can also be prepared with, for example, the tetramethyl-ammonium ion.

The effectiveness of an orally administered drug is dependent upon the drug's efficient transport across the mucosal epithelium and its stability in entero-hepatic circulation. Drugs that are effective after parenteral administration but less effective orally, or whose plasma half-life is considered too short, may be chemically modified into a prodrug form.

A prodrug is a drug that has been chemically modified and may be biologically inactive at its site of action, but which may be degraded or modified by one or more enzymatic or other in vivo processes to the parent bioactive form.

PC26111A

This chemically modified drug, or prodrug, should have a different pharmacokinetic profile than the parent drug, enabling easier absorption across the mucosal epithelium, better salt formulation, improved solubility, enhanced systemic stability (for an increase in plasma half-life, for example), and the like. These chemical modifications include, but are not limited to (1) ester or amide derivatives which may be cleaved by, for example, esterases or lipases; (2) peptides, which may be recognized by specific or nonspecific proteinases; (3) derivatives that accumulate at a site of action through membrane selection of a prodrug form or modified prodrug form; and (4) any combination of (1) to (3). The ester or amides prodrugs may be derived from the carboxylic acid moiety of the parent drug molecule or from the carboxylic acid moiety or the amine moiety of the parent drug molecule, respectively, by known means. In addition, the peptide prodrug may be coupled to the parent drug molecule via amide bond formation with the amine or carboxylic acid moiety of the parent drug molecule using known techniques.

Current research in animal experiments has shown that the oral absorption of certain drugs may be increased by the preparation of "soft" quaternary salts. The quaternary salt is termed a "soft" quaternary salt since, unlike normal quaternary salts, *e.g.*, $R\text{-}N^{+}(CH_3)_3$, it can release the active drug upon hydrolysis.

Soft quaternary salts have useful physical properties compared with the basic drug or its salts. Water solubility may be increased compared with other salts, such as the hydrochloride, but more important there may be an increased absorption of the drug from the intestine. Increased absorption is probably due to the fact that the soft quaternary salt has surfactant properties and is capable of forming micelles and unionized ion pairs with bile acids, etc., which are able to penetrate the intestinal epithelium more effectively. The prodrug, after absorption, is rapidly hydrolyzed with release of the active parent drug.

For a discussion of prodrugs and soft quaternary salts, see E. Palomino, *Drugs of the Future* 15(4):361-68 (1990). See also,

with sat. aq. ammonium chloride solution. The crude reaction mixture was extracted with diethyl ether. The ether was removed under reduced pressure, and the crude residue was purified by column chromatography (9:1 hexanes/ EtOAc eluent) which gave 1.57 g (46%) of 2-tert-butyl-5-[2-(2,4-difluoro-benzyl)-butyl]-3-methyl-4-oxo-tetrahydro-pyrimidine-1-carboxylic acid methyl ester as a white solid.

(2R,4R)-2-Aminomethyl-4-(2,4-difluoro-benzyl)-hexanoic acid

A flask was charged with 0.5 g (1.2 mmol) of 2-tert-butyl-5-[2-(2,4-difluoro-benzyl)-butyl]-3-methyl-4-oxo-tetrahydro-pyrimidine-1-carboxylic acid methyl ester, 20 mL dioxane, and 20 mL of conc. HCl solution. The mixture was stirred and heated at 110°C for 4 days. The solvents were removed under reduced pressure. The residue was taken up in 20 mL water and 4 drops of conc. HCl solution. The aqueous layer was washed with dichloromethane. The aqueous layer was collected and the water was removed under reduced pressure. The residue was treated with 2 mL of triethylamine, and the excess triethylamine was removed under reduced pressure. The remaining solid was purified by column chromatography (1:8:27 NH_4OH, MeOH, dichloromethane eluent). The resulting white solid was washed with acetonitrile and dried under vacuum. This gave 80 mg (24%) of (2R,4R)-2-aminomethyl-4-(2,4-difluoro-benzyl)-hexanoic acid as a white solid.


It should be noted that, as used in this specification and the appended claims, singular articles such as "a," "an," and "the," may refer to a single object or to a plurality of objects unless the context clearly indicates otherwise. Thus, for example, reference to a composition containing "a compound" may include a single compound or two or more compounds.

It is to be understood that the above description is intended to be illustrative and not restrictive. Many embodiments will be apparent to those of skill in the art upon reading the above description. The scope of the invention should, therefore, be determined not with reference to the above description, but should instead be determined with reference to the appended claims.

PC28111A

CLAIMS

1. A compound having a structure represented by formula III




III

or a pharmaceutically acceptable salt thereof, wherein

R_1 is a (C_1-C_6)alkyl optionally substituted with from one to five fluorine atoms; and

R_3 is (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl, (C_3-C_6)cycloalkyl-(C_1-C_3)alkyl, phenyl, phenyl-(C_1-C_3)alkyl, pyridyl, or pyridyl-(C_1-C_3)alkyl, wherein the alkyl and cycloalkyl moieties or substituents are optionally substituted with from one to five fluorine atoms, and the phenyl and pyridyl substituents and the phenyl and pyridyl moieties of the phenyl-(C_1-C_3)alkyl and the pyridyl-(C_1-C_3)alkyl substituents are optionally substituted with from one to five substituents independently selected from chloro, fluoro, amino, nitro, cyano, hydroxy, (C_1-C_3)alkylamino, (C_1-C_3)alkyl optionally substituted with from one to three fluorine atoms, and (C_1-C_3)alkoxy optionally substituted with from one to three fluorine atoms.

2. A compound as in Claim 1 having a structure represented by formula IV



IV

or a pharmaceutically acceptable salt thereof, wherein R_3 is defined as in Claim 1.

3. A compound selected from the following compounds and their pharmaceutically acceptable salts:


3-Amino-4,5-dimethyl-heptanoic acid;
3-Amino-4,5-dimethyl-octanoic acid;
3-Amino-4,5-dimethyl-nonanoic acid;
3-Amino-4,5-dimethyl-decanoic acid;
3-Amino-4-ethyl-5-methyl-heptanoic acid;
3-Amino-4-ethyl-5-methyl-octanoic acid;
3-Amino-4-ethyl-5-methyl-nonanoic acid;
3-Amino-4-ethyl-5,6-dimethyl-heptanoic acid;
3-Amino-4-ethyl-5,7-dimethyl-octanoic acid;
3-Amino-4-ethyl-5,8-dimethyl-nonanoic acid;
3-Amino-5-ethyl-4-methyl-octanoic acid;
3-Amino-5-ethyl-4-methyl-nonanoic acid;
3-Amino-4,5-diethyl-heptanoic acid;
3-Amino-4,5-diethyl-octanoic acid;
3-Amino-4,5-diethyl-nonanoic acid;
3-Amino-5-ethyl-4,7-dimethyl-octanoic acid;
3-Amino-5-ethyl-4,8-dimethyl-nonanoic acid;
3-Amino-4,5-diethyl-6-methyl-heptanoic acid;
3-Amino-4,5-diethyl-7-methyl-octanoic acid;
3-Amino-4,5-diethyl-8-methyl-nonanoic acid;
3-Amino-4,5,6-trimethyl-heptanoic acid;
3-Amino-4,5,7-trimethyl-octanoic acid;
3-Amino-4,5,8-trimethyl-nonanoic acid;
3-Amino-5-ethyl-4-methyl-octanoic acid;
3-Amino-5-ethyl-4-methyl-heptanoic acid;
3-Amino-4-methyl-5-propyl-octanoic acid;
3-Amino-4-methyl-6-ethyl-octanoic acid;
3-Amino-4-methyl-6-ethyl-nonanoic acid;
3-Amino-4,6-diethyl-octanoic acid;
3-Amino-4,6-diethyl-nonanoic acid;

3-Amino-7-cyclopentyl-4,5-dimethyl-heptanoic acid;
3-Amino-5-ethyl-4,6-dimethyl-heptanoic acid;
3-Amino-5-ethyl-4,7-dimethyl-octanoic acid;
3-Amino-5-ethyl-4,8-dimethyl-nonanoic acid;
3-Amino-8-cyclohexyl-4,5-dimethyl-octanoic acid;
3-Amino-8-cyclohexyl-4,5-dimethyl-octanoic acid;
3-Amino-4,6-dimethyl-octanoic acid;
3-Amino-4,6-dimethyl-nonanoic acid;
3-Amino-4,6-dimethyl-decanoic acid;
3-Amino-4,6,7-trimethyl-octanoic acid;
3-Amino-4,6,8-trimethyl-nonanoic acid;
3-Amino-4,6,9-trimethyl-decanoic acid;
3-Amino-6-cyclopropyl-4-methyl-heptanoic acid;
3-Amino-6-cyclobutyl-4-methyl-heptanoic acid;
3-Amino-6-cyclopentyl-4-methyl-heptanoic acid;
3-Amino-6-cyclohexyl-4-methyl-heptanoic acid;
3-Amino-7-cyclopropyl-4,6-dimethyl-heptanoic acid;
3-Amino-7-cyclobutyl-4,6-dimethyl-heptanoic acid;
3-Amino-7-cyclopentyl-4,6-dimethyl-heptanoic acid;
3-Amino-7-cyclohexyl-4,6-dimethyl-heptanoic acid;
3-Amino-8-cyclopropyl-4,6-dimethyl-octanoic acid;
3-Amino-8-cyclobutyl-4,6-dimethyl-octanoic acid;
3-Amino-8-cyclopentyl-4,6-dimethyl-octanoic acid;
3-Amino-8-cyclohexyl-4,6-dimethyl-octanoic acid;
3-Amino-4-ethyl-6-methyl-octanoic acid;
3-Amino-4-ethyl-6-methyl-nonanoic acid;
3-Amino-4-ethyl-6-methyl-decanoic acid;
3-Amino-4-ethyl-6,7-dimethyl-octanoic acid;
3-Amino-4-ethyl-6,8-dimethyl-nonanoic acid;
3-Amino-4-ethyl-6,9-dimethyl-decanoic acid;
3-Amino-6-cyclopropyl-4-ethyl-heptanoic acid;
3-Amino-6-cyclobutyl-4-ethyl-heptanoic acid;

3-Amino-6-cyclopentyl-4-ethyl-heptanoic acid;
3-Amino-6-cyclohexyl-4-ethyl-heptanoic acid;
3-Amino-7-cyclopropyl-4-ethyl-6-methyl-heptanoic acid;
3-Amino-7-cyclobutyl-4-ethyl-6-methyl-heptanoic acid;
3-Amino-7-cyclopentyl-4-ethyl-6-methyl-heptanoic acid;
3-Amino-7-cyclohexyl-4-ethyl-6-methyl-heptanoic acid;
3-Amino-8-cyclopropyl-4-ethyl-6-methyl-octanoic acid;
3-Amino-8-cyclobutyl-4-ethyl-6-methyl-octanoic acid;
3-Amino-8-cyclopentyl-4-ethyl-6-methyl-octanoic acid;
3-Amino-8-cyclohexyl-4-ethyl-6-methyl-octanoic acid;
3-Amino-4-methyl-heptanoic acid;
3-Amino-4-methyl-heptanoic acid;
3-Amino-7-cyclopropyl-4-ethyl-heptanoic acid;
3-Amino-7-cyclobutyl-4-ethyl-heptanoic acid;
3-Amino-6-cyclopentyl-4-ethyl-hexanoic acid;
3-Amino-7-cyclopentyl-4-ethyl-heptanoic acid;
3-Amino-7-cyclohexyl-4-ethyl-heptanoic acid;
3-Amino-4,4,5-trimethyl-heptanoic acid;
3-Amino-4,4,5-trimethyl-octanoic acid;
3-Amino-4,5,5-trimethyl-heptanoic acid;
3-Amino-4,5,5-trimethyl-octanoic acid; and
(3R,4R,5R)-3-Amino-4,5-dimethyl-heptanoic acid;
(3S,4R,5R)-3-Amino-4,5-dimethyl-heptanoic acid;
(3R,4S,5R)-3-Amino-4,5-dimethyl-heptanoic acid;
(3R,4R,5S)-3-Amino-4,5-dimethyl-heptanoic acid;
(3R,4R,5R)-3-Amino-4,5-dimethyl-octanoic acid;
(3S,4R,5R)-3-Amino-4,5-dimethyl-octanoic acid;
(3R,4S,5R)-3-Amino-4,5-dimethyl-octanoic acid;
(3R,4R,5S)-3-Amino-4,5-dimethyl-octanoic acid;
(3R,4R,5R)-3-Amino-4,5-dimethyl-nonanoic acid;
(3S,4R,5R)-3-Amino-4,5-dimethyl-nonanoic acid;
(3R,4S,5R)-3-Amino-4,5-dimethyl-nonanoic acid;

(3R,4R,5S)-3-Amino-4,5-dimethyl-nonanoic acid;
(3R,4R,5R)-3-Amino-4,5-dimethyl-decanoic acid;
(3S,4R,5R)-3-Amino-4,5-dimethyl-decanoic acid;
(3R,4S,5R)-3-Amino-4,5-dimethyl-decanoic acid;
(3R,4R,5S)-3-Amino-4,5-dimethyl-decanoic acid;
and opposite enantiomers thereof.

4. A compound having a structure represented by formula V



V

or a pharmaceutically acceptable salt thereof, wherein

R_1, R_2, R_4, and R_5 are each independently a hydrogen atom or (C_1-C_6)alkyl optionally substituted with from one to five fluorine atoms, with the proviso that R_1, R_2, R_4 and R_5 are not simultaneously hydrogen atoms; and


R_3 is a phenyl or benzyl, each optionally substituted with from one to five substituents independently selected from chloro, fluoro, amino, nitro, cyano, hydroxy, (C_1-C_2)alkylamino, (C_1-C_3)alkyl optionally substituted with from one to three fluorine atoms, and (C_1-C_3)alkoxy optionally substituted with from one to three fluorine atoms.

5. A compound as in Claim 4, wherein R_4 and R_5 are both hydrogen atoms.

6. A compound as in Claim 4 selected from the following compounds and their pharmaceutically acceptable salts:
2-Aminomethyl-4-(4-methoxy-2-methyl-benzyl)-hexanoic acid;
2-Aminomethyl-5-(4-methoxy-2-methyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-4-(4-methoxy-3-methyl-benzyl)-hexanoic acid;

2-Aminomethyl-5-(4-methoxy-3-methyl-phenyl)-4-methyl-pentanoic acid;
2-Aminomethyl-5-(4-methoxy-phenyl)-3-methyl-pentanoic acid;
2-Aminomethyl-4-(2-methoxy-phenyl)-3-methyl-butyric acid;
2-Aminomethyl-4-(4-methoxy-phenyl)-3-methyl-butyric acid;
2-Aminomethyl-3-methyl-4-phenyl-butyric acid;
2-Aminomethyl-3-methyl-5-phenyl-pentanoic acid;
2-Aminomethyl-3-methyl-4-(3-trifluoromethyl-phenyl)-butyric acid;
2-Aminomethyl-3-methyl-4-p-tolyl-butyric acid;
2-Aminomethyl-4-(4-fluoro-phenyl)-3-methyl-butyric acid;
(2R,4R)-2-Aminomethyl-4-(2,4-difluoro-benzyl)-hexanoic acid;
(2S,4R)-2-Aminomethyl-4-(2,4-difluoro-benzyl)-hexanoic acid;
(2R,4S)-2-Aminomethyl-4-(2,4-difluoro-benzyl)-hexanoic acid;
(2S,4S)-2-Aminomethyl-4-(2,4-difluoro-benzyl)-hexanoic acid;
(2S,4S)-2-Aminomethyl-4-(3,5-difluoro-benzyl)-hexanoic acid;
(2S,4S)-2-Aminomethyl-4-(2-fluoro-benzyl)-hexanoic acid;
(2S,4S)-2-Aminomethyl-5-(2,4-difluoro-phenyl)-4-methyl-pentanoic acid;
(2S)-2-Aminomethyl-5-(2,4-difluoro-phenyl)-pentanoic acid;
(2S,4S)-2-Aminomethyl-4-(2,6-difluoro-benzyl)-hexanoic acid;
(2S,4S)-2-Aminomethyl-4-(4-fluoro-benzyl)-hexanoic acid;
(2S,4S)-2-Aminomethyl-4-(2,5-difluoro-benzyl)-hexanoic acid;
(2S,4S)-2-Aminomethyl-4-(3-fluoro-benzyl)-hexanoic acid;
(2S,4S)-2-Aminomethyl-4-pentafluorophenylmethyl-hexanoic acid; and
(2S,4S)-2-Aminomethyl-4-(4-trifluoromethyl-benzyl)-hexanoic acid.

7. A compound having a structure represented by formula VI



VI

or a pharmaceutically acceptable salt thereof, wherein

R_3 is a phenyl or benzyl, each optionally substituted with from one to five substituents independently selected from chloro, fluoro, amino, nitro, cyano, hydroxy, (C_1-C_3)alkylamino, (C_1-C_3)alkyl optionally substituted with from one to three fluorine atoms, and (C_1-C_3)alkoxy optionally substituted with from one to three fluorine atoms; and

R_4 and R_5 are each independently a hydrogen atom or (C_1-C_8)alkyl optionally substituted with from one to five fluorine atoms, with the proviso that R_4 and R_5 are not simultaneously hydrogen atoms.

8. A compound as in Claim 7 selected from the following compounds and their pharmaceutically acceptable salts:

2-Aminomethyl-5-phenyl-hexanoic acid;
2-Aminomethyl-5-(3-chloro-phenyl)-hexanoic acid;
2-Aminomethyl-5-(3-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-5-(4-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-5-(3-chloro-phenyl)-heptanoic acid;
2-Aminomethyl-5-(3-trifluoromethyl-phenyl)-heptanoic acid;
2-Aminomethyl-5-(4-trifluoromethyl-phenyl)-heptanoic acid;
2-Aminomethyl-5-methyl-6-phenyl-hexanoic acid;
2-Aminomethyl-6-(3-chloro-phenyl)-5-methyl-hexanoic acid;
2-Aminomethyl-5-methyl-6-(3-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-5-methyl-6-(4-trifluoromethyl-phenyl)-hexanoic acid;
2-Aminomethyl-5-benzyl-heptanoic acid;
2-Aminomethyl-5-(3-chloro-benzyl)-heptanoic acid;
2-Aminomethyl-5-(3-trifluoromethyl-benzyl)-heptanoic acid; and
2-Aminomethyl-5-(4-trifluoromethyl-benzyl)-heptanoic acid.

9. A pharmaceutical composition comprising:

a therapeutically effective amount of a compound according to any one of Claims 1 to 8 or a pharmaceutically acceptable salt thereof; and

a pharmaceutically acceptable carrier.

10. A method of treating a disorder or condition in a mammal, including a human, the disorder or condition selected from:

epilepsy, faintness attacks, fibromyalgia, hypokinesia, cranial disorders; hot flashes, and essential tremor;

chemical dependencies and addictions to alcohol, amphetamines or amphetamine-like substances, caffeine, cannabis, cocaine, heroin, hallucinogens, tobacco, inhalants and aerosol propellants, nicotine, opioids, phenylglycidine derivatives, sedatives, hypnotics, benzodiazepines and other anxiolytics;

withdrawal symptoms associated with the dependencies, addictions, or addictive behaviors, including gambling; and

migraine, spasticity, muscle spasticity, hypotonia with paralysis, arthritis, irritable bowel syndrome, chronic pain, acute pain, neuropathic pain, post herpetic neuralgia, lower back pain, surgical pain, vascular headache, sinus headache, chronic headache, inflammatory disorders, rheumatoid arthritis, osteoarthritis, psoriasis, disease modification of osteoarthritis disease, diuresis, premenstrual syndrome, premenstrual dysphoric disorder, tinnitus, and gastric damage;

the method comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to any one of Claims 1 to 8 or a pharmaceutically acceptable salt thereof.

11. A method of treating a disorder or condition in a mammal, including a human, the disorder or condition selected from:

delirium, dementia, and amnestic or other cognitive or neurodegenerative disorders; including Parkinson's disease, Huntington's disease, Alzheimer's disease, senile dementia, dementia of the Alzheimer's type, memory disorder, vascular dementia, and other dementias, including dementia due to HIV disease, head trauma, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, or due to multiple aetiologies;

movement disorders including akinesias, dyskinesias, including familial paroxysmal dyskinesias, spasticities, Tourette's syndrome, Scott syndrome, PALSYS and akinetic-rigid syndrome;

extra-pyramidal movement disorders including medication-induced movement disorders, including neuroleptic-induced Parkinsonism, neuroleptic malignant syndrome, neuroleptic-induced acute dystonia, neuroleptic-induced acute akathisia, neuroleptic-induced tardive dyskinesia and medication-induced postural tremour;

Down's syndrome;

demyelinating diseases including multiple sclerosis and amyiolateral sclerosis, peripheral neuropathy, including diabetic and chemotherapy-induced-neuropathy, or postherpetic neuralgia, trigeminal neuralgia, segmental or intercostal neuralgia and other neuralgias; and

cerebral vascular disorders due to acute or chronic cerebrovascular damage including cerebral infarction, subarachnoid haemorrhage or cerebral oedema;

the method comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound according to any one of Claims 1 to 8 or a pharmaceutically acceptable salt thereof.

12. A method of treating a disorder or condition in a mammal, including a human, the disorder or condition selected from sleep disorders, insomnia, drug-associated sleeplessness, REM sleep disorders, hypersomnia, narcolepsy, sleep-wake cycle disorders, sleep apnea syndromes, parasomnias, restless leg syndrome, jet lag, periodic limb movement disorder, altered sleep architecture, or sleep disorders associated with shift work and irregular work hours, the method comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound according to any one of Claims 1 to 8 or a pharmaceutically acceptable salt thereof.

13. A method of treating a disorder or condition in a mammal, including a human, the disorder or condition selected from:

mood disorders, including depression or depressive disorders, including single episodic or recurrent major depressive disorders, dysthymic disorders, depressive neurosis and neurotic depression, melancholic depression, including anorexia, weight loss, insomnia, early morning waking and psychomotor retardation, atypical depression or reactive depression, including increased appetite, hypersomnia, psychomotor agitation or irritability, seasonal affective disorder and pediatric depression;

bipolar disorders or manic depression, including bipolar I disorder, bipolar II disorder and cyclothymic disorder;

conduct disorder and disruptive behavior disorder;

anxiety disorders, including panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobias, including specific animal phobias, social anxiety, social phobia, obsessive-compulsive disorder, stress disorders, including post-traumatic stress disorder and acute stress disorder, and generalized anxiety disorders;

borderline personality disorder;

schizophrenia and other psychotic disorders, including schizophreniform disorders, schizoaffective disorders, delusional disorders, brief psychotic disorders, shared psychotic disorders, psychotic disorders with delusions or hallucinations, psychotic episodes of anxiety, anxiety associated with psychosis, psychotic mood disorders including severe major depressive disorder;

mood disorders associated with psychotic disorders including acute mania and depression associated with bipolar disorder, mood disorders associated with schizophrenia; and

behavioral disturbances associated with mental retardation, autistic disorder, and conduct disorder;

the method comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound according to Claims 1 to 8 or a pharmaceutically acceptable salt thereof.

INTERNATIONAL SEARCH REPORT

Int ional Application No
PCT/IB2004/002985

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07C229/08 C07C229/28 C07C229/34 A61K31/197 A61P25/00

According to International Patent Classification (IPC) or to both national classification and IPC

B FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07C A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and where practical search terms used)
EPO-Internal, BEILSTEIN Data, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication where appropriate of the relevant passages	Relevant to claim No
X	WO 98/40055 A (QUEEN'S UNIVERSITY AT KINGSTON; WEAVER, DONALD, F; MILNE, PAUL, H; TAN) 17 September 1998 (1998-09-17) table 3, page 62; the beta-substituted-beta-alanine mentioned in claims 18-20	1,2,7,8

-/--

[X] Further documents are listed in the continuation of box C

[X] Patent family members are listed in annex

* Special categories of cited documents

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure use exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
12 May 2005	20 06. 2005

Name and mailing address of the ISA	Authorized officer
European Patent Office P B 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel (+31-70) 340-2040 Tx 31 651 epo nl Fax (+31-70) 340-3016	Seufert, G

Form PCT/ISA/210 (second sheet) (January 2004)

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document with indication where appropriate of the relevant passages	Relevant to claim No
X	C. Y. K. TAN ET AL.: "N-, .alpha., and .beta -Substituted 3-Aminopropionic Acids: Design, Syntheses and Antiseizure Activities" BIOORG. MED. CHEM., vol. 11, no. 1, 2 January 2003 (2003-01-02), pages 113-122, XP002317976 tables 1 and 2, compounds (5) and (6), compounds /7) and (8) page 117, right-hand column, last paragraph - page 118, left-hand column, line 7	1,5-8
X	DATABASE BEILSTEIN BEILSTEIN INSTITUT ZUR FÖRDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; XP002317982 Database accession no. BRN 7914440, 1926943, 1747371, 7914190, 1755620 abstract & L. LAZAR ET AL.: SYNTH. COMMUN., vol. 28, no. 2, 1998, pages 219-224,	1,2,12
X	T. YAMADA ET AL.: "THE RELATION BETWEEN CD SPECTRA OF N-DITHIOETHOXYCARBONYL DERIVATIVES OF .BETA.-AMINO ACIDS AND THEIR CONFIGURATIONS" TETRAHEDRON LETT., vol. 19, no. 21, 1978, pages 1813-1816, XP002317977 page 1816, table 3, .beta.-Leu, .beta.-Hil, .beta.-Hle	1,2,12
X	DATABASE BEILSTEIN BEILSTEIN INSTITUT ZUR FÖRDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; XP002317983 Database accession no. BRN 1723420, 6118186 abstract & RODIONOW, SWORYKINA: ZH. OBSHCH. KHIM., vol. 26, 1956, pages 793-796,	1,2
X	YA. L. GOL'DFARB ET AL.: "THIOPHENE AND ITS HOMOLOGUES AS STARTING COMPOUNDS FOR THE PREPARATION OF ALIPHATIC AMINO ACIDS" TETRAHEDRON, vol. 18, no. 21, 1962, pages 21-36, XP002317978 table 2 on page 26	1,2

-/--

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document with indication where appropriate, of the relevant passages	Relevant to claim No
X	CH. W. JEFFORD, J. WANG: "An Enantiospecific Synthesis of .beta.-Amino Acids" TETRAHEDRON LETT., vol. 34, no. 7, 1993, pages 1111-1114, XP002070480 scheme 1, compounds 19-22	1,2
X	DATABASE BEILSTEIN BEILSTEIN INSTITUT ZUR FÖRDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; XP002317984 Database accession no. BRN 1722065 abstract & ALEKSEEWA, WAWER: CHIMIJA CHIM. TECHNOL., 1958, page 545,	1,2
X	J. MITTENDORF ET AL.: BIOROG. MED. CHEM. LETT., vol. 13, no. 3, 10 February 2003 (2003-02-10), pages 433-436, XP002317979 table 1, compound 12	1,2
X	S. GEDEY ET AL.: "Preparation of highly enantiopure .beta.-amino esters by Candida antarctica lipase A" TETRAHEDRON ASYMMETRY, vol. 12, no. 1, 2001, pages 105-110, XP002317980 table 1, compounds 1c-1e	1,2
X	MORICONI, EMIL J. ET AL: "Olefinic intermediates in the reaction of 1,1-dimethyl-1,1,2-trimethyl and 1,1,2,2-tetramethylcyclopropanes with chlorosulfonyl isocyanate" JOURNAL OF ORGANIC CHEMISTRY, vol. 33, no. 9, 1968, - 1968 pages 3448-52, XP002317981 page 3452, left-hand column, line 18 - line 23	1
X	DATABASE BEILSTEIN BEILSTEIN INSTITUT ZUR FÖRDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; XP002317985 Database accession no. BRN 1755430, 1755636 abstract & PHILIPPI ET AL.: MONATSHEFTE, 69, 1936, page 279,	1

-/--

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document with indication where appropriate of the relevant passages	Relevant to claim No
A	WO 00/76958 A (WARNER-LAMBERT COMPANY; BELLIOTTI, THOMAS, RICHARD; BRYANS, JUSTIN, ST) 21 December 2000 (2000-12-21) page 12, line 1 - page 19, line 5; claims; examples	1-15
A	WO 98/17627 A (WARNER-LAMBERT COMPANY; BRYANS, JUSTIN, STEPHEN; HORWELL, DAVID, CHRIS) 30 April 1998 (1998-04-30) page 27, line 20 - page 30, line 3; claims; examples	1-15
P,X	WO 03/082807 A (WARNER-LAMBERT COMPANY LLC; BARTA, NANCY, SUE; SCHWARZ, JACOB, BRADLEY) 9 October 2003 (2003-10-09) the whole document	1-15
X	JUARISTI E ET AL: "Enantioselective Synthesis of beta-Amino Acids. 7. Preparation of Enantiopure alpha-Substituted beta-Amino Acids from 1-Benzoyl-2(S)-tert-butyl-3-methylperhydro pyrimidin-4-one" TETRAHEDRON: ASYMMETRY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 7, no. 8, August 1996 (1996-08), pages 2233-2246, XP004048279 ISSN: 0957-4166 page 2243, lines 4-12, 21-28	5,6
X	E JUARISTI ET AL.: "Asymmetric Synthesis of .beta.-Amino Acids. 1. Hoghly Diastereoselective Addition of a Racemic .beta.-Alanine Enolate Derivative to Electrophiles" JOURNAL OF ORGANIC CHEMISTRY, vol. 56, no. 7, 1991, pages 2553-2557, XP002327935 page 2557, left-hand column, line 22 - right-hand column, line 6	5,6
X	DATABASE BEILSTEIN BEILSTEIN INSTITUT ZUR FÖRDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; XP002327936 Database accession no. BRN 2324477 abstract & J. J. GORDON ET AL.: J. CHEM. SOC. PERKIN TRANS. 1, 1975, pages 819-825,	5,6

-/--

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document with indication where appropriate of the relevant passages	Relevant to claim No
X	DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, SCHREIBER, JURG V. ET AL: "Sequencing of .beta.-peptides by mass spectrometry" XP002327937 retrieved from STN Database accession no. 1999:819713 abstract & CHIMIA, vol. 53, no. 12, 1999, pages 621-26, -----	5,6
X	DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; HUCK, JACQUES ET AL: "Synthesis of structurally diversified .alpha.-substituted .beta.-amino acids and derivatives via conjugate radical additions and Heck reactions" XP002327938 retrieved from STN Database accession no. 2001:675328 abstract & SYNLETT, no. 9, 2001, pages 1467-69, -----	5
X	US 5 968 942 A (VAZQUES, MICHAEL L. ET AL) 19 October 1999 (1999-10-19) table 2 in example 9, entry 2, 3, 10, 13 -----	5
P,X	WO 2004/016259 A (PFIZER LIMITED; FIELD, MARK, JOHN; WILLIAMS, RICHARD, GRIFFITH; PFIZER) 26 February 2004 (2004-02-26) page 7, line 1 - line 15; claims; examples 1-15 -----	1-15
P,X	US 2004/157847 A1 (FIELD, MARK JOHN ET AL) 12 August 2004 (2004-08-12) column 3, paragraph 9-17; claims; examples -----	1-15
E	WO 2005/027975 A (PFIZER LIMITED) 31 March 2005 (2005-03-31) examples page 35, line 5 - line 8 -----	1-15
E	WO 2005/018622 A1 (PFIZER INC., USA) 3 March 2005 (2005-03-03) claims -----	1-15

436

SUPERINDUSTRIA Y COMERCIO
Radicacion : 06028475 00000000 Folios: 435
Fecha (AMD): 2006-03-22 17:29:04
Tramite : 011 PCT-PATENT 378 FASE NACI 411 PRESENTAC
Dependencia: 2020 DIVISION DE NUEVAS CREACIONES

Industria y Comercio

SUPERINTENDENCIA

Delegatura de Propiedad Industrial
División de Nuevas Creaciones

REQUISITOS NECESARIOS PARA PRESENTACIÓN Y AGILIZACIÓN DEL TRAMITE

PCT

	USUARIO	RADICADOR
PATENTE DE INVENCIÓN (X) MODELO DE UTILIDAD ( )	( )	( )
-Indicación de que se solicita la concesión de una patente.	( )	(X)
-Datos de identificación del solicitante o de la persona que se presenta la solicitud.	( )	(X)
-Descripción de la invención.	( )	(X)
-Dibujos de ser estos pertinentes.	( )	(X)
-Comprobante de Pago de las tasas establecidas.	( )	(X)
COMPLETA (X) INCOMPLETA ( )	( )	( )
DISEÑO INDUSTRIAL ( )		
-Indicación de que se solicita el registro de Diseño Industrial.	( )	( )
-Datos de identificación del solicitante o de la persona que se presenta la solicitud.	( )	( )
-Representación gráfica y fotográfica del Diseño Industrial o muestra del Material que incorpora el diseño.	( )	( )
-Comprobante de Pago de las tasas establecidas.	( )	( )
COMPLETA ( ) INCOMPLETA ( )	( )	( )
ESQUEMA DE TRAZADO ( )		
-Indicación de que se solicita el registro de Diseño Industrial.	( )	( )
-Datos de identificación del solicitante o de la persona que se presenta la solicitud.	( )	( )
-Representación gráfica del Esquema Trazado.	( )	( )
-Comprobante de Pago de las tasas establecidas.	( )	( )
COMPLETA ( ) INCOMPLETA ( )	( )	( )

Firma Responsable: _____

Fecha: _____

REPUBLICA DE COLOMBIA

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

Folio 437

2020
Bogotá D.C.,

Doctor(a)
OLARTE GARCIA CARLOS REINALDO
Apoderado(a) y/o Representante de
WARNER LAMBERT COMPANY

REFERENCIA	Radicación No.	06 28475
	Solicitud internacional	IB2004/002985
	Fecha inicio fase nacional	25/04/2006
	Trámite	11
	Evento	379
	Actuación	416
	Oficio No.	900
	Folios	1

Teniendo en cuenta que la solicitud de privilegio de patente que se tramita bajo el expediente indicado en la referencia, reúne los requisitos de forma establecidos en la Decisión 486 de la Comisión de la Comunidad Andina, el Tratado de Cooperación en Materia de Patentes (PCT), el Reglamento y la Circular Única de la Superintendencia de Industria y Comercio, se envía el extracto de la solicitud a la Oficina de Comunicaciones para efecto de su publicación en la Gaceta de Propiedad Industrial.

Cúmplase
Dado en Bogotá DC, 10 JUL. 2006

ALIX CARMENZA CESPEDES DE VERGEL
Jefe de la división de Nuevas Creaciones

jramos